

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

The American Thyroid Association Guidelines Task Force
on Pediatric Thyroid Cancer

Gary L. Francis,^{1,*} Steven G. Waguespack,^{2,*} Andrew J. Bauer,^{3,4,*} Peter Angelos,⁵ Salvatore Benvenega,⁶ Janete M. Cerutti,⁷ Catherine A. Dinauer,⁸ Jill Hamilton,⁹ Ian D. Hay,¹⁰ Markus Luster,^{11,12} Marguerite T. Parisi,¹³ Marianna Rachmiel,^{14,15} Geoffrey B. Thompson,¹⁶ and Shunichi Yamashita¹⁷

Background: Previous guidelines for the management of thyroid nodules and cancers were geared toward adults. Compared with thyroid neoplasms in adults, however, those in the pediatric population exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. Furthermore, therapy that may be recommended for an adult may not be appropriate for a child who is at low risk for death but at higher risk for long-term harm from overly aggressive treatment. For these reasons, unique guidelines for children and adolescents with thyroid tumors are needed.

Methods: A task force commissioned by the American Thyroid Association (ATA) developed a series of clinically relevant questions pertaining to the management of children with thyroid nodules and differentiated thyroid cancer (DTC). Using an extensive literature search, primarily focused on studies that included subjects ≤ 18 years of age, the task force identified and reviewed relevant articles through April 2014. Recommendations were made based upon scientific evidence and expert opinion and were graded using a modified schema from the United States Preventive Services Task Force.

Results: These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with DTC are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided.

¹Division of Pediatric Endocrinology, Virginia Commonwealth University, Children's Hospital of Richmond, Richmond, Virginia.

²Department of Endocrine Neoplasia and Hormonal Disorders and Department of Pediatrics-Patient Care, Children's Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, Texas.

³Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

⁴Department of Pediatrics, The University of Pennsylvania, The Perelman School of Medicine, Philadelphia, Pennsylvania.

⁵Section of General Surgery and Surgical Oncology, Department of Surgery, University of Chicago Medicine, Chicago, Illinois.

⁶University of Messina, Interdepartmental Program on Clinical & Molecular Endocrinology, and Women's Endocrine Health, A.O.U. Policlinico Universitario G. Martino, Messina, Italy.

⁷Department of Morphology and Genetics, Division of Genetics, Federal University of São Paulo, São Paulo, Brazil.

⁸Department of Surgery, Division of Pediatric Surgery, Department of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, Connecticut.

⁹Division of Endocrinology, University of Toronto, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.

¹⁰Division of Endocrinology, Mayo Clinic and College of Medicine, Rochester, Minnesota.

¹¹University of Marburg, Marburg, Germany.

¹²Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.

¹³Departments of Radiology and Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Department of Radiology, Seattle, Washington.

¹⁴Pediatric Division, Assaf Haroffeh Medical Center, Zerifin, Israel.

¹⁵Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

¹⁶Department of Surgery, Division of Subspecialty GS (General Surgery), Mayo Clinic, Rochester, Minnesota.

¹⁷Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

*Designates Chair (GLF) and Co-Chairs (AJB and SGW). Guidelines Task Force in alphabetical order following the Chairs.

Conclusions: In response to our charge as an independent task force appointed by the ATA, we developed recommendations based on scientific evidence and expert opinion for the management of thyroid nodules and DTC in children and adolescents. In our opinion, these represent the current optimal care for children and adolescents with these conditions.

INTRODUCTION

IN ORDER TO PROMOTE BEST PRACTICE STANDARDS for the diagnosis and management of thyroid cancers, The American Thyroid Association (ATA) (1), the American Association of Clinical Endocrinologists (2), the National Comprehensive Cancer Network (NCCN) (3), and the British Thyroid Association/Royal College of Physicians (4), previously published guidelines specifically addressing the evaluation, treatment and follow-up of thyroid nodules and differentiated thyroid cancer (DTC) in adults. In most cases, the evaluation, treatment and follow-up of children with thyroid neoplasia have followed adult guidelines. Heretofore, this approach resulted in a high proportion of cure, but required all children to undergo therapy that included total thyroidectomy followed by radioactive iodine (RAI) ablation with iodine-131 (¹³¹I). The goal was to eliminate any evidence of disease, documented by a negative whole-body RAI scan and, most recently, by an undetectable serum thyroglobulin (Tg) level. Unfortunately, recent studies with follow-up spanning several decades reveal an increase in all-cause mortality for survivors of childhood DTC, predominately due to second malignancies in children treated with radiation (5–7). These observations, coupled with a better understanding of the excellent prognosis associated with pediatric DTC (5,8–15), have now prompted the ATA to specifically address treatment of children with benign and malignant thyroid tumors.

This inaugural pediatric task force acknowledges that no randomized double-blind controlled clinical trial exists for the treatment of children with DTC. Published data are from retrospective cohorts and are potentially subject to investigator bias or nonrandom assignment to various treatment groups. Further limiting the development of treatment guidelines is the fact that previous series of DTC in children averaged only 10 years of follow-up. This constraint has made it difficult to determine if any treatment results in decreased risk of recurrence, mortality, or complications of therapy for children. Nevertheless, retrospective analysis of therapeutic options has led to a reconsideration of the former concept that all children with DTC should be similarly treated and has provided the opportunity for this task force to broaden the scope of acceptable therapy in an attempt to provide aggressive therapy when warranted and to limit overtreatment of those children who are unlikely to benefit.

BACKGROUND

According to the Surveillance, Epidemiology and End Results (SEER) program, new cases of thyroid cancer in people age <20 represent 1.8% of all thyroid malignancies diagnosed in the United States (16). Unfortunately, the incidence appears to be increasing (17). Among 15- to 19-year-old adolescents, thyroid cancer is the eighth most frequently diagnosed cancer and the second most common cancer among girls (8,18). Adolescents have a 10-fold greater incidence than younger children, and there is a female to male preponderance (5:1) during adolescence that is not seen in

young children (8,18–21). The most common presentation for DTC in children is that of a thyroid nodule. However, papillary thyroid cancer (PTC) also frequently presents as cervical adenopathy with or without a palpable thyroid lesion, or as an incidental finding after imaging or surgery for an unrelated condition (11). Occasionally, the diagnosis is made only after the discovery of distant metastases (22–24).

The pathological classification of DTCs in children is based on standard definitions set by the World Health Organization (WHO), with histological criteria the same for children and adults (25). PTC accounts for 90% or more of all childhood cases (10,12,20,26–28). Follicular thyroid cancer (FTC) is uncommon, while medullary thyroid cancer (MTC), poorly differentiated tumors, and frankly undifferentiated (anaplastic) thyroid carcinomas are rare in young patients. Pediatric PTC may present with a variety of histological variants all having a distinctive but shared set of nuclear characteristics.

Subtypes of PTC in pediatrics include the following histologic variants: classic, solid, follicular, and diffuse sclerosing (25,29). Children, especially those <10 years of age, may not have the classic papillary morphology seen in adults, and such tumors can be un-encapsulated and widely invasive throughout the gland and have a follicular and solid architecture with unique nuclear features and abundant psammoma bodies (30,31). The major risk factor for developing PTC is radiation exposure to the thyroid (32–34). Children, especially those <5 years of age, are the most sensitive (33,35,36). Radiation-induced PTC does not appear to differ in clinical behavior compared with sporadic PTC (37). Activation of the RAS-RAF-MEK-ERK (mitogen-activated protein kinase) pathway is critical for thyroid malignancies (38–40). An estimated 5% of patients with nonmedullary thyroid cancer (NMTC) have a family history of nonsyndromic NMTC (35,41) with conflicting evidence in regard to whether it behaves more aggressively (42).

PTC and FTC exhibit major clinical differences. PTC is frequently multifocal and bilateral and metastasizes to regional neck lymph nodes in the vast majority of children (10,12,13,15,23,24,31,43–47). Hematogenous metastases to the lungs occur in up to 25% of cases (9,11,14,24,31,43,48–52) and generally occur only with significant regional lymph node metastases (10,53). FTC is typically a unifocal tumor and more prone to initial hematogenous metastases to lungs and bones. Metastases to regional lymph nodes are uncommon in FTC. Histologic variants of FTC include: Hürthle cell (oncocyctic), clear cell, and insular (poorly differentiated) carcinoma (25).

Based on the rarity of FTC in children and the major clinical and biological differences between PTC and FTC in children, the current guidelines have been developed specifically for PTC in children, and we have chosen to include a separate section dedicated to the treatment of FTC.

METHODOLOGY

The ATA selected a task force using a strategy similar to that of previous ATA Guidelines task forces. Members were

TABLE 1. STRENGTH OF PANELISTS' RECOMMENDATIONS BASED ON AVAILABLE EVIDENCE

<i>Rating</i>	<i>Definition</i>
A: Strongly recommends	The recommendation is based on good evidence that the service or intervention can improve important health outcomes. Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
B: Recommends	The recommendation is based on fair evidence that the service or intervention can improve important health outcomes. The evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence on health outcomes.
C: Recommends	The recommendation is based on expert opinion.
D: Recommends against	The recommendation is based on expert opinion.
E: Recommends against	The recommendation is based on fair evidence that the service or intervention does not improve important health outcomes or that harms outweigh benefits.
F: Strongly recommends against	The recommendation is based on good evidence that the service or intervention does not improve important health outcomes or that harms outweigh benefits.
I: Recommends neither for nor against	The panel concludes that the evidence is insufficient to recommend for or against providing the service or intervention because evidence is lacking that the service or intervention improves important health outcomes, the evidence is of poor quality, or the evidence is conflicting. As a result, the balance of benefits and harms cannot be determined.

approved by the ATA and represent an international community of experts from a variety of disciplines including endocrinology, molecular biology, nuclear medicine, radiology, and surgery. None of the scientific or medical content of the manuscript was dictated by the ATA. The task force met by conference calls and in person and developed a series of clinically relevant questions pertaining to the management of children with thyroid nodules and DTC. Task force members were assigned to subcommittees structured along the lines of these clinical questions and attempted to answer them using an extensive literature search, primarily focused on studies that included subjects ≤ 18 years of age, in addition to expert opinion. Similar to other ATA guidelines, the strength of the recommendations was categorized using a modified schema proposed by the U.S. Preventive Services Task Force (54) (see Table 1). With contributions from all

authors, the document was primarily written by the chair and coauthors (GLF, AJB, and SGW). The Pediatric Endocrine Society (PES) codeveloped and endorsed the guidelines. The final document was approved by the ATA (Board of Directors and membership) and the PES (Drug and Therapeutics Committee and Board of Directors).

Table 2 presents the organization of the task force's results and recommendations. Readers of the print version are referred to the page number for information about specific topics and recommendations. The location key can be used if viewing the guidelines in a file or web page. Each location key is unique and can be copied into the Find or Search functions to rapidly navigate to the section of interest. Specific recommendations are presented as bulleted points in the main body. Table 3 includes definitions to the abbreviations used in the guidelines.

TABLE 2. ORGANIZATION OF THE PEDIATRIC THYROID NODULE AND DIFFERENTIATED THYROID CANCER GUIDELINES AND RECOMMENDATIONS

<i>Location key^a</i>	<i>Page</i>	<i>Section</i>	<i>Recommendation no.</i>	<i>Rating</i>
[A1]	720	Why do we need specific guidelines for children with thyroid nodules and thyroid cancer?		
[A2]	720	To what age group should these guidelines apply?	1	C
[A3]	720–721	Should treatment of children with DTC be stratified into more than one age group?	2	B
[A4]	721–722	What are the goals of therapy for DTC in children?	3	C
[B1]	722	Thyroid nodule guidelines		
[B2]	722	How common are thyroid nodules in children and what is the risk for malignancy?		
[B3]	722–723	Are there high-risk groups who might benefit from prospective screening for thyroid nodules and thyroid cancer?	4(A) 4(B) 4(C) 4(D)	B I C B

(continued)

TABLE 2. (CONTINUED)

<i>Location key^a</i>	<i>Page</i>	<i>Section</i>	<i>Recommendation no.</i>	<i>Rating</i>
[B4]	723–725	What is the optimal evaluation of children with thyroid nodules?	5	B
[B5]	725	Are there molecular signatures that complement FNA and improve the diagnostic utility of FNA in children?	6	E
[B6]	725	How should thyroid nodules be treated in children?		
[B7]	725	What is the recommended approach for children with benign thyroid cytopathology?		
[B8]	725–726	Is there a role for levothyroxine suppression therapy?	7	I
[B9]	726	Is there a role for surgery in children with benign nodules?	8	B
[B10]	726	What is the optimal management of the child with an autonomous thyroid nodule?	9	A
[C1]	726	Papillary thyroid cancer—initial management guidelines		
[C2]	726–727	What is the optimal preoperative evaluation for the child with newly diagnosed PTC?	10	A
[C3]	727	What is the recommended surgical approach for the patient with a diagnosis of PTC?	11	A
[C4]	727–728	Should central neck dissection be performed?	12(A) 12(B) 12(C) 12(D)	B C A C
[C5]	728	What are the indications for lateral neck dissection?	13	B
[C6]	728–729	What are the possible complications of surgery and what should be done to minimize the risks of surgery?	14(A) 14(B)	B B
[C7]	729–730	What tumor classification systems can be used for pediatric PTC?	15(A) 15(B)	B B
[C8]	730–732	What postoperative staging is recommended?	16	B
[C9]	733	What are the goals of ¹³¹ I treatment?		
[C10]	733	What is the impact of ¹³¹ I therapy on recurrence and survival for children with PTC?		
[C11]	733	Which children might benefit from therapeutic ¹³¹ I?	17	B
[C12]	733–734	How should a child be prepared for ¹³¹ I?	18	A
[C13]	734–736	What should be considered for administration of ¹³¹ I?	19(A) 19(B)	C F
[C14]	736	How is the activity of therapeutic ¹³¹ I determined?	20	I
[C15]	736	Should a posttreatment whole-body scan be obtained?	21	B
[C16]	736–737	What are the acute and long-term risks of ¹³¹ I therapy in children?	22	C
[D1]	737	Surveillance and follow-up of PTC In children		
[D2]	737–739	What is the role of Tg testing in the follow-up of PTC in children?	23(A) 23(B) 23(C) 23(D) 23(E)	A A B A A
[D3]	739	What is the role of ultrasound in the follow-up of PTC in children?	24	A
[D4]	739–740	How are diagnostic RAI scans best used in the follow-up of PTC in children?	25(A) 25(B) 25(C)	C B B
[D5]	740	What imaging studies should be considered in the pediatric PTC patient who is Tg positive but who has no evidence of disease on cervical ultrasound or DxWBS?	26(A) 26(B) 26(C)	B D D
[D6]	740–741	What are the goals and potential risks of TSH suppression therapy?	27	B
[D7]	741	What is the optimal approach to the patient with persistent / recurrent cervical disease?	28(A) 28(B) 28(C) 28(D)	C B B C
[D8]	741–742	How should children with pulmonary metastases be managed?	29(A) 29(B) 29(C) 29(D) 29(E) 29(F)	A B B B E C

(continued)

TABLE 2. (CONTINUED)

Location key ^a	Page	Section	Recommendation	
			no.	Rating
[D9]	742	How does one approach the child with an incidental PTC identified after surgery for another thyroid condition?	30	B
[D10]	742–743	What are the optimal approaches to the pediatric patient who develops progressive thyroid cancer that no longer concentrates or responds to ¹³¹ I?	31	C
[E1]	743–744	Follicular thyroid cancer	32(A) 32(B) 32(C)	C C C
[F1]	744	What are the unique issues that may affect children diagnosed with DTC?	33	C
[G1]	744–745	How long should a child with PTC be monitored?	34	B
[G2]	745	What are the areas for future research?		

^aIf viewing these guidelines on the Web, or in a File, copy the Location Key to the Find or Search Function to navigate rapidly to the desired section. DTC, differentiated thyroid cancer; DxWBS, diagnostic whole-body scan; FNA, fine-needle aspiration; PTC, papillary thyroid cancer; Tg, thyroglobulin; TSH, thyrotropin.

[A1] WHY DO WE NEED SPECIFIC GUIDELINES FOR CHILDREN WITH THYROID NODULES AND THYROID CANCER?

There are important clinical, molecular, and pathological differences in DTC among children compared to adults that prompt the development of unique pediatric guidelines. From a clinical perspective, thyroid nodules are uncommon in children. However, nodules diagnosed in children carry a greater risk of malignancy compared to those in adults (22%–26% versus 5%–10% in most series) (27,55,56). Second, when histology and tumor size are controlled for, children with PTC are more likely to have regional lymph node involvement, extrathyroidal extension, and pulmonary metastasis (9–15,23,24,31,43–53). Third, despite extensive disease at clinical presentation, children are much less likely to die from disease (2% or less long-term cause-specific mortality) than are adults (5,8–15), and many children with pulmonary metastases (30%–45%) develop persistent albeit stable disease following ¹³¹I therapy (24,57). This is associated with a more favorable progression-free survival in children compared to adults with persistent DTC (9,10,13,14,47,48,51,52). Finally, there may be a continued clinical response demonstrated by a decline in Tg levels after cessation of RAI therapy in children with pulmonary metastases (58).

Compared with adult PTC, childhood PTC is characterized by a higher prevalence of gene rearrangements and a lower frequency of point mutations in the proto-oncogenes implicated in PTC. Recent molecular studies have shown that *BRAF* mutations are the most common abnormality in adult PTC (36%–83% of cases) (38), but they are rare in children with PTC (59) and virtually absent from the youngest patients. This may be important because point mutations of *RAS* and *BRAF* lead to genomic instability and dedifferentiation manifested by decreased expression of the sodium-iodide symporter (NIS) (60,61). In contrast, *RET/PTC* rearrangements are more common in PTC from children (20,26,40,62) and do not lead to genomic instability. These molecular differences might be one of the reasons for better response to RAI therapy in children with PTC and could partially explain their low mortality and rare progression to less-differentiated tumors. Consistent with this hypothesis, a small study of PTC from children and adolescents found distant metastases and recurrence only in tumors with undetectable NIS, and the activity of ¹³¹I required to achieve remission was greater in

those cancers with undetectable NIS (63). Finally, these molecular differences may have an impact on the utility of molecular testing for diagnosis of thyroid malignancies in children with thyroid nodules (see Section B5).

[A2] TO WHAT AGE GROUP SHOULD THESE GUIDELINES APPLY?

Studies of pediatric DTC have variously included individuals extending up to 21 years of age (5,8–10,13,14,47,48,51,52). With uncommon exception, the majority of pediatric patients have completed growth and development by ≤ 18 years of age. To more accurately define the impact of the physiologic changes of growth and development on tumor behavior, the upper limit for pediatrics should be defined as patients ≤ 18 years of age.

■ RECOMMENDATION 1

The pediatric age should be limited to a patient ≤ 18 years of age. Establishing a uniform upper limit of age will afford an opportunity to better define the potential impact of growth on tumor behavior. From a pragmatic point of view, individual centers may transition pediatric patients to adult care anywhere between 18 and 21 years of age. Clinicians may manage the “child” under these guidelines until transition has been completed.

Recommendation rating: C

[A3] SHOULD TREATMENT OF CHILDREN WITH DTC BE STRATIFIED INTO MORE THAN ONE AGE GROUP?

Several studies have compared the clinical presentation and outcomes for children diagnosed with DTC < 10–15 years of age with that of patients 10–18 years of age. The data are unclear as to whether younger age portends greater risk for extensive disease or recurrence. All studies are retrospective and most include only small numbers of children < 10–15 years of age. In general, studies in which 25%–30% of the cohort are of younger age have shown that young age is associated with persistent disease or recurrence, whereas studies with fewer young children have not confirmed this (10,14,50,53,64–66). In addition, treatment regimens varied, which may impact outcomes. For example, surgeons may be less aggressive in lymph node dissection in younger children, and this factor, rather than age, may impact recurrence rates.

TABLE 3. DEFINITIONS OF ABBREVIATIONS USED IN THE PEDIATRIC THYROID NODULE AND DIFFERENTIATED THYROID CANCER GUIDELINES

AJCC	American Joint Committee on Cancer
AMES	Age-metastasis-extent of disease-size of tumor
ATA	American Thyroid Association
AUS/FLUS	Atypia or follicular lesion of undetermined significance
CND	Central neck dissection
CT	Computed tomography
DFS	Disease-free survival
DTC	Differentiated thyroid cancer
DxWBS	Diagnostic whole-body scan
ETE	Extrathyroidal extension
FDA	Food and Drug Administration
¹⁸ FDG-PET/CT	[¹⁸ F]-fluoro-deoxyglucose positron emission tomography/computed tomography
FNA	Fine-needle aspiration
FNMTc	Familial nonmedullary thyroid cancer
FTC	Follicular thyroid cancer
Gy	Gray unit of measurement: absorbed dose (of ionizing radiation)
iPTH	Intact parathyroid hormone
LT ₄	Levothyroxine
MACIS	Metastasis-age-completeness of resection-invasion-size
MRI	Magnetic resonance imaging
MTC	Medullary thyroid cancer
NCCN	National Comprehensive Cancer Network
NIS	Sodium-iodide symporter
NMTC	Nonmedullary thyroid cancer
PTC	Papillary thyroid cancer
<i>PTEN</i>	Gene: phosphatase and tensin homolog
PTMC	Papillary thyroid microcarcinoma
RAI	Radioactive iodine
rhTSH	Recombinant human TSH
RLN	Recurrent laryngeal nerve
RxWBS	Post-treatment whole-body scan
SPECT/CT	Single photon emission computed tomography with integrated conventional CT
Tg	Thyroglobulin
TgAb	Thyroglobulin antibody
TNM	Tumor-Node-Metastasis
TSH	Thyrotropin
TT	Total or near-total thyroidectomy
US	Ultrasound
WBS	Whole-body scan
WHO	World Health Organization

In some series, extrathyroidal extension (ETE) (50,66), regional node involvement (50,67), distant metastases (64,67), and lymph node recurrence (10,65,66) have an increased prevalence in younger children, but this is not seen in all series (14,44,50,53). The largest study included 740 children from Belarus (10), 92% of whom had exposure to radionuclides at the time of the Chernobyl disaster. By multivariate regression analysis, younger age was associated with an increased risk of recurrent nodal disease and lung metastases after adjustment for other risk factors. Unfortunately, several features of that study preclude generalization of the data. The Belarus cohort was exposed to radiation, and the relationship between age and outcome might be explained by the heightened sensitivity to radiation in younger children rather than age *per se* (68).

■ RECOMMENDATION 2

It remains unclear if younger children (<10–15 years of age) are at greater risk for more extensive disease or higher rates of recurrence. Other factors aside from age (treatment approaches, genetic susceptibility, and/or radiation exposure) may interact to modify this risk. However, those studies with a larger proportion of young children show an increased risk of persistent disease/recurrence. In an effort to increase the descriptive nature of these discussions, the committee recommends that “prepubertal” and “pubertal/postpubertal” should be incorporated into future studies to increase uniformity and more accurately represent the potential influence of pubertal development on the incidence and behavior of DTC within the pediatric population.

Recommendation rating: B

[A4] WHAT ARE THE GOALS OF THERAPY FOR DTC IN CHILDREN?

Given the fact that disease-specific mortality for children with DTC is very low, it is unlikely that modification of current treatment protocols will further reduce the disease-specific mortality. However, the apparent increased risk of second malignancies and overall mortality among childhood DTC survivors who were treated with radiation (see Section C16) underscores the need to better risk-stratify children with DTC so that more aggressive therapy is reserved for those at highest risk for morbidity and mortality and avoided in those children who are unlikely to derive long-term benefit. The goals for improved treatment are to

1. Maintain the low disease-specific mortality currently experienced by children with DTC.
2. Reduce potential complications from therapy.

A major task in this process is to prospectively identify the minority of children who will benefit from aggressive therapy and to better understand the clinical characteristics that predict a response to such therapies. It is possible that in this search to develop “lower-intensity” therapy, we might increase the risk for residual/recurrent disease and the numbers of patients surviving with low-volume, persistent but progression-free disease. Two major differences in these guidelines compared with previous treatment guidelines are recommendations directed toward:

1. Pre- and postoperative staging
2. Selective use of ¹³¹I in children with DTC

The 2009 ATA thyroid cancer guidelines for adult patients recommend that staging should be performed for all patients with DTC using the Tumor-Node-Metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) (69). In this system, children are classified as either stage I (no distant metastases) or stage II disease (with distant metastases). However, stage I includes a widely diverse group of children: those with a solitary lesion confined to the thyroid, those with extensive locoregional disease and neck nodal metastases, and those with microscopic PTC. Treatment and prognosis for these varied lesions should ideally be stratified to represent the risks of persistent/recurrent disease, and that will require an additional risk-stratification scheme beyond TNM classification.

Studies have confirmed the notion that children with DTC have lower rates of complications when surgery is performed by experienced thyroid surgeons (70–72). For this reason, the current task force recommends that children with DTC should be operated upon by experienced thyroid surgeons. Furthermore, it is our opinion that children with DTC should be cared for by teams of physicians experienced in the management of DTC in children to include, not only high-volume thyroid surgeons, but also experts in nuclear medicine and endocrinology who have experience in managing children with DTC. Evaluation and care should be provided in centers with a full range of pediatric and oncologic resources, which should be organized into a multidisciplinary team that regularly conducts patient review and/or tumor board conferences. This will facilitate interdisciplinary decisions regarding optimal therapy and will help to reduce the possibility that treatment and long-term follow-up will be either overly aggressive or inadequate.

■ RECOMMENDATION 3

Children with DTC should be cared for by teams of physicians experienced in the management of DTC in children. This will facilitate interdisciplinary decisions regarding optimal therapy and will help to reduce the possibility that treatment and long-term follow-up will be either overly aggressive or inadequate.

Recommendation rating: C

[B1] THYROID NODULE GUIDELINES

[B2] How Common Are Thyroid Nodules in Children and What is the Risk for Malignancy?

Thyroid nodules are less common among children than adults but are more likely to be malignant in children referred for evaluation of nodular thyroid disease (22%–26% versus

approximately 5%) (27,55,56). Estimates from ultrasound (US) and postmortem examination suggest that 1%–1.5% of children and up to 13% of older adolescents or young adults have thyroid nodules (73,74), although it is unclear how many of these would have become clinically apparent. Recent data from a large Japanese series using high-resolution US confirm the incidence of solid nodules at 1.65% but also identified cystic lesions in 57% of children and adolescents (75). Such high-resolution US data have not yet been replicated in other pediatric populations, and it remains unclear if thyroid nodules are this prevalent in other regions. Nevertheless, it appears from multiple studies that the prevalence of thyroid nodules is much greater in children than is generally appreciated. It also remains unclear how many of these nodules would reach a clinical threshold during childhood.

[B3] Are There High-Risk Groups Who Might Benefit from Prospective Screening for Thyroid Nodules and Thyroid Cancer?

Several risk factors are associated with the development of thyroid nodules in children, including iodine deficiency, prior radiation exposure, a history of antecedent thyroid disease, and several genetic syndromes (Table 4). One high-risk population is that of childhood cancer survivors who were treated for their primary malignancy with radiation therapy, especially survivors of Hodgkin lymphoma, leukemia, and central nervous system tumors (76,77). Thyroid nodules, many of which can only be detected by US, develop in cancer survivors at a rate of about 2% annually and reach a peak incidence 15–25 years after exposure (78–80). In general the risk is greatest among those who received radiation therapy at a younger age and with doses up to 20–29 Gy (77,81,82). High resolution US may identify small subclinical thyroid tumors (83,84). However, insufficient data exist to determine if early detection of non-palpable tumors will significantly improve the quality and or

TABLE 4. HEREDITARY TUMOR SYNDROMES ASSOCIATED WITH THYROID NODULES/DIFFERENTIATED THYROID CANCER

<i>Hereditary syndrome^a</i>	<i>Gene (chromosomal location)</i>	<i>Type of thyroid neoplasia</i>
<i>APC</i> -associated polyposis (familial adenomatous polyposis [FAP], attenuated FAP, Gardner syndrome, and Turcot syndrome)	• <i>APC</i> (5q21-q22)	• PTC (cribriform-morular variant)
Carney complex	• <i>PRKARIA</i> (17q24.2) • “ <i>CNC2</i> ” (2p16)	• Multinodular goiter • Follicular adenomas • DTC (PTC and FTC)
<i>DICER1</i> Syndrome	• <i>DICER1</i> (14q32.13)	• Multinodular goiter • DTC (due to second somatic mutation in <i>DICER1</i> , possibly related to treatment of pleuropulmonary blastoma)
<i>PTEN</i> hamartoma tumor syndrome (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, <i>PTEN</i> -related Proteus syndrome, and Proteus-like syndrome)	• <i>PTEN</i> (10q23)	• Multinodular goiter • Follicular adenomas • DTC (FTC overrepresented)
Werner syndrome	• <i>WRN</i> (8p12)	• DTC (PTC and FTC)

^aAlthough DTC has also been reported to occur in patients with Beckwith–Wiedemann syndrome, the familial paraganglioma syndromes, Li–Fraumeni Syndrome, McCune–Albright syndrome, and Peutz–Jeghers syndrome, it remains unclear if these tumors are a direct result of the underlying genetic defect.

longevity of life in patients screened by a standardized protocol using US and fine-needle aspiration (FNA). Furthermore, routine US screening may also identify incidental findings, such as ectopic thymus, that may confuse the clinical picture and potentially lead to unnecessary testing (75).

A variety of genetic disorders predispose to thyroid neoplasia (85,86) (Table 4). Benign and malignant thyroid tumors can occur in patients with *APC*-associated polyposis (87), the Carney complex (88), the *DICER1* syndrome (89,90), the *PTEN* hamartoma tumor syndrome (91–93), and Werner syndrome (94). Cases of DTC have also been reported in Beckwith–Wiedemann syndrome (95), the familial paraganglioma syndromes (96), Li–Fraumeni Syndrome (97), McCune–Albright syndrome (98), and Peutz–Jeghers syndrome (99).

Furthermore, children from kindreds with familial non-medullary thyroid cancer (FNMTC) may have a predisposition to tumor development (100–105). No clear recommendations exist for prospective screening (outside of routine physical examination) in most cases. However, updated recommendations for US screening have been put forth for both the *PTEN* hamartoma tumor syndrome and *APC*-associated polyposis (91,92,106). In addition, in nonsyndromic FNMTC, US surveillance of family members has been shown to detect earlier stages of disease as reflected by smaller tumor size (0.8 vs. 2.85 cm; $p < 0.001$), a lower incidence of lymph node metastasis (23.2% vs. 65.6%; $p < 0.001$) as well as a lower incidence of ETE (20.9% vs. 56.2%; $p = 0.002$) compared to the proband (107).

Limited data exist on children with autoimmune thyroiditis. However, one report shows an increased prevalence of thyroid nodules perhaps as high as 30% with 7 of 11 PTC only detected by US examination (108). It is unclear how many of these would have achieved clinical importance, however. The presence of a palpable thyroid nodule or asymmetry with or without palpable cervical lymphadenopathy warrants referral to an experienced thyroid ultrasonographer and consideration of FNA as indicated based on suspicious sonographic features (see Section B4) or growth over time. There are increasing data to suggest that patients with a nodule and thyrotropin (TSH) levels in the upper tertiles of the reference range may be at increased risk for malignancy (109).

From these data we conclude that thyroid nodules are common in childhood cancer survivors who received radiation therapy, and they are associated with a modest risk of malignancy. Other groups of children with tumor syndromes, as well as those born into a kindred with FNMTC, have an increased risk for thyroid nodules and/or cancers. Some of these cancers are small and not likely to be detected without US. Although this task force could not recommend thyroid US as a routine screening tool in all of these patients, we do encounter children who have incidental nodules identified via screening thyroid US. Similar to palpable nodules, nodules detected in this setting should be interrogated by US performed by an experienced ultrasonographer, and FNA should be performed if the nodule has concerning sonographic features or growth over time.

■ RECOMMENDATION 4(A)

An annual physical examination is recommended in children at high risk for thyroid neoplasia. Additional imaging should be pursued if palpable nodules, thyroid

asymmetry, and/or abnormal cervical lymphadenopathy are found on examination.

Recommendation rating: B

■ RECOMMENDATION 4(B)

In children with a history of radiation exposure to the thyroid, the data show that US can detect small thyroid nodules, but the panel is not yet convinced that detection of subclinical disease by US prior to a palpable abnormality on physical examination impacts long-term outcomes. Therefore, routine screening US in high-risk children can neither be recommended for nor against until more data become available.

Recommendation rating: I

■ RECOMMENDATION 4(C)

Patients at increased risk of developing familial DTC should be referred to centers of excellence so that appropriate evaluation, follow-up, genetic counseling, and/or treatment can be undertaken without subjecting patients and families to unwarranted and aggressive therapy.

Recommendation rating: C

■ RECOMMENDATION 4(D)

For patients with autoimmune thyroiditis, evaluation by an experienced thyroid ultrasonographer should be pursued in any patient with a suspicious thyroid examination (suspected nodule or significant gland asymmetry), especially if associated with palpable cervical lymphadenopathy.

Recommendation rating: B

[B4] What Is the Optimal Evaluation of Children with Thyroid Nodules?

The 2009 ATA adult guidelines indicate that the evaluation and treatment of thyroid nodules in children should be the same as in adults (Recommendation 18). In general, this task force agrees with that sentiment, but there are specific areas in which we feel the approach should differ (Fig. 1).

The 2009 adult guidelines indicate that FNA is not warranted for the evaluation of a nodule < 1 cm in size unless the patient is considered high-risk, most commonly with a history of exposure to ionizing radiation, or the nodule is associated with pathologic regional lymph nodes. A size criterion is more problematic in children because thyroid volume changes with age and the size of the nodule alone does not predict malignant histology (110–112). Therefore, US characteristics and clinical context should be used more preferentially to identify nodules that warrant FNA. US features such as hypoechogenicity, irregular margins, and increased intranodular blood flow are more common in malignant lesions (110,113). In addition, the presence of microcalcifications and abnormal cervical lymph nodes increase the likelihood of malignancy (110,113). In all children with a suspicious nodule, US evaluation of the cervical lymph nodes should be performed.

The 2009 adult guidelines indicate that FNA is not warranted for the evaluation of a hyperfunctioning nodule in the adult. Although we concur that preoperative FNA of a




FIG. 1. Initial evaluation, treatment, and follow-up of the pediatric thyroid nodule. ¹Assumes a solid or partially cystic nodule ≥ 1 cm or a nodule with concerning ultrasonographic features in a patient without personal risk factors for thyroid malignancy (see Sections B3 and B4). ²A suppressed TSH indicates a value below the lower limits of normal. ³Refer to PTC management guidelines (Section C1) or MTC management guidelines. ⁴Surgery can always be considered based upon suspicious ultrasound findings, concerning clinical presentation, nodule size >4 cm, compressive symptoms, and/or patient/family preference. ⁵Surgery implies lobectomy plus isthmusectomy in most cases. Surgery may be deferred in patients with an autonomous nodule and subclinical hyperthyroidism, but FNA should be considered if the nodule has features suspicious for PTC. (See Section B10.) Consider intraoperative frozen section for indeterminate and suspicious lesions. Can consider total thyroidectomy for nodules suspicious for malignancy on FNA. ⁶Consider completion thyroidectomy \pm RAI versus observation \pm TSH suppression based upon final pathology (see Section E1).

hyperfunctioning nodule in a child is similarly not warranted, this is based on the understanding that all hyperfunctioning nodules in children will be surgically removed (see Section B10).

The 2009 adult guidelines indicate that calcitonin screening for MTC in adults with thyroid nodules may be cost effective, but it was neither recommended for nor against. In children and adolescents, the prevalence of sporadic MTC is extremely low. In addition, calcitonin reference ranges in children have not yet been widely validated, especially in children who have background thyroid disease such as thyroiditis. Further studies are needed to determine the cost-effectiveness of adding calcitonin to the evaluation of thyroid nodules in children.

The 2009 adult guidelines indicate that US-guided FNA is preferred for lesions with a higher likelihood of nondiagnostic cytology or sampling error. The sensitivity, specificity, and overall accuracy of FNA in children are similar to that of adults (114–119). However, based on the higher proportion of malignant nodules in children and the potential difficulty in obtaining repeat samples from children, this task force recommends that all FNA in children should be performed with US guidance. This is particularly relevant for complex cystic lesions, which require FNA of

the solid portion, and it may also reduce the need for repeat FNA. The latter is important since FNA may alter the ultrasonographic features of thyroid nodules (120), thus making short-term follow-up more difficult.

A unique but very important difference in children is that PTC may present as diffusely infiltrating disease that results in diffuse enlargement of a lobe or the entire gland. For this reason, diffuse thyroid enlargement, especially if associated with palpable cervical lymph nodes, should prompt imaging. With rare exception, the diffuse infiltrating form of PTC is associated with microcalcifications that warrant FNA.

Finally, for both children and adults, cytopathology findings on FNA are categorized according to The Bethesda System for Reporting Thyroid Cytopathology (121). In this six-tier system, FNA results are reported as (a) nondiagnostic or unsatisfactory, (b) benign, (c) atypia or follicular lesion of undetermined significance (AUS/FLUS), (d) follicular/Hürthle neoplasm or suspicious for follicular/Hürthle neoplasm, (e) suggestive of malignancy, or (f) malignant. Insufficient or nondiagnostic cytopathology refers to a specimen with limited cellularity (fewer than six follicular cell groups each containing 10–15 cells per group from at least two separate aspirates), absence of follicular cells or poor fixation and preservation (122). There is a 1%–4% risk of malignancy in

insufficient samples from adults (121), but very few data in children. Repeat FNA is an option in children but should be delayed for a minimum of 3 months in order to decrease the potential for atypical cellular features that may arise during the reparative process (123). In adults, the risk of malignancy in indeterminate nodules ranges from ~5% to 15% in the AUS/FLUS category to 15%–30% in the follicular neoplasm or suggestive of neoplasm group (122). The limited data available suggest these indeterminate FNA categories account for ~35% of pediatric FNA and that, in children, 28% of AUS/FLUS lesions and 58% of suggestive of follicular or Hürthle cell neoplasm are malignant (26,124). The 2009 adult guidelines suggested that repeat FNA was an option for adults with indeterminate cytopathology. However, due to the apparent increased probability of malignancy among these indeterminate categories in children, the task force recommends definitive surgery (lobectomy plus isthmusectomy) for indeterminate FNA findings in children (see Fig. 1).

■ RECOMMENDATION 5

The evaluation and treatment of thyroid nodules in children (Fig. 1) should be the same as in adults with the exceptions that (a) US characteristics and clinical context should be used rather than size alone to identify nodules that warrant FNA, (b) all FNA in children should be performed under US guidance, (c) preoperative FNA of a hyperfunctioning nodule in a child is not warranted as long as the lesion is removed, (d) a diffusely infiltrative form of PTC may occur in children and should be considered in a clinically suspicious gland, and (e) surgery (lobectomy plus isthmusectomy) is favored over repeat FNA for most nodules with indeterminate cytology.

Recommendation rating: B

[B5] Are There Molecular Signatures That Complement FNA and Improve the Diagnostic Utility of FNA in Children?

Studies in adults have shown that molecular testing aids in the management of thyroid nodules with indeterminate cytopathology (125–130). However, these diagnostic approaches have not yet been validated in pediatric patients. Mutational analysis has been used to examine thyroid nodules in children in limited single institution studies (26,131). Approximately 17% of pediatric FNAs may be positive for a mutation or rearrangement, the presence of which correlated with malignancy in 100% (26). However, the cytopathologic classification for these malignant tumors were AUS/FLUS, suggestive of follicular or Hürthle neoplasm, suggestive of malignancy, or malignant, all of which would have led to surgical removal regardless of the mutational analysis. Although a proprietary multi-gene expression classifier has been validated to corroborate a benign diagnosis in adults with indeterminate nodules (126), there are no studies determining its usefulness in the evaluation of the indeterminate pediatric thyroid nodule. Therefore, although current molecular diagnostics might improve the diagnostic acumen for indeterminate cytopathology in children, additional studies are required before a formal recommendation can be proffered.

■ RECOMMENDATION 6

A positive mutational test appears highly likely to be associated with malignancy. Conversely, insufficient data exist in children to rely on negative genetic studies to reliably exclude malignancy. Although molecular studies hold promise for complementing the results of FNA, particularly for nodules that yield indeterminate cytology, they have not yet been sufficiently validated in children and cannot be routinely recommended in routine clinical practice until further studies are conducted.

Recommendation rating: E

[B6] How Should Thyroid Nodules Be Treated in Children?

The surgical approach to the child with a thyroid nodule is dictated by the FNA results (see Fig. 1). Every effort should be made to ensure the FNA is performed in a controlled setting designed to accommodate age-appropriate anesthesia and pediatric advanced life support monitoring and intervention. In an effort to provide clarity, the proposed classification scheme from the National Cancer Institute Thyroid FNA State of Science conference is used as a guide to stratify surgical intervention (122).

[B7] What Is the Recommended Approach for Children with Benign Thyroid Cytopathology?

A key element in this question is whether or not “benign” lesions in children as defined by absence of suspicious US findings and benign FNA are ever subsequently found to be malignant. There are insufficient data to answer this question in children, but there are studies that have included both children and adults (132–134). The false-negative rate appears to be quite low, in the range of 3%–5% (114); however, the false negative rate may be higher in larger lesions secondary to an increased risk of sampling error (27,135–137).

[B8] Is There a Role for Levothyroxine Suppression Therapy?

The literature in this area is conflicting. Not all studies have used the same methodology nor have they always separated spontaneous thyroid nodules from radiation-induced thyroid nodules. Furthermore, some but not all benign thyroid nodules regress spontaneously, and this might be more common in small cystic lesions (138,139). Levothyroxine (LT₄) suppression therapy has been evaluated for its efficacy to reduce nodule size or to reduce the risk of subsequent nodule formation. However, there are only minimal data regarding long-term safety and potential side-effects of LT₄ therapy (140,141).

LT₄ therapy has been prescribed to reduce the size of benign thyroid nodules, but the clinical benefit of a small to modest reduction in size is not clear (142–147). About a third (30.6%) of euthyroid children had a ≥50% reduction in nodule size, which was directly correlated with TSH levels ($r=0.640, p<0.001$) and inversely with LT₄ dose ($r=-0.389, p=0.009$) (140).

Thyroid hormone has also been used in pediatric patients with radiation-induced thyroid nodules in which the formation

of subsequent nodules has been shown to be reduced (148,149). It is not clear if this data can be extrapolated to pediatric patients with spontaneous nodules, and LT₄ therapy had no effect on the incidence of thyroid cancer (148).

Whether LT₄ therapy is used or not, an increase in nodule size is more commonly associated with malignant disease and should prompt re-evaluation and/or surgical resection (see Section B9). Alternatives to surgery have been evaluated in adults, but they have not yet been evaluated in children and their use cannot be recommended.

■ RECOMMENDATION 7

We are unable to recommend for or against the routine use of LT₄ therapy for children with benign thyroid nodules. In general, the data support the efficacy of LT₄ therapy to reduce the size and risk of subsequent nodule formation, but there are no data to weigh this potential benefit against the potential risks of long-term suppression therapy. In patients with compressive symptoms or a history of radiation exposure the benefits of LT₄ therapy may be more apparent.

Recommendation rating: I

[B9] Is There a Role for Surgery in Children with Benign Nodules?

For the subset of children who have benign cytopathology, surgery may be considered due to increasing size, compressive symptoms, cosmetic reasons, or patient/parent choice. For growing nodules (defined in adults as a $\geq 50\%$ increase in volume or $\geq 20\%$ increase in at least two dimensions) or nodules that have developed suspicious US characteristics, repeat FNA should be performed prior to surgery to assist with surgical planning and preoperative staging. FNA of nodules > 4 cm appears to have decreased sensitivity for the diagnosis of malignancy (27,135–137). Given the high false-negative rate of FNA in large lesions, and also to simplify long-term follow-up, surgery should be considered for FNA-documented benign nodules > 4 cm, especially if they are solid. If surgery is undertaken, lobectomy is preferred to minimize the risk for complications.

■ RECOMMENDATION 8

Benign lesions should be followed by serial US (see Fig. 1) and undergo repeat FNA if suspicious features develop or the lesion continues to grow. Lobectomy may be performed in patients with compressive symptoms and cosmetic concerns or according to patient/parent preference and should be considered in all apparently benign solid thyroid nodules > 4 cm, those lesions demonstrating significant growth, or in the presence of other clinical concerns for malignancy.

Recommendation rating: B

[B10] What Is the Optimal Management of the Child with an Autonomous Thyroid Nodule?

Pediatric patients are occasionally found to have an autonomously functioning nodule (toxic adenoma) diagnosed by a suppressed TSH and increased, nodule-specific uptake on nuclear medicine radioisotope scan (^{99m}Tc pertechnetate

or iodine-123 [^{123}I] (150,151). These lesions are most frequently associated with somatic activating mutations within the genes encoding the TSH receptor or the G_s-alpha subunit (151). On examination, children are either euthyroid or may have mild signs or symptoms of hyperthyroidism.

In adults, the treatment options for autonomous nodules include ^{131}I ablation, surgical resection, or ethanol injection. Because of concerns of the mutagenic effect of low-activity radioiodine on the normal thyroid tissue, and reports that up to one third of patients may be found to have an incidentally discovered DTC associated with autonomous nodules (150), surgical resection is the usual recommendation for most pediatric patients because the safety of observation or alternative treatments is unstudied in children. However, in asymptomatic patients with an autonomous nodule and subclinical hyperthyroidism, surgery may be deferred, but FNA should be considered if the nodule has features suggestive of PTC.

■ RECOMMENDATION 9

For pediatric patients with a suppressed TSH associated with a thyroid nodule, thyroid scintigraphy should be pursued. Increased uptake within the nodule is consistent with autonomous nodular function. Surgical resection, most commonly lobectomy, is the recommended approach for most autonomous nodules in children and adolescents.

Recommendation rating: A

[C1] PAPILLARY THYROID CANCER—INITIAL MANAGEMENT GUIDELINES

[C2] What Is the Optimal Preoperative Evaluation for the Child with Newly Diagnosed PTC?

The preoperative evaluation of the newly diagnosed pediatric PTC patient is critical for optimizing surgical outcome and medical therapy. In all cases, a comprehensive neck US using a high-resolution probe (7.5 MHz or higher) and Doppler technique should be obtained by an experienced ultrasonographer. All regions of the neck should be interrogated, recognizing that US has decreased sensitivity to identify malignant lymphadenopathy in the central neck (level VI) (152,153). A complete US examination should be performed prior to surgery if it was not performed with the FNA. The goal is to identify locoregional metastatic disease otherwise not appreciated on physical examination (154–157).

Given the very high rate of cervical lymph node metastases in children with PTC, the preoperative identification of suspicious lymph nodes affords the surgeon an opportunity to more thoughtfully plan comprehensive, compartment-oriented, lymph node dissection during the initial surgery with the intent to decrease recurrence rates and the need for additional surgery (154,157). In patients with large or fixed thyroid masses or bulky metastatic lymphadenopathy, US may be less sensitive at detecting metastatic disease to deep tissue regions, such as the superior mediastinum (level VII), the retropharyngeal, parapharyngeal, and subclavicular spaces (152,153). The addition of cross-sectional imaging using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), depending on local

expertise and preference, should be considered, especially if there is any concern for invasion of the aero-digestive tract (158–161). If iodinated contrast agents are used, further evaluation and treatment with RAI may need to be delayed for 2–3 months until total body iodine burden decreases. The advantage of CT over MRI is that CT has shorter image acquisition times, making scheduling more accessible and reducing the need for conscious sedation in younger patients.

A chest x-ray and/or chest CT may be considered in those with substantial cervical lymph node disease, in whom the prevalence of lung metastases is increased (9,10,24,65,162,163). Pediatric-specific protocols should be used to minimize ionizing radiation exposure. Routine chest CT is not recommended for patients with minimal neck disease because pulmonary metastases are likely to be identified when the child is subsequently staged with a stimulated Tg and diagnostic whole-body scan (DxWBS) (see Section C8) (24,49,164–166).

Thyroid nuclear scintigraphy for the evaluation of newly diagnosed PTC should only be pursued if the patient presents with a suppressed TSH. Decreased uptake on thyroid scintigraphy is nonspecific for thyroid malignancy (119). Additionally, the task force does not recommend the routine use of additional imaging (e.g., bone scan or [¹⁸F]-fluoro-deoxyglucose positron emission tomography/computed tomography [¹⁸FDG-PET/CT]) in the evaluation of children for PTC. These studies are not validated in this setting and the likelihood of finding disease in an otherwise asymptomatic patient is low and nonspecific (see Section D5).

■ RECOMMENDATION 10

A comprehensive neck US to interrogate all regions of the neck is required in order to optimize the preoperative surgical plan. FNA of suspicious lateral neck lymph nodes is recommended (see Recommendation 13). Anatomic imaging by MRI or CT with contrast should be considered in patients with large or fixed thyroid masses, vocal cord paralysis, or bulky metastatic lymphadenopathy in order to optimize surgical planning.

Recommendation rating: A

[C3] What Is the Recommended Surgical Approach for the Patient with a Diagnosis of PTC?

For the majority of patients with PTC, total thyroidectomy (TT) is the recommended initial surgical approach. In this procedure, the left and right thyroid lobes, the pyramidal lobe (when present), and the isthmus are resected. Alternatively, in patients with a small unilateral tumor confined to the thyroid gland, a near-TT, whereby a small amount of thyroid tissue (<1%–2%) is left in place at the entry point of the recurrent laryngeal nerve (RLN) and/or superior parathyroid glands, might be considered in an effort to decrease the risk of permanent damage to these structures. This recommendation for more comprehensive thyroid surgery in pediatric patients is based on data showing an increased incidence of bilateral and multifocal disease (30% and 65%, respectively) (11,14,47,52,167), as well as an increased risk for recurrence and subsequent second surgical procedures when less than a near-TT or TT is performed (5,14,15,44,47,51,168). In long-term analysis of 215 pedi-

atric patients with PTC, bilateral lobar resection compared with lobectomy was shown to decrease the incidence of local recurrence from 35% to 6% over 40 years of follow-up (5). Bilateral thyroid surgery also optimizes the use of RAI for imaging and/or treatment and Tg as a marker to detect persistent/recurrent disease (8,169–171). Using an intracapsular approach, the superior parathyroid glands may be most easily preserved by maintaining arterial inflow and venous drainage (172–174).

■ RECOMMENDATION 11

For the majority of children, TT is recommended. The rationale for this approach is based on multiple studies showing an increased incidence of bilateral and multifocal disease. In long-term analysis, bilateral lobar resection compared with lobectomy has been shown to decrease the risk for persistent/recurrent disease.

Recommendation rating: A

[C4] Should Central Neck Dissection Be Performed?

In patients with preoperative evidence of central and/or lateral neck metastasis, a therapeutic central neck dissection (CND) should be performed. For this subgroup of patients, who are also at increased risk of pulmonary metastases (10,14,65), CND is associated with a decreased risk of persistent/recurrent locoregional disease as well as the potential to increase the efficacy of ¹²⁵I treatment for distant metastases (14,15,22,47,48).

The increased incidence of cervical metastasis in children suggests that prophylactic CND, as defined in the 2009 ATA consensus statement on the terminology and classification of CND for thyroid cancer (175), should be considered at the time of initial surgery for pediatric patients with PTC. This is particularly relevant given that decreased disease-free survival (DFS) is most strongly correlated with the presence of persistent or recurrent locoregional disease (5,13–15,22,47,52).

Unfortunately, there are no data that reliably predict which subgroup of patients is at increased risk for locoregional metastasis. Larger tumor size (>4 cm) has been shown to correlate with an increased risk of lymph node metastases (10,11,176). However, up to 36% of tumors ≤4 cm have cervical lymph node metastasis (10). In addition, several of the panel experts have cared for children with regional metastasis found in children with primary tumors ≤1 cm in size. In adults, these tumors are labeled papillary thyroid microcarcinoma (PTMC) and scoring systems have been described to predict the likelihood of metastasis (177). However, the thyroid volume is smaller in young children so that the size criteria used for tumor staging (see Section B4), as well as the diagnosis of PTMC, may not apply to children (178).

While data suggest that pediatric patients with thyroid cancer typically have 100% 10-year disease-specific survival (5,8,162,179), the extent of initial surgery appears to have the greatest impact on improving long-term DFS (5,47). However, without long-term, prospective data and a reliable set of criteria to stratify which patients would benefit from more aggressive surgical resection, one must weigh the risks of more aggressive surgery with the potential benefit of decreasing the incidence of persistent/recurrent disease.

The limited data suggest that, in children, TT with prophylactic CND is associated with increased DFS, as high as 95% at 5 and 10 years (46,163). However, the data are mixed and possibly related to the use of adjunctive RAI remnant ablation. In a retrospective study examining 75 children with PTC, 80% of whom underwent TT with ¹³¹I remnant ablation, the type and extent of neck dissection did not impact the risk for locoregional or distant metastasis (15). Conversely, another study suggested that TT with prophylactic CND may reduce the risk for reoperation that was as high as 77% in those without CND (44). Some groups suggest routinely considering a prophylactic CND, particularly for larger tumors (1,180,181), whereas others suggest making this decision based upon intraoperative findings (182).

If and when performed, CND should only be performed by a surgeon highly experienced in the procedure. To reduce the risk of recurrence, a comprehensive and compartment-based lymph node dissection should be pursued rather than “berry picking” (183). In patients with unifocal disease, data from adult patients suggest that ipsilateral, prophylactic CND may provide the same potential benefit while decreasing the higher complication rate associated with bilateral CND (184). During ipsilateral CND, the incorporation of frozen section to stratify which patients should undergo contralateral (complete) prophylactic CND may achieve a balance between the potential risks and benefits of this procedure (185).

With these considerations in mind, the following recommendations are made in an attempt to balance the goal of achieving surgical remission with the potential increased risk of complications that may be unnecessary for patients with minimal or no locoregional metastasis.

■ RECOMMENDATION 12(A)

CND is recommended for children with malignant cytology and clinical evidence of gross extrathyroidal invasion and/or locoregional metastasis on preoperative staging or intraoperative findings. This approach may be associated with a decreased need for second surgical procedures and increased DFS.

Recommendation rating: B

■ RECOMMENDATION 12(B)

For patients with PTC and no clinical evidence of gross extrathyroidal invasion and/or locoregional metastasis, prophylactic CND may be selectively considered based upon tumor focality and size and the experience of the surgeon. For patients with unifocal disease, ipsilateral CND, with pursuit of contralateral CND based on intraoperative findings, may help balance the risks and benefits.

Recommendation rating: C

■ RECOMMENDATION 12(C)

Compartment-oriented resection is the recommended approach for lymph node dissection. Berry picking and attempting to use palpation to determine if metastatic disease is present in a lymph node are not recommended.

Recommendation rating: A

■ RECOMMENDATION 12(D)

Future studies to assess if TT with prophylactic CND dissection will lead to reduced reliance on ¹³¹I treatment, re-operative procedures, and improved DFS are recommended.

Recommendation rating: C

[C5] What Are the Indications for Lateral Neck Dissection?

Pediatric patients occasionally present with bulky disease to the lateral neck and may have suspicious lymph nodes in the lateral neck on preoperative US imaging. US findings suggestive of metastasis to a lymph node include increased size, rounded shape, loss of central hilum, cystic appearance, peripheral vascularity on Doppler imaging, and microcalcifications (186), with the latter two features having the highest specificity for malignancy (113). The US appearance of the lymph nodes may be considered sufficient evidence to pursue lateral lymph node dissection; however, in patients undergoing surgery, FNA to confirm metastasis to the lateral neck lymph nodes should be performed prior to lateral neck dissection. The addition of a Tg measurement in the FNA washout fluid may be used to confirm equivocal cytological evidence of metastatic disease, even in the presence of serum anti-Tg antibodies (TgAb) (187–191) (see Section D2). When indicated, compartment-oriented lateral neck dissection (levels III, IV, anterior V, and II) is associated with a reduction in persistent/recurrent disease and improved DFS (10,14,47).

■ RECOMMENDATION 13

Cytological confirmation of metastatic disease to lymph nodes in the lateral neck is recommended prior to surgery. Routine prophylactic lateral neck dissection (levels III, IV, anterior V, and II) is not recommended. However, lateral neck dissection should be performed on patients with cytologic evidence of metastases to the lateral neck. Measurement of Tg in the FNA washout can be considered if the cytological diagnosis is equivocal.

Recommendation rating: B

[C6] What Are the Possible Complications of Surgery and What Should Be Done to Minimize the Risks of Surgery?

The lower incidence of thyroid disease requiring surgical intervention in children combined with a higher incidence of locoregional lymph node metastasis has been associated with an increased risk of complications for pediatric patients undergoing TT. Utilizing high-volume thyroid surgeons, defined as a surgeon who performs 30 or more cervical endocrine procedures annually, can reduce the rate of complications (70,71). In a cross-sectional analysis of over 600 pediatric patients undergoing thyroid surgery, there were fewer general complications (8.7% vs. 13.4%) and endocrine complications (5.6% vs. 11%) when the procedures were performed by high-volume surgeons (71). In addition, the duration of stay and cost were significantly lower when the procedure was performed by a high-volume surgeon (71).

The most common complications after thyroidectomy are endocrine related and include transient or permanent hypoparathyroidism, with an average rate of approximately 5%–15%. In a high-volume tertiary endocrine surgical practice, the risk of permanent hypoparathyroidism is <2.5% (72). Surgery specific, non-endocrine-related complications include RLN damage, spinal accessory nerve injury, and Horner syndrome, with an average rate of 1%–6% (10,13,46,47,70,72). In patients younger than 10 years of age, there is an increased risk of complications associated with the presence of ETE, lymph node dissection, and repeat surgery (10,70,168).

The risk of hypoparathyroidism correlates with the extent of surgery. Even in patients in whom the parathyroid glands are identified and viability of gland function is likely, manipulation of the parathyroid glands may lead to transient or permanent hypoparathyroidism. Auto-transplantation of parathyroid tissue after frozen-section confirmation is utilized if there is any concern of devitalization, and it is associated with a decreased risk of permanent hypoparathyroidism (192,193). Postoperatively, several approaches can predict which patients are at an increased risk of developing hypocalcemia, including serial measurements of serum calcium (194) as well as measurement of a peri-operative intact parathyroid hormone (iPTH) level. The utility of postoperative iPTH is fairly well established with a level of <10–15 pg/mL correlating with an increased risk to develop clinically significant hypocalcemia (195,196). An elevated postoperative serum phosphorus may also be predictive (197). The use of peri-operative iPTH and/or phosphorus monitoring may decrease morbidity and allow for stratification of patients who would benefit from more intensive monitoring and treatment with calcium and calcitriol. An alternative to this approach is to place all patients who have undergone TT, especially those who undergo concomitant CND, on empiric calcium with or without calcitriol replacement therapy.

No monitoring devices have been shown to decrease the rate of non-endocrine surgical complications. The use of intraoperative RLN monitoring may be considered as an adjunct monitoring device and may be considered for younger patients (<10 years of age), in patients undergoing CND, and in patients undergoing repeat surgical procedures. However, the use of RLN monitoring has not been clearly shown to lower the incidence of RLN damage (198).

■ RECOMMENDATION 14(A)

Pediatric thyroid surgery should be performed in a hospital with the full spectrum of pediatric specialty care, to include, but not be limited to endocrinology, radiology (US and anatomic imaging), nuclear medicine, anesthesia, a high-volume thyroid surgeon, and intensive care. Pediatric thyroid surgery, especially if compartment-focused lymph node resection is indicated, should ideally be performed by a surgeon who performs at least 30 or more cervical endocrine procedures annually. Thyroid surgery performed under these guidelines is associated with lower complications rates, decreased hospital stay, and lower cost.

Recommendation rating: B

■ RECOMMENDATION 14(B)

The early incorporation of calcium and calcitriol in patients at high risk for hypocalcemia may decrease the risks of symptomatic hypocalcemia. Postoperative iPTH measurement may be used to help predict which patients would benefit from more intensive monitoring and treatment.

Recommendation rating: B

[C7] What Tumor Classification Systems Can Be Used for Pediatric PTC?

No single postoperative staging system has been validated in children with PTC, and the utility of extrapolating adult staging systems into the pediatric setting is limited by the observed clinical disparity between the two age groups. Specifically, the age-metastasis-extent of disease-size of tumor (AMES) and metastasis-age-completeness of resection-invasion-size (MACIS) have been examined, but the data are limited and the utility of these staging systems in pediatric patients with PTC remains unclear (176, 199). The AJCC TNM classification system (Table 5) is the most widely used system for describing the extent of disease and prognosis in the adult population (69). However, due to the extremely low disease-specific mortality in children with PTC and the fact that all patients aged <45 years have either stage I (no distant metastases) or stage II disease (with distant metastases), the TNM classification system remains limited in terms of determining prognosis in children. Despite this, the TNM classification is an excellent system with which to describe the extent of disease as well as to stratify an approach to evaluation and management. Especially useful to risk-stratify the pediatric PTC patient is knowledge regarding lymph node status. Children with PTC who have gross cervical lymph node disease at diagnosis are more likely to have multifocal disease (89% vs. 16%), an increased incidence of pulmonary metastasis (20% versus none), and increased persistent (30% versus none) and/or recurrent (53% versus none) disease compared with children without palpable nodal disease (53,65).

Therefore, using the TNM classification system, specifically regional lymph node and distant metastasis staging, one can categorize pediatric patients into one of three risk groups. This categorization strategy does not define the risk of mortality (which is low for both stage I and II patients) but identifies patients at risk of persistent cervical disease and helps to determine which patients should undergo postoperative staging to screen for the presence of distant metastasis (Table 6 and Section C8). These three groups are

1. ATA Pediatric Low-Risk

Disease grossly confined to the thyroid with N0 or NX disease or patients with incidental N1a metastasis in which “incidental” is defined as the presence of microscopic metastasis to a small number of central neck lymph nodes. These patients appear to be at lowest risk for distant metastasis but may still be at risk for residual cervical disease, especially if the initial surgery did not include a CND.

2. ATA Pediatric Intermediate-Risk

Extensive N1a or minimal N1b disease. These patients appear to be at low risk for distant metastasis but are at

TABLE 5. AMERICAN JOINT COMMITTEE ON CANCER TNM CLASSIFICATION SYSTEM FOR DIFFERENTIATED THYROID CARCINOMA^a

Primary tumor (T)		
TX		Size not assessed, limited to the thyroid
T1	T1a	≤ 1 cm, limited to the thyroid
	T1b	> 1 cm but ≤ 2 cm, limited to the thyroid
T2		> 2 cm but ≤ 4 cm, limited to the thyroid
T3		> 4 cm, limited to the thyroid, or any tumor with minimal extrathyroid extension
T4	T4a	Tumor extends beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
	T4b	Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels
Lymph nodes (N)		
NX		Regional lymph nodes not assessed
N0		No regional lymph node metastasis
N1	N1a	Metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/ Delphian lymph nodes)
	N1b	Metastasis to unilateral, bilateral, or contralateral cervical levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (level VII)
Distant metastasis (M)		
MX		Distant metastasis not assessed
M0		No distant metastasis
M1		Distant metastasis

^aPediatric patients are considered to have stage II disease if distant metastases are identified (M1); otherwise, all pediatric patients are considered to have stage I disease.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 7th edition (2010) published by Springer Science and Business Media LLC, www.springer.com (69).

an increased risk for incomplete lymph node resection and persistent cervical disease.

The impact of the pathologic identification of microscopic (ETE) (T3 disease) on management and outcomes has not been well studied in children with PTC, but patients with minimal ETE are probably either ATA Pediatric Low- or Intermediate-Risk, depending on other clinical factors.

3. ATA Pediatric High-Risk

Regionally extensive disease (extensive N1b) or locally invasive disease (T4 tumors), with or without distant metastasis. Patients in this group are at the highest risk for incomplete resection, persistent disease, and distant metastasis.

■ RECOMMENDATION 15(A)

The AJCC TNM classification system should be used to describe the extent of disease in pediatric patients with PTC (Table 5). Children with PTC should be stratified into risk levels (ATA Pediatric Low-, Intermediate-, or High-Risk) based on clinical presentation, tumor size, and evidence of regional invasion and metastasis (Table 6). The extent of disease in the neck at diagnosis appears to correlate best with the risk for distant metastasis and/or persistent disease that may require additional treatment.

Recommendation rating: B

■ RECOMMENDATION 15(B)

Patients found to have disease confined to the thyroid gland, as well as incidental evidence of minimal, microscopic disease to lymph nodes in the central neck (level VI), fall into the ATA Pediatric Low-Risk level (Table 6).

The presence of extensive, extrathyroidal invasion or metastasis defines patients at greater risk for persistent regional or distant metastasis. Patients with these features are categorized within the ATA Pediatric Intermediate- or High-Risk levels (Table 6). Within these categories, additional postoperative staging is warranted to better define which patients may or may not benefit from additional therapy.

Recommendation rating: B

[C8] What Postoperative Staging Is Recommended?

For most patients, initial staging (Fig. 2) is typically performed within 12 weeks postoperatively. This affords the patient and family time to recover from surgery, while at the same time avoiding delay in additional therapy, if needed. The purpose of postoperative staging is to assess for evidence of persistent locoregional disease and to identify patients who are likely to benefit from additional therapy with ¹³¹I, such as those suspected or known to have distant metastases. The individual patient's risk level (Table 6) helps to determine the extent of postoperative testing. While the committee recognizes that no prospective studies have been performed to validate a stratified risk-based approach in children with PTC, an individualized approach incorporating pathologic findings and postoperative clinical data is founded on well-accepted approaches to therapy in adults (1,3) as well as personal experience in certain pediatric practices (200). The foundation of this stratification system for pediatric patients, however, assumes complete and accurate preoperative staging for regional disease (see Section C2) and appropriate surgery that is performed by a high-volume thyroid cancer surgeon.

TABLE 6. AMERICAN THYROID ASSOCIATION PEDIATRIC THYROID CANCER RISK LEVELS AND POSTOPERATIVE MANAGEMENT IN CHILDREN WITH PAPILLARY THYROID CARCINOMA

ATA pediatric risk level ^a	Definition	Initial postoperative staging ^b	TSH goal ^c	Surveillance of patients with no evidence of disease ^d
Low	Disease grossly confined to the thyroid with N0/Nx disease or patients with incidental N1a disease (microscopic metastasis to a small number of central neck lymph nodes)	Tg ^e	0.5–1.0 mIU/L	US at 6 months postoperatively and then annually × 5 years Tg ^e on LT ₄ every 3–6 months for 2 years and then annually
Intermediate	Extensive N1a or minimal N1b disease	TSH-stimulated Tg ^e and diagnostic ¹²³ I scan in most patients (see Fig. 2)	0.1–0.5 mIU/L	US at 6 months postoperatively, every 6–12 months for 5 years, and then less frequently Tg ^e on LT ₄ every 3–6 months for 3 years and then annually Consider TSH-stimulated Tg ^e ± diagnostic ¹²³ I scan in 1–2 years in patients treated with ¹³¹ I
High	Regionally extensive disease (extensive N1b) or locally invasive disease (T4 tumors), with or without distant metastasis	TSH-stimulated Tg ^e and diagnostic ¹²³ I scan in all patients (see Fig. 2)	<0.1 mIU/L	US at 6 months postoperatively, every 6–12 months for 5 years, and then less frequently Tg ^e on LT ₄ every 3–6 months for 3 years and then annually TSH-stimulated Tg ^e ± diagnostic ¹²³ I scan in 1–2 years in patients treated with ¹³¹ I

Please refer to Table 5 for AJCC TNM classification system.

^a“Risk” is defined as the likelihood of having persistent cervical disease and/or distant metastases after initial total thyroidectomy ± lymph node dissection by a high volume thyroid surgeon and is not the risk for mortality, which is extremely low in the pediatric population. See Section C7 for further discussion.

^bInitial postoperative staging that is done within 12 weeks after surgery.

^cThese are initial targets for TSH suppression and should be adapted to the patient’s known or suspected disease status; in ATA Pediatric Intermediate- and High-risk patients who have no evidence of disease after 3–5 years of follow-up, the TSH can be allowed to rise to the low normal range.

^dPostoperative surveillance implies studies done at 6 months after the initial surgery and beyond in patients who are believed to be disease free; the intensity of follow-up and extent of diagnostic studies are determined by initial postoperative staging, current disease status, and whether or not ¹³¹I was given; may not necessarily apply to patients with known or suspected residual disease (see Fig. 3) or FTC.

^eAssumes a negative TgAb (see Section D2); in TgAb-positive patients, consideration can be given (except in patients with T4 or M1 disease) to deferred postoperative staging to allow time for TgAb clearance.

ATA, American Thyroid Association; LT₄, levothyroxine; TgAb, thyroglobulin antibody; US, ultrasound.

For ATA Pediatric Low-risk patients, initial postoperative staging includes a TSH-suppressed Tg. The interpretation of serum Tg and most importantly, interpretation of the trend in serum Tg over time are summarized in Section D2.

In contrast, for ATA Pediatric Intermediate- and High-Risk patients, a TSH-stimulated Tg and DxWBS are generally recommended for further risk stratification and determination of treatment with ¹³¹I (Fig. 2). Children who fall into the ATA Pediatric Intermediate- and High-Risk categories are prepared following standard guidelines for ¹³¹I therapy (see Section C12), and the TSH-stimulated Tg and DxWBS data are used to assess for evidence of residual disease (Fig. 2). In patients without evidence of TgAb, the TSH-stimulated Tg is a reliable marker for evaluating for the presence or absence of residual disease (see Section D2). In a recent study examining 218 consecutive adult DTC patients across all ATA risk stratifi-

cation levels, a TSH-stimulated Tg <2 ng/mL had a 94.9% predictive value for the absence of disease (201).

Whether a DxWBS might image disease that is not identified through neck US is a matter of debate and few data in children address this. In one pediatric study, US and DxWBS equally identified lymph node metastases in the majority of patients (35/45); however, in six patients, lymph node metastases were found only with a posttreatment RAI WBS (202). Two of the patients were TgAb positive, reinforcing the potential benefit of DxWBS in patients who are TgAb positive (202,203). DxWBS may also visualize disease in the lungs or mediastinum that would not otherwise be shown by neck US or other cross-sectional imaging (49).

For patients with cervical iodine uptake, the addition of hybrid imaging using single photon emission computed tomography with integrated conventional CT (SPECT/CT)




FIG. 2. Initial postoperative staging for American Thyroid Association pediatric intermediate- and high-risk pediatric thyroid carcinoma. ¹Assumes a negative TgAb (see Section D2) and a TSH >30 mIU/L; in TgAb-positive patients, consideration can be given (except in patients with T4 tumors or clinical M1 disease) to deferred evaluation to allow time for TgAb clearance (“delayed” staging). ²Imaging includes neck ultrasonography ± SPECT/CT at the time of the diagnostic thyroid scan. ³Consider ¹³¹I in patients with thyroid bed uptake and T4 tumors or known residual microscopic cervical disease. ⁴While there are no prospective studies in patients ≤ 18 years of age, the use of ¹³¹I remnant ablation may not decrease the risk for persistent or recurrent disease. Consider surveillance rather than ¹³¹I with further therapy determined by surveillance data. ⁵Repeat postoperative staging 3–6 months after surgery. ⁶See Table 6 and Figures 3 and 4.

offers improved anatomic imaging to determine whether cervical uptake is secondary to remnant thyroid tissue or metastasis to regional lymph nodes (204–206).

A potential drawback of DxWBS imaging is that if ¹³¹I is used, the small diagnostic activity may theoretically “stun” the iodine-avid tissue and reduce subsequent ¹³¹I uptake if high-activity ¹³¹I treatment is then used (207,208). This issue can be reduced by selecting the lowest possible activity of ¹³¹I (2.7–4.0 mCi = 100–148 MBq) (209) or by using ¹²³I (207,210). Due to its lower cost, ¹³¹I is more commonly used, but ¹²³I provides superior imaging quality and generates lower absorbed doses of radiation to the tissues (207,211), which favors its use in children.

Taken together, postoperative staging is used to further stratify which children may or may not benefit from additional treatment with surgery and/or RAI therapy. Irrespective of initial risk stratification, all patients will enter surveillance, ensuring that appropriate therapy will be given if evidence of disease is ultimately identified. As long as the patient is maintained on tailored LT₄ suppression and a proper surveillance plan is followed (Table 6, Fig. 2), delayed treatment is not expected to alter the already low disease-specific mortality due to the indolent nature of PTC in children. Furthermore, a more individualized and conservative approach to postoperative staging and treatment will de-

crease unnecessary exposure to ¹³¹I in children without evidence of disease, in whom the risks of routine ¹³¹I therapy likely outweigh any benefit. Because of the lack of high-level evidence to help guide these difficult medical decisions, families should be fully informed about the options and their risks/benefits as the surveillance and treatment plans are being formulated.

■ RECOMMENDATION 16

Postoperative staging is usually performed within 12 weeks after surgery (Fig. 2) and allows for stratification of patients who may or may not benefit from further therapy, to include additional surgery or ¹³¹I therapy. ATA Pediatric Low-Risk patients may be initially assessed and followed with a TSH-suppressed Tg alone. In contrast, a TSH-stimulated Tg and a DxWBS is typically recommended to assess for evidence of persistent disease in ATA Pediatric Intermediate- and High-Risk patients. Additional imaging, to include neck US and/or hybrid imaging using SPECT/CT, may be used conjunctively to more accurately define the anatomic location of RAI uptake noted on a DxWBS. Whenever possible, ¹²³I should be used for the DxWBS.

Recommendation rating: B

[C9] What Are the Goals of ¹³¹I Treatment?

The traditional approach to managing pediatric patients with DTC included reflexive postsurgical ¹³¹I therapy, which was prescribed in an effort to eliminate residual thyroid tissue in order to increase the sensitivity for using serum Tg as a biomarker for recurrent disease. In addition, ¹³¹I was prescribed in an effort to decrease the risk of recurrent disease (see Section C10).

The goal of ¹³¹I therapy is to decrease the risks of thyroid cancer recurrence and theoretically to improve mortality by eliminating iodine-avid disease. RAI was proposed as a specific treatment for DTC in 1946 after an adult with functional thyroid cancer metastases responded to multiple RAI treatments (212), and ¹³¹I therapy has since been broadly incorporated into treatment protocols for both adults and children (1,213). A recent survey indicates that use of therapeutic ¹³¹I for all thyroid cancers, regardless of tumor size, has increased from 1990 to 2008 (214).

With increased awareness of the potential long-term side effects of ¹³¹I treatment (see Section C16), there are increased efforts to identify patients who have a high likelihood of benefit from therapy. Unfortunately, the majority of available data are based on a nonstratified approach in which all children underwent TT and variable extent of lymph node dissection, and the majority received therapeutic ¹³¹I. The challenge is to reduce or eliminate unnecessary ¹³¹I exposure for children who may not benefit without increasing disease-specific morbidity and mortality. The following sections address various aspects of this question.

[C10] What Is the Impact of ¹³¹I Therapy on Recurrence and Survival for Children with PTC?

Adjunctive ¹³¹I therapy may improve DFS in young adults (including some adolescents) but this has not been universally shown for those with small, stage I lesions (215). Reflective of this, the 2009 ATA guidelines and the current NCCN guidelines support the selective rather than universal administration of ¹³¹I, especially for young patients (<45 years of age) with intrathyroidal PTC and either no or limited lymph node disease (1,3).

Studies specifically examining the potential benefits of ¹³¹I therapy in children have been difficult to perform because the number of patients is small and the prognosis is favorable, regardless of adjunctive therapy (11,169,216,217). Arguments in favor of universal therapeutic ¹³¹I for children have been based on the observation that retention of the normal thyroid remnant may decrease the sensitivity for detecting metastases or recurrent disease by serum Tg and/or DxWBS (218,219). Arguments against the universal prescription of therapeutic ¹³¹I are based on the known short- and long-term toxicities (220), lack of data showing conclusive benefit from routine ¹³¹I therapy (5,13), a possible increase in the risk of secondary malignancies (5–7,221,222), and studies showing that Tg can remain useful and become undetectable in patients post TT despite not having received ¹³¹I (223–225).

Most of the data regarding ¹³¹I use in children have examined treatment of known residual disease rather than ablation of the normal thyroid remnant only (9). In patients with known residual disease, ¹³¹I therapy appears to decrease

recurrence (9,43,51,162,226). However, large retrospective series in children show conflicting results regarding the potential for benefit from adjunctive ¹³¹I. In one study, ¹³¹I remnant ablation did not clearly decrease the risk for locoregional recurrence, distant metastases, or all-sites recurrence compared with surgery alone, but there was a trend toward reduction in the risk of distant metastases ($p=0.06$) (5). Unfortunately, overall survival was reduced in patients who had received external beam therapy, radium implants, or ¹³¹I, primarily secondary to an increase in nonthyroid, second malignancies. Another study also found no improvement in DFS following remnant ablation (13), but additional studies revealed a significant improvement in DFS for children with PTC treated with ¹³¹I and no clear increase in the risk of second primary malignancies (169).

[C11] Which Children Might Benefit from Therapeutic ¹³¹I?

¹³¹I is indicated for treatment of nodal or other locoregional disease that is not amenable to surgery as well as distant metastases that are known or presumed to be iodine-avid (169). In addition, some experts also advocate routine ¹³¹I therapy for children with T3 tumors or extensive regional nodal involvement (extensive N1a or N1b disease) (9,169).

Published studies show that children with iodine-avid pulmonary metastases benefit from ¹³¹I treatment, and complete remission is achievable for many patients, particularly those with microscopic and small-volume lung disease (9,57,58,162,227). Thus, for patients with pulmonary metastases, ¹³¹I is considered therapeutic, with the understanding that increasing burden of disease may ultimately require administration of multiple activities (57) (see Section D8).

■ RECOMMENDATION 17

¹³¹I is indicated for treatment of iodine-avid persistent locoregional or nodal disease that cannot be resected as well as known or presumed iodine-avid distant metastases. For patients with persistent disease following ¹³¹I administration, the decision to pursue additional ¹³¹I therapy should be individualized according to clinical data and previous response (see Fig. 3 and 4). The potential risks and benefits must be weighed on an individual basis.

Recommendation rating: B

[C12] How Should a Child Be Prepared for ¹³¹I?

If ¹³¹I is prescribed, the TSH should be above 30 mIU/L to facilitate uptake (21,228,229). The majority of children will achieve this level of TSH by ≥ 14 days of LT₄ withdrawal (230). For that reason, triiodothyronine supplementation during LT₄ withdrawal is not usually required but can be considered for children who are especially sensitive to hypothyroid symptoms or if the withdrawal period extends beyond 3 weeks.

Recombinant human TSH (rhTSH) has been used for remnant ablation as well as for treatment of intermediate- and high-risk DTC in adults (231–233) and may result in a lower absorbed radiation activity to the blood (as much as one third lower) (234). However, data regarding the use of rhTSH in




FIG. 3. Management of the pediatric patient with known or suspected residual/recurrent disease (no known distant metastases). This algorithm is intended to be used in children who are known or suspected to have residual or recurrent disease based upon the suppressed Tg level and knowledge of previous disease extent 6–12 months after all primary therapies have been completed. ¹Assumes a negative TgAb (see Section D2); in TgAb-positive patients, the presence of TgAb alone cannot be interpreted as a sign of disease unless the titer is clearly rising. ²Imaging includes SPECT/CT at the time of the diagnostic thyroid scan and/or contrast-enhanced CT/MRI neck. ³Repeat ¹³¹I therapy in patients previously treated with high-dose ¹³¹I should generally be undertaken only if iodine-avid disease is suspected and a response to previous ¹³¹I therapy was observed (see Sections D7 and D8).

children are limited (235,236). Experience in children would suggest that the typical adult dose of rhTSH (two doses of 0.9 mg given 24 hours apart) appears to be safe and generates sufficient TSH levels (169,236,237). In particular, rhTSH might have a role in situations in which endogenous hypothyroidism should be avoided (e.g., significant medical comorbidities) or is impossible (e.g., TSH deficiency) (169,236).

To facilitate RAI uptake, a low-iodine diet is generally prescribed for 2 weeks prior to therapy, but the efficacy of this practice in children has not been specifically demonstrated. Nevertheless, a low-iodine diet has been shown to increase the effective radiation dose to the thyroid by 50%–150% in adults (238). For that reason, a low-iodine diet is commonly recommended. In children who received intravenous contrast during preoperative staging, it is advisable to wait approximately 2–3 months or to confirm normal (median normal 24-hour urine iodine excretion = 143 μ g/24 hour, 5%–95% range = 75–297 μ g/24 hour) (239) or low 24-hour urine iodine values before performing either a DxWBS or administering therapeutic ¹³¹I.

RECOMMENDATION 18

In order to facilitate ¹³¹I uptake by residual iodine-avid cancer, the TSH level should be above 30 mIU/L. This can be achieved in almost all children by withdrawing LT₄ for \geq 14 days. In selected patients who cannot mount an adequate TSH response or cannot tolerate profound hypothyroidism, rhTSH may be considered. Low-iodine diets have not been specifically evaluated in children but may enhance the effective radiation activity of ¹³¹I and are recommended.

Recommendation rating: A

[C13] What Should Be Considered for Administration of ¹³¹I?

General guidelines for safety in the administration of ¹³¹I were reviewed by the ATA Task Force on Radiation Safety in 2011 (240). There are few specific references to children, but the overall document pertains to children as well as adults. Once the decision to administer ¹³¹I is made, the safety of




FIG. 4. Management of the pediatric patient with known distant metastases. ¹Assumes a negative TgAb (see Section D2); in TgAb-positive patients, the presence of TgAb alone cannot be interpreted as a sign of disease unless the titer is clearly rising; a declining TgAb titer would suggest continued response to treatment. ²Tg can transiently rise after ¹³¹I therapy and should not be misinterpreted as evidence for progression. ³Repeat ¹³¹I therapy in patients previously treated with high-dose ¹³¹I should be undertaken only if iodine-avid disease is suspected and if there was a previous response to therapy (see Section D7 and D8).

family members and classmates will help guide the decision for inpatient or outpatient therapy. This will be largely based on patient age and ability to comprehend the tasks required for outpatient therapy. Other factors to consider are the amount of radiation retained by the patient and the potential exposure time and distance between patient and others (240). In general, children and adolescents with PTC are primarily a radiation risk to others during the first 1–2 days after ¹³¹I therapy. For young children, this may be especially problematic, if they are not yet toilet trained or are frightened to sleep alone. Detailed instructions for the daily care of children who have received ¹³¹I are provided in the ATA guidelines on radiation safety and abbreviated in appendix 1 of that document (240).

Adjunctive therapies to minimize the risk of ¹³¹I to the treated child have not been well studied. Adequate hydration is essential to enhance ¹³¹I clearance and should be encouraged. Regular bowel evacuation is also important, so stool softeners or laxatives may be considered. Nausea and/or vomiting are common following ¹³¹I therapy, particularly in young children and those receiving higher ¹³¹I activities. In such cases, antiemetics like the serotonin 5-HT₃ receptor antagonists can be considered. Accelerating ¹³¹I clearance from the salivary glands may reduce the risk of sialadenitis, but the use of sialagogues such as sour candy or lemon juice is poorly studied in children. Some studies in adults found benefit by starting lemon

drops 24 hours after ¹³¹I dosing (241), but some experts do not recommend this practice. Similarly, the use of the radioprotectant amifostine has not been validated in children, and a recent review of randomized control trials in adults found no benefit from amifostine therapy (242).

Adjunctive treatments to increase the efficacy of ¹³¹I therapy have also not been well studied in children. In adults with PTC, co-treatment with lithium has been suggested to increase ¹³¹I retention and improve the efficacy of treatment of metastatic tumors (243). To our knowledge, no study of children with PTC has evaluated the safety and efficacy of lithium co-treatment. Because the expression of NIS is more common and more robust in pediatric PTC, the effect of lithium on ¹³¹I retention might be less than that found in adults (169).

■ RECOMMENDATION 19(A)

Adequate hydration should be ensured in all children receiving therapeutic ¹³¹I to facilitate clearance of the radioisotope, and additional supportive care with antiemetic medications and stool softeners/laxatives should be considered. Sour candy or lemon drops can be given after ¹³¹I treatment, but not all experts ascribe to this practice.

Recommendation rating: C

■ RECOMMENDATION 19(B)

The routine use of lithium and amifostine cannot be recommended.

Recommendation rating: F

[C14] How Is the Activity of Therapeutic ¹³¹I Determined?

Therapeutic ¹³¹I administration is commonly based on either empiric dosing or whole body dosimetry. There are no standardized activities of ¹³¹I for children and, to our knowledge, there are no data that compare the efficacy, safety, or long-term outcomes from ¹³¹I administration in children using these different approaches.

Empiric dosing offers the advantage of simplicity. Some adjust ¹³¹I activity according to weight or body surface area and give a fraction (e.g., child's weight in kilograms/70 kg) based on the typical adult activity used to treat similar disease extent (1,3,21,219,229). Others suggest that ¹³¹I activities to treat residual disease should be based on body weight alone (1.0–1.5 mCi/kg; 37–56 MBq/kg), while still others feel this may not be as reliable as dosing based on body surface area. In general terms, a 15-year-old may require five sixths of the adult activity, a 10-year-old may require one half of the adult activity, and a 5-year-old may only require one third of the adult activity for similar extent of disease (169).

For children with diffuse lung uptake or significant distant metastases, those undergoing multiple ¹³¹I treatments, or children who may have limited bone marrow reserve due to prior chemotherapy or radiation therapy, whole-body dosimetry can be used to calculate the largest activity of ¹³¹I that could theoretically be administered so that the absorbed activity to the blood does not exceed 200 rads (cGy) and that the whole-body retention 48 hours after administration does not exceed 4.44 GBq (120 mCi) in the absence, or 2.96 GBq (80 mCi) in the presence, of iodine-avid diffuse lung metastases, respectively (244–246). Lesional dosimetry can also be performed to select effective activities of ¹³¹I for children with substantial lung involvement or large tumor burden at distant sites such as bone (209,210,245,247,248). One must keep in mind that these toxicity constraints have not been validated in pediatrics and may be associated with significant toxicity in young children (249,250). Furthermore, these protocols are time consuming and not routinely available at all referral centers.

■ RECOMMENDATION 20

Based on the lack of data comparing empiric treatment and treatment informed by dosimetry, we are unable to recommend for or against either approach in most patients. Many experts provide the first activity of ¹³¹I based on an empiric estimate and reserve dosimetry for patients with diffuse pulmonary metastases or subsequent activities of ¹³¹I in patients with iodine-avid distant metastases who require additional therapy. However, dosimetry can be considered prior to the first ¹³¹I treatment in small children and in patients with limited bone marrow reserve. Due to the differences in body size and iodine clearance in children compared with adults, it is recommended that all activities of ¹³¹I should be calculated by experts with experience in dosing children.

Recommendation rating: I

[C15] Should a Posttreatment Whole-Body Scan Be Obtained?

Approximately 4–7 days after ¹³¹I therapy, a posttreatment whole-body scan should be performed to take advantage of the increased sensitivity associated with administration of the larger activity of ¹³¹I used for therapy (208). Newer gamma-camera systems allow scanning as early as 72 hours after ¹³¹I therapy (251). On occasion, the posttreatment WBS (RxWBS) may reveal metastatic disease (regional or pulmonary) that was not apparent on the DxWBS (218), but it remains uncertain if this knowledge informs future treatment or outcomes. If new lesions are identified on the RxWBS, the addition of SPECT/CT to the RxWBS may afford greater definition of residual disease during postoperative restaging (252).

In addition, the clearance of RAI from thyroid cancers has been shown to vary substantially with biological half-life ranging from 3 to 12 days (253). Rapid turnover of iodine might clear ¹³¹I by the time standard imaging protocols are performed, while other lesions might be better revealed with delayed imaging (254). For the rare child with elevated serum Tg and negative RxWBS, serial acquisition times may be beneficial in documenting disease and iodine avidity.

■ RECOMMENDATION 21

A posttreatment WBS is recommended for all children 4–7 days after ¹³¹I therapy. The addition of SPECT/CT may help to distinguish the anatomic location of focal uptake.

Recommendation rating: B

[C16] What Are the Acute and Long-Term Risks of ¹³¹I Therapy in Children?

There are both acute and long-term side effects and complications associated with exposure to therapeutic ¹³¹I. The side effects can be organized by organ system, and the majority are explained by mechanistic exposure based on the method of delivery, absorption, distribution, and clearance.

The short-term side effects of ¹³¹I are well known and include damage to tissues that incorporate iodine, resulting in sialadenitis, xerostomia, dental caries, stomatitis, ocular dryness, and nasolacrimal duct obstruction (255,256). Strategies exist to help treat or prevent ¹³¹I-related side effects (257,258); however, even a single activity of ¹³¹I may lead to permanent salivary gland dysfunction with life-long xerostomia, an increased incidence of dental caries, and an increase in the risk for salivary gland malignancy (258,259). The use of sour candy or lemon juice, starting 24 hours after ¹³¹I dosing, with vigorous hydration for 3–5 days may protect salivary gland function (241). The use of rhTSH has not been shown to decrease salivary gland toxicity compared to thyroid hormone withdrawal (260); however, lacrimal dysfunction (watery eyes) was more frequent in patients undergoing thyroid hormone withdrawal (261). None of these prophylactic measures or other sialogogues have been formally studied in the pediatric population.

Gonadal damage has been reported in both women and men (262,263). In postpubertal males, transient rise in follicle-stimulating hormone is common and may persist for up to 18 months after ¹³¹I exposure (263,264). Increasing cumulative activities of ¹³¹I may lead to decreased spermatogenesis generally without an effect on testosterone production

(263,265,266). Current guidelines recommend that males avoid attempts at conception for at least 4 months post ^{131}I therapy. Postpubertal testes appear to be more vulnerable than prepubertal testes to the toxic effects of ionizing radiation (267). Therefore, postpubertal males should be counseled and sperm banking should be considered for those receiving cumulative activities ≥ 400 mCi (14.8 GBq) (268).

Transient amenorrhea and menstrual irregularities are reported in up to 17% of females under the age of 40 years. This is true despite the fact that 65% of young women received a single low activity of ^{131}I (average = 81 mCi; 3 GBq) (269). Other studies have not shown an increase in infertility, miscarriage, or birth defects following ^{131}I (262,270,271). Collectively, these data have led to the recommendation that conception should be avoided during the year immediately following ^{131}I administration (272).

Acute suppression of bone marrow may occur but hematologic parameters usually normalize within 60 days after ^{131}I exposure. Commonly a decline in leukocyte ($\sim 57\%$) and platelet counts ($\sim 44\%$) occurs within the first month after treatment. This is followed by a less pronounced decline in erythrocyte count ($\sim 10\%$) by the second month after treatment, but usually all parameters normalize ~ 3 months post therapy (273). Long-term bone marrow suppression is rare; however, there are reported cases of leukemia after multiple high activities of ^{131}I administered over a short span of time (274). Therefore, it is important to allow for recovery of bone marrow between ^{131}I treatments.

In support of these clinical observations, ^{131}I has been shown in peripheral lymphocytes to induce a significant increase in the number of dicentric chromosomes (275–277), and the aberrations of chromosomes 1, 4, and 10 are not only more prevalent but are still apparent after 4 years (276). A recent report comparing thyroid hormone withdrawal to rhTSH suggests a lower frequency of lymphocyte chromosomal rearrangements after ^{131}I dosing using rhTSH preparation (278).

A few studies combining patients of all ages have shown that ^{131}I therapy is associated with an increased risk for second malignancies and an increase in overall mortality for patients with DTC (7). A large study by Brown *et al.* (6) reviewed data from over 30,000 subjects and found a significant increase in second malignancies among patients treated with ^{131}I (relative risk 1.16, $p < 0.05$). They also noted that the risk was greater for younger patients. In a study that exclusively evaluated children, Hay *et al.* (5) found that children who were treated with radiation (external beam radiation, radium implants, or ^{131}I) developed a variety of second cancers (leukemia, stomach, bladder, colon, salivary gland, and breast) and had increased mortality compared with the general population. However, only 4 of the 15 patients that died from nonthyroid second primary malignancies were associated with the sole administration of ^{131}I (one acute myelogenous leukemia, one lung, one adenocarcinoma, and one breast cancer) (5). Whether this resulted from aggressive treatment, an underlying predisposition to cancer, or from a direct effect of ^{131}I is unknown, but the increase in overall mortality following ^{131}I treatment of a disease with low disease-specific mortality is of growing concern.

It is difficult to determine from these data if there is a “safe” cumulative exposure to ^{131}I or if the increase in second malignancies occurs following any amount of ^{131}I . Further complicating this question is the fact that the effects

of RAI may be amplified in children because a given activity of ^{131}I is distributed over shorter distances, taken up by smaller organs, and accumulated by cells with increased growth and proliferation potential. Despite these limitations, Rubino *et al.* (7) proposed an activity–response relationship in which the relative risk for second malignancy appears to increase above a cumulative activity of 200 mCi (7.4 GBq) ^{131}I , and Rivkees *et al.* (220) suggested an increased risk above a cumulative exposure to 300 mCi (11.1 GBq) ^{131}I . However, there are anecdotal reports of acute myelogenous leukemia after 85 mCi (3.1 GBq) ^{131}I , lung cancer after 150 mCi (5.6 GBq) ^{131}I , and adenocarcinoma after 200 mCi (7.4 GBq) ^{131}I (5). Unfortunately, there is a lack of long-term data to define a “safe” activity of ^{131}I , and additional study is clearly warranted.

Lastly, for pediatric patients with lung metastases, a significant risk exists for ^{131}I -induced pulmonary fibrosis when the retained ^{131}I activity exceeds 80 mCi (3 GBq) (228,279). For that reason, patients with significant uptake on DxWBS are candidates for dosimetry or reduced ^{131}I dosing.

In summary, there are clear benefits and risks, both acute and chronic, following administration of ^{131}I . The challenge is to define the subgroup of patients who will not experience an increase in morbidity or disease-specific mortality if ^{131}I is deferred or withheld.

■ RECOMMENDATION 22

There are clear benefits and risks, both acute and chronic, following administration of ^{131}I during childhood. The challenge is to identify the patients for whom the benefits of ^{131}I therapy outweigh the risks. Families should be provided full disclosure of the risks and benefits of ^{131}I , and their opinion must be considered in the final decision.

Recommendation rating: C

[D1] SURVEILLANCE AND FOLLOW-UP OF PTC IN CHILDREN

[D2] What Is the Role of Tg Testing in the Follow-Up of PTC in Children?

Tg is a thyroid-specific glycoprotein that is synthesized and secreted by the normal thyroid and by differentiated thyroid carcinomas. Following surgery and ^{131}I therapy, serum Tg levels serve as a sensitive marker of residual or recurrent disease (280–283); the magnitude of serum Tg elevation appears to correlate with the site(s) of metastatic disease and with the tumor subtype (280).

Highly sensitive and specific immunometric analyses for serum Tg have been shown to be more sensitive for detecting residual thyroid cancer in adults compared with the DxWBS (281,284–286). Currently, most laboratories use immunometric methods for Tg measurement, and these should be calibrated against the CRM-457 international standard (1). However, even with standardization, there can be significant differences in Tg results between various assays (171). For that reason, serial Tg measurements should ideally be performed in the same laboratory using the same assay.

In the absence of TgAb (see following section), serum Tg has a high degree of sensitivity and specificity to detect

residual/recurrent DTC, with the highest sensitivity noted following TSH stimulation (TSH-stimulated Tg) (282). Serum Tg levels rise with TSH stimulation, and the duration of stimulation is generally longer in the hypothyroid state, resulting in higher serum Tg levels than occur after rhTSH in the euthyroid state (281). In adults, a TSH-stimulated serum Tg level > 2 ng/mL has a high predictive value for disease (287).

Previous studies of children with DTC have focused on DxWBS as the “gold standard” for disease status (11,219,288), and there are few data regarding the interpretation of Tg levels in children with DTC. Because data suggest that serum Tg levels might be higher in children compared with adults with a similar extent of disease (58,289), application of data from adult studies to children is difficult. Therefore, it is not yet clear if elevated Tg levels have the same prognostic value for children, who may have a different Tg threshold for what would be considered clinically relevant or “actionable” disease.

Incorporating Tg levels into clinical care

In conjunction with neck US and other imaging procedures (see Sections D3–D5), the measurement of serum Tg is a critical component in the management of the pediatric DTC patient, both at the time of initial postoperative staging (see Table 6, Fig. 2) as well as during long-term surveillance and subsequent restaging (see Table 6, Fig. 3 and 4). At the same degree of TSH suppression, the Tg level on LT₄ is thought to be the best predictor of changes in tumor mass (281,290). Therefore, monitoring of the nonstimulated Tg (in addition to neck US; see Section D3) is the ideal approach to assess for recurrence or disease progression, noting that a negative Tg on LT₄ therapy may not reliably predict a negative TSH-stimulated Tg response (291–293). The use of highly sensitive Tg assays may ultimately obviate the need to perform a stimulated Tg measurement (292–297), although data in children are lacking.

Based on adult studies, a negative TSH-stimulated Tg after surgery and ¹³¹I identifies patients with a high probability of being disease-free (286,287,298–300). Therefore, an undetectable TSH-stimulated Tg in children is similarly considered to be an indicator of disease remission, although a mildly positive stimulated Tg (< 10 ng/mL) in such patients should not be considered an actionable finding in the absence of other evidence for active disease. This is due to multiple factors, including our understanding that some adult patients with a TSH-stimulated Tg level > 2 ng/mL but < 10 ng/mL will remain free of clinical disease and will have stable or decreasing TSH-stimulated Tg levels over time (281,287,301) and the fact that patients with DTC can demonstrate a continued decline in Tg levels over many years despite receiving no additional therapy (281,301,302).

If the Tg on LT₄ is detectable, there is no added value from performing a TSH-stimulated Tg because the likelihood of persistent or recurrent disease is high. In these patients, a rising Tg level indicates disease that is likely to become clinically apparent (281,283,301,303–305). In this setting, routine surveillance is recommended with imaging and treatment determined by the degree of Tg elevation and its trend over time (see Fig. 3 and Sections D3–5). However, when imaging fails to confirm or localize disease, the clinical importance of a low-level disease burden identified only by Tg testing in children is not yet clear, and there is no absolute serum Tg value above which empiric treatment is indicated (281,301). The Tg level

above which additional studies and or an empiric activity of RAI therapy (see Section D5) should be considered has not been delineated in children and adolescents. A mildly positive TSH-stimulated Tg (< 10 ng/mL) in such patients should not be considered an automatic, actionable finding in the absence of evidence for progressive disease.

Although repeating a TSH-stimulated Tg in patients whose Tg is undetectable on suppressive therapy but previously detectable after TSH stimulation may help to confirm the absence of disease, there is no need to repeat a TSH-stimulated Tg level in patients with an undetectable Tg on LT₄ and a previously negative TSH-stimulated Tg, since these patients are likely in remission (287,298–300).

Finally, in the patient who has not been treated with ¹³¹I, the Tg level while on LT₄ can still be reliable (223–225) assuming the initial surgery was done by an experienced thyroid surgeon. A TSH-stimulated Tg is of no value in this situation outside of its use in initial postoperative staging (Fig. 2).

Children with Tg autoantibodies

TgAb are detected in up to 20%–25% of patients with DTC, primarily PTC, and they interfere with Tg measurements in a qualitative, quantitative, and method-dependent manner, rendering the Tg level uninterpretable (304,306–310). Antibody interference with the most commonly used Tg immunometric assays always results in underestimation of Tg (i.e., a potentially false negative test), whereas interference with radioimmunoassay has the potential to cause either under- or overestimation of Tg, depending on the characteristics of the patient-specific TgAb and the radioimmunoassay reagents (307,310). All specimens sent for Tg measurement require concomitant TgAb testing because TgAb status can change over time and even very low TgAb concentrations can interfere (310). Similar to measuring Tg levels, the measurement of TgAb levels should be performed in the same laboratory using the same assay every time (307). Newer technologies using liquid chromatography–tandem mass spectrometry to measure Tg in TgAb-positive samples are now available (311). However, further studies are required before these methods can be broadly incorporated into clinical practice.

Because TgAb concentrations respond to changes in the levels of circulating Tg antigen, and thereby indirectly represent changes in thyroid tissue mass, the TgAb level can serve as a surrogate tumor marker for DTC (306,307). Most studies have reported that the *de novo* appearance, persistence, or a rising trend in TgAb concentrations in the postoperative period are significant risk factors for persistent or recurrent disease (312–316). However, it is unknown if a positive TgAb correlates with extent or invasiveness of disease or the prognosis. A decline in TgAb titers indicates a declining disease burden, but it may take a median of 3 years to clear TgAb after cure of DTC (317). A significant rise in Tg antibodies suggests disease progression that warrants further evaluation. Patients may have persistent TgAb during the first year after diagnosis and may even exhibit a rise in (or *de novo* appearance of) TgAb during the 6 months following ¹³¹I treatment, when there is release of Tg antigen secondary to ¹³¹I-induced damage to thyroid tissue (310,314,318). Likewise, persistence of a low TgAb concentration years after the initial surgery does not necessarily indicate the presence of disease, especially if the TgAb titers display a

declining trend (315). Similar to the Tg, the trend in TgAb concentrations is more relevant for disease detection than any single TgAb concentration. Once the child becomes Tg antibody negative, the Tg level on LT₄ or after TSH stimulation is considered interpretable.

■ **RECOMMENDATION 23(A)**

Tg serves as a sensitive tumor marker in the evaluation, treatment, and long-term follow-up of DTC in children, even in children not previously treated with ¹³¹I. TgAb levels should be simultaneously measured in all samples because the presence of TgAb will render the Tg result uninterpretable. Tg and TgAb levels should be measured using the same laboratory and assay technique. The trend in serial Tg and/or TgAb levels is much more informative in regard to determining disease status than any single measurement.

Recommendation rating: A

■ **RECOMMENDATION 23(B)**

An undetectable TSH-stimulated Tg (with negative TgAb) identifies patients in remission with a very high probability to remain completely free of disease during follow-up and in whom the intensity of disease surveillance and the magnitude of TSH suppression should be relaxed. Monitoring the TSH-suppressed Tg level on LT₄ treatment is the recommended approach to long-term follow-up, with the trend of this value being the most reliable indicator of disease activity. Repeat TSH-stimulated Tg levels are not necessary if the TSH-suppressed Tg is detectable or if a previous TSH-stimulated Tg was undetectable.

Recommendation rating: A

■ **RECOMMENDATION 23(C)**

Detection of a low-level TSH-stimulated Tg (<10 ng/mL) in a patient who has undergone surgery and therapeutic ¹³¹I may indicate persistent disease. However, this value may decline over time without additional therapy. Continued follow-up with serial TSH-suppressed Tg and TgAb levels as well as radiologic imaging (neck US) are indicated in this situation.

Recommendation rating: B

■ **RECOMMENDATION 23(D)**

Increasing or frankly elevated levels of TSH-stimulated Tg (>10 ng/mL) warrant further evaluation to localize disease and inform the decision as to whether additional surgery and/or ¹³¹I therapy would be beneficial or whether one should pursue continued observation.

Recommendation rating: A

■ **RECOMMENDATION 23(E)**

The Tg level cannot be interpreted in children with positive TgAb. In this setting, the TgAb trend should be followed using the same assay. If the TgAb trend is clearly rising, then further evaluation is warranted.

Recommendation rating: A

[D3] What Is the Role of Ultrasound in the Follow-Up of PTC in Children?

Children with PTC who have residual/recurrent disease are most likely to have cervical lymph node disease (5,9,11,14,163,217,319). US, in conjunction with Tg levels, has proven highly effective in identifying and localizing regional nodal metastases in both adults and children with PTC (113,190,191,202,283,286) and appears even more sensitive than a TSH-stimulated Tg to identify disease (190,202,297). US has also proven useful for directing FNA of suspicious lesions/lymph nodes in the thyroid bed or lateral neck that can then be evaluated by routine cytology and Tg immunoassay of the needle washout, especially if cytopathology is equivocal or uninformative (187–191). Therefore, US is the most important clinical tool for identifying cervical disease and is recommended at routine intervals based upon the patient's ATA Pediatric Risk level and clinical concern for persistent or recurrent disease (see Table 6, Fig. 2 and 3).

■ **RECOMMENDATION 24**

Neck US is recommended in the follow-up of children with PTC (Table 6 and Fig. 3). Neck US should be performed at least 6 months after initial surgery and then at 6- to 12-month intervals for ATA Pediatric Intermediate- and High-Risk patients and at annual intervals for ATA Pediatric Low-Risk patients. Follow-up beyond 5 years should be individualized based on recurrence risk.

Recommendation rating: A

[D4] How Are Diagnostic RAI Scans Best Used in the Follow-Up of PTC in Children?

A DxWBS is usually performed as part of the postoperative staging following initial surgery in ATA Pediatric Intermediate- and High-Risk patients and can be considered in ATA Pediatric Low-Risk patients who have evidence of residual disease after short-term follow-up (see Table 6, Fig. 2 and 3, and Sections C8/C12).

Routine surveillance for persistent or recurrent disease in children with DTC has historically relied on sequential DxWBS (11,219,288). However, serial neck US and measures of serum Tg appear to be sensitive indicators of disease status in the vast majority of pediatric patients. For that reason, there is no role for serial thyroid scintigraphy in a child who has not previously been treated with ¹³¹I, unless evidence exists for persistent or recurrent disease (see Fig. 3).

For the child who has received therapeutic ¹³¹I, there may be a role for a follow-up DxWBS, typically 1–2 years following the initial treatment with ¹³¹I (Table 6). Children with known iodine-avid metastases based upon a prior posttreatment scan are the most likely to benefit from subsequent staging with a DxWBS. Ideally, the DxWBS should be performed only after a significant period of time has elapsed to assess the response from the last dose of therapeutic ¹³¹I, recognizing that clinical response can continue for years (58) (see Fig. 4 and Section D8). Finally, once a DxWBS is negative, repeating the procedure has no utility unless disease is clinically suspected.

■ RECOMMENDATION 25(A)

During the follow-up of children with PTC who are suspected to have residual disease, a DxWBS can be used to inform the decision of whether or not to use ^{131}I and the activity of ^{131}I to be administered (Fig. 3). A final DxWBS can be considered to confirm the absence of iodine-avid disease in children who were previously treated with ^{131}I and who have no evidence of disease 1–2 years after initial therapy.

Recommendation rating: C

■ RECOMMENDATION 25(B)

A DxWBS should be performed in children with ATA Pediatric High-Risk disease who were previously treated with ^{131}I or known to have iodine-avid metastatic disease based upon a previous posttreatment scan. The DxWBS should be obtained after at least 12 months of clinical follow-up, and deferred even longer in children who continue to demonstrate a clinical response to previous treatment.

Recommendation rating: B

■ RECOMMENDATION 25(C)

Once a negative DxWBS is obtained, there is no benefit from serial DxWBS to survey for disease recurrence as long as the patient otherwise remains without clinical evidence of disease.

Recommendation rating: B

[D5] What Imaging Studies Should Be Considered in the Pediatric PTC Patient Who Is Tg Positive but Who Has No Evidence of Disease on Cervical Ultrasound or DxWBS?

The child previously treated with surgery and ^{131}I who has a serum Tg suggestive of residual/recurrent disease but no other evidence of disease presents a particularly challenging clinical situation. In this setting, one should first ensure that cervical US has been performed by an experienced radiologist and also confirm that iodinated contrast agents were not given to the patient within the 3 months prior to an RAI scan. Treatment algorithms have been proposed for adults who are “Tg-positive, scan-negative” and generally focus on anatomic imaging of the neck and chest, ^{18}F FDG-PET/CT, and additional therapeutic ^{131}I with a posttreatment scan (1,3,320).

In children, the neck and chest are the most likely sites of persistent disease, and contrast-enhanced imaging of these areas with CT or MRI is favored when US cannot identify disease. ^{18}F FDG-PET/CT has become a commonly used tool in the evaluation of adults with persistent non-iodine-avid thyroid cancer (3,321–326) and appears to offer prognostic information that might change clinical management (327–330). However, there are extremely limited data regarding the use of ^{18}F FDG-PET/CT in children except for a case report (331), isolated pediatric subjects embedded within adult studies, and unpublished data that suggest low sensitivity of ^{18}F FDG-PET/CT to identify residual disease in children that otherwise cannot be identified via cervical US and cross-sectional imaging of the neck and chest (personal commu-

nication, SGW). Whether or not the use of ^{18}F -FDG PET has similar prognostic value or will change disease management in children with thyroid cancer remains to be determined. Finally, empiric treatment with ^{131}I does not appear to be effective in adults who have a negative DxWBS (332,333). Although children are more likely to have RAI-responsive disease compared with adults, empiric treatment with high-activity ^{131}I is not generally advocated to identify disease unless there is evidence for clinical progression (e.g., a rising Tg level) and a documented clinical response to previous ^{131}I therapy (see Fig. 3).

■ RECOMMENDATION 26(A)

For the child with a detectable TSH-suppressed Tg but a negative cervical US and DxWBS, contrast-enhanced cross-sectional imaging of the neck and chest should be considered once iodine excess has been eliminated as a cause of a false-negative DxWBS.

Recommendation rating: B

■ RECOMMENDATION 26(B)

The utility of ^{18}F FDG-PET/CT is poorly studied in pediatric DTC, and ^{18}F FDG-PET/CT cannot be routinely recommended in the care of children who have persistent evidence of DTC on follow-up.

Recommendation rating: D

■ RECOMMENDATION 26(C)

Empiric ^{131}I therapy and a posttreatment scan are not recommended to localize disease in the child with DTC and a negative DxWBS unless there is evidence for clinical progression (e.g., a rising Tg level) and a documented clinical response to previous ^{131}I therapy.

Recommendation rating: D

[D6] What Are the Goals and Potential Risks of TSH Suppression Therapy?

DTCs in children are well-differentiated tumors that may respond to TSH stimulation with increased growth and Tg production. For that reason, TSH suppression has been an important cornerstone of treatment, especially for high-risk groups (217,334–336). However, there are no data in children with which to compare the outcomes, risks, and benefits of various TSH suppression strategies. Some experts recommend initial TSH suppression to <0.1 mIU/L followed by relaxation to 0.5 mIU/L following remission of DTC (337). The ATA guidelines for adults stratify target TSH levels based on the risk of recurrence (1). Recognizing the paucity of data regarding TSH suppression in children with DTC, the panel has concluded that the initial TSH goal should be tied to ATA Pediatric Risk level and current disease status (Table 6). In children without evidence of disease, the TSH can be normalized to the low-normal range after an appropriate period of surveillance.

The actual risks of TSH suppression in children with DTC have been poorly studied. Extrapolating from patients with Graves' disease, the potential risks of TSH suppression include growth acceleration, advanced bone age, early onset puberty, reduced bone mineral content, poor academic performance,

tachyarrhythmia, and others (338,339). It should be emphasized, however, that patients with Graves' disease generally have much greater elevations in thyroxine levels than do patients on TSH-suppressive therapy for DTC. Thus, the applicability of these data to long-term DTC management is currently unknown.

■ RECOMMENDATION 27

TSH suppression in children with DTC should be determined by ATA Pediatric Risk level and current disease status (Table 6). In children with known or suspected persistent disease, TSH suppression should be maintained. In children with no evidence of disease, the TSH can be normalized to the low-normal range after an appropriate period of surveillance.

Recommendation rating: B

[D7] What Is the Optimal Approach to the Patient with Persistent/Recurrent Cervical Disease?

The majority of residual/recurrent PTC in children will be identified in cervical lymph nodes (5,9,11,14,163,217,319), and the optimal management depends on several factors, including the location and size of disease, the previous surgical and ^{131}I treatment history, the presence of distant metastases, and whether or not the disease is iodine-avid (see Fig. 3). Patients with cervical RAI uptake due to disease that is small (i.e., < 1 cm) or that cannot be visualized via cross-sectional imaging can be considered for treatment with therapeutic ^{131}I , which may reduce future recurrence risk but is unlikely to improve mortality (9,14,169). Although repeat surgery may also be an option, finding a small recurrence in the neck intraoperatively may be difficult. In most cases, children with small volume residual disease < 1 cm can be safely observed while continuing TSH suppression. Given the overall excellent prognosis, and the low risk for clinically significant progression, the risk to benefit ratio for the treatment of small-volume disease in a child who has already undergone surgery and ^{131}I is unfavorable.

On the other hand, in patients with structural disease > 1 cm in size that is visualized by US and/or anatomic imaging (CT or MRI) and confirmed via FNA, surgical resection is preferable to ^{131}I and can result in safe and effective long-term control of disease, especially when surgery is performed by a high-volume surgeon (340,341).

■ RECOMMENDATION 28(A)

The decision to treat or to observe structurally identifiable cervical disease should be individualized and include considerations of age, initial ATA Pediatric Risk classification, the presence of distant metastases, and prior treatment history (including complications from previous therapy), in addition to the size, extent, anatomic location, and iodine avidity of the disease (see Fig. 3).

Recommendation rating: C

■ RECOMMENDATION 28(B)

Children with macroscopic cervical disease (>1 cm in size) should be assessed by a high-volume thyroid surgeon to determine the feasibility of additional surgery.

Recommendation rating: B

■ RECOMMENDATION 28(C)

Iodine-avid cervical disease (visualized with DxWBS) could be treated with surgery or ^{131}I depending on individual patient risks and the presence or absence of distant metastases. Surgery would be favored for disease localized to the neck, especially if located in a lymph node compartment not previously operated upon.

Recommendation rating: B

■ RECOMMENDATION 28(D)

If repeat surgery is performed, postoperative restaging can be utilized to determine whether additional ^{131}I treatment is warranted, especially in the patient who has not received previous therapeutic ^{131}I .

Recommendation rating: C

[D8] How Should Children with Pulmonary Metastases Be Managed?

The majority of children with pulmonary metastases have micronodular disease that typically demonstrates excellent RAI uptake. Because of this, distant metastases in children are more amenable and responsive to ^{131}I therapy compared with adults. Serial ^{131}I treatments can result in remission in many, but not all, children with pulmonary metastases from PTC, the vast majority of whom will demonstrate stable metastatic disease and low disease-specific mortality (10,57,58,162,176,179,227,289,319,342–344). The optimal frequency of ^{131}I treatment has not been determined. The maximal clinical and biochemical response from an administered activity of ^{131}I may not be reached for up to 15–18 months (302), and recent studies have also demonstrated a continuous improvement in serum Tg levels for years following discontinuation of ^{131}I therapy in children with pulmonary metastases (58), all of which suggests that the effects of therapy can be seen well beyond the first years after treatment. Because children with pulmonary metastases have historically been treated aggressively with repeated activities of ^{131}I , it remains unknown how these pediatric patients would respond to the less-aggressive use of ^{131}I . Given that a majority of children with pulmonary metastases will not have a complete response to therapy and because it may take years to see the full response of ^{131}I , an undetectable Tg level should no longer be the sole goal of treatment of children with pulmonary metastases. Furthermore, longer intervals between ^{131}I therapy would seem prudent in the child who does not demonstrate progressive disease.

For patients with persistent pulmonary metastases who have already received treatment with high-activity ^{131}I , the decision to re-treat should be individualized (see Fig. 4). Because of our improved understanding regarding prognosis and duration of response in children with pulmonary metastases, and to minimize the long-term risks associated with high cumulative activities of ^{131}I (see Section C16), it is logical to monitor the TSH-suppressed Tg and imaging studies in these children, deferring repeat evaluation and treatment with RAI until the full response to previous ^{131}I is demonstrated. In the rare event of disease progression, further evaluation and treatment would be warranted, as long as it has been > 12 months from the previous activity of ^{131}I (see Fig. 4). For serologic progression,

waiting at least 12 months would better establish a trend to ensure that the rise in the Tg or TgAb levels is not spurious or due to previous ^{131}I -induced tumor destruction. Furthermore, a longer interval between treatments may minimize the risk of late effects of ^{131}I (see Section C16). In all cases, therapeutic ^{131}I should be considered only if the patient is known or presumed to have RAI-responsive disease and has not already received high cumulative activities of ^{131}I . If the child did not have previous RAI uptake on a posttreatment scan or if their disease continued to progress despite high-activity ^{131}I , further ^{131}I therapy is unlikely to be helpful and should not be given. In these cases, continued observation and TSH suppression are indicated, with alternative therapies considered if progression of iodine-refractory disease becomes clinically significant (Section D10).

As children with pulmonary metastases may have diffuse RAI uptake in the lungs, there is a real concern about treatment-induced pulmonary fibrosis (57,258,345–348). In these cases, administering lower ^{131}I activities and employing dosimetry should be considered to limit radiation exposure to the nontarget normal lung parenchyma (244–246,347,349) (Section C14). The utility and optimal intervals at which to perform pulmonary function testing in children with lung metastases have not been studied, but many experts recommend that pulmonary function testing be done intermittently in children with pulmonary metastases, especially if multiple ^{131}I treatments are planned.

■ RECOMMENDATION 29(A)

Children with RAI-avid pulmonary metastases visualized with a DxWBS are good candidates for ^{131}I therapy.

Recommendation rating: A

■ RECOMMENDATION 29(B)

After a therapeutic activity of ^{131}I , the TSH-suppressed Tg level and imaging studies should be monitored until the full clinical and biochemical (Tg) response is reached.

Recommendation rating: B

■ RECOMMENDATION 29(C)

If the full clinical and biochemical (Tg) response suggests persistent disease or if there is documented disease progression >12 months after ^{131}I therapy, further evaluation with a DxWBS and a TSH-stimulated Tg is indicated.

Recommendation rating: B

■ RECOMMENDATION 29(D)

Re-treatment of RAI-avid pulmonary metastases should be considered in children who have demonstrated progression of disease and a previous response to ^{131}I , with each treatment carefully individualized based on the child's unique clinical course, side-effect profile, risk tolerance, and cumulative administered ^{131}I activity. Treatment with ^{131}I should be performed by experts with experience in managing children with pulmonary metastases.

Recommendation rating: B

■ RECOMMENDATION 29(E)

Re-treatment of pulmonary metastases with ^{131}I is not recommended in children who do not have uptake on a DxWBS and who have not demonstrated a previous response to ^{131}I .

Recommendation rating: E

■ RECOMMENDATION 29(F)

Pulmonary function testing should be considered in all children with diffuse pulmonary metastases, especially if multiple ^{131}I treatments are planned.

Recommendation rating: C

[D9] How Does One Approach the Child with an Incidental PTC Identified After Surgery for Another Thyroid Condition?

Small foci of PTC may be incidentally discovered on histological examination of thyroid tissue resected for other benign diseases such as Graves' disease, autonomous nodule(s), or multinodular goiter. No consensus exists regarding the benefit of completion thyroidectomy (assuming lobectomy was initially performed) or ^{131}I therapy for children with incidental PTC. However, these children should undergo neck US, if not already performed, and be managed similar to other children with ATA Pediatric Low-Risk PTC (Table 6).

■ RECOMMENDATION 30

Children with incidental PTC should be managed similarly to other children with ATA Pediatric Low-Risk disease. Neck US is recommended to detect contralateral disease or disease in the regional lymph nodes. Completion thyroidectomy is not required in those children who had less than a TT unless there is US evidence and cytologic confirmation of contralateral thyroid disease or malignant lymphadenopathy.

Recommendation rating: B

[D10] What Are the Optimal Approaches to the Pediatric Patient Who Develops Progressive Thyroid Cancer That No Longer Concentrates or Responds to ^{131}I ?

Very rarely, children with thyroid cancer may develop progressive symptomatic and/or life-threatening disease that is not amenable to further surgery or ^{131}I . In such cases, systemic therapy should be considered. Clinical trials would be preferred, but there has not yet been a clinical trial developed for children with ^{131}I -refractory DTC. Some drugs with potential efficacy may be available through phase I pediatric studies. Doxorubicin remains the only United States Food and Drug Administration (FDA)-approved cytotoxic chemotherapy for this indication and has been used either as a single agent or in combination with cisplatin or interferon- α (39,350,351), but it is generally ineffective in treating advanced DTC.

Molecularly targeted therapies using oral small molecule kinase inhibitors have brought newer options to the

management of ¹³¹I-refractory thyroid cancer in adults (39,352). The pediatric experience has been limited to published case reports and anecdotal clinical experience, primarily with sorafenib (353,354), which is FDA-approved for the treatment of advanced iodine-refractory DTC in adults based upon the results of a phase III trial (355). [Subsequent to the completion of these guidelines, lenvatinib was also approved by the FDA based upon a pivotal phase III clinical trial in adults (356).] Although more study is required regarding the use of these agents in children, particularly with respect to dosing and toxicity, the use of molecularly targeted therapies may be contemplated in the rare situation in which a child warrants systemic treatment. However, it is difficult to define iodine-refractory disease in pediatric DTC, and iodine-refractory DTC can remain stable over years of follow-up. For that reason, all children being considered for anti-neoplastic therapy should be referred to centers familiar with the use of these novel therapeutic agents in thyroid cancer. In all cases, a systematic approach to care and toxicity evaluation should be undertaken (357).

■ RECOMMENDATION 31

Most children with asymptomatic and nonprogressive ¹³¹I-refractory disease can be safely monitored while continuing TSH suppression. Systemic treatment for advanced thyroid cancer in children remains unstudied and at this time should be considered the purview of specialized centers for the treatment of children with thyroid cancer. Consultation with experts in this area should be invited prior to initiation of treatment. In exceptional cases in which systemic treatment is contemplated, clinical trials are preferred. If unavailable, the use of oral kinase inhibitors may be considered.

Recommendation rating: C

[E1] FOLLICULAR THYROID CANCER

Pediatric FTC is a rare and poorly studied malignancy with an age-adjusted annual incidence of 0.5 cases per million population (8). FTC currently represents 10% or less of thyroid cancer cases diagnosed in children or young adults (8,50,358–360), and the prevalence of true FTC appears to be decreasing over time (361). FTC is most commonly diagnosed in adolescents, and there is less of a female to male preponderance compared with PTC (9,11,50,51,226). Iodine deficiency is the one clear risk factor for the development of FTC, and iodine-deficient countries have a higher prevalence of FTC compared with PTC (226,358,362,363). Unlike for PTC, the role of ionizing radiation in the pathogenesis of FTC is much less clear (20,364).

The major histopathologic variants of FTC are the oncocytic (Hürthle cell) and clear cell variants. Poorly differentiated thyroid carcinomas (e.g., insular carcinomas) can arise from a pre-existing FTC and are defined by the WHO as follicular cell malignancies with limited evidence of follicular cell differentiation (25). Such tumors are exceedingly rare in the pediatric population (365,366).

Although mutations in *RAS* and the *PAX8/PPAR γ* rearrangement have been implicated in adult FTC (130,367), the somatic genetic events that contribute to the pathogenesis of pediatric FTC remain largely unstudied. FTC can be a

component of the *PTEN* hamartoma tumor syndrome (including Cowden syndrome) that results from germline mutations in *PTEN* (see Table 4) (91,92,197,368–370). Therefore, there should be a high index of suspicion for an underlying *PTEN* mutation in children with FTC, particularly in those with macrocephaly, penile freckling, or a suggestive family history (92,324,369,371). FTC may also develop as part of other genetic syndromes (see Section B3 and Table 4).

FTC is typically an encapsulated lesion and the diagnosis is based on the pathologic identification of capsular and/or vascular invasion in the resected tumor (358,372,373). The diagnosis can only be secured after surgical resection and a thorough examination of the tumor capsule as it interfaces with the thyroid. FNA is not sufficient for making the diagnosis of FTC, which usually has an indeterminate result, such as “atypia of undetermined significance,” “follicular lesion of undetermined significance,” “follicular neoplasm,” or “suspicious for follicular neoplasm” (see Section B4) (121,374,375).

The clinical behavior of FTC in children is distinct from PTC. Pediatric FTC may be less aggressive than PTC and is generally associated with less advanced disease, fewer distant metastases, and a lower rate of recurrence (9,11,50,167,376). Except for the aggressive variants, FTC is typically a unifocal tumor that rarely spreads to regional lymph nodes (11,25,50,51,358,372,376–379) and may have autonomous function (380–382). However, unlike PTC, FTC is prone to early hematogenous metastases, which occurs even in the absence of cervical node involvement (383,384). Despite that, conventional FTC has an excellent prognosis when diagnosed during childhood, and long-term survival is the norm (8,385,386).

Depending on the extent of invasion, FTC is currently subdivided into two major groups: minimally invasive and widely invasive FTC (367,373). Tumors with microscopic capsular invasion alone and/or very limited vascular invasion are typically classified as minimally invasive carcinomas, whereas grossly invasive neoplasms that show widespread infiltration into blood vessels and/or adjacent thyroid tissue and often lack complete tumor encapsulation are deemed widely invasive FTC.

Minimally invasive FTC has the lowest risk for recurrence and/or metastases, whereas widely invasive FTC is associated with significant morbidity and mortality in adults (358,367,372,373,378,383,387–392). Vascular invasion appears to be the most important clinical prognostic indicator, and any degree of vascular invasion, especially if more than three blood vessels are involved, may portend more advanced disease and a worse prognosis (372,373,387–390,393). However, not all studies support the negative impact of vascular invasion (383,394). Furthermore, size of the primary tumor appears to be an important factor, with metastases less likely to occur in smaller cancers (377,383,384,391,393).

In clinical practice, the initial evaluation and treatment of FTC in children is generally the same as for PTC (200,395). Surgery by a high-volume thyroid surgeon is the definitive therapy, and at a minimum the child with an FNA that demonstrates an indeterminate lesion should undergo an ipsilateral thyroid lobectomy and isthmusectomy (see Section B4 and Fig. 1). Intraoperative frozen section can be considered, primarily to assess for PTC, but frozen section cannot reliably distinguish FTC from benign disease and is not routinely recommended (396). With a minimally invasive

FTC, lobectomy alone may be sufficient treatment (378,392). However, if more than three vascular invasions are identified or if the tumor is >4 cm, completion thyroidectomy is recommended because of the higher risk of distant metastasis (373). In children who have had a TT, postoperative staging (Fig. 2) can help to identify the children with FTC who may benefit from ¹³¹I treatment (200). Further studies are required to understand the benefit of routine ¹³¹I treatment in children with no evidence for iodine-avid metastases and a stimulated Tg ≤ 10 ng/mL.

The follow-up of children with FTC is similar to PTC and will include serial monitoring of serum Tg levels and TSH suppression (see Table 6). One notable difference is that routine neck US is typically of lesser importance for the pediatric patient with conventional FTC who has had a TT, especially when there is no evidence of disease based upon the Tg data. However, intermittent ultrasonography in children who have had only lobectomy may be valuable.

Pediatric FTC is a rare malignancy. Because of the paucity of data regarding FTC in children, strong recommendations regarding therapy cannot be made and further studies are required to better understand the long-term outcomes and to risk-stratify children who would benefit from more extensive thyroid surgery and ¹³¹I therapy.

■ **RECOMMENDATION 32(A)**

Patients with clear evidence of vascular invasion (more than three involved blood vessels), known distant metastasis, and/or tumor size >4 cm should be treated with TT and staged postoperatively with RAI.

Recommendation rating: C

■ **RECOMMENDATION 32(B)**

Minimally invasive FTC <4 cm in size and with no or minimal vascular invasion (three or fewer involved blood vessels) should be treated on a case-by-case basis, but lobectomy alone rather than TT with ¹³¹I therapy may be sufficient.

Recommendation rating: C

■ **RECOMMENDATION 32(C)**

In all children diagnosed with FTC, consideration should be given to genetic counseling and genetic testing for germline *PTEN* mutations particularly in the child with macrocephaly or with a family history suggestive of the *PTEN* hamartoma tumor syndrome.

Recommendation rating: C

[F1] WHAT ARE THE UNIQUE ISSUES THAT MAY AFFECT CHILDREN DIAGNOSED WITH DTC?

Long-term psychosocial issues have been reported in survivors of other childhood cancers and appear to be more pronounced in the unemployed, the poorly educated, and those with poor financial resources (397). Parents perceive children with cancer to be more vulnerable than their peers, and this may lead to overprotection and a reduction in the child's

quality of life (398), a measure that may not be directly related to the severity of the cancer prognosis (399). Furthermore, this perception of vulnerability has been shown to persist for at least 5–10 years after completion of therapy (400). One small study in children and adolescents treated for thyroid cancer demonstrated no difference in quality of life or anxiety levels compared to children treated for hypothyroidism or normative controls (401); however, this was a cross-sectional study and 11 of 16 patients were in remission at the time of completing the survey. Further exploration of the psychosocial impact of thyroid cancer on the patient and his or her parents and siblings is required (402). Based on the data from other forms of childhood cancer, similar parental perceptions of vulnerability and other psychosocial issues may occur in children with DTC as they age. Providers should be aware of this possibility and remain alert to signs of psychosocial distress.

As with any chronic illness, adherence to life-long LT₄ therapy is an issue, and it is not uncommon for children to have elevated levels of TSH when not required for evaluation or treatment with RAI (403). Therefore, medication adherence can be a challenge and frequent assessments of thyroid hormone levels along with education about the benefit of TSH suppression in the long-term management of DTC are important. Motivational interviewing may be a nonjudgmental means by which to improve compliance (404,405). For patients who received ¹³¹I therapy, health care providers should also continue to be aware of the potential for second malignancies and chronic adverse effects from ¹³¹I treatment (see Section C16).

■ **RECOMMENDATION 33**

Children with DTC may experience adverse psychosocial effects and be nonadherent with LT₄ therapy. Attention to these possibilities and supportive counseling as required are important adjuncts in the long-term follow-up of children with DTC. Future studies on the impact of a DTC diagnosis and treatment on quality of life in children are required.

Recommendation rating: C

[G1] HOW LONG SHOULD A CHILD WITH PTC BE MONITORED?

Overall recurrence rates for children with PTC are approximately 30%. In some studies, more than half of recurrences were seen in the first 7 years after treatment (11), while others found equal recurrence rates in the first and second decades after surgery (169). Delayed recurrence as long as 20–40 years after diagnosis has also been reported (5,217). From these data, it would appear that children with PTC should be followed for several decades to detect all late recurrences. However, Tg levels were not reported for patients in these earlier studies, and it remains unclear if these recurrence data apply to children with an undetectable stimulated Tg. Until additional long-term data are available, we suggest that all children with PTC should be followed prospectively but with reduced intensity over time, especially for those with undetectable TSH-stimulated Tg (see Table 6).

■ **RECOMMENDATION 34**

Recurrence of DTC in children has been reported as long as 40 years after initial therapy. For that reason,

children with DTC should be followed for life, albeit with decreasing intensity for those with no evidence for disease.

Recommendations rating: B

[G2] WHAT ARE THE AREAS FOR FUTURE RESEARCH?

The treatment of children with DTC is evolving. We have moved from an era of intensive therapy in which all children received TT and ^{131}I to an era of personalized therapy in which treatment is individualized based on pre- and postoperative staging and continuous risk stratification. Although the current recommendations have been made based on the best available data and clinical experience, such evolution in care generates uncertainty in providers, parents, and patients. The greatest uncertainty surrounds the proper use of ^{131}I , the interpretation of Tg and TgAb levels, the role of prospective US monitoring in presymptomatic children at risk for thyroid neoplasia, the use of novel targeted therapies for advanced disease that is unresponsive to ^{131}I , and the long-term psychosocial impacts of this disease on children and their families. These areas require well-designed long-term, multicenter studies that will be difficult to perform because of the rarity of pediatric DTC and the prolonged follow-up required to reach meaningful end-points. Further research should be facilitated by ensuring that children with DTC are treated when possible at centers with multidisciplinary interest and expertise in this disease.

ACKNOWLEDGMENTS

The task force would like to thank Ms. Shirlyn Barger, ATA assistant to the task force, for her diligence, ever-pleasant nature, and incredible support during the guidelines development process. We acknowledge Martha Zeigler, MD (ATA board liaison) for her helpful contributions to our discussions and all of our colleagues who have indirectly contributed to these guidelines via informal discussions and patient care. Finally, we acknowledge and thank our patients and families who have impassioned us to develop these guidelines and who continue to inspire and teach us.

ENDORSEMENTS

The final document was officially endorsed by the British Nuclear Medicine Society; Canadian Society of Otolaryngology-Head and Neck Surgery; European Association for Cranio-Maxillo-Facial Surgery; European Association of Nuclear Medicine; International Association of Endocrine Surgeons; International Federation of Head and Neck Oncologic Societies; Latin American Thyroid Society; The Endocrine Society; The Endocrine Society of Australia.

DISCLAIMER

It is our goal in formulating these inaugural guidelines, and the ATA's goal in providing support for the development of these guidelines, that they assist in the clinical care of patients and improve the standard of care of children with thyroid neoplasia. These guidelines include what we believe to be contemporary, rational, and optimal medical practice, but they are not intended to be inclusive of all proper approaches

to care nor exclusive of other treatments that are reasonably directed at the same outcomes. We developed these guidelines based on the evidence available in the recent literature and the expert opinion of the task force. It is not the intent of these guidelines to replace individual decision making, the wishes of the patient or family, or clinical judgment.

AUTHOR DISCLOSURE STATEMENT

These guidelines were funded by the ATA without support from any commercial sources. The patient organization, ThyCa: Thyroid Cancer Survivors' Association, Inc., also contributed an unrestricted educational grant toward the development of the pediatric thyroid cancer guidelines.

AJB was a consultant for Akrimax; SB received research support from IBSA Institute Biochimique; GLF received research support from Grifols, Novo Nordisk, and Juvenile Diabetes Research Foundation; MR was a speaker for Pfizer and Novo Nordisk and served as a consultant and received research support from Eli Lilly; SGW was a consultant for Novo Nordisk. M.L. was a consultant for AstraZeneca, Bayer Healthcare, Genzyme, and Sobi and has received speaker honoraria and research support from Genzyme, Henning, and Merck. AJB, GLF, and SGW also served as advisors to ThyCa. PA, JMC, CAD, JH, IDH, ML, MTP, GBT, and SY reported no financial interests, arrangements, or affiliations with the manufacturer of any products or devices.

REFERENCES

- Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* **19**:1167–1214.
- Cobin RH, Gharib H, Bergman DA, Clark OH, Cooper DS, Daniels GH, Dickey RA, Duick DS, Garber JR, Hay ID, Kukora JS, Lando HM, Schorr AB, Zeiger MA; Thyroid Carcinoma Task Force 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. *American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract* **7**:202–220.
- The NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma (Version 2.2013). Available at www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (accessed October 3, 2013).
- British Thyroid Association. Royal College of Physicians 2007 Guidelines for the Management of Thyroid Cancer. Second edition. Royal College of Physicians, London.
- Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB 2010 Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. *World J Surg* **34**:1192–1202.
- Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* **93**:504–515.
- Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C,

- Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. *Br J Cancer* **89**:1638–1644.
8. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE 2009 Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. *J Surg Res* **156**:167–172.
 9. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Mang O, Lau WH 2004 Differentiated thyroid carcinoma in childhood and adolescence—clinical course and role of radioiodine. *Pediatr Blood Cancer* **42**:176–183.
 10. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S 2006 Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. *Ann Surg* **243**:525–532.
 11. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. *Clin Endocrinol* **49**:619–628.
 12. Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuchi A 1992 Differentiated thyroid carcinoma in children and adolescents. *World J Surg* **16**:547–553; discussion 553–544.
 13. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb GW, 3rd, Sklar C, Vlamis V, Haase GM, La Quaglia MP 1998 Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. *Ann Surg* **227**:533–541.
 14. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulka A, Prokurat A, Wygoda Z, Jarzab B 2007 Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. *J Nucl Med* **48**:879–888.
 15. Popovtzer A, Shpitzer T, Bahar G, Feinmesser R, Segal K 2006 Thyroid cancer in children: management and outcome experience of a referral center. *Otolaryngol Head Neck Surg* **135**:581–584.
 16. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975–2010. Available at http://seer.cancer.gov/csr/1975_2010/ (updated June 14, 2013; accessed November 18, 2013).
 17. Vergamini LB, Frazier AL, Abrantes FL, Ribeiro KB, Rodriguez-Galindo C 2014 Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. *J Pediatr* **164**:1481–1485.
 18. Wu XC, Chen VW, Steele B, Roffers S, Klotz JB, Correa CN, Carozza SE 2003 Cancer incidence in adolescents and young adults in the United States, 1992–1997. *J Adolesc Health* **32**:405–415.
 19. Waguespack S, Wells S, Ross J, Bleyer A 2006 Thyroid cancer. In: Bleyer A, O'Leary M, Barr R, Ries L (eds) *Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival 1975–2000*. Vol NIH Pub. No. 06-5767. National Cancer Institute, Bethesda, MD, pp 143–154.
 20. Demidchik YE, Saenko VA, Yamashita S 2007 Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. *Arq Bras Endocrinol Metabol* **51**:748–762.
 21. Spoudeas HA 2005 Paediatric Endocrine Tumours: A Multi-Disciplinary Consensus Statement of Best Practice from a Working Group Convened Under the Auspices of the The British Society of Paediatric Endocrinology & Diabetes and the United Kingdom Children's Cancer Study Group. Novo Nordisk Ltd, West Sussex, United Kingdom.
 22. Feinmesser R, Lubin E, Segal K, Noyek A 1997 Carcinoma of the thyroid in children—a review. *J Pediatr Endocrinol Metab* **10**:561–568.
 23. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H 1990 Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. *Am J Surg* **160**:341–343.
 24. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, Cangir A, Haynie TP 1993 Pulmonary metastases in children and young adults with differentiated thyroid cancer. *Cancer* **71**:1348–1352.
 25. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 *Pathology and Genetics of Tumours of Endocrine Organs* World Health Organization Classification of Tumours, Volume 8. IARC Press, Lyon, France.
 26. Monaco SE, Pantanowitz L, Khalbuss WE, Benkovich VA, Ozolek J, Nikiforova MN, Simons JP, Nikiforov YE 2012 Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. *Cancer Cytopathol* **120**:342–350.
 27. Gupta A, Ly S, Castroneves LA, Frates MC, Benson CB, Feldman HA, Wassner AJ, Smith JR, Marqusee E, Alexander EK, Barletta J, Doubilet PM, Peters HE, Webb S, Modi BP, Paltiel HJ, Kozakewich H, Cibas ES, Moore FD Jr, Shamberger RC, Larsen PR, Huang SA 2013 A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults. *J Clin Endocrinol Metab* **98**:3238–3245.
 28. Halac I, Zimmerman D 2005 Thyroid nodules and cancers in children. *Endocrinol Metab Clin North Am* **34**:725–744, x.
 29. Koo JS, Hong S, Park CS 2009 Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. *Thyroid* **19**:1225–1231.
 30. Harach HR, Williams ED 1995 Childhood thyroid cancer in England and Wales. *Br J Cancer* **72**:777–783.
 31. Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS, McConahey WM 1988 Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. *Surgery* **104**:1157–1166.
 32. Tucker MA, Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE, et al. 1991 Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. *Cancer Res* **51**:2885–2888.
 33. Sinnott B, Ron E, Schneider AB 2010 Exposing the thyroid to radiation: a review of its current extent, risks, and implications. *Endocr Rev* **31**:756–773.
 34. Yamashita S 2014 Tenth Warren K. Sinclair keynote address—the Fukushima nuclear power plant accident and comprehensive health risk management. *Health Physics* **106**:166–180.
 35. Schlumberger M, Pacini F 2003 *Thyroid Tumors*. Vol. Nucleon, Paris.
 36. Faggiano A, Coulot J, Bellon N, Talbot M, Caillou B, Ricard M, Bidart JM, Schlumberger M 2004 Age-dependent

- variation of follicular size and expression of iodine transporters in human thyroid tissue. *J Nucl Med* **45**:232–237.
37. Naing S, Collins BJ, Schneider AB 2009 Clinical behavior of radiation-induced thyroid cancer: factors related to recurrence. *Thyroid* **19**:479–485.
 38. Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P 2008 Intragenic mutations in thyroid cancer. *Endocrinol Metab Clin North Am* **37**:333–362, viii.
 39. Woyach J, Shah M 2009 New therapeutic advances in the management of progressive thyroid cancer. *Endocr Relat Cancer* **16**:715–731.
 40. Yamashita S, Saenko V 2007 Mechanisms of disease: molecular genetics of childhood thyroid cancers. *Nat Clin Pract Endocrinol Metab* **3**:422–429.
 41. Kebebew E 2008 Hereditary non-medullary thyroid cancer. *World J Surg* **32**:678–682.
 42. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, Treseler PA, Weier HU, Freimer N, Siperstein AE, Duh QY, Takami H, Clark OH 2000 Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. *Surgery* **128**:1043–1051.
 43. Samuel AM, Sharma SM 1991 Differentiated thyroid carcinomas in children and adolescents. *Cancer* **67**:2186–2190.
 44. Machens A, Lorenz K, Nguyen Thanh P, Brauckhoff M, Dralle H 2010 Papillary thyroid cancer in children and adolescents does not differ in growth pattern and metastatic behavior. *J Pediatr* **157**:648–652.
 45. Wada N, Sugino K, Mimura T, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Rino Y, Masuda M, Ito K 2009 Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival. *BMC Cancer* **9**:306.
 46. Savio R, Gosnell J, Palazzo FF, Sywak M, Agarwal G, Cowell C, Shun A, Robinson B, Delbridge LW 2005 The role of a more extensive surgical approach in the initial multimodality management of papillary thyroid cancer in children. *J Pediatr Surg* **40**:1696–1700.
 47. Jarzab B, Handkiewicz Junak D, Wloch J, Kalembe B, Roskosz J, Kukulska A, Puch Z 2000 Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. *Eur J Nucl Med* **27**:833–841.
 48. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M 1987 Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. *J Clin Endocrinol Metab* **65**:1088–1094.
 49. Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S 2004 Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? *Thyroid* **14**:217–225.
 50. O’Gorman CS, Hamilton J, Rachmiel M, Gupta A, Ngan BY, Daneman D 2010 Thyroid cancer in childhood: a retrospective review of childhood course. *Thyroid* **20**:375–380.
 51. Giuffrida D, Scollo C, Pellegriti G, Lavenia G, Iurato MP, Pezzin V, Belfiore A 2002 Differentiated thyroid cancer in children and adolescents. *J Endocrinol Invest* **25**:18–24.
 52. Grigsby PW, Gal-or A, Michalski JM, Doherty GM 2002 Childhood and adolescent thyroid carcinoma. *Cancer* **95**:724–729.
 53. Wada N, Sugino K, Mimura T, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Yukawa N, Rino Y, Masuda M, Ito K 2009 Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. *Ann Surg Oncol* **16**:3442–3449.
 54. U.S. Preventive Services Task Force Ratings: Grade Definitions. Available at www.uspreventiveservicestaskforce.org/page/name/us-preventive-services-task-force-ratings (accessed June 3, 2015).
 55. Niedziela M 2006 Pathogenesis, diagnosis and management of thyroid nodules in children. *Endocr Relat Cancer* **13**:427–453.
 56. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, Duick DS, Guglielmi R, Hamilton CR Jr, Zeiger MA, Zini M 2006 American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. *Endocr Pract* **12**:63–102.
 57. Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B 2010 Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following ¹³¹I treatment: a systematic review. *Thyroid* **20**:1095–1101.
 58. Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V 2011 Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. *Eur J Nucl Med Mol Imaging* **38**:651–655.
 59. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Tuttle RM, Francis G 2005 BRAF mutations are uncommon in papillary thyroid cancer of young patients. *Thyroid* **15**:320–325.
 60. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA 2005 Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. *Cancer Res* **65**:2465–2473.
 61. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA 2000 The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. *Oncogene* **19**:3948–3954.
 62. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. *J Clin Endocrinol Metab* **85**:1170–1175.
 63. Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis GL 2002 Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. *Pediatr Res* **52**:737–744.
 64. Bal CS, Padhy AK, Kumar A 2001 Clinical features of differentiated thyroid carcinoma in children and adolescents from a sub-Himalayan iodine-deficient endemic zone. *Nucl Med Commun* **22**:881–887.
 65. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL 2004 Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. *World J Surg* **28**:1088–1092.
 66. Alessandri AJ, Goddard KJ, Blair GK, Fryer CJ, Schultz KR 2000 Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. *Med Pediatr Oncol* **35**:41–46.
 67. Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch-Gavan M, Phillip M 2009 Differentiated thyroid carcinoma in

- pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. *J Pediatr* **154**:708–714.
68. Zablotska LB, Ron E, Rozhko AV, Hatch M, Polyanskaya ON, Brenner AV, Lubin J, Romanov GN, McConnell RJ, O’Kane P, Evseenko VV, Drozdovitch VV, Luckyanov N, Minenko VF, Bouville A, Masyakin VB 2011 Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chernobyl accident. *Br J Cancer* **104**:181–187.
 69. 2010 Thyroid. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) *AJCC Cancer Staging Manual*. Seventh edition. Springer, New York, NY, pp 87–96.
 70. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. *J Clin Endocrinol Metab* **93**:3058–3065.
 71. Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas DC, Udelsman R, Ann Sosa J 2008 Pediatric endocrine surgery: who is operating on our children? *Surgery* **144**:869–877; discussion 877.
 72. Kundel A, Thompson GB, Richards ML, Qiu LX, Cai Y, Schwenk FW, Lief AN, Pittock ST, Kumar S, Tebben PJ, Hay ID, Grant CS 2014 Pediatric endocrine surgery: a 20-year experience at the Mayo Clinic. *J Clin Endocrinol Metab* **99**:399–406.
 73. Niedziela M, Korman E, Breborowicz D, Trejster E, Harasymczuk J, Warzywoda M, Rolski M, Breborowicz J 2004 A prospective study of thyroid nodular disease in children and adolescents in western Poland from 1996 to 2000 and the incidence of thyroid carcinoma relative to iodine deficiency and the Chernobyl disaster. *Pediatr Blood Cancer* **42**:84–92.
 74. Oertel JE, Klinck GH 1965 Structural changes in the thyroid glands of healthy young men. *Med Ann Dist Columbia* **34**:75–77.
 75. Hayashida N, Imaizumi M, Shimura H, Okubo N, Asari Y, Nigawara T, Midorikawa S, Kotani K, Nakaji S, Otsuru A, Akamizu T, Kitaoka M, Suzuki S, Taniguchi N, Yamashita S, Takamura N; Investigation Committee for the Proportion of Thyroid Ultrasound Findings 2013 Thyroid ultrasound findings in children from three Japanese prefectures: Aomori, Yamanashi and Nagasaki. *PLoS One* **8**:e83220.
 76. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L 2000 Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab* **85**:3227–3232.
 77. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD 2009 Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. *J Clin Oncol* **27**:2356–2362.
 78. Mazzaferri EL 1993 Management of a solitary thyroid nodule. *N Engl J Med* **328**:553–559.
 79. Schneider AB, Bekerman C, Leland J, Rosengarten J, Hyun H, Collins B, Shore-Freedman E, Gierlowski TC 1997 Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. *J Clin Endocrinol Metab* **82**:4020–4027.
 80. Ito M, Yamashita S, Ashizawa K, Namba H, Hoshi M, Shibata Y, Sekine I, Nagataki S, Shigematsu I 1995 Childhood thyroid diseases around Chernobyl evaluated by ultrasound examination and fine needle aspiration cytology. *Thyroid* **5**:365–368.
 81. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res* **141**:259–277.
 82. Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Mertens AC, Liu Y, Hammond S, Land CE, Neglia JP, Donaldson SS, Meadows AT, Sklar CA, Robison LL, Inskip PD 2006 Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. *Radiat Res* **166**:618–628.
 83. Brignardello E, Corrias A, Isolato G, Palestini N, Cordero di Montezemolo L, Fagioli F, Boccuzzi G 2008 Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. *J Clin Endocrinol Metab* **93**:4840–4843.
 84. Metzger ML, Howard SC, Hudson MM, Gow KW, Li CS, Krasin MJ, Merchant T, Kun L, Shelso J, Pui CH, Shochat SJ, McCarville MB 2006 Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. *Pediatr Blood Cancer* **46**:314–319.
 85. Son EJ, Nose V 2012 Familial follicular cell-derived thyroid carcinoma. *Front Endocrinol (Lausanne)* **3**:61.
 86. Kalkan E, Waguespack SG 2013 Endocrine tumors associated with neurofibromatosis type 1, Peutz-Jeghers syndrome and other familial neoplasia syndromes. *Front Horm Res* **41**:166–181.
 87. Septer S, Slowik V, Morgan R, Dai H, Attard T 2013 Thyroid cancer complicating familial adenomatous polyposis: mutation spectrum of at-risk individuals. *Hered Cancer Clin Pract* **11**:13.
 88. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, Rene-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner LS, Bertagna X, Carney JA, Stratakis CA 2009 Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. *J Clin Endocrinol Metab* **94**:2085–2091.
 89. de Kock L, Sabbaghian N, Soglio DB, Guillerman RP, Park BK, Chami R, Deal CL, Priest JR, Foulkes WD 2014 Exploring the association between DICER1 mutations and differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **99**:E1072–E1077.
 90. Doros L, Schultz KA, Stewart DR, Bauer AJ, Williams G, Rossi CT, Carr A, Yang J, Dehner LP, Messinger Y, Hill DA 1993 DICER1-related disorders. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds) *GeneReviews*, Seattle, WA.
 91. Smith JR, Marqusee E, Webb S, Nose V, Fishman SJ, Shamberger RC, Frates MC, Huang SA 2011 Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. *J Clin Endocrinol Metab* **96**:34–37.
 92. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C 2011 Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. *J Clin Endocrinol Metab* **96**:E2063–E2071.
 93. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E 2013 Cowden syndrome and the PTEN

- hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst* **105**:1607–1616.
94. Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr 2013 Spectrum and risk of neoplasia in Werner syndrome: a systematic review. *PLoS One* **8**:e59709.
 95. Lapunzina P 2005 Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. *Am J Med Genet C Semin Med Genet* **137C**:53–71.
 96. Papatomas TG, Gaal J, Corssmit EP, Oudijk L, Korper-shoek E, Heimdal K, Bayley JP, Morreau H, van Dooren M, Pappaspyrou K, Schreiner T, Hansen T, Andresen PA, Restuccia DF, van Kessel I, van Leenders GJ, Kros JM, Looijenga LH, Hofland LJ, Mann W, van Nederveen FH, Mete O, Asa SL, de Krijger RR, Dinjens WN 2014 Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. *Eur J Endocrinol* **170**:1–12.
 97. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE 2008 F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. *JAMA* **299**:1315–1319.
 98. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A 2003 Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. *J Clin Endocrinol Metab* **88**:4413–4417.
 99. Triggiani V, Guastamacchia E, Renzulli G, Giagulli VA, Tafaro E, Licchelli B, Resta F, Sabba C, Bagnulo R, Lastella P, Stella A, Resta N 2011 Papillary thyroid carcinoma in Peutz-Jeghers syndrome. *Thyroid* **21**:1273–1277.
 100. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brill L, Pazaitou-Panayiotou K, Carli A, Caruso G, Toti P, Capitani S, Pammolli A, Pacini F 2008 Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. *Endocr Relat Cancer* **15**:1075–1081.
 101. Charkes ND 2006 On the prevalence of familial non-medullary thyroid cancer in multiply affected kindreds. *Thyroid* **16**:181–186.
 102. Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H, Sippel RS 2012 In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. *Thyroid* **22**:3–8.
 103. Moses W, Weng J, Kebebew E 2011 Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. *Thyroid* **21**:367–371.
 104. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutsky I, Weinstein R, Lazar L, Serov S, Singer J, Hirsch D, Shimon I, Benbassat C 2011 Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. *Thyroid* **21**:43–48.
 105. Sippel RS, Caron NR, Clark OH 2007 An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. *World J Surg* **31**:924–933.
 106. Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, Stadler ZK, Markowitz AJ 2012 The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. *Clin Colorectal Cancer* **11**:304–308.
 107. Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Lacerda RX, Calsolari MR 2012 Ultrasonographic screening for thyroid cancer in siblings of patients with apparently sporadic papillary carcinoma. *Thyroid* **22**:805–808.
 108. Corrias A, Cassio A, Weber G, Mussa A, Wasniewska M, Rapa A, Gastaldi R, Einaudi S, Baronio F, Vigone MC, Messina MF, Bal M, Bona G, de Sanctis C 2008 Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. *Arch Pediatr Adolesc Med* **162**:526–531.
 109. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL 2012 Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. *J Clin Endocrinol Metab* **97**:2682–2692.
 110. Lyshchik A, Drozd V, Demidchik Y, Reiners C 2005 Diagnosis of thyroid cancer in children: value of gray-scale and power doppler US. *Radiology* **235**:604–613.
 111. McHenry CR, Huh ES, Machevano RN 2008 Is nodule size an independent predictor of thyroid malignancy? *Surgery* **144**:1062–1068; discussion 1068–1069.
 112. Drozd VM, Lushchik ML, Polyanskaya ON, Fridman MV, Demidchik YE, Lushchik AP, Biko J, Reiners C, Shibata Y, Saenko VA, Yamashita S 2009 The usual ultrasonographic features of thyroid cancer are less frequent in small tumors that develop after a long latent period after the Chernobyl radiation release accident. *Thyroid* **19**:725–734.
 113. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* **92**:3590–3594.
 114. Stevens C, Lee JK, Sadatsafavi M, Blair GK 2009 Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. *J Pediatr Surg* **44**:2184–2191.
 115. Amrikachi M, Ponder TB, Wheeler TM, Smith D, Ramzy I 2005 Thyroid fine-needle aspiration biopsy in children and adolescents: experience with 218 aspirates. *Diagn Cytopathol* **32**:189–192.
 116. Liel Y, Ariad S, Barchana M 2001 Long-term follow-up of patients with initially benign thyroid fine-needle aspirations. *Thyroid* **11**:775–778.
 117. Yokozawa T, Fukata S, Kuma K, Matsuzuka F, Kobayashi A, Hirai K, Miyauchi A, Sugawara M 1996 Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. *World J Surg* **20**:848–853; discussion 853.
 118. Izquierdo R, Shankar R, Kort K, Khurana K 2009 Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. *Thyroid* **19**:703–705.
 119. Corrias A, Einaudi S, Chiorboli E, Weber G, Crino A, Andreo M, Cesaretti G, de Sanctis L, Messina MF, Segni M, Cicchetti M, Vigone M, Pasquino AM, Spera S, de Luca F, Mussa GC, Bona G 2001 Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. *J Clin Endocrinol Metab* **86**:4644–4648.
 120. Sohn YM, Kim EK, Moon HJ, Kim SJ, Kwak JY 2011 Suspiciously malignant findings on ultrasound after fine

- needle aspiration biopsy in a thyroid nodule with initially benign ultrasound and cytologic result: to repeat or to follow-up. *Clin Imaging* **35**:470–475.
121. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* **19**:1159–1165.
 122. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:425–437.
 123. Baloch ZW, LiVolsi VA 1999 Post fine-needle aspiration histologic alterations of thyroid revisited. *Am J Clin Pathol* **112**:311–316.
 124. Smith M, Pantanowitz L, Khalbuss WE, Benkovich VA, Monaco SE 2013 Indeterminate pediatric thyroid fine needle aspirations: a study of 68 cases. *Acta Cytol* **57**:341–348.
 125. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metab* **96**:3390–3397.
 126. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, Livolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JJ, Zeiger MA, Lanman RB, Haugen BR 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. *N Engl J Med* **367**:705–715.
 127. Cerutti JM 2011 Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy. *Curr Genomics* **12**:589–596.
 128. Duick DS 2012 Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer. *Endocr Pract* **18**:611–615.
 129. Ferraz C, Eszlinger M, Paschke R 2011 Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. *J Clin Endocrinol Metab* **96**:2016–2026.
 130. Nikiforov YE, Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. *Nat Rev Endocrinol* **7**:569–580.
 131. Buryk MA, Monaco SE, Witchel SF, Mehta DK, Gurtunca N, Nikiforov YE, Simons JP 2013 Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. *Int J Pediatr Otorhinolaryngol* **77**:1697–1700.
 132. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A, Pacini F 2001 RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. *J Clin Endocrinol Metab* **86**:3211–3216.
 133. Millman B, Pellitteri PK 1997 Nodular thyroid disease in children and adolescents. *Otolaryngol Head Neck Surg* **116**:604–609.
 134. Orlandi A, Puscar A, Capriata E, Fideleff H 2005 Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. *Thyroid* **15**:274–278.
 135. Pinchot SN, Al-Wagih H, Schaefer S, Sippel R, Chen H 2009 Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. *Arch Surg* **144**:649–655.
 136. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH 2007 The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. *Surgery* **142**:837–844; discussion 844 e831–833.
 137. Wharry LI, McCoy KL, Stang MT, Armstrong MJ, Lebeau SO, Tublin ME, Sholosh B, Silbermann A, Ohori NP, Nikiforov YE, Hodak SP, Carty SE, Yip L 2014 Thyroid nodules (>=4 cm): can ultrasound and cytology reliably exclude cancer? *World J Surg* **38**:614–621.
 138. Burch HB 1995 Evaluation and management of the solid thyroid nodule. *Endocrinol Metab Clin North Am* **24**:663–710.
 139. Lawrence W Jr, Kaplan BJ 2002 Diagnosis and management of patients with thyroid nodules. *J Surg Oncol* **80**:157–170.
 140. Corrias A, Mussa A, Wasniewska M, Segni M, Cassio A, Salerno M, Gastaldi R, Vigone MC, Bal M, Matarazzo P, Weber G, De Luca F 2011 Levothyroxine treatment in pediatric benign thyroid nodules. *Horm Res Paediatr* **75**:246–251.
 141. Faber J, Galloe AM 1994 Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur J Endocrinol* **130**:350–356.
 142. Celani MF, Mariani M, Mariani G 1990 On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. *Acta Endocrinol (Copenh)* **123**:603–608.
 143. Gharib H, Mazzaferri EL 1998 Thyroxine suppressive therapy in patients with nodular thyroid disease. *Ann Intern Med* **128**:386–394.
 144. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbri R, Pacella CM 1998 Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. *J Clin Endocrinol Metab* **83**:780–783.
 145. Shimaoka K, Sokal JE 1974 Suppressive therapy of nontoxic goiter. *Am J Med* **57**:576–583.
 146. Wemeau JL, Caron P, Schwartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V 2002 Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. *J Clin Endocrinol Metab* **87**:4928–4934.
 147. Sdano MT, Falciglia M, Welge JA, Steward DL 2005 Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. *Otolaryngol Head Neck Surg* **133**:391–396.
 148. Fogelfeld L, Wiviott MB, Shore-Freedman E, Blend M, Bekerman C, Pinsky S, Schneider AB 1989 Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. *N Engl J Med* **320**:835–840.
 149. Subbiah S, Collins BJ, Schneider AB 2007 Factors related to the recurrence of thyroid nodules after surgery for benign radiation-related nodules. *Thyroid* **17**:41–47.
 150. Niedziela M, Breborowicz D, Trejster E, Korman E 2002 Hot nodules in children and adolescents in western Poland

- from 1996 to 2000: clinical analysis of 31 patients. *J Pediatr Endocrinol Metab* **15**:823–830.
151. Schwab KO, Pfarr N, van der Werf-Grohmann N, Pohl M, Radecke J, Musholt T, Pohlenz J 2009 Autonomous thyroid adenoma: only an adulthood disease? *J Pediatr* **154**:931–933 e932.
 152. Hwang HS, Orloff LA 2011 Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *Laryngoscope* **121**:487–491.
 153. Park JS, Son KR, Na DG, Kim E, Kim S 2009 Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. *AJR Am J Roentgenol* **192**:66–72.
 154. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* **134**:946–954; discussion 954–945.
 155. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL 3rd 2004 Surgeon-performed ultrasound in the management of thyroid malignancy. *Am Surg* **70**:576–580; discussion 580–572.
 156. Gonzalez HE, Cruz F, O'Brien A, Goni I, Leon A, Claire R, Camus M, Dominguez F, Mosso L, Arteaga E, Gonzalez G, Lopez JM, Rodriguez JA, Carrasco C, Fardella C 2007 Impact of preoperative ultrasonographic staging of the neck in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* **133**:1258–1262.
 157. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, Reading CC, Charboneau JW 2006 Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. *Arch Surg* **141**:489–494; discussion 494–486.
 158. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T 1998 Preoperative staging of thyroid papillary carcinoma with ultrasonography. *Eur J Radiol* **29**:4–10.
 159. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK 2009 Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. *AJR Am J Roentgenol* **193**:871–878.
 160. Mihailovic J, Prvulovic M, Ivkovic M, Markoski B, Martinov D 2010 MRI versus ¹³¹I whole-body scintigraphy for the detection of lymph node recurrences in differentiated thyroid carcinoma. *AJR Am J Roentgenol* **195**:1197–1203.
 161. Miyakoshi A, Dalley RW, Anzai Y 2007 Magnetic resonance imaging of thyroid cancer. *Top Magn Reson Imaging* **18**:293–302.
 162. Brink JS, van Heerden JA, McIver B, Salomao DR, Farley DR, Grant CS, Thompson GB, Zimmerman D, Hay ID 2000 Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. *Surgery* **128**:881–886; discussion 886–887.
 163. Jarzab B, Handkiewicz-Junak D 2007 Differentiated thyroid cancer in children and adults: same or distinct disease? *Hormones (Athens)* **6**:200–209.
 164. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. *J Nucl Med* **29**:1790–1794.
 165. Kuo SF, Chen ST, Kao PF, Chang YC, Chou SC, Lin JD 2004 Papillary thyroid cancer with chest metastases only detected using radioactive iodine. *Chang Gung Med J* **27**:663–672.
 166. Ilgan S, Karacalioglu AO, Pabuscu Y, Atac GK, Arslan N, Ozturk E, Gunalp B, Ozguven MA 2004 Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. *Eur J Nucl Med Mol Imaging* **31**:825–830.
 167. La Quaglia MP, Corbally MT, Heller G, Exelby PR, Brennan MF 1988 Recurrence and morbidity in differentiated thyroid carcinoma in children. *Surgery* **104**:1149–1156.
 168. Bargren AE, Meyer-Rochow GY, Delbridge LW, Sidhu SB, Chen H 2009 Outcomes of surgically managed pediatric thyroid cancer. *J Surg Res* **156**:70–73.
 169. Jarzab B, Handkiewicz-Junak D, Wloch J 2005 Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. *Endocr Relat Cancer* **12**:773–803.
 170. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. *J Clin Endocrinol Metab* **87**:1499–1501.
 171. Spencer CA, Lopresti JS 2008 Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. *Nat Clin Pract Endocrinol Metab* **4**:223–233.
 172. Toni R, Casa CD, Castorina S, Roti E, Ceda G, Valenti G 2005 A meta-analysis of inferior thyroid artery variations in different human ethnic groups and their clinical implications. *Ann Anat* **187**:371–385.
 173. Toni R, Della Casa C, Castorina S, Malaguti A, Mosca S, Roti E, Valenti G 2004 A meta-analysis of superior thyroid artery variations in different human groups and their clinical implications. *Ann Anat* **186**:255–262.
 174. Nobori M, Saiki S, Tanaka N, Harihara Y, Shindo S, Fujimoto Y 1994 Blood supply of the parathyroid gland from the superior thyroid artery. *Surgery* **115**:417–423.
 175. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC Jr, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R 2009 Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid* **19**:1153–1158.
 176. Powers PA, Dinuer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL 2003 Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescents. *J Pediatr Endocrinol Metab* **16**:693–702.
 177. Buffet C, Golmard JL, Hoang C, Tresallet C, Du Pasquier Fediaevsky L, Fierrard H, Aurengo A, Menegaux F, Leenhardt L 2012 Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. *Eur J Endocrinol* **167**:267–275.
 178. Farahati J, Reiners C, Demidchik EP 1999 Is the UICC/AJCC classification of primary tumor in childhood thyroid carcinoma valid? *J Nucl Med* **40**:2125.
 179. Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN 1998 Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. *Head Neck* **20**:549–555.
 180. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L 2006 Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in

- papillary thyroid cancer. *Surgery* **140**:1000–1005; discussion 1005–1007.
181. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB 2008 Recent advances in thyroid cancer. *Curr Probl Surg* **45**:156–250.
 182. Shen WT, Ogawa L, Ruan D, Suh I, Duh QY, Clark OH 2010 Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. *Surgery* **148**:398–403.
 183. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA 2003 Greater local recurrence occurs with “berry picking” than neck dissection in thyroid cancer. *Am Surg* **69**:191–196; discussion 196–197.
 184. Moo TA, Umunna B, Kato M, Butriago D, Kundel A, Lee JA, Zarnegar R, Fahey TJ 3rd 2009 Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. *Ann Surg* **250**:403–408.
 185. Giordano D, Valcavi R, Thompson GB, Pedroni C, Renna L, Gradoni P, Barbieri V 2012 Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. *Thyroid* **22**:911–917.
 186. Fish SA, Langer JE, Mandel SJ 2008 Sonographic imaging of thyroid nodules and cervical lymph nodes. *Endocrinol Metab Clin North Am* **37**:401–417, ix.
 187. Baskin HJ 2004 Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. *Thyroid* **14**:959–963.
 188. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S 2006 The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. *J Clin Endocrinol Metab* **91**:1364–1369.
 189. Cunha N, Rodrigues F, Curado F, Ilheu O, Cruz C, Naidenov P, Rascao MJ, Ganho J, Gomes I, Pereira H, Real O, Figueiredo P, Campos B, Valido F 2007 Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. *Eur J Endocrinol* **157**:101–107.
 190. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. *Cancer* **97**:90–96.
 191. Giovannella L, Bongiovanni M, Trimboli P 2013 Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. *Curr Opin Oncol* **25**:6–13.
 192. Skinner MA, Norton JA, Moley JF, DeBenedetti MK, Wells SA Jr 1997 Heterotopic autotransplantation of parathyroid tissue in children undergoing total thyroidectomy. *J Pediatr Surg* **32**:510–513.
 193. Barczynski M, Cichon S, Konturek A, Cichon W 2008 Applicability of intraoperative parathyroid hormone assay during total thyroidectomy as a guide for the surgeon to selective parathyroid tissue autotransplantation. *World J Surg* **32**:822–828.
 194. Walsh SR, Kumar B, Coveney EC 2007 Serum calcium slope predicts hypocalcaemia following thyroid surgery. *Int J Surg* **5**:41–44.
 195. Grodski S, Lundgren CI, Sidhu S, Sywak M, Delbridge L 2009 Postoperative PTH measurement facilitates day 1 discharge after total thyroidectomy. *Clin Endocrinol* **70**:322–325.
 196. Grodski S, Serpell J 2008 Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia. *World J Surg* **32**:1367–1373.
 197. Sam AH, Dhillon WS, Donaldson M, Moolla A, Meeran K, Tolley NS, Palazzo FF 2011 Serum phosphate predicts temporary hypocalcaemia following thyroidectomy. *Clin Endocrinol* **74**:388–393.
 198. Angelos P 2009 Recurrent laryngeal nerve monitoring: state of the art, ethical and legal issues. *Surg Clin North Am* **89**:1157–1169.
 199. Powers PA, Dinauer CA, Tuttle RM, Francis GL 2004 The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. *J Pediatr Endocrinol Metab* **17**:339–343.
 200. Waguespack SG, Francis G 2010 Initial management and follow-up of differentiated thyroid cancer in children. *J Natl Compr Canc Netw* **8**:1289–1300.
 201. Lee JI, Chung YJ, Cho BY, Chong S, Seok JW, Park SJ 2013 Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. *Surgery* **153**:828–835.
 202. Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, Ferrannini E 2003 Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. *Thyroid* **13**:479–484.
 203. Rosario PW, Mineiro Filho AF, Lacerda RX, dos Santos DA, Calsolari MR 2012 The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation. *Thyroid* **22**:113–116.
 204. Barwick TD, Dhawan RT, Lewington V 2012 Role of SPECT/CT in differentiated thyroid cancer. *Nucl Med Commun* **33**:787–798.
 205. Kim HY, Gelfand MJ, Sharp SE 2011 SPECT/CT imaging in children with papillary thyroid carcinoma. *Pediatr Radiol* **41**:1008–1012.
 206. Xue YL, Qiu ZL, Song HJ, Luo QY 2013 Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature. *Eur J Nucl Med Mol Imaging* **40**:768–778.
 207. Cohen JB, Kalinyak JE, McDougall IR 2004 Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans. *Nucl Med Commun* **25**:129–134.
 208. Hurley JR 2000 Management of thyroid cancer: radioiodine ablation, “stunning,” and treatment of thyroglobulin-positive, (131)I scan-negative patients. *Endocr Pract* **6**:401–406.
 209. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M 2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. *Eur J Nucl Med Mol Imaging* **35**:1405–1412.
 210. Luster M, Lassmann M, Freudenberg LS, Reiners C 2007 Thyroid cancer in childhood: management strategy,

- including dosimetry and long-term results. *Hormones (Athens)* **6**:269–278.
211. Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, Mandel SJ 2007 Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. *Eur J Nucl Med and molecular imaging* **34**:1012–1017.
 212. Seidlin SM, Marinelli LD, Oshry E 1946 Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. *J Am Med Assoc* **132**:838–847.
 213. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG 1996 Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. *American Thyroid Association. Arch Intern Med* **156**:2165–2172.
 214. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. *JAMA* **306**:721–728.
 215. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. *J Clin Endocrinol Metab* **71**:414–424.
 216. La Quaglia MP, Telander RL 1997 Differentiated and medullary thyroid cancer in childhood and adolescence. *Semin Pediatr Surg* **6**:42–49.
 217. Landau D, Vini L, A'Hern R, Harmer C 2000 Thyroid cancer in children: the Royal Marsden Hospital experience. *Eur J Cancer* **36**:214–220.
 218. Nemeč J, Rohling S, Zamrazil V, Pohunkova D 1979 Comparison of the distribution of diagnostic and therapeutic I-131 in the evaluation of differentiated thyroid cancers. *J Nucl Med* **20**:92–97.
 219. Hung W, Sarlis NJ 2002 Current controversies in the management of pediatric patients with well-differentiated non-medullary thyroid cancer: a review. *Thyroid* **12**:683–702.
 220. Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R 2011 The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. *Endocr Rev* **32**:798–826.
 221. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer* **117**:4439–4446.
 222. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. *Thyroid* **19**:451–457.
 223. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S 2012 Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? *J Clin Endocrinol Metab* **97**:2748–2753.
 224. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciantè V, Di Giorgio A, Bruno R, Filetti S, Trischitta V 2006 Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab* **91**:60–63.
 225. Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Dandreis D, Hartl D, Lumbroso J, Chougnet CN, Baudin E, Schlumberger M, Lebouilleux S 2013 Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. *Eur J Endocrinol* **169**:689–693.
 226. Kumar A, Bal CS 2003 Differentiated thyroid cancer. *Indian J Pediatr* **70**:707–713.
 227. La Quaglia MP, Black T, Holcomb GW 3rd, Sklar C, Azizkhan RG, Haase GM, Newman KD 2000 Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. *J Pediatr Surg* **35**:955–959; discussion 960.
 228. Rachmiel M, Charron M, Gupta A, Hamilton J, Wherrett D, Forte V, Daneman D 2006 Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. *J Pediatr Endocrinol Metab* **19**:1377–1393.
 229. Dinauer C, Francis GL 2007 Thyroid cancer in children. *Endocrinol Metab Clin North Am* **36**:779–806, vii.
 230. Kuijt WJ, Huang SA 2005 Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. *J Clin Endocrinol Metab* **90**:6123–6125.
 231. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* **154**:787–803.
 232. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. *J Nucl Med* **49**:764–770.
 233. Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM 2012 Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. *Thyroid* **22**:1007–1015.
 234. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. *J Nucl Med* **47**:648–654.
 235. Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ 2006 Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. *Intern Med J* **36**:564–570.
 236. Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taieb D, Cruz O, Hitzel A, Casas JA, Mader U, Dottorini ME 2009 Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multi-center retrospective study. *J Clin Endocrinol Metab* **94**:3948–3953.

237. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM 2005 Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. *J Clin Endocrinol Metab* **90**:6553–6555.
238. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW 2003 Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. *Clin Endocrinol* **58**:428–435.
239. Knudsen N, Christiansen E, Brandt-Christensen M, Nygaard B, Perrild H 2000 Age- and sex-adjusted iodine/creatinine ratio. A new standard in epidemiological surveys? Evaluation of three different estimates of iodine excretion based on casual urine samples and comparison to 24 h values. *Eur J Clin Nutr* **54**:361–363.
240. Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C 2011 Radiation safety in the treatment of patients with thyroid diseases by radioiodine ¹³¹I: practice recommendations of the American Thyroid Association. *Thyroid* **21**:335–346.
241. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? *J Nucl Med* **46**:261–266.
242. Ma C, Xie J, Jiang Z, Wang G, Zuo S 2010 Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* **37**:1778–1785.
243. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J 1999 Lithium as a potential adjuvant to ¹³¹I therapy of metastatic, well differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **84**:912–916.
244. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. *J Nucl Med* **47**:1587–1591.
245. Lassmann M, Hanscheid H, Verburg FA, Luster M 2011 The use of dosimetry in the treatment of differentiated thyroid cancer. *Q J Nucl Med Mol Imaging* **55**:107–115.
246. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *Am J Roentgenol Radium Ther Nucl Med* **87**:171–182.
247. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD 1992 Radioiodine-¹³¹I therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. *J Nucl Med* **33**:1132–1136.
248. Tuttle RM, Grewal RK, Larson SM 2007 Radioactive iodine therapy in poorly differentiated thyroid cancer. *Nat Clin Pract Oncol* **4**:665–668.
249. Sgouros G, Song H, Ladenson PW, Wahl RL 2006 Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. *J Nucl Med* **47**:1977–1984.
250. Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE, Ladenson PW, Sgouros G 2009 ¹²⁴I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. *J Nucl Med* **50**:1844–1847.
251. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* **35**:1941–1959.
252. Ciappuccini R, Heutte N, Trzepla G, Rame JP, Vaur D, Aide N, Bardet S 2011 Postablation (¹³¹I) scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. *Eur J Endocrinol* **164**:961–969.
253. Stanbury JB, Brownell GL, Riggs DS, Perinetti H, Del Castillo E, Itoiz J, Houssay A, Trucco E, Yaciofano AC 1952 The iodine-deficient human thyroid gland; a preliminary report. *J Clin Endocrinol Metab* **12**:191–207.
254. Lee JW, Lee SM, Koh GP, Lee DH 2011 The comparison of (¹³¹I) whole-body scans on the third and tenth day after (¹³¹I) therapy in patients with well-differentiated thyroid cancer: preliminary report. *Ann Nucl Med* **25**:439–446.
255. Goolden AW, Kam KC, Fitzpatrick ML, Munro AJ 1986 Oedema of the neck after ablation of the thyroid with radioactive iodine. *Br J Radiol* **59**:583–586.
256. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. *J Clin Endocrinol Metab* **87**:5817–5820.
257. Kloos RT 2009 Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. *Thyroid* **19**:925–928.
258. Lee SL 2010 Complications of radioactive iodine treatment of thyroid carcinoma. *J Natl Compr Canc Netw* **8**:1277–1286; quiz 1287.
259. Klubo-Gwiedzinska J, Van Nostrand D, Burman KD, Vasko V, Chia S, Deng T, Kulkarni K, Wartofsky L 2010 Salivary gland malignancy and radioiodine therapy for thyroid cancer. *Thyroid* **20**:647–651.
260. Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM 2009 Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. *J Nucl Med* **50**:1605–1610.
261. Schlumberger M, Catargi B, Borget I, Deandreis D, Zeroud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E 2012 Strategies of radioiodine ablation in patients with low-risk thyroid cancer. *N Engl J Med* **366**:1663–1673.
262. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP 2008 A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. *Clin Endocrinol* **69**:479–490.
263. Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, Thabane L, Rotstein L, Gafni A, Ezzat S, Goldstein DP 2008 A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. *Clin Endocrinol* **68**:610–617.
264. Rosario PW, Barroso AL, Rezende LL, Padrao EL, Borges MA, Guimaraes VC, Purisch S 2006 Testicular function after radioiodine therapy in patients with thyroid cancer. *Thyroid* **16**:667–670.

265. Edmonds CJ, Smith T 1986 The long-term hazards of the treatment of thyroid cancer with radioiodine. *Br J Radiol* **59**:45–51.
266. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C 2002 Testicular dose and fertility in men following I(131) therapy for thyroid cancer. *Clin Endocrinol* **56**:755–758.
267. Wallace WH 2011 Oncofertility and preservation of reproductive capacity in children and young adults. *Cancer* **117**:2301–2310.
268. Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, Martino E, Pinchera A 1994 Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. *J Nucl Med* **35**:1418–1422.
269. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C 2002 Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. *Postgrad Med J* **78**:92–93.
270. Smith MB, Xue H, Takahashi H, Cangir A, Andrassy RJ 1994 Iodine 131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects. *Ann Surg Oncol* **1**:128–131.
271. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbe M, Ceccarelli C, Schwartz C, Henri-Amar M, Bardet S, de Vathaire F 2008 Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. *J Nucl Med* **49**:845–852.
272. Casara D, Rubello D, Saladini G, Piotto A, Pelizzo MR, Girelli ME, Busnardo B 1993 Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. *Eur J Nucl Med* **20**:192–194.
273. Verburg FA, Hanscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M 2010 Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. *Eur J Nucl Med Mol Imaging* **37**:896–903.
274. Van Nostrand D, Neutze J, Atkins F 1986 Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. *J Nucl Med* **27**:1519–1527.
275. Baugnet-Mahieu L, Lemaire M, Leonard ED, Leonard A, Gerber GB 1994 Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. *Radiat Res* **140**:429–431.
276. Puerto S, Marcos R, Ramirez MJ, Galofre P, Creus A, Surralles J 2000 Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. *Mutat Res* **469**:147–158.
277. Richter HE, Lohrer HD, Hieber L, Kellerer AM, Lengfelder E, Bauchinger M 1999 Microsatellite instability and loss of heterozygosity in radiation-associated thyroid carcinomas of Belarussian children and adults. *Carcinogenesis* **20**:2247–2252.
278. Frigo A, Dardano A, Danese E, Davi MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F, Ferdeghini M 2009 Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. *J Clin Endocrinol Metab* **94**:3472–3476.
279. Thompson GB, Hay ID 2004 Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. *World J Surg* **28**:1187–1198.
280. Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, Tuttle RM 2004 Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. *J Clin Endocrinol Metab* **89**:6010–6016.
281. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* **88**:1433–1441.
282. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J 2004 Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. *Clin Endocrinol* **61**:61–74.
283. Durante C, Costante G, Filetti S 2013 Differentiated thyroid carcinoma: defining new paradigms for postoperative management. *Endocr Relat Cancer* **20**:R141–154.
284. Mazzaferri EL, Massoll N 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. *Endocr Relat Cancer* **9**:227–247.
285. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? *J Clin Endocrinol Metab* **87**:3242–3247.
286. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **88**:3668–3673.
287. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. *J Clin Endocrinol Metab* **90**:5047–5057.
288. McClellan DR, Francis GL 1996 Thyroid cancer in children, pregnant women, and patients with Graves' disease. *Endocrinol Metab Clin North Am* **25**:27–48.
289. Hanscheid H, Verburg FA, Biko J, Diessl S, Demidchik YE, Drozd V, Reiners C 2011 Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. *Eur J Nucl Med Mol Imaging* **38**:1296–1302.
290. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. *Eur J Endocrinol* **150**:105–112.
291. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. *J Clin Endocrinol Metab* **95**:5241–5248.
292. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G 2011 Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. *J Clin Endocrinol Metab* **96**:1703–1709.

293. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J 2010 Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. *Thyroid* **20**:587–595.
294. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourech V 2007 Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. *J Clin Endocrinol Metab* **92**:82–87.
295. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, Colato C, Zucchelli GC 2007 Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. *Clin Endocrinol* **67**:434–441.
296. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schwartz C, Dejux S, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet C, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. *J Clin Endocrinol Metab* **92**:2487–2495.
297. Chindris AM, Diehl NN, Crook JE, Fatourech V, Smallridge RC 2012 Undetectable sensitive serum thyroglobulin (<0.1 ng/mL) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. *J Clin Endocrinol Metab* **97**:2714–2723.
298. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. *J Clin Endocrinol Metab* **93**:76–81.
299. Han JM, Kim WB, Yim JH, Kim WG, Kim TY, Ryu JS, Gong G, Sung TY, Yoon JH, Hong SJ, Kim EY, Shong YK 2012 Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. *Thyroid* **22**:784–790.
300. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? *Clin Endocrinol* **74**:111–117.
301. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. *J Clin Endocrinol Metab* **88**:1107–1111.
302. Padovani RP, Robenshtok E, Brokhin M, Tuttle RM 2012 Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. *Thyroid* **22**:778–783.
303. Schaap J, Eustatia-Rutten CF, Stokkel M, Links TP, Diamant M, van der Velde EA, Romijn JA, Smit JW 2002 Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma? *Clin Endocrinol* **57**:117–124.
304. Schaadt B, Feldt-Rasmussen U, Rasmusson B, Topping H, Foder B, Jorgensen K, Hansen HS 1995 Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. *Thyroid* **5**:165–170.
305. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H, Tomoda C, Yabuta T, Masuoka H 2011 Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. *Thyroid* **21**:707–716.
306. Spencer CA 2013 Commentary on: Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position paper. *Thyroid* **23**:1190–1192.
307. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Rimmele H, Seregini E, Smit JW, Theimer C, Giovanella L 2013 Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. *Thyroid* **23**:1211–1225.
308. Schneider AB, Pervos R 1978 Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. *J Clin Endocrinol Metab* **47**:126–137.
309. Feldt-Rasmussen U, Rasmussen AK 1985 Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. *J Endocrinol Invest* **8**:571–576.
310. Spencer CA 2011 Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). *J Clin Endocrinol Metab* **96**:3615–3627.
311. Hoofnagle AN, Roth MY 2013 Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry. *J Clin Endocrinol Metab* **98**:1343–1352.
312. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **83**:1121–1127.
313. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY 2002 Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. *Clin Endocrinol* **57**:215–221.
314. Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE 2005 Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. *Eur J Endocrinol* **153**:49–55.
315. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **93**:4683–4689.
316. Seo JH, Lee SW, Ahn BC, Lee J 2010 Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. *Clin Endocrinol* **72**:558–563.

317. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. *Ann Intern Med* **139**:346–351.
318. Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM 1994 Significance of antithyroglobulin auto-antibodies in differentiated thyroid carcinoma. *Thyroid* **4**:199–202.
319. Powers PA, Dinauer CA, Tuttle RM, Francis GL 2003 Treatment of recurrent papillary thyroid carcinoma in children and adolescents. *J Pediatr Endocrinol Metab* **16**:1033–1040.
320. Kloos RT 2008 Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. *J Clin Endocrinol Metab* **93**:1519–1525.
321. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, 3rd, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Mangan RJ Jr, Siegel BA, Singhal S, Tyler DS, Wong RJ 2009 NCCN task force: clinical utility of PET in a variety of tumor types. *J Natl Compr Canc Netw* **7** Suppl **2**: S1–26.
322. Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, Sun F, Luo XG 2009 Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. *Nucl Med Commun* **30**:639–650.
323. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M 2011 Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. *Head Neck* **33**:562–565.
324. Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S 2012 Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? *Ann Nucl Med* **26**:77–85.
325. Esteve D, Muros MA, Llamas-Elvira JM, Jimenez Alonso J, Villar JM, Lopez de la Torre M, Muros T 2009 Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. *Ann Surg Oncol* **16**:2006–2013.
326. Treglia G, Muoio B, Giovanella L, Salvatori M 2013 The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. *Eur Arch Otorhinolaryngol* **270**: 1783–1787.
327. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *J Clin Endocrinol Metab* **91**:498–505.
328. Mirallie E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodere F 2007 Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. *Surgery* **142**:952–958; discussion 952–958.
329. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. *J Nucl Med* **48**:221–226.
330. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. *Thyroid* **11**:1169–1175.
331. Armstrong S, Worsley D, Blair GK 2002 Pediatric surgical images: PET evaluation of papillary thyroid carcinoma recurrence. *J Pediatr Surg* **37**:1648–1649.
332. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK 2010 Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. *J Clin Endocrinol Metab* **95**:1169–1173.
333. Rosario PW, Mourao GF, Dos Santos JB, Calsolari MR 2014 Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? *Thyroid* **24**:533–536.
334. Hurley JR 2011 Historical note: TSH suppression for thyroid cancer. *Thyroid* **21**:1175–1176.
335. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab* **1**:32–40.
336. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR 3rd 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. *Thyroid* **8**:737–744.
337. Leboulleux S, Baudin E, Hartl DW, Travagli JP, Schlumberger M 2005 Follicular cell-derived thyroid cancer in children. *Horm Res* **63**:145–151.
338. Rivkees SA 2010 Pediatric Graves' disease: controversies in management. *Horm Res Paediatr* **74**:305–311.
339. Bauer AJ 2011 Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted? *J Clin Endocrinol Metab* **96**:580–588.
340. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI 2011 Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. *Thyroid* **21**:1309–1316.
341. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI 2009 Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. *Head Neck* **31**:1152–1163.
342. Hindie E, Melliere D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, Lange J, Perlemuter L, Askenazy S 2003 Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? *Eur J Nucl Med Mol Imaging* **30**:974–981.
343. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L 1997 Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. *J Nucl Med* **38**:669–675.
344. Samuel AM, Rajashekharrao B, Shah DH 1998 Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. *J Nucl Med* **39**:1531–1536.

345. Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A, Beer M, Reiners C 2011 Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. *Eur J Nucl Med Mol Imaging* **38**:1683–1690.
346. Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjak S, Baranowski O, Marlowe RJ, Demidchik E, Drozd V, Demidchik Y 2013 Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **98**:3039–3048.
347. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R 2010 Pulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinoma. *Thyroid* **20**:337–340.
348. Lee J, Sogutlu G, Leard L, Zarnegar R, Bailey J, Golden J, Hays S, Kebebew E, Duh QY, Clark O 2007 Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma. *Thyroid* **17**:367–369.
349. Verburg FA, Reiners C, Hanscheid H 2013 Approach to the patient: role of dosimetric RAI Rx in children with DTC. *J Clin Endocrinol Metab* **98**:3912–3919.
350. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE 2008 A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. *Invest New Drugs* **26**:183–188.
351. Sherman SI 2010 Cytotoxic chemotherapy for differentiated thyroid carcinoma. *Clin Oncol (R Coll Radiol)* **22**:464–468.
352. Haugen BR, Sherman SI 2013 Evolving approaches to patients with advanced differentiated thyroid cancer. *Endocr Rev* **34**:439–455.
353. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE 2009 The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. *Thyroid* **19**:407–412.
354. Iyer P, Mayer JL, Ewig JM 2014 Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. *Thyroid* **24**:169–174.
355. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ, investigators D 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet* **384**:319–328.
356. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI 2015 Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *N Engl J Med* **372**:621–630.
357. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL 2013 The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. *J Clin Endocrinol Metab* **98**:31–42.
358. McHenry CR, Phitayakorn R 2011 Follicular adenoma and carcinoma of the thyroid gland. *Oncologist* **16**:585–593.
359. Raval MV, Bentrem DJ, Stewart AK, Ko CY, Reynolds M 2010 Utilization of total thyroidectomy for differentiated thyroid cancer in children. *Ann Surg Oncol* **17**:2545–2553.
360. Roy R, Kouniavsky G, Schneider E, Allendorf JD, Chabot JA, Logerfo P, Dackiw AP, Colombani P, Zeiger MA, Lee JA 2011 Predictive factors of malignancy in pediatric thyroid nodules. *Surgery* **150**:1228–1233.
361. Otto KJ, Lam JS, MacMillan C, Freeman JL 2010 Diminishing diagnosis of follicular thyroid carcinoma. *Head Neck* **32**:1629–1634.
362. Woodruff SL, Arowolo OA, Akute OO, Afolabi AO, Nwariaku F 2010 Global variation in the pattern of differentiated thyroid cancer. *Am J Surg* **200**:462–466.
363. Mishra A, Mishra SK, Agarwal A, Das BK, Agarwal G, Gambhir S 2002 Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area. *World J Surg* **26**:153–157.
364. LiVolsi VA, Abrosimov AA, Bogdanova T, Fadda G, Hunt JL, Ito M, Rosai J, Thomas GA, Williams ED 2011 The Chernobyl thyroid cancer experience: pathology. *Clin Oncol (R Coll Radiol)* **23**:261–267.
365. Lo CY, Lam KY, Wan KY 2000 Insular thyroid carcinoma in adolescents. *Eur J Surg* **166**:585–588.
366. Yusuf K, Reyes-Mugica M, Carpenter TO 2003 Insular carcinoma of the thyroid in an adolescent: a case report and review of the literature. *Curr Opin Pediatr* **15**:512–515.
367. DeLellis RA 2006 Pathology and genetics of thyroid carcinoma. *J Surg Oncol* **94**:662–669.
368. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* **16**:64–67.
369. Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, Porter K, Eng C, Ringel MD, Kloos RT 2011 Frequency of germline PTEN mutations in differentiated thyroid cancer. *Thyroid* **21**:505–510.
370. Scholz S, Smith JR, Chaignaud B, Shamberger RC, Huang SA 2011 Thyroid surgery at Children's Hospital Boston: a 35-year single-institution experience. *J Pediatr Surg* **46**:437–442.
371. Mester JL, Tilot AK, Rybicki LA, Frazier TW 2nd, Eng C 2011 Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. *Eur J Hum Genet* **19**:763–768.
372. Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T 2011 Follicular thyroid carcinoma. *Mod Pathol* **24(Suppl 2)**:S10–S18.
373. Dionigi G, Kraimps JL, Schmid KW, Hermann M, Sheu-Grabellus SY, De Wailly P, Beaulieu A, Tanda ML, Sessa F 2014 Minimally invasive follicular thyroid cancer (MIFTC)-a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbecks Arch Surg* **399**:165–184.
374. Bongiovanni M, De Saussure B, Kumar N, Pache JC, Cibas ES 2009 A quality control study on cytotechnologist-cytopathologist concordance and its relationship to the number of dots on the slide. *Acta Cytol* **53**:653–658.
375. Layfield LJ, Cibas ES, Gharib H, Mandel SJ 2009 Thyroid aspiration cytology: current status. *CA Cancer J Clin* **59**:99–110.
376. Farahati J, Bucsky P, Parlowsky T, Mader U, Reiners C 1997 Characteristics of differentiated thyroid carcinoma in children and adolescents with respect to age, gender, and histology. *Cancer* **80**:2156–2162.

377. Machens A, Holzhausen HJ, Dralle H 2005 The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. *Cancer* **103**:2269–2273.
378. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS 2001 A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. *Cancer* **91**:505–524.
379. Alfalah H, Cranshaw I, Jany T, Arnalsteen L, Leteurtre E, Cardot C, Pattou F, Carnaille B 2008 Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma. *World J Surg* **32**:2623–2626.
380. Tan C, Sidhu S, Sywak M, Delbridge L 2009 Management of hyperfunctioning single thyroid nodules in the era of minimally invasive thyroid surgery. *ANZ J Surg* **79**:386–389.
381. Yalla NM, Reynolds LR 2011 Hürthle cell thyroid carcinoma presenting as a “hot” nodule. *Endocr Pract* **17**:e68–72.
382. Croom RD 3rd, Thomas CG Jr, Reddick RL, Tawil MT 1987 Autonomously functioning thyroid nodules in childhood and adolescence. *Surgery* **102**:1101–1108.
383. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Kameyama K, Ito K 2011 Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. *Thyroid* **21**:751–757.
384. Lin JD, Chao TC, Chen ST, Huang YY, Liou MJ, Hsueh C 2007 Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. *Surg Oncol* **16**:107–113.
385. Kowalski LP, Goncalves Filho J, Pinto CA, Carvalho AL, de Camargo B 2003 Long-term survival rates in young patients with thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* **129**:746–749.
386. Lee YM, Lo CY, Lam KY, Wan KY, Tam PK 2002 Well-differentiated thyroid carcinoma in Hong Kong Chinese patients under 21 years of age: a 35-year experience. *J Am Coll Surg* **194**:711–716.
387. Lang W, Choritz H, Hundeshagen H 1986 Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. *Am J Surg Pathol* **10**:246–255.
388. van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, Grant CS 1992 Follicular thyroid carcinoma with capsular invasion alone: a non-threatening malignancy. *Surgery* **112**:1130–1136; discussion 1136–1138.
389. Lo CY, Chan WF, Lam KY, Wan KY 2005 Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. *Ann Surg* **242**:708–715.
390. D’Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH 2004 Follicular thyroid carcinoma: histology and prognosis. *Cancer* **100**:1123–1129.
391. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M, Niederle B 2009 Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. *Ann Surg* **249**:1023–1031.
392. Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Suzuki A, Masaki C 2012 Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. *Thyroid* **22**:798–804.
393. Mai KT, Khanna P, Yazdi HM, Perkins DG, Veinot JP, Thomas J, Lamba M, Nair BD 2002 Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma. *Pathology* **34**:239–244.
394. Furlan JC, Bedard YC, Rosen IB 2004 Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. *J Am Coll Surg* **198**:341–348.
395. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ 2010 Thyroid carcinoma. *J Natl Compr Canc Netw* **8**:1228–1274.
396. Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL 2001 Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. *Ann Surg* **233**:716–722.
397. Massimo L, Zarri D, Caprino D 2005 Psychosocial aspects of survivors of childhood cancer or leukemia. *Minerva Pediatr* **57**:389–397.
398. Hullmann SE, Wolfe-Christensen C, Meyer WH, McNall-Knapp RY, Mullins LL 2010 The relationship between parental overprotection and health-related quality of life in pediatric cancer: the mediating role of perceived child vulnerability. *Qual Life Res* **19**:1373–1380.
399. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, Schulte T 2012 Quality of life in patients with thyroid cancer compared with the general population. *Thyroid* **22**:117–124.
400. Vrijmoet-Wiersma CM, Egeler RM, Koopman HM, Bresters D, Norberg AL, Grootenhuis MA 2010 Parental stress and perceived vulnerability at 5 and 10 years after pediatric SCT. *Bone Marrow Transplant* **45**:1102–1108.
401. Oren A, Benoit MA, Murphy A, Schulte F, Hamilton J 2012 Quality of life and anxiety in adolescents with differentiated thyroid cancer. *J Clin Endocrinol Metab* **97**:E1933–E1937.
402. Mostoufi-Moab S, Barakat LP, Bauer AJ 2012 Quality of life in adolescent patients with differentiated thyroid cancer: moving beyond survival. *J Clin Endocrinol Metab* **97**:3453–3456.
403. Morris LF, Waguespack SG, Warneke CL, Ryu H, Ying AK, Anderson BJ, Sturgis EM, Clayman GL, Lee JE, Evans DB, Grubbs EG, Perrier ND 2012 Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy. *Surgery* **152**:1165–1171.
404. Pinto BM, Floyd A 2008 Theories underlying health promotion interventions among cancer survivors. *Semin Oncol Nurs* **24**:153–163.
405. Martins RK, McNeil DW 2009 Review of Motivational Interviewing in promoting health behaviors. *Clin Psychol Rev* **29**:283–293.

Address correspondence to:

Gary L. Francis, MD, PhD

Division of Pediatric Endocrinology

Virginia Commonwealth University

Children’s Hospital of Richmond

PO Box 980140

Richmond, VA 23298

E-mail: glfrancis@vcu.edu

This article has been cited by:

1. Mohammed Mohsen, Omar Hamdy, Ahmad Ramadan, Shadi Awany, Khaled Zalata, Mohamed Ezat. 2024. Poorly differentiated papillary thyroid carcinoma in a 5-year-old girl: a case report. *Egyptian Pediatric Association Gazette* 72:1. . [[Crossref](#)]
2. Yanling Su, Feng Wang, Shunjin Chen, Xiyu Yao. 2024. Effects of different surgical approaches on health-related quality of life in pediatric and adolescent patients with papillary thyroid carcinoma. *Discover Oncology* 15:1. . [[Crossref](#)]
3. Hongxi Wang, Chao Zhang, Qianrui Li, Tian Tian, Rui Huang, Jiajun Qiu, Rong Tian. 2024. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches. *BMC Cancer* 24:1. . [[Crossref](#)]
4. Zhihong Wang, He Wang, Yan Zhou, Lu Li, Mengge Lyu, Chunlong Wu, Tianen He, Lingling Tan, Yi Zhu, Tiannan Guo, Hongkun Wu, Hao Zhang, Yaoting Sun. 2024. An individualized protein-based prognostic model to stratify pediatric patients with papillary thyroid carcinoma. *Nature Communications* 15:1. . [[Crossref](#)]
5. Laney Zhang, Chinting Wong, Yungeng Li, Tianyi Huang, Jiawen Wang, Chenghe Lin. 2024. Artificial intelligence assisted diagnosis of early tc markers and its application. *Discover Oncology* 15:1. . [[Crossref](#)]
6. Binqian Zhou, Jianxin Liu, Yaqin Yang, Xuewei Ye, Yang Liu, Mingfeng Mao, Xiaofeng Sun, Xinwu Cui, Qin Zhou. 2024. Ultrasound-based nomogram to predict the recurrence in papillary thyroid carcinoma using machine learning. *BMC Cancer* 24:1. . [[Crossref](#)]
7. Bo Peng, Wu Lin, Wenjun Zhou, Yan Bai, Anguo Luo, Shenghua Xie, Lixue Yin. 2024. Enhanced pediatric thyroid ultrasound image segmentation using DC-Contrast U-Net. *BMC Medical Imaging* 24:1. . [[Crossref](#)]
8. Changrui Zhao, Jiaqiang Bo, Tianyu Li, Jiameng Tian, Tian Long, Yingying He, Siyu Chen, Chang Liu. 2024. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. *Cell Communication and Signaling* 22:1. . [[Crossref](#)]
9. Monika Kujdowicz, Dominika Januś, Jan Radliński, Aleksandra Kiszka-Wiłkojć, Anna Taczanowska-Niemczuk, Damian Młynarski, Wojciech Górecki, Jerzy B. Starzyk, Dariusz Adamek. 2024. Thyroid cytology in pediatric patients: a single-center study from 2015 to 2023—is there a necessity for distinct treatment approaches for patients with and without autoimmune thyroiditis?. *Virchows Archiv* 13. . [[Crossref](#)]
10. Yizhuo Wei, Liu Xiao, Lina Liu, Lei Shi, Yu Wang, Bin Liu. 2024. Prognostic implications of lymph node yield in pediatric patients with N1b papillary thyroid cancer. *Oral Oncology* 158, 106984. [[Crossref](#)]
11. Carlos A. Ortega, Jean-Nicolas Gallant, Irem Kilic, Siddharth Patel, Sheau-Chiann Chen, C. Burton Wood, Ryan Adams, Fadi Azer, Huiying Wang, Jiancong Liang, Sara H. Duffus, Ryan H. Belcher, Rochelle F. Andreotti, Rekha Krishnasarma, Jennifer E. Lim-Dunham, Güliz A. Barkan, Fei Ye, Vivian L. Weiss. 2024. Evaluation and application of American College of Radiology Thyroid Imaging Reporting and Data System for improved malignancy detection in paediatric thyroid nodules. *Cytopathology* 35:6, 749-756. [[Crossref](#)]
12. Ophir Winder, Liora Lazar, Roy Hod, Thomas Shpitzer, Aviram Mizrahi, Gideon Bachar. 2024. Age Stratification and Prognostic Factor Analysis in Pediatric Differentiated Thyroid Cancer. *The Laryngoscope* 134:11, 4818-4825. [[Crossref](#)]
13. Monica S. Trent, Brooke M. Su-Velez, Gurpreet Ahuja, Kevin Huoh. 2024. Utility of intraoperative Delphian lymph node sampling in pediatric thyroid surgery. *International Journal of Pediatric Otorhinolaryngology* 186, 112144. [[Crossref](#)]
14. Amy L. Dimachkieh, Priya Mahajan. 2024. Management of pediatric thyroid carcinoma. *Current Opinion in Otolaryngology & Head & Neck Surgery* 42. . [[Crossref](#)]
15. Shivee Gilja, Arvind Kumar, Aldo V. Londino, Diana N. Kirke, Scott A. Roof, Maaïke van Gerwen. 2024. Pathologic Characteristics and Surgical Outcomes of Pediatric Versus Adult Well-Differentiated Thyroid Cancer. *Otolaryngology-Head and Neck Surgery* 40. . [[Crossref](#)]
16. Maren Y. Fuller, Sujana Shrestha, Swikrity U. Baskota. 2024. International perspective on pediatric cytology. *Cancer Cytopathology* 15. . [[Crossref](#)]
17. Yoshiko Matsumoto, Yurie Kobashi, Yukie Yamaya, Mizuki Sekino, Erina Suzuki, Koki Shio, Akihiko Ozaki, Satoshi Suzuki, Satoru Suzuki, Hiroki Shimura, Susumu Yokoya, Yuko Hashimoto, Tetsuya Ohira, Fumihiko Furuya, Shinichi Suzuki. Clinicopathological Findings of 220 Pediatric, Adolescent, and Young Adult Patients with Thyroid Cancer in Fukushima Medical University Hospital. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
18. V. I. Vovk. 2024. CYTOLOGICAL DIAGNOSTICS OF THYROID DISEASES: BASIC PRINCIPLES AND FEATURES OF APPLICATION IN MODERN CONDITIONS. *Ukrainian Journal of Laboratory Medicine* 2:3. . [[Crossref](#)]
19. Daniël J. van de Berg, Pedro M. Rodriguez Schaap, Faridi S. Jamaludin, Hanneke M. van Santen, Sarah C. Clement, Menno R. Vriens, A. S. Paul van Trotsenburg, Christiaan F. Mooij, Eveline Bruinstroop, Schelto Kruijff, Robin P. Peeters, Frederik A. Verburg,

- Romana T. Netea-Maier, Els J. M. Nieveen van Dijkum, Joep P. M. Derikx, Anton F. Engelsman. The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
20. Eman Toraih, Alyssa Webster, Eric Pineda, Dylan Pinion, Lily Baer, Emily Persons, Marcela Herrera, Mohammad Hussein, Emad Kandil. 2024. Radioactive iodine ablation therapy reduces the risk of recurrent disease in pediatric differentiated thyroid carcinoma. *Surgical Oncology* **56**, 102120. [[Crossref](#)]
 21. Esther Diana Rossi, Huiying Wang, Vivian Lee Weiss. 2024. Paediatric thyroid lesions: lessons from recent guidelines. *The Lancet Diabetes & Endocrinology* **12**:10, 690-692. [[Crossref](#)]
 22. Juliana Chaves Garcia, Ligia Vera Montali de Assumpção, Maria Cândida Ribeiro Parisi, Denise Engelbrecht Zantut-Wittmann. 2024. Impact of age on tumor characteristics and treatment outcomes in pediatric Differentiated Thyroid Carcinoma. *Endocrine* **86**:1, 315-323. [[Crossref](#)]
 23. Yan-Jing Zhang, Tian Xue, Chang Liu, Yan-Hong Hao, Xiao-Hui Yan, Li-Ping Liu. 2024. Radiomics Combined with ACR TI-RADS for Thyroid Nodules: Diagnostic Performance, Unnecessary Biopsy Rate, and Nomogram Construction. *Academic Radiology* **27**. . [[Crossref](#)]
 24. Aleksandra Kropinska, Aleksandra Ledwon, Ewa Paliczka Cieslik, Tomasz Olczyk, Aleksandra Blewaska, Marcela Krzempek, Agata Wilk, Alexander Cortez, Agnieszka Czarniecka, Barbara Jarzab, Daria Handkiewicz Junak. 2024. Changing Clinical Presentation of Pediatric Differentiated Thyroid Cancer in Poland: A Retrospective Cohort Study Spanning 45 Years. *Thyroid* **34**:10, 1234-1245. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
 25. Merve Duman Küçükcuray, Ayşe Karaman, Semra Çetinkaya, Şenay Savaş Erdeve, Çiğdem Üner, Nebiyye Genel, İbrahim Karaman. 2024. Preliminary results of thyroid surgery from a tertiary comprehensive children's hospital. *Journal of Pediatric Surgery Open* **8**, 100168. [[Crossref](#)]
 26. Linghu Wu, Yuli Zhou, Mengmeng Liu, Sijing Huang, Youhuan Su, Xiaoshu Lai, Song Bai, Keen Yang, Yitao Jiang, Chen Cui, Siyuan Shi, Jinfeng Xu, Nan Xu, Fajin Dong. 2024. Video-based AI module with raw-scale and ROI-scale information for thyroid nodule diagnosis. *Heliyon* **10**:19, e37924. [[Crossref](#)]
 27. Ulgen Celtik, Yesim Ertan, Samim Ozen, Damla Goksen, Ahmet Celik. 2024. Is Conservative Management of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP) Possible in Children?. *Pediatric and Developmental Pathology*. [[Crossref](#)]
 28. Emran Askari, Bahare Saidi, Laura Evangelista. 2024. Indications for diagnostic whole-body iodine scan: a review of guidelines. *Nuclear Medicine Communications* **81**. . [[Crossref](#)]
 29. Harvey K. Chiu, Theodore S. Nowicki, Masha J. Livhits, James X. Wu, Noah Federman. 2024. Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma. *Journal of Pediatric Endocrinology and Metabolism*. [[Crossref](#)]
 30. Christopher Puchi, Mehul V. Raval, Yao Tian, Jami Josefson, Jill Samis, Douglas R. Johnston, John Maddalozzo, Jeffrey Rastatter, Inbal Hazkani. 2024. Assessing national trends in indications for pediatric total thyroidectomy. *American Journal of Otolaryngology* **45**:5, 104440. [[Crossref](#)]
 31. Shachi Srivatsa, Ameer Al-Hadidi, Joseph Stanek, Kyle Horvath, Lauren Parsons, Claudia Martinez-Rios, Amanda Hopp, Samuel Engle, Matthew Plunk, Gali Shapira-Zaltsberg, Sapna Nagar, Sean Masters, Sayf Al-Katib, Rennard Tucker, Lamya A. Atweh, Summit Shah, Adam Bobbey, Robert Hoffman, Jennifer H. Aldrink. 2024. Assessing the Diagnostic Accuracy of TI-RADS in Pediatric Thyroid Nodules: A Multi-institutional Review. *Journal of Pediatric Surgery* **58**, 161924. [[Crossref](#)]
 32. Alyssa Stetson, Saurabh Saluja, Danielle B. Cameron, Sara A. Mansfield, Stephanie F. Polites, Joshua N. Honeyman, John P. Dahl, Mary T. Austin, Jennifer H. Aldrink, Emily R. Christison-Lagay. 2024. Surgical management of rare tumors (Part 1). *Pediatric Blood & Cancer* **14**. . [[Crossref](#)]
 33. Consuelo Pino, José Miguel Dominguez, Antonieta Solar, Pablo Zoroquiain, Francisco Cruz, Cristian Garcia, Florencia De Barbieri, Lorena Mosso, Nicole Lustig, Hernán Gonzalez, Augusto León, Ignacio Goñi, Andy Contreras, Francisca Grob. 2024. Two Decades of Thyroid Nodule Cytology in Children: Malignancy Risk Assessment at a Tertiary Care Center. *Hormone Research in Paediatrics* **1**-8. [[Crossref](#)]
 34. Luz E Castellanos, Mark E Zafereo, Erich M Sturgis, Jennifer R Wang, Anita K Ying, Steven G Waguespack. 2024. Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine. *The Journal of Clinical Endocrinology & Metabolism* **145**. . [[Crossref](#)]
 35. Julia Baran, Amber Isaza, Mya Bojarsky, Lama Alzoebe, Minkeun Song, Stephen Halada, Lindsay Sisko, Stephanie Gonzales, Sogol Mostoufi-Moab, Andrew J. Bauer. 2024. Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy. *Frontiers in Endocrinology* **15**. . [[Crossref](#)]

36. Domenico Corica, Fabio Toscano, Mariacarla Moleti, Giorgia Pepe, Alfredo Campenni, Guido Fadda, Gianlorenzo Dionigi, Carmelo Romeo, Tommaso Aversa, Malgorzata Wasniewska. 2024. Case Report: Plummer's adenoma in Prader–Willi syndrome. *Frontiers in Pediatrics* 12. . [[Crossref](#)]
37. Tariq Nasser, Bsaim Abdulsalam Altirkistani, Suaad Muhammad Bougis, Asma Hassan Abu Ghasham, Ibrahim Basem Nafadi. 2024. Outcomes of Differentiated Thyroid Cancer in Children and Adolescents at King Abdulaziz Medical City, Jeddah. *Cureus* 10. . [[Crossref](#)]
38. Peter J. Abraham, Brenessa M. Lindeman. 2024. Management of Incidental Thyroid Nodules. *Surgical Clinics of North America* 104:4, 711-723. [[Crossref](#)]
39. Carla Gambale, José Vicente Rocha, Alessandro Prete, Elisa Minaldi, Rossella Elisei, Antonio Matrone. 2024. Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules. *Journal of Imaging* 10:8, 189. [[Crossref](#)]
40. Marina S. Marzukie, Gali Shapira-Zaltsberg, Claudia Martinez-Rios. 2024. Assessment of the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS™) with modification of the management recommendations for pediatric thyroid nodules. *Pediatric Radiology* 54:9, 1476-1485. [[Crossref](#)]
41. Anuradha S Dnyanmote, Himashree M P, Sandeep Kumar, Kinjal Vasava. 2024. Double Trouble: A Rare Case of Synchronous Breast and Thyroid Carcinomas. *Cureus* 63. . [[Crossref](#)]
42. Congcong Wang, Yutian Li, Guoqiang Wang, Xinfeng Liu, Yingying Zhang, Chenghui Lu, Jiao Li, Na Han, Zenghua Wang, Zengmei Si, Fengqi Li, Gaixia Lu, Renfei Wang, Xufu Wang. 2024. Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China. *Frontiers in Endocrinology* 15. . [[Crossref](#)]
43. Wei Li, Shanling Zhang, Zilu Gao, Yingjie Tao, Xudong Wang, Junping Cheng. 2024. Children and adolescents with differentiated thyroid cancer from 1998 to 2018: a retrospective analysis. *Journal of Pediatric Endocrinology and Metabolism* . [[Crossref](#)]
44. Caixin Qiu, Shipeng Wu, Jiehua Li. 2024. Central lymph node ratio is an important recurrence prognostic factor for pediatric differentiated thyroid cancer. *Frontiers in Endocrinology* 15. . [[Crossref](#)]
45. Hongxia Zhang, Mingzhu Yu, Jingyu Chen, Caihui Hu, Yi Tang, Zhenzhen Zhao, Yifei Du, Jian Sun, Jianwu Zhou, Chao Yang, Xiaobin Deng, Xiangru Kong. 2024. Clinical analysis of ultrasound-guided microwave ablation for pediatric thyroid nodules- a single center research. *Pediatric Discovery* 16. . [[Crossref](#)]
46. AndreasMachens, KerstinLorenz, FrankWeber, HenningDralle. 2024. Anatomical Patterns of Nodal Spread in Unilateral Papillary and Medullary Thyroid Cancer. *Thyroid* 34:7, 871-879. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
47. Marinda G. Scrusby, Christopher Liu, Ximena Lopez, Diana Diesen. 2024. Prenatal presentation of a hyperfunctioning thyroid nodule. *Journal of Pediatric Endocrinology and Metabolism* 37:6, 569-570. [[Crossref](#)]
48. Junu Kim, Ja Seung Koo, Ji-In Bang, Jin Kyong Kim, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung. 2024. Relationship between recurrence and age in the diffuse sclerosing variant of papillary thyroid carcinoma: clinical significance in pediatric patients. *Frontiers in Endocrinology* 15. . [[Crossref](#)]
49. Maria E. Street, Anna-Mariia Shulhai, Maddalena Petraroli, Viviana Patianna, Valentina Donini, Antonella Giudice, Margherita Gnocchi, Marco Masetti, Anna G. Montani, Roberta Rotondo, Sergio Bernasconi, Lorenzo Iughetti, Susanna M. Esposito, Barbara Predieri. 2024. The impact of environmental factors and contaminants on thyroid function and disease from fetal to adult life: current evidence and future directions. *Frontiers in Endocrinology* 15. . [[Crossref](#)]
50. Yuguo Wang, Hui Wang, Gongxun Tan, Xiping Wu, Bin Wang, Zhihan Tan, Jing Du, Xiuying Li, Ying Xu, Na Yan, Xiaoqin Qian. 2024. Application value of multi-gene mutation detection in the clinical management of pediatric papillary thyroid carcinoma: a preliminary exploration. *Frontiers in Endocrinology* 15. . [[Crossref](#)]
51. Tikamporn Jitpasutham, Stefen Andrianus, Maria Gubbiotti, Vania Nosé, Zubair W. Baloch, Emilio Madrigal, William C. Faquin. 2024. Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases. *Cancer Cytopathology* 132:6, 370-385. [[Crossref](#)]
52. Wenyuan Shi, Wenjia Cai, Shengcai Wang, Yuanjin Gao, Rui Yang, Qinglin Liu, Yuanhu Liu, Yun Peng, Xin Ni. 2024. Safety and efficacy of microwave ablation for symptomatic benign thyroid nodules in children. *European Radiology* 34:6, 3851-3860. [[Crossref](#)]
53. Yan Tan, Jia Zhong, Taiqing Zheng, Yusi Fu, Minghui Liu, Guotao Wang. 2024. Associations of BRAFV600E mutation with the American College of Radiology Thyroid Imaging Reporting and Data System and clinicopathological characteristics in pediatric patients with papillary thyroid carcinoma. *Pediatric Radiology* 54:7, 1128-1136. [[Crossref](#)]
54. Paulo Alonso Garcia Alves-Junior, Marise Codeço de Andrade Barreto, Fernanda Accioly de Andrade, Daniel Alves Bulzico, Rossana Corbo, Fernanda Vaisman. 2024. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of

- distant metastasis and association with response to treatment in pediatric thyroid cancer patients. *Endocrine* **84**:3, 1081-1087. [[Crossref](#)]
55. Jiaqiang Dan, Jingya Tan, Yao Guo, Yang Xu, Lin Zhou, Junhua Huang, Zhiying Yuan, Xiang Ai, Junyan Li. 2024. Construction and validation of a nomogram for predicting lateral lymph node metastasis in pediatric and adolescent with differentiated thyroid carcinoma. *Endocrine* **84**:3, 1088-1096. [[Crossref](#)]
 56. Jung-Eun Moon, So Won Oh, Ho-Cheol Kang, Bon Seok Koo, Keunyoung Kim, Sun Wook Kim, Won Woong Kim, Jung-Han Kim, Dong Gyu Na, Sohyun Park, Young Joo Park, Jun-Ook Park, Ji-In Bang, Kyorim Back, Youngduk Seo, Young Shin Song, Seung Hoon Woo, Ho-Ryun Won, Chang Hwan Ryu, Sang-Woo Lee, Eun Kyung Lee, Joon-Hyop Lee, Jieun Lee, Cho Rok Lee, Dong-Jun Lim, Jae-Yol Lim, Ari Chong, Yun Jae Chung, Chae Moon Hong, Hyungju Kwon, Young Ah Lee. 2024. Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part V. Pediatric Differentiated Thyroid Cancer 2024. *International Journal of Thyroidology* **17**:1, 193-207. [[Crossref](#)]
 57. Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung, Yoon Young Cho, Yun Jae Chung, Won Bae Kim, Ka Hee Yi, Ho-Cheol Kang, Do Joon Park. 2024. Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024. *International Journal of Thyroidology* **17**:1, 208-244. [[Crossref](#)]
 58. Sarah L. Spaulding, Marah Maayah, Catherine A. Dinauer, Manju Prasad, Armine Darbinyan, Raffaella Morotti, Emily R. Christison-Lagay. 2024. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules. *Journal of Pediatric Surgery* **59**:5, 975-980. [[Crossref](#)]
 59. Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, Anil K. D'Cruz. 2024. Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma. *Journal of Clinical Medicine* **13**:10, 2904. [[Crossref](#)]
 60. Guan Li, Jesse W. Tai, Peter K. Moon, Uchechukwu C. Megwalu. 2024. Update on Pediatric Thyroid Cancer Incidence and Mortality Trends in the United States, 2000-2018. *Cancer Investigation* **42**:4, 357-360. [[Crossref](#)]
 61. Saraladevi Manimaran, Ramya Ramanathan, Sundari Subramanian. 2024. Pediatric Challenges With Cowden Syndrome and Graves' Disease: A Case Report. *Cureus* **7**. . [[Crossref](#)]
 62. Robert J. McConnell, Olga Kamysh, Patrick L. O'Kane, Ellen Greenebaum, Alexander V. Rozhko, Vasilina V. Yauseyenko, Victor F. Minenko, Vladimir Drozdovitch, Yuliya Yarets, Tatiana Kukhta, Kiyohiko Mabuchi, Mark P. Little, Elizabeth K. Cahoon, Lydia B. Zablotska. 2024. Radiation Dose Does Not Affect the Predictive Value of Thyroid Biopsy for Diagnosing Papillary Thyroid Cancer in a Belarusian Cohort Exposed to Chernobyl Fallout. *Acta Cytologica* **68**:1, 34-44. [[Crossref](#)]
 63. M. V. Reinberg, A. V. Kiyayev, R. A. Chernikov, I. V. Veresenko, K. Yu. Slashchuk. 2024. Dynamic Observation in Children and Adolescents Following Management of Differentiated Thyroid Cancer. *Clinical and experimental thyroidology* **19**:2, 4-10. [[Crossref](#)]
 64. Vyacheslav V. Polkin, Pavel A. Isaev, Alexey A. Ilyin, Alice K. Plugar, Sergey A. Ivanov, Andrei D. Kaprin. 2024. Transoral endoscopic thyroidectomy in the thyroid cancer in children. *Russian Journal of Pediatric Surgery* **28**:1, 63-72. [[Crossref](#)]
 65. Dominika Januś, Monika Kujdowicz, Konrad Kaleta, Kamil Możdżeń, Jan Radliński, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Marcin Maślanka, Wojciech Górecki, Jerzy B. Starzyk. 2024. Ultrasound–Histopathological Presentation of Thyroid and Ovary Lesions in Adolescent Patients with DICER1 Syndrome: Case Reports and Literature Overview. *Children* **11**:4, 403. [[Crossref](#)]
 66. Diani Kartini, Merlynda Ayu Rara Dini. 2024. Case Series of Surgical Treatment in Pediatric Thyroid Carcinoma in a Single Institution. *Indian Journal of Otolaryngology and Head & Neck Surgery* **76**:2, 2018-2025. [[Crossref](#)]
 67. Priscilla Koirala, Reema K. Tawfiq, David Raslau. 2024. 22-Year-Old Man With Seizures. *Mayo Clinic Proceedings* **99**:4, 661-664. [[Crossref](#)]
 68. Hou-fang Kuang, Wen-liang Lu. 2024. Predictive factors for lung metastasis in pediatric differentiated thyroid cancer: a clinical prediction study. *Journal of Pediatric Endocrinology and Metabolism* **37**:3, 250-259. [[Crossref](#)]
 69. Jing Yu, Yiyang Cui, Chao Fu, Xiao Ma, Caifeng Si, Yuanjing Huang, Kefei Cui, Yan Zhang. 2024. Comparison of ultrasound risk stratification systems for pediatric thyroid nodules. *Frontiers in Endocrinology* **15**. . [[Crossref](#)]
 70. Tetsuya Ohira, Masanori Nagao, Fumikazu Hayashi, Hiroki Shimura, Satoru Suzuki, Seiji Yasumura, Hideto Takahashi, Satoshi Suzuki, Manabu Iwadate, Mitsuaki Hosoya, Akira Sakai, Tetsuo Ishikawa, Fumihiko Furuya, Shinichi Suzuki, Susumu Yokoya, Hitoshi Ohto, Kenji Kamiya. 2024. Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey. *The Journal of Clinical Endocrinology & Metabolism* **10**. . [[Crossref](#)]

71. Farnaz Nesari Javan, Emran Askari, Susan Shafiei, Vahid Roshanravan, Atena Aghaei, Narjess Ayati, Seyed Rasoul Zakavi. 2024. The Prognostic Power of Preablation Stimulated Thyroglobulin in Children With Differentiated Thyroid Cancer. *Endocrine Practice* **30**:3, 209-217. [[Crossref](#)]
72. Eijun Nishihara, Takashi Akamizu. 2024. Comparable Remission Rates for ATA Low-Risk Pediatric Thyroid Cancer Patients Treated and Those Not Treated with Radioactive Iodine Therapy. *Clinical Thyroidology*[®] **36**:3, 87-89. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
73. Pinar OZGEN KIRATLI, Bilge VOLKAN-SALANCI. 2024. Current approach to pediatric differentiated thyroid cancer. *The Quarterly Journal of Nuclear Medicine and Molecular Imaging* **68**:1. . [[Crossref](#)]
74. Laura Banks, Natalie A. Kelly, Amanda Onwuka, Abdulrahman Althubaiti, Cecilia Damilano, Robert P. Hoffman, Jennifer H. Aldrink, Kris R. Jatana, Patrick Walz. 2024. Does preoperative calcium and 1, 25 OH vitamin D supplementation impact postoperative hypocalcemia and length of stay following pediatric thyroidectomy?. *International Journal of Pediatric Otorhinolaryngology* **178**, 111895. [[Crossref](#)]
75. Nicolle Burgwardt, James M. Healy, Ana Menendez, Maia Regan, Douglas Moote, Nordie Bilbao, Rebecca Riba-Wolman, Michael Brimacombe, Christine Finck. 2024. Validating the Modified McGill Thyroid Nodule Score for Assessment of Preoperative Risk of Pediatric Thyroid Malignancy. *Journal of Pediatric Surgery* **20**. . [[Crossref](#)]
76. Eun Kyung Lee, Young Joo Park, Chan Kwon Jung, Dong Gyu Na. 2024. A Narrative Review of the 2023 Korean Thyroid Association Management Guideline for Patients with Thyroid Nodules. *Endocrinology and Metabolism* **39**:1, 61-72. [[Crossref](#)]
77. Sunanda Tirupati, Pradeep Puthenveetil, Shilpa Lakkundi, Anudeep Gaddam, Vijaya Sarathi. 2024. High Malignancy Risk and Its Predictors in South Indian Patients With Bethesda II Thyroid Nodules. *Cureus* **10**. . [[Crossref](#)]
78. Yaqian Mao, Jinwen Wang, Yinghua Luo, Wei Lin, Jin Yao, Junping Wen, Gang Chen. 2024. Socioeconomic disparities and regional environment are associated with cervical lymph node metastases in children and adolescents with differentiated thyroid cancer: developing a web-based predictive model. *Frontiers in Endocrinology* **15**. . [[Crossref](#)]
79. Arnaldo Piccardo, Francesco Fiz, Gianluca Bottoni, Luca Foppiani, Domenico Albano, Francesco Bertagna, Ugo Catrambone, Federica Mariani, Beatrice Sambucco, Michela Massollo, Giorgio Treglia, Pierpaolo Trimboli. 2024. Does it work in childhood and adolescence? The predictive role of postoperative/preablative stimulated thyroglobulin levels in paediatric thyroid cancer. A systematic review of the literature. *Reviews in Endocrine and Metabolic Disorders* **25**:1, 53-63. [[Crossref](#)]
80. Maria Sharmila Alina de Sousa, Isabela Nogueira Nunes, Yasmin Paz Christiano, Luiza Sisdelli, Janete Maria Cerutti. 2024. Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review. *Reviews in Endocrine and Metabolic Disorders* **25**:1, 35-51. [[Crossref](#)]
81. Carolina Ferraz. 2024. Molecular testing for thyroid nodules: Where are we now?. *Reviews in Endocrine and Metabolic Disorders* **25**:1, 149-159. [[Crossref](#)]
82. Marco Russo, Valeria Bottici, Giulia Sapuppo, Gabriella Pellegriti, Eleonora Molinaro. 2024. Gestione del carcinoma tiroideo in età pediatrica. *L'Endocrinologo* **25**:1, 68-74. [[Crossref](#)]
83. Sharanappa Vikram, Anjali Mishra, Vijayalakshmi Bhatia, Sabaretnam Mayilvagnan, Gyan Chand, Gaurav Agarwal, Amit Agarwal, Preeti Dabadghao, Saroj Kanta Mishra. 2024. Clinico-pathologic profile and outcomes of pediatric endocrine patients managed by endocrine surgeons: Experience over three decades in a tertiary center in India. *World Journal of Surgery* **6**. . [[Crossref](#)]
84. Najla Ben Ghashir, Abdulghani Elomami, Reham Al Masoud, Vito Carlo Alberto Caponio, Eiman Al Seddeeqi. 2024. Recurrence and survival for patients with thyroid carcinoma in the pediatric age group in the Emirate of Abu Dhabi: retrospective analysis of a multicentre cohort. *Journal of Pediatric Endocrinology and Metabolism* **37**:1, 52-61. [[Crossref](#)]
85. Patrycja Sosnowska-Sienkiewicz, Dajana Danielewicz, Danuta Januszkiewicz-Lewandowska, Paulina Rusak, Iwona Anderko, Maciej Rzepecki, Marek Niedziela, Jerzy Harasymczuk, Przemysław Mańkowski. 2024. Thyroid diseases in children and adolescents requiring surgical treatment—indications, techniques, results, and complications based on 10 years of the single center's own experience. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
86. Rui Du, Ying Zhang, Jiedong Kou, Jingting Li, Chengqiu Sui, Daqi Zhang, Yantao Fu, Le Zhou, Qingfeng Fu, Fang Li, Gianlorenzo Dionigi, Nan Liang, Hui Sun. 2024. A novel risk stratification model based on tumor size and multifocality to predict recurrence in pediatric PTC: comparison with adult PTC. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
87. John M. Skaugen, Yuri E. Nikiforov. Molecular testing in thyroid cancer 461-474. [[Crossref](#)]
88. Matthew A. Loberg, Megan L. Tigue, Jean-Nicolas Gallant, Huiying Wang, Sule Canberk, Vivian L. Weiss. 2024. Evolving approaches in paediatric thyroid cytopathology: A review. *Cytopathology* **35**:1, 60-69. [[Crossref](#)]
89. Shuhei Aoyama, Kohei Fukuoka, Hirohito Kubota, Kotaro Narita, Ko Kudo, Yuichi Mitani, Koichi Oshima, Makiko Mori, Yuki Arakawa, Kayoko Ichimura, Kiminori Terui, Yutaka Tanami, Hiroshi Kawashima, Atsuko Nakazawa, Takehiro Niitsu, Yoshiyuki Takahashi, Katsuyoshi Koh. 2024. Early chemotherapeutic intervention to avoid thyroidectomy in pediatric Langerhans cell

- histiocytosis with thyroid involvement accompanying tracheal stenosis: a report of two cases. *International Journal of Hematology* 119:1, 99-103. [[Crossref](#)]
90. Leandra Piscopo, Emilia Zampella, Michele Klain. 2024. New opportunities for dosimetric approach in patients with differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* 51:2, 330-331. [[Crossref](#)]
91. Bin Zhou, Hu Hei, Jugao Fang, Jianwu Qin, Hong Ge. 2024. More aggressive biological behavior in pediatric than in adult papillary thyroid carcinoma. *Asian Journal of Surgery* 47:1, 443-449. [[Crossref](#)]
92. Anna Chin, Renee Robilliard, Jan C. Groblewski, John M. Tarro, Sonja Chen, Lisa Swartz Topor. 2024. Occult Metastatic Papillary Thyroid Cancer in an Adolescent. *AACE Clinical Case Reports* 10:1, 27-30. [[Crossref](#)]
93. Han Li, Yuqin He, Li Zhao, Yixuan Song, Yang Liu, Yiming Zhu, Shaoyan Liu. 2024. Impact of lateral cervical lymph node metastasis on lung metastasis in pediatric thyroid cancer: A correlation study. *American Journal of Otolaryngology* 45:1, 104063. [[Crossref](#)]
94. Akram Al-Ibraheem, Mohamed Al-Shammaa, Ahmed Saad Abdulkadir, Feras Istatieh, Ula Al-Rasheed, Thomas Pascual, Rawad Rihani, Hadeel Halalsheh, Taleb Ismael, Aysar Khalaf, Iyad Sultan, Issa Mohamad, Hikmat Abdel-Razeq, Asem Mansour. 2024. Survival Trends in Pediatric Differentiated Thyroid Cancer: A Middle Eastern Perspective. *Life* 14:1, 158. [[Crossref](#)]
95. Heeyung Kim, Yasuhiro Naiki, Megumi Iwahashi-Odano, Satoshi Narumi, Koichi Ito, Akira Ishiguro. 2024. A thyroid adenoma in a pubertal male with thyroxine-binding globulin deficiency. *Clinical Pediatric Endocrinology* 33:1, 23-26. [[Crossref](#)]
96. George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. Radiojodtherapie bei differenziertem Schilddrüsenkrebs 185-200. [[Crossref](#)]
97. George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. PET-CT bei differenziertem Schilddrüsenkrebs 219-231. [[Crossref](#)]
98. Joanne C. Blair, Attila Patocs. Pediatric Endocrine Tumors and Syndromes 1-64. [[Crossref](#)]
99. Julia A. Baran, Stephen Halada, Andrew J. Bauer, Yimei Li, Amber Isaza, Tasleema Patel, Lindsay Sisko, Jill P. Ginsberg, Ken Kazahaya, N. Scott Adzick, Sogol Mostoufi-Moab. 2024. Thyroid Ultrasound Screening in Childhood Cancer Survivors following Radiotherapy. *Hormone Research in Paediatrics* 97:3, 243-253. [[Crossref](#)]
100. Tian Zhou, Ning Ma, Yong-lin Zhang, Xing-hong Chen, Xue Luo, Mai Zhang, Qing-jun Gao, Dai-wei Zhao. 2024. Transcription factor FOXP4 inversely governs tumor suppressor genes and contributes to thyroid cancer progression. *Heliyon* 10:2, e23875. [[Crossref](#)]
101. Kutay Bahadir, Selin Ural, Javid Abdullayev, Abdurrahman Karaman, Mesut Parlak, Adil Boz, Gungor Karaguzel. 2024. Thyroid surgery in children: a single-center experience of 20 years. *Revista da Associação Médica Brasileira* 70:7. . [[Crossref](#)]
102. Laura M Jacobsen, Brittany S Bruggeman, William E Winter. Thyroid gland 51-86. [[Crossref](#)]
103. Wassim Chemaitilly, Laurie E. Cohen. Endocrine late effects in childhood cancer survivors . [[Crossref](#)]
104. Swayamjeet Satapathy, Chandrasekhar Bal. 2024. Chapter 11: Pediatric Differentiated Thyroid Cancers. *Journal of Head & Neck Physicians and Surgeons* 12:Suppl 1, S58-S64. [[Crossref](#)]
105. Jae Won Cho, Cheong-Sil Rah, Won Woong Kim, Yu-mi Lee, Seong Chul Kim, Jung Hwan Baek, Dong Eun Song, Won Gu Kim, Ki-Wook Chung, Suck Joon Hong, Tae-Yon Sung. 2024. Concurrent Association of Multifocality, Bilaterality, and Recurrence in Pediatric Papillary Thyroid Cancer Patients. *Yonsei Medical Journal* 65. . [[Crossref](#)]
106. Lin Chen, Ningning Ren, Qing Yang, Xingsong Tian. 2024. Short-Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic-Psycho Relevance. *International Journal of Endocrinology* 2024:1. . [[Crossref](#)]
107. Ke Zheng, Jingxin Mao. 2024. Comparison and Analysis of Clinical Features of Papillary Thyroid Cancer Complicated With Hashimoto's Thyroiditis. *Clinical Medicine Insights: Oncology* 18. . [[Crossref](#)]
108. Anthony Sheyn. Thyroid Mass 1-8. [[Crossref](#)]
109. Birhanu Hailu Tirkaso, Gersam Abera Mulugeta, Tewodros Deneke Belete, Melkamu Mitikie Melak. 2024. Papillary thyroid carcinoma in an 8-year-old Ethiopian child: A case report with literature review. *SAGE Open Medical Case Reports* 12. . [[Crossref](#)]
110. Lucas Krauel, Rosalia Carrasco Torrents, Maria Coronas. Thyroid Tumors in Children 111-116. [[Crossref](#)]
111. N. Zwaveling-Soonawala, A. S. van Trotsenburg. Overview of Thyroid Disease in Children and Adolescents 85-114. [[Crossref](#)]
112. Joanne C. Blair, Attila Patocs. Pediatric Endocrine Tumors and Syndromes 521-584. [[Crossref](#)]
113. Siyu Jia, Dengpeng Tang, Wen Peng. 2023. Risk factors for recurrence of differentiated thyroid carcinoma in children and adolescents: A retrospective cohort study. *Medicine* 102:50, e36585. [[Crossref](#)]

114. Joachim Schüz, Evgenia Ostroumova, Ausrele Kesminiene, Louise Davies, Hyeong Sik Ahn, Kayo Togawa, Salvatore Vaccarella. 2023. Response to Toshihide Tsuda, Yumiko Miyano and Eiji Yamamoto [1]. *Environmental Health* **22**:1. . [[Crossref](#)]
115. Yunxia Huang, Jieyu Liu, Taiqing Zheng, Jia Zhong, Yan Tan, Minghui Liu, Guotao Wang. 2023. Modification of size cutoff for biopsy based on the American College of Radiology Thyroid Imaging Reporting and Data System (TI-RADS) for thyroid nodules in patients younger than 19 years. *European Radiology* **33**:12, 9328-9335. [[Crossref](#)]
116. Jianshe Yang, Zhongwei Lv. 2023. China is moving towards the standardised management of paediatric differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* **51**:1, 226-229. [[Crossref](#)]
117. DAVID H. MARGARIT, MARCELA V. REALE, ARIEL F. SCAGLIOTTI, LILIA M. ROMANELLI. 2023. ABSORBING MARKOV CHAINS TO CHARACTERIZE AND PREDICT METASTASIS PATHWAYS IN CHILDHOOD CANCER. *Journal of Biological Systems* **31**:04, 1455-1475. [[Crossref](#)]
118. Julio C. Ricarte-Filho, Aime T. Franco. 2023. The evolving genomic landscape of pediatric papillary thyroid cancer. *Current Opinion in Endocrine and Metabolic Research* **33**, 100483. [[Crossref](#)]
119. Riwa Meshaka, Lorenzo Biassoni, Greg Chambers, Stephan Voss, Katharine Orr. 2023. Nuclear medicine techniques in paediatric body oncology: Present and future. *EJC Paediatric Oncology* **2**, 100120. [[Crossref](#)]
120. Yangmengyuan Xu, Lei Shi, Jie Wu, Huilan Li, Yu Wang, Bin Liu. 2023. Prognostic Value of Tumor Multifocality in Pediatric Papillary Thyroid Carcinoma: A Real-Life Multicentric Study. *Otolaryngology-Head and Neck Surgery* **169**:6, 1606-1614. [[Crossref](#)]
121. Kris Ann P. Schultz, Murali Chintagumpala, Jin Piao, Kenneth S. Chen, Rachana Shah, Robyn D. Gartrell, Emily Christison-Lagay, Farzana Pashnakar, Jesse L. Berry, Allison F. O'Neill, Lauren M. Vasta, Ashley Flynn, Sarah G. Mitchell, Brittani KN. Seynnaeve, Jeremy Rosenblum, Samara L. Potter, Junne Kamihara, Carlos Rodriguez-Galindo, Douglas S. Hawkins, Theodore W. Laetsch. 2023. Rare tumors: Opportunities and challenges from the Children's Oncology Group perspective. *EJC Paediatric Oncology* **2**, 100024. [[Crossref](#)]
122. Swayamjeet Satapathy, Althaf K Majeed, Sanjana Ballal, Chandrasekhar Bal. 2023. Differentiated Thyroid Cancers in Young Adults Versus Children: Clinical Characteristics and 10-year Follow-up Outcomes. *The Journal of Clinical Endocrinology & Metabolism* **108**:12, e1670-e1677. [[Crossref](#)]
123. Mya Bojarsky, Julia A Baran, Stephen Halada, Amber Isaza, Hongming Zhuang, Lisa States, Frederick D Grant, Stephanie Robbins, Lindsay Sisko, Julio C Ricarte-Filho, Ken Kazahaya, N Scott Adzick, Sogol Mostoufi-Moab, Andrew J Bauer. 2023. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy. *The Journal of Clinical Endocrinology & Metabolism* **108**:12, 3338-3344. [[Crossref](#)]
124. Daniel W Scholfield, Joseph Lopez, Alana Eagan, Zoltan Antal, R Michael Tuttle, Ronald Ghossein, Michael LaQuaglia, Ashok R Shaha, Jatin P Shah, Richard J Wong, Snehal G Patel, Ian Ganly. 2023. Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?. *The Journal of Clinical Endocrinology & Metabolism* **108**:12, 3135-3144. [[Crossref](#)]
125. Theresia Weber, Rainer Hummel, Christian Vorländer, Andreas Zielke, Michael Hermann, Anna Krappitz, Thomas Negele, Cornelia Dotzenrath, Arnold Trupka, Jochen Schabram, Irene Schmidtman, Carsten Klinger, Kerstin Lorenz. 2023. Thyroid surgery in children and adolescents: results from a multi-institutional German and Austrian database. *British Journal of Surgery* **110**:12, 1808-1814. [[Crossref](#)]
126. Daniel W. Scholfield, Joseph Lopez, Natalie Deana Badillo, Alana Eagan, Helena Levyn, Michael LaQuaglia, Ashok R. Shaha, Jatin P. Shah, Richard J. Wong, Snehal G. Patel, Ian Ganly. 2023. Complications of Thyroid Cancer Surgery in Pediatric Patients at a Tertiary Cancer Center. *Annals of Surgical Oncology* **30**:12, 7781-7788. [[Crossref](#)]
127. Jin Peng, Qingfeng Zhang, Fei Lin, Chao Ke, Wuguo Deng, Ankui Yang, Xuan Su. 2023. Epigenetic signature discriminates lymphatic metastasis in BRAF wild-type thyroid carcinoma: methylation role of GRIK2. *Epigenomics* **15**:21, 1101-1119. [[Crossref](#)]
128. Sandeep Kumar Parvathareddy, Abdul K. Siraj, Padmanaban Annaiyappanaidu, Nabil Siraj, Maha Al-Rasheed, Wael Al-Haqawi, Zeeshan Qadri, Khawar Siddiqui, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya. 2023. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
129. Caroline Burgard, Mathias Johannes Zacherl, Andrei Todica, Julia Hornung, Freba Grawe, Isabell Pekrul, Petra Zimmermann, Christine Schmid-Tannwald, Roland Ladurner, Detlef Krenz, Arnold Trupka, Johanna Wagner, Peter Bartenstein, Christine Spitzweg, Vera Wenter. 2023. Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy. *Frontiers in Oncology* **13**. . [[Crossref](#)]
130. Fahad Rind, Songzhu Zhao, Catherine Haring, Stephen Y Kang, Amit Agrawal, Enver Ozer, Matthew O Old, Ricardo L. Carrau, Nolan B Seim. 2023. Body Mass Index (BMI) Related Morbidity with Thyroid Surgery. *The Laryngoscope* **133**:10, 2823-2830. [[Crossref](#)]

131. Jean-Nicolas Gallant, Vivian L. Weiss, Sheau-Chiann Chen, Jiancong Liang, Ryan H. Belcher, Fei Ye, Hernan Correa, Huiying Wang. 2023. Hashimoto's Thyroiditis and the Risk of Papillary Thyroid Cancer in Children. *Cancers* **15**:19, 4902. [[Crossref](#)]
132. Oksana K. Baeva, Natalya S. Kiseleva, Elina E. Biktasheva, Liliya R. Gazizova, Margarita I. Fimina, Ilyuza I. Akhmetova, Anastasiya E. Kazakova, Kirill D. Yadrenkin, Darya A. Dautova, Anastasiya D. Grishnikova, Elvira D. Gaisina, Ilina A. Galiaskarova. 2023. Molecular features of thyroid cancer in children. *Russian Pediatric Journal* **4**:3, 73-84. [[Crossref](#)]
133. Mariacarla Moleti, Tommaso Aversa, Salvatore Crisafulli, Gianluca Trifirò, Domenico Corica, Giorgia Pepe, Laura Cannavò, Maria Di Mauro, Giuseppe Paola, Andrea Fontana, Fabrizio Calapai, Salvatore Cannavò, Malgorzata Wasniewska. 2023. Global incidence and prevalence of differentiated thyroid cancer in childhood: systematic review and meta-analysis. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
134. Stylianos Monos, Christian Fritz, Jacob Harris, Dominic Romeo, Jinggang J. Ng, Katherine Xu, Benjamin Cooperberg, Alvaro Moreira, Karthik Rajasekaran. 2023. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal. *Otolaryngology-Head and Neck Surgery* . [[Crossref](#)]
135. Ja Kyung Lee, Jee-Hye Choi, Woochul Kim, JungHak Kwak, Hyeong Won Yu, Su-jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee. 2023. Bilateral axillo-breast approach robotic thyroidectomy in pediatric patients with thyroid disease and cancer. *Endocrine* **81**:3, 532-539. [[Crossref](#)]
136. Yangmengyuan Xu, Lei Shi, Jie Wu, Huilan Li, Yu Wang, Bin Liu. 2023. No Association of Preablation Thyroglobulin Antibody Positivity and Outcome in Pediatric Patients With Papillary Thyroid Carcinoma. *Clinical Nuclear Medicine* **48**:9, 763-767. [[Crossref](#)]
137. Kelly E. Daniels, Amber D. Shaffer, Steven Garbin, Judy H. Squires, Kevin G. Vaughan, Pushpa Viswanathan, Selma F. Witchel, Kevin P. Mollen, Linwah Yip, Sara E. Monaco, Umamaheswar Duvvuri, Jeffrey P. Simons. 2023. Validity of the American College of Radiology Thyroid Imaging Reporting and Data System in Children. *The Laryngoscope* **133**:9, 2394-2401. [[Crossref](#)]
138. 2023. AIUM Practice Parameter for the Performance and Interpretation of Diagnostic Ultrasound of the Thyroid and Extracranial Head and Neck. *Journal of Ultrasound in Medicine* **42**:9. . [[Crossref](#)]
139. Kris Ann P. Schultz, Murali Chintagumpala, Jin Piao, Kenneth S. Chen, Robyn Gartrell, Emily Christison-Lagay, Jesse L. Berry, Rachana Shah, Theodore W. Laetsch. 2023. Children's Oncology Group's 2023 blueprint for research: Rare tumors. *Pediatric Blood & Cancer* **70**:S6. . [[Crossref](#)]
140. Costanza Chiapponi, Milan Janis Michael Hartmann, Boris Decarolis, Thorsten Simon, Christiane Josephine Bruns, Michael Faust, Anne Maria Schultheis, Matthias Schmidt, Hakan Alakus. 2023. Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment. *Journal of Clinical Research in Pediatric Endocrinology* **15**:3, 257-263. [[Crossref](#)]
141. Congcong Wang, Gaixia Lu, Yutian Li, Xinfeng Liu, Guoqiang Wang, Chenghui Lu, Jiao Li, Qiong Luo, Qian Zhang, Ming Sun, Xufu Wang, Renfei Wang. 2023. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
142. Gerdi Tuli, Jessica Munarin, Patrizia Matarazzo, Antonio Marino, Andrea Corrias, Nicola Palestini, Francesco Quaglino, Luisa De Sanctis. 2023. Clinical features of thyroid cancer in paediatric age. Experience of a tertiary centre in the 2000-2020 period. *Endocrine* **81**:2, 322-329. [[Crossref](#)]
143. Steven W. Bruch. 2023. Surgery for Thyroid Disease in Children. *Advances in Pediatrics* **70**:1, 123-130. [[Crossref](#)]
144. Yue Jie, Jingliang Ruan, Man Luo, Rongbin Liu. 2023. Ultrasonographic, clinical, and pathological features of papillary thyroid carcinoma in children and adolescents with or without Hashimoto's thyroiditis. *Frontiers in Oncology* **13**. . [[Crossref](#)]
145. Jennifer R. Hess, Dane C. Van Tassel, Charles E. Runyan, Zachary Morrison, Alexandra M. Walsh, Kristian T. Schafernak. 2023. Performance of ACR TI-RADS and the Bethesda System in Predicting Risk of Malignancy in Thyroid Nodules at a Large Children's Hospital and a Comprehensive Review of the Pediatric Literature. *Cancers* **15**:15, 3975. [[Crossref](#)]
146. Faya Liang, Peiliang Lin, Ping Han, Xijun Lin, Renhui Chen, Jingyi Wang, Lanlan Deng, Xin Zou, Tan Cheng, Xiaoming Huang. 2023. Comparison of 980-nm/1470-nm Dual-Wavelength Fiber Laser Versus Ultrasonic Scalpel Device in Open Thyroidectomy. *Photobiomodulation, Photomedicine, and Laser Surgery* **41**:8, 422-428. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
147. Calogero Virgone, Tal Ben Ami, Jelena Roganovic, Ewa Bien, Yves Reguerre, Andrea Ferrari, Daniel Orbach, Jan Godzinski, Gianni Bisogno, Nuno Jorge Farinha, Luca Bergamaschi, Rita Alaggio, Michaela Kuhlen, Michael Abele, Abbas Agaimy, Dominik T Schneider, Ines B. Brecht. 2023. Age-related biological differences in children's and adolescents' very rare tumors. *EJC Paediatric Oncology* **110**, 100027. [[Crossref](#)]
148. Leen Matalka, AKM Fazlur Rahman, Sarah Sparks, Brenessa Lindeman, Pallavi Iyer. 2023. Evaluation and management of pediatric thyroid nodules and thyroid cancer at a single institution after adoption of the American Thyroid Association 2015 guidelines. *Journal of Pediatric Endocrinology and Metabolism* **36**:7, 659-666. [[Crossref](#)]

149. Swayamjeet Satapathy, Althaf K. Majeed, Sanjana Ballal, Chandrasekhar Bal. 2023. Appropriateness of 14-year cutoff in pediatric differentiated thyroid cancer: Comparison of clinical characteristics and long-term outcomes in 14 years and younger and 15–18 years age groups. *Pediatric Blood & Cancer* . [[Crossref](#)]
150. Zhengwu Lei, Zhongxiang He, Ying Mei, Xiaoya Qi, Pingping Yu, Guoqiong Xu, Hongfeng Cheng, Ruixue Bai, Jing Deng. 2023. Associations of psychological status and ultrasonic characteristics of thyroid nodules in adults during the COVID-19 pandemic. *Frontiers in Psychology* 14. . [[Crossref](#)]
151. Marjan Shahrokh, Mohammad Alsultan, Younes Kabalan. 2023. The relationship between papillary thyroid carcinoma and preoperative TSH level: A cross-sectional study from Syria. *Medicine* 102:28, e34283. [[Crossref](#)]
152. Brooke M. Su-Velez, Gary E. Hartman, Hilary Seeley, Lisa A. Orloff, Julia E. Noel, Kara D. Meister. 2023. Parathyroid Autofluorescence in Pediatric Thyroid Surgery: Experience With False Positive and False Negative Results. *Otolaryngology–Head and Neck Surgery* 169:1, 185–189. [[Crossref](#)]
153. Hendry Irawan, Putu Anda Tusta Adiputra. 2023. Inaccurate Examination of Neck Lump as Regional Metastasis of Papillary Thyroid Carcinoma in Children: A Case Report. *Biomedical and Pharmacology Journal* 16:2, 827–833. [[Crossref](#)]
154. Hoàng Hiệp Phan. 2023. Management of low-risk differentiated thyroid cancer: Current controversial issues?. *Vietnam Journal of Endolaparoscopic Surgery* 13:2. . [[Crossref](#)]
155. Ngọc Lương Trần. 2023. Results of surgical treatment for pediatric patients with thyroid cancer at the National Hospital of Endocrinology. *Vietnam Journal of Endolaparoscopic Surgery* 13:2. . [[Crossref](#)]
156. Ian D Hay, Robert A Lee, Carl C Reading, Siobhan T Pittock, Animesh Sharma, Geoffrey B Thompson, J William Charboneau. 2023. Long-term Effectiveness of Ethanol Ablation in Controlling Neck Nodal Metastases in Childhood Papillary Thyroid Cancer. *Journal of the Endocrine Society* 7:7. . [[Crossref](#)]
157. Duy Quoc Ngo, Duong The Le, Quy Xuan Ngo, Quang Van Le. 2023. Transoral endoscopic thyroidectomy vestibular approach as a novel technique for pediatric populations: Results from a single surgeon. *Frontiers in Endocrinology* 14. . [[Crossref](#)]
158. A. Yu. Shurinov, E. V. Borodavina. 2023. Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician. *Head and Neck Tumors (HNT)* 13:1, 91–101. [[Crossref](#)]
159. Chanchal Rana, Neha Nigam, Shipra Agarwal, Prabhakar Mishra, Akanksha Singh, Andrey Bychkov. 2023. Cytological evaluation of thyroid nodules in children and young adults: a multi-institutional experience. *Endocrine* 80:3, 580–588. [[Crossref](#)]
160. Emilia Zampella, Leandra Piscopo, Mariarosaria Manganelli, Fabio Volpe, Carmela Nappi, Valeria Gaudieri, Leonardo Pace, Martin Schlumberger, Alberto Cuocolo, Michele Klain. 2023. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer. *Endocrine* 80:3, 612–618. [[Crossref](#)]
161. Jonathan C. Slack, Monica Hollowell, Justine A. Barletta. 2023. Thyroid Nodules and Follicular Cell-Derived Thyroid Carcinomas in Children. *Endocrine Pathology* 34:2, 165–175. [[Crossref](#)]
162. Tapoi Dana Antonia, Lambrescu Ioana Maria, Gheorghisan-Galateanu Ancuta-Augustina. 2023. Preoperative evaluation of thyroid nodules – Diagnosis and management strategies. *Pathology - Research and Practice* 246, 154516. [[Crossref](#)]
163. Judy H. Squires, Claudia Martinez-Rios, James C. Davis, Kelly R. Dietz, Monica S. Epelman, Hollie A. Lai, Jennifer E. Lim-Dunham, Janice D. McDaniel, Joyce C. Mhlanga, Neeta Pandit-Taskar, Marguerite T. Parisi, Andrew T. Trout, Elizabeth K. Weidman, Adina L. Alazraki. 2023. Imaging of pediatric thyroid tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. *Pediatric Blood & Cancer* 70:S4. . [[Crossref](#)]
164. Hongxi Wang, Lei Shi, Rui Huang, Bin Liu, Rong Tian. 2023. The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid cancer. *Frontiers in Endocrinology* 14. . [[Crossref](#)]
165. Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehee Joo, Yuh-Seog Jung, Chan Kwon Jung, Yoon Young Cho, Yun Jae Chung, Won Bae Kim, Ka Hee Yi, Ho-Cheol Kang, Do Joon Park. 2023. 2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules. *International Journal of Thyroidology* 16:1, 1–31. [[Crossref](#)]
166. Dominika Januś, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Witkojć, Monika Kujdowicz, Małgorzata Czogała, Wojciech Górecki, Jerzy B. Starzyk. 2023. Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000–2022. *Frontiers in Endocrinology* 14. . [[Crossref](#)]
167. Althaf K Majeed, Swayamjeet Satapathy, Sanjana Ballal, Chandrasekhar Bal. 2023. Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers. *The Journal of Clinical Endocrinology & Metabolism* 108:6, e208–e215. [[Crossref](#)]

168. Zhichao Xing, Yuxuan Qiu, Jingqiang Zhu, Anping Su, Wenshuang Wu. 2023. Diagnostic performance of adult-based ultrasound risk stratification systems in pediatric thyroid nodules: a systematic review and meta-analysis. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
169. Chantal Anne Lebbink, Hanneke Margo van Santen, Alan Daneman, Jonathan Daniel Wasserman. 2023. Does Ultrasound Really Contribute to Detection of Residual/Recurrent Disease After Pediatric Thyroidectomy? Preliminary Data Supporting a “Thyroglobulin-First” Approach. *Thyroid* **33**:5, 645-649. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
170. Rossella Di Paola, Ananya De, Anna Capasso, Sofia Giuliana, Roberta Ranieri, Carolina Ruosi, Antonella Sciarra, Caterina Vitagliano, Alessandra F. Perna, Giovambattista Capasso, Mariadelina Simeoni. 2023. Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed. *Journal of Personalized Medicine* **13**:5, 813. [[Crossref](#)]
171. Tikamporn Jitpasutham, William C. Faquin, Vanda F. Torous, Vania Nosé. 2023. Thyroblastoma: A DICER1-associated embryonal neoplasm and fine needle aspiration diagnostic criteria. *Diagnostic Cytopathology* **51**:5. . [[Crossref](#)]
172. E. L. Choinzonov, I. V. Reshetov, S. A. Ivanov, A. P. Polyakov, M. A. Kropotov, A. M. Mudunov, V. V. Polkin, P. A. Isaev, A. A. Ilyin, D. G. Beltsevich, V. E. Vanushko, P. O. Rummyantsev, G. A. Melnichenko, Yu. V. Alymov, I. S. Romanov, A. V. Ignatova, E. V. Borodavina, V. V. Krylov, A. Yu. Shurinov, N. V. Severskaya, Z. A. Radjabova, D. E. Kulbakin, A. A. Nevolskikh, A. R. Gevorkov, E. V. Khmelevsky, S. I. Kutukova, A. O. Guz, I. V. Sleptsov, R. A. Chernikov, A. M. Stepanova, N. A. Falaleeva, S. O. Podvyaznikov, N. A. Rubtsova, A. N. Rudyk, Sh. I. Musin, I. A. Gulidov, L. Yu. Vladimirova, T. Yu. Semiglazova, T. A. Aghababyan, E. V. Kostromina. 2023. Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients. *Endocrine Surgery* **16**:2, 5-29. [[Crossref](#)]
173. Megan N Perez, Stephen Halada, Amber Isaza, Lindsay Sisko, Sogol Mostoufi-Moab, Andrew J Bauer, Lamia P Barakat. 2023. Health-Related Quality of Life at Diagnosis for Pediatric Thyroid Cancer Patients. *The Journal of Clinical Endocrinology & Metabolism* **108**:5, e169-e177. [[Crossref](#)]
174. Seth J. Crapp, Rachel Pevsner Crum, Nolan Altman, Jyotsna Kochiyil, Eshani Sheth, Caldon J. Esdaille. Correlative Imaging of Pediatric Diseases 693-716. [[Crossref](#)]
175. Davide Seminati, Stefano Ceola, Angela Ida Pincelli, Davide Leni, Andrea Gatti, Mattia Garancini, Vincenzo L’Imperio, Alessandro Cattoni, Fabio Pagni. 2023. The Complex Cyto-Molecular Landscape of Thyroid Nodules in Pediatrics. *Cancers* **15**:7, 2039. [[Crossref](#)]
176. Flurin Mueller-Diesing, Wiltrud Lederle, Anne Rix, Susanne Koletnik, Dennis Doleschel, Maximilian Snelting, Felix Gremse, Fabian Kiessling. 2023. Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid. *International Journal of Molecular Sciences* **24**:8, 7060. [[Crossref](#)]
177. Yanhui Ma, Qi Zhang, Kexin Zhang, Yunzi liang, Fangbing Ren, Jingwen Zhang, Chengxia Kan, Fang Han, Xiaodong Sun. 2023. NTRK fusions in thyroid cancer: Pathology and clinical aspects. *Critical Reviews in Oncology/Hematology* **184**, 103957. [[Crossref](#)]
178. Yunsoo Choe, Yun Jeong Lee, Choong Ho Shin, Eun-Jae Chung, Young Ah Lee. 2023. Risk factors of postoperative hypoparathyroidism after total thyroidectomy in pediatric patients with thyroid cancer. *Annals of Pediatric Endocrinology & Metabolism* **28**:1, 26-33. [[Crossref](#)]
179. T. M. Geliashvili, B. I. Dolgushin, V. G. Polyakov. 2023. Comments to the Section on Radioiodine Therapy for Differentiated Thyroid Cancer in Children of the European Thyroid Association Guidelines 2022. *Journal of oncology: diagnostic radiology and radiotherapy* **6**:1, 19-25. [[Crossref](#)]
180. Kadir Alper KÜÇÜKER, İsa Burak GÜNEY, Zeynep YAPAR. 2023. Factors associated with resistant disease in pediatric differentiated thyroid carcinomas. *Cukurova Medical Journal* **48**:1, 20-28. [[Crossref](#)]
181. Guanghan Li, Bo Zhang, Jia Liu, Ying Xiong. 2023. The diagnostic efficacy and inappropriate biopsy rate of ACR TI-RADS and ATA guidelines for thyroid nodules in children and adolescents. *Frontiers in Endocrinology* **14**. . [[Crossref](#)]
182. Lindsay A. Bischoff. 2023. Radioactive Iodine-Refractory Lung Metastases Are More Common in Pediatric Patients Younger than 15 Years of Age than in Those 15 to 20 Years Old. *Clinical Thyroidology* **35**:3, 102-104. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
183. Lydia B. Zablotska, David B. Richardson, Ashley Golden, Elisa Pasqual, Brian Smith, Estelle. Rage, Paul A. Demers, Minh Do, Nora Fenske, Veronika Deffner, Michaela Kreuzer, Jonathan Samet, Stephen Bertke, Kaitlin Kelly-Reif, Mary K. Schubauer-Berigan, Ladislav Tomasek, Charles Wiggins, Dominique Laurier, Iulian Apostoaei, Brian A. Thomas, Steven L. Simon, F. Owen Hoffman, John D. Boice, Lawrence T. Dauer, Sara C. Howard, Sarah S. Cohen, Michael T. Mumma, Elizabeth D. Ellis, Keith F. Eckerman, Rich W. Leggett, David J. Pawel. 2023. The epidemiology of lung cancer following radiation exposure. *International Journal of Radiation Biology* **99**:3, 569-580. [[Crossref](#)]
184. Francesco Quaglini, Alex Bruno Bellocchia, Gerdi Tuli, Jessica Munarin, Patrizia Matarazzo, Luca Cestino, Federico Festa, Giulia Carbonaro, Salvatore Oleandri, Claudia Manini, Riccardo Vergano, Luisa De Sanctis. 2023. Pediatric thyroid surgery:

- Retrospective analysis on the first 25 pediatric thyroidectomies performed in a reference center for adult thyroid diseases. *Frontiers in Endocrinology* 14. . [[Crossref](#)]
185. Ryan H. Belcher, Giju Thomas, Parker A. Willmon, Jean-Nicolas Gallant, Naira Baregamian, Monica E. Lopez, Carmen C. Solórzano, Anita Mahadevan-Jansen. 2023. Identifying Parathyroids in Pediatric Thyroid/Parathyroid Surgery by Near Infrared Autofluorescence. *The Laryngoscope* 2. . [[Crossref](#)]
186. Brent A. Willobee, Carlos T. Huerta, Hallie J. Quiroz, Melissa L. Mao, Emily L. Ryon, Anthony Ferrantella, Chad M. Thorson, Juan E. Sola, Eduardo A. Perez. 2023. Higher Complication Rates for Total versus Partial Thyroidectomy in the Pediatric Population. *Journal of Surgical Research* 283, 449-458. [[Crossref](#)]
187. Kyorim Back, Tae Hyuk Kim, Jiyeon Lee, Jee Soo Kim, Jun-Ho Choe, Young Lyun Oh, Anna Cho, Jung-Han Kim. 2023. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis. *Journal of Pediatric Surgery* 58:3, 568-573. [[Crossref](#)]
188. Jichen Yang, Laura C. Page, Lars Wagner, Benjamin Wildman-Tobriner, Logan Bisset, Donald Frush, Maciej A. Mazurowski. 2023. Thyroid Nodules on Ultrasound in Children and Young Adults: Comparison of Diagnostic Performance of Radiologists' Impressions, ACR TI-RADS, and a Deep Learning Algorithm. *American Journal of Roentgenology* 220:3, 408-417. [[Crossref](#)]
189. Heming H. Zhao, Cole Pickney, Anuja L. Sarode, Anne Kim-Mackow, Scott M. Wilhelm. 2023. Varying impact of patient age on the rising rate of pediatric thyroid cancer: Analysis of NCDB database (2004–2017). *The American Journal of Surgery* 225:3, 532-536. [[Crossref](#)]
190. Elena Moschos, Hans-Joachim Mentzel. 2023. Ultrasound findings of the thyroid gland in children and adolescents. *Journal of Ultrasound* 26:1, 211-221. [[Crossref](#)]
191. Audra J. Reiter, Andrew Hu, Gwyneth A. Sullivan, Eli Stein, Jill H. Samis, Jami L. Josefson, Jeffrey C. Rastatter, Mehul V. Raval. 2023. Short-Term Complications After Total Thyroidectomy in Children. *Journal of Surgical Research* 283, 758-763. [[Crossref](#)]
192. Jessica W. Thiesmeyer, Caitlin E. Egan, Jacques A. Greenberg, Toni Beninato, Rasa Zarnegar, Thomas J. Fahey III, Brendan M. Finnerty. 2023. Prepubertal Children with Papillary Thyroid Carcinoma Present with More Invasive Disease Than Adolescents and Young Adults. *Thyroid* 33:2, 214-222. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
193. Praveen Kumar, Nishikant Avinash Damle, Chandrasekhar Bal. 2023. Radioiodine Therapy in Pediatric Differentiated Thyroid Cancer. *Clinical Nuclear Medicine* 48:2, 158-167. [[Crossref](#)]
194. Inês Damásio, Daniela Dias, Sara Pinheiro, Susana Esteves, Valeriano Leite, Rita Santos. 2023. Differentiated Thyroid Cancer in a Pediatric Population: Estimating the Risk of Recurrence and Evolution Over Time. *Cureus* 46. . [[Crossref](#)]
195. Tian Tian, Shuhui Huang, Hongyuan Dai, Mengfang Qi, Bin Liu, Rui Huang. 2023. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults. *The Journal of Clinical Endocrinology & Metabolism* 108:2, 306-314. [[Crossref](#)]
196. Julia Isabelle Staubitz, Thomas J. Musholt. Besondere Aspekte der Schilddrüsenchirurgie bei Kindern 253-258. [[Crossref](#)]
197. Pyeong Hwa Kim, Hee Mang Yoon, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee, Jin Seong Lee, Ah Young Jung, Young Ah Cho, Boram Bak, Dong Gyu Na. 2023. Diagnostic performance of the 2021 Korean thyroid imaging reporting and data system in pediatric thyroid nodules. *European Radiology* 33:1, 172-180. [[Crossref](#)]
198. Ichelle Maa van Roessel, Boudewijn Bakker, Hanneke M van Santen, Wassim Chemaitilly. 2023. Hormone replacement in survivors of childhood cancer and brain tumors: safety and controversies. *Endocrine Connections* 12:1. . [[Crossref](#)]
199. Michimasa Fujiogi, Takaaki Konishi, Nobuaki Michihata, Yohei Hashimoto, Hiroki Matsu, Tetsuya Ishimaru, Kiyohide Fushimi, Hideo Yasunaga, Jun Fujishiro. 2023. Perioperative outcomes of thyroid cancer surgery in children and adults: a nationwide inpatient database study in Japan. *Annals of Clinical Epidemiology* 5:1, 20-29. [[Crossref](#)]
200. Christopher W. Snyder, Sacha A. Williams, Paul D. Danielson, Nicole M. Chandler. 2023. Risk factors for prolonged hospitalization and readmission after total thyroidectomy in children: Associations with surgical subspecialty. *The American Journal of Surgery* 225:1, 66-69. [[Crossref](#)]
201. Tomoyo Itonaga, Yukihiko Hasegawa, Shinji Higuchi, Mari Satoh, Hirotake Sawada, Kazuhiro Shimura, Ikuko Takahashi, Noriyuki Takubo, Keisuke Nagasaki. 2023. Knowns and unknowns about congenital hypothyroidism: 2022 update. *Clinical Pediatric Endocrinology* 32:1, 11-25. [[Crossref](#)]
202. Dong Gyu Na. 2023. Clinical Application of the 2021 Korean Thyroid Imaging Reporting and Data System (K-TIRADS). *Journal of the Korean Society of Radiology* 84:1, 92. [[Crossref](#)]
203. Melody Shi, Laura C. Page. Endocrine disorders in infants, children, and adolescents 555-575. [[Crossref](#)]
204. Christine E. Cherella, Ari J. Wassner. 2023. Pediatric thyroid cancer: Recent developments. *Best Practice & Research Clinical Endocrinology & Metabolism* 37:1, 101715. [[Crossref](#)]

205. Dennis M. Styne. Disorders of the Thyroid Gland 121-161. [[Crossref](#)]
206. Meiwu Zhang, Yan Zhang, Yuqin Qiu, Huilin Wei, Shuyi Lyu. 2023. A nomogram based on ultrasound characteristics to predict large-number cervical lymph node metastasis in papillary thyroid carcinoma. *Endocrine Journal* **70**:5, 481-488. [[Crossref](#)]
207. Amit Agarwal, Ranil Fernando, Rajeev Parameswaran, Anand Mishra, Roma Pradhan. Child with DTC 321-328. [[Crossref](#)]
208. Martha-Conley E. Ingram, Olivia A. Keane, Goeto Dantes, Matthew T. Santore, Matthew S. Clifton. Pediatric Surgery 657-718. [[Crossref](#)]
209. # #. 2023. Current Research Status of Bilateral Thyroid Cancer. *Advances in Clinical Medicine* **13**:07, 12038-12044. [[Crossref](#)]
210. Jeffrey Krane, Lan Chen, Ronald Ghossein, Dong Eun Song, Vivian Weiss, Ritu Nayar. Atypia of Undetermined Significance 53-79. [[Crossref](#)]
211. Arzu Or Koca, Gülçin Güler Şimşek. 2023. Post-radiotherapy cribriform-morular thyroid carcinoma. *Journal of Clinical Laboratory Analysis* **37**:1. . [[Crossref](#)]
212. De-qian Chen, En-qing Zhou, Hui-fen Chen, Yong Zhan, Chun-Jing Ye, Yi Li, Shu-yang Dai, Jun-feng Wang, Lian Chen, Kui-ran Dong, Rui Dong. 2023. Deciphering pathological behavior of pediatric medullary thyroid cancer from single-cell perspective. *PeerJ* **11**, e15546. [[Crossref](#)]
213. Barry Shulkin, Thomas Neil Pascual. Thyroid 57-74. [[Crossref](#)]
214. N. Zwaveling-Soonawala, A. S. van Trotsenburg. Overview of Thyroid Disease in Children and Adolescents 1-30. [[Crossref](#)]
215. Ghadah Al-Naqeeb, Neelam Baral, James Welch, Joanna Klubo-Gwiedzinska. Familial Thyroid Cancer Syndromes in Children and Adolescents 75-106. [[Crossref](#)]
216. Gabriel Dunya, Logan Dance, J. Fredrik Grimmer. 2023. Comparing ATA guidelines vs TI-RADS for evaluation of pediatric thyroid lesions. *International Journal of Pediatric Otorhinolaryngology* **164**, 111411. [[Crossref](#)]
217. Dong Gyu Na, Ji-hoon Kim, Eun Ju Ha. Ultrasonography in Diagnosis and Management of Thyroid Cancer: Current International Recommendations 31-58. [[Crossref](#)]
218. Ian D. Hay. Childhood Papillary Thyroid Carcinoma 249-277. [[Crossref](#)]
219. Olivia A. Keane, Shasha Bai, Kristina Cossen, Briana C. Patterson, Kara K. Prickett, Kurt F. Heiss, Matthew T. Santore. 2023. Outcomes in pediatric total thyroidectomy following implementation of a two-surgeon operative approach. *International Journal of Pediatric Otorhinolaryngology* **164**, 111402. [[Crossref](#)]
220. Marc Pusztaszeri, Beatrix Cochand-Priollet, Massimo Bongiovanni. AUS/FLUS in the Third Edition of the Bethesda System 175-182. [[Crossref](#)]
221. Chanchal Rana, Huy Gia Vuong. Thyroid Carcinoma of Young Adults and Children 791-796. [[Crossref](#)]
222. Young Ah Lee. Thyroid Nodules in Children and Adolescents 783-789. [[Crossref](#)]
223. Esther Diana Rossi. The Role of Thyroid FNA Cytology in Pediatric Malignant Lesions: Case Illustrations and Literature Review 797-805. [[Crossref](#)]
224. Yuqin He, Han Li, Kai Wang, Jian Wang, Yiming Zhu, Song Ni, Shaoyan Liu. 2023. Fourteen years old as the best age cutoff to differentiate prepubertal from pubertal papillary thyroid carcinoma. *Head & Neck* **45**:1, 85-94. [[Crossref](#)]
225. Yue Jie, Jingliang Ruan, Yuechang Cai, Man Luo, Rongbin Liu. 2023. Comparison of ultrasonography and pathology features between children and adolescents with papillary thyroid carcinoma. *Heliyon* **9**:1, e12828. [[Crossref](#)]
226. Alessandro Cattoni, Silvia Molinari, Benedetta Riva, Santo Di Marco, Marta Adavastro, Martha Caterina Faraguna, Vittoria Garella, Francesco Medici, Maria Laura Nicolosi, Claudia Pellegrinelli, Martina Lattuada, Donatella Fraschini, Fabio Pagni, Andrea Biondi, Adriana Balduzzi. 2022. Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up. *Frontiers in Endocrinology* **13**. . [[Crossref](#)]
227. Peter K. Moon, Z. Jason Qian, Julia E. Noel, Lisa A. Orloff, Hilary Seeley, Gary E. Hartman, Shellie Josephs, Kara D. Meister. 2022. Sociodemographic Disparities in the Diagnostic Management of Pediatric Thyroid Nodules. *JAMA Otolaryngology-Head & Neck Surgery* **148**:12, 1097. [[Crossref](#)]
228. Faridul Haq, Andrey Bychkov, Chan Kwon Jung. 2022. A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model. *Endocrine Pathology* **33**:4, 472-483. [[Crossref](#)]
229. Yangsen Li, Yuanyuan Wang, Liwen Li, Xinguang Qiu. 2022. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas. *Scientific Reports* **12**:1. . [[Crossref](#)]

230. Marek Niedziela, Karl Muchantef, William D. Foulkes. 2022. Ultrasound features of multinodular goiter in DICER1 syndrome. *Scientific Reports* 12:1. . [[Crossref](#)]
231. Fahad Al Juraibah, Khalid Al Noaim, Abdulaziz AlDbas, Ahmed AlMuallimi, Omar AlOtaibi, Mozon AlShareef, Alanoud AlSuhibani, Ahmed AlZaharani, Mohammed AlDubayee, Amir Babiker. 2022. Prevalence of thyroid nodules and characteristics of thyroid ultrasound in children with goiter: a single center experience. *BMC Pediatrics* 22:1. . [[Crossref](#)]
232. Yuan Qin, Dai Zhang, Huan Zhang, Lan Hou, Zhe Wang, Liu Yang, Mingkun Zhang, Ge Zhao, Qing Yao, Rui Ling, Juliang Zhang. 2022. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. *Cancer Cell International* 22:1. . [[Crossref](#)]
233. Ahmed Elgendy, Emad M. Shehata, Sherif M. Shehata. 2022. Outcome and complications after surgery for thyroid carcinoma in pediatric age—an evaluation of practice. *World Journal of Surgical Oncology* 20:1. . [[Crossref](#)]
234. Shaohao Cheng, Ruochuan Cheng, Shunshun Zhao, Min Zhang, Chang Diao, Yunhai Ma, Jun Qian, Yanjun Su. 2022. The impact of the initial operation of PTC in children on recurrence: 9-year experience in a single center. *World Journal of Surgical Oncology* 20:1. . [[Crossref](#)]
235. Chantal A Lebbink, Thera P Links, Agnieszka Czarniecka, Renuka P Dias, Rossella Elisei, Louise Izatt, Heiko Krude, Kerstin Lorenz, Markus Luster, Kate Newbold, Arnaldo Piccardo, Manuel Sobrinho-Simões, Toru Takano, A S Paul van Trotsenburg, Frederik A Verburg, Hanneke M van Santen. 2022. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. *European Thyroid Journal* 11:6. . [[Crossref](#)]
236. Andrew J Bauer, Jonathan D Wasserman, Steven G Waguespack. 2022. Pediatric thyroid cancer guidelines: challenges in stratifying care based on limited data. *European Thyroid Journal* 11:6. . [[Crossref](#)]
237. Wen Jiang, Matt Hall, Ron Newfield, Jay G. Berry. 2022. Short-term pediatric thyroidectomy outcome: Analysis of the Pediatric Health Information System (PHIS) database. *International Journal of Pediatric Otorhinolaryngology* 163, 111340. [[Crossref](#)]
238. Jessica L Sandy, Angela Titmuss, Shihab Hameed, Yoon Hi Cho, Gideon Sandler, Paul Benitez-Aguirre. 2022. Thyroid nodules in children and adolescents: Investigation and management. *Journal of Paediatrics and Child Health* 58:12, 2163-2168. [[Crossref](#)]
239. Pedro W Rosario, Gabriela F Mourão. 2022. Ultrasonography screening in children and adolescents who have one parent with familial non-medullary thyroid carcinoma. *Journal of Paediatrics and Child Health* 58:12, 2254-2257. [[Crossref](#)]
240. Chunquan Zhang, Dan Liu, Long Huang, Yu Zhao, Lili Chen, Youmin Guo. 2022. Classification of Thyroid Nodules by Using Deep Learning Radiomics Based on Ultrasound Dynamic Video. *Journal of Ultrasound in Medicine* 41:12, 2993-3002. [[Crossref](#)]
241. Neetika Gupta, Anilawan Fleury, Hongming Zhuang. 2022. Cerebellar Metastasis From Thyroid Carcinoma With Prominent 123I Uptake But Less Impressive MRI Findings in a Pediatric Patient. *Clinical Nuclear Medicine* 47:12, 1071-1073. [[Crossref](#)]
242. Régis Coutant, Alexandre Lugat, Éric Mirallié, Isabelle Oliver-Petit, Athanasia Stoupa, Delphine Druil. 2022. SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules : Thyroid nodules in children. *Annales d'Endocrinologie* 83:6, 431-434. [[Crossref](#)]
243. Svetlana Bukarica, Jelena Antić, Ivana Fratrić, Dragan Kravarušić, Miloš Pajić, Radoica Jokić. 2022. Thyroid Surgery in Children: A 5-Year Retrospective Study at a Single Paediatric Surgical Center and Systematic Review. *Children* 9:12, 1818. [[Crossref](#)]
244. Prerna Guleria, Radhika Srinivasan, Chanchal Rana, Shipra Agarwal. 2022. Molecular Landscape of Pediatric Thyroid Cancer: A Review. *Diagnostics* 12:12, 3136. [[Crossref](#)]
245. Stephen Halada, Julia A. Baran, Andrew J. Bauer, Julio C. Ricarte-Filho, Amber Isaza, Tasleema Patel, Aime T. Franco, Sogol Mostoufi-Moab, N. Scott Adzick, Ken Kazahaya, Tricia R. Bhatti, Zubair Baloch, Lea F. Surrey. 2022. Clinicopathologic Characteristics of Pediatric Follicular Variant of Papillary Thyroid Carcinoma Subtypes: A Retrospective Cohort Study. *Thyroid* 32:11, 1353-1361. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
246. Claudio Spinelli, Marco Ghionzoli, Chiara Oreglio, Beatrice Sanna, Luigi De Napoli, Riccardo Morganti, Alessandro Antonelli, Antonino Morabito, Paolo Miccoli. 2022. Increased trend of thyroid cancer in childhood over the last 30 years in EU countries: a call for the pediatric surgeon. *European Journal of Pediatrics* 181:11, 3907-3913. [[Crossref](#)]
247. Luigi De Napoli, Antonio Matrone, Carlo Enrico Ambrosini, Chiara Becucci, Erica Pieroni, Filippo Vagelli, Giacomo Taddei, Benard Gjeloshi, Liborio Torregrossa, Rossella Elisei, Claudio Spinelli, Gabriele Materazzi. 2022. Impact of energy-based devices in pediatric thyroid surgery. *Journal of Pediatric Surgery* 57:11, 740-745. [[Crossref](#)]
248. Rahul K. Sharma, Siddharth Patel, Jean-Nicolas Gallant, Brandon I. Esianor, Sara Duffus, Huiying Wang, Vivian L. Weiss, Ryan H. Belcher. 2022. Racial, ethnic, and socioeconomic disparities in the presentation and management of pediatric thyroid cancer. *International Journal of Pediatric Otorhinolaryngology* 162, 111331. [[Crossref](#)]
249. L Q Li, O Hilmi, J England, N Tolley. 2022. An update on the management of thyroid nodules: rationalising the guidelines. *The Journal of Laryngology & Otology* 328, 1-6. [[Crossref](#)]

250. Matthew Maksimoski, Andrew J. Bauer, Ken Kazahaya, Scott C. Manning, Sanjay R. Parikh, Jeffrey P. Simons, Jill D'Souza, John Maddalozzo, Matthew R. Purkey, Karen Rychlik, Brian Ho, Michael J. Rutter, Wen Jiang, Jeremy D. Prager, Gillian Diercks, Evan J. Propst, R. Christopher Miyamoto, Brendan C. Stack, Gregory W. Randolph, Jeffrey C. Rastatter. 2022. Outcomes in Pediatric Thyroidectomy: Results From a Multinational, Multi-institutional Database. *Otolaryngology–Head and Neck Surgery* 167:5, 869-876. [[Crossref](#)]
251. Hanna Borysewicz-Sańczyk, Beata Sawicka, Filip Bossowski, Janusz Dziecioł, Artur Bossowski. 2022. Elastographic Evaluation of Thyroid Nodules in Children and Adolescents with Hashimoto's Thyroiditis and Nodular Goiter with Reference to Cytological and/or Histopathological Diagnosis. *Journal of Clinical Medicine* 11:21, 6339. [[Crossref](#)]
252. Soyun Park, Beth Osterbauer, Grace Sahyouni, Connie Paik, Juliana Austin, Gabriel Gomez, Nick Shillingford, Daniel Kwon. 2022. Malignancy Rates by Bethesda Subcategory in the Pediatric Population. *Pediatric and Developmental Pathology* 25:6, 598-603. [[Crossref](#)]
253. Chenyu Li, Yuan Gao, Peng Zhou, Tao Yue, Jing Xu, Changxiu Shao, Yongxiang Liu, Dayong Zhuang, Qingqing He, Xiaolei Li. 2022. Comparison of the Robotic Bilateral Axillo-Breast Approach and Conventional Open Thyroidectomy in Pediatric Patients: A Retrospective Cohort Study. *Thyroid* 32:10, 1211-1219. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
254. Sydney L. Olson, Martha-Conley E. Ingram, Jill Samis, Jami L. Josefson, Jeff C. Rastatter, David H. Rothstein, Melissa E. Danko, Kevin P. Moriarty, Barrie S. Rich, Mehul V Raval. 2022. Surgeon perceptions of volume threshold and essential practices for pediatric thyroidectomy#. *Journal of Pediatric Surgery* 57:10, 414-420. [[Crossref](#)]
255. Duy Quoc Ngo, Duong The Le, Quy Xuan Ngo, Quang Van Le. 2022. Risk factors for lateral lymph node metastasis of papillary thyroid carcinoma in children. *Journal of Pediatric Surgery* 57:10, 421-424. [[Crossref](#)]
256. Pyeong Hwa Kim, Hee Mang Yoon, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee, Jin Seong Lee, Ah Young Jung, Young Ah Cho, Boram Bak, Dong Gyu Na. 2022. Diagnostic Performance of Five Adult-based US Risk Stratification Systems in Pediatric Thyroid Nodules. *Radiology* 305:1, 190-198. [[Crossref](#)]
257. Antoinette D Reichert, Marloes Nies, Wim J E Tissing, Anneke C Muller Kobold, Mariëlle S Klein Hesselink, Adrienne H Brouwers, Bas Havekes, Marry M van den Heuvel-Eibrink, Helena J H van der Pal, John T M Plukker, Hanneke M van Santen, Eleonora P M Corssmit, Romana T Netea-Maier, Robin P Peeters, Eveline W C M van Dam, Johannes G M Burgerhof, Peter van der Meer, Gianni Bocca, Thera P Links. 2022. Progressive diastolic dysfunction in survivors of pediatric differentiated thyroid carcinoma. *European Journal of Endocrinology* 187:4, 497-505. [[Crossref](#)]
258. Melanie Goldfarb, Catherine Dinauer. 2022. Differences in the management of thyroid nodules in children and adolescents as compared to adults. *Current Opinion in Endocrinology, Diabetes & Obesity* 29:5, 466-473. [[Crossref](#)]
259. Qian Zhang, Weina Xu. 2022. Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer. *Nuclear Medicine Communications* 43:10, 1051-1057. [[Crossref](#)]
260. Mustafa Gök, Reyhan Deveci Sevim, Sercan Öztürk, Ahmet Anık. 2022. Evaluation of Thyroid Pathologies Detected During School Screening in Healthy School-Age Children. *Trends in Pediatrics* 3:3, 77-85. [[Crossref](#)]
261. M.D. Tronko, M.Yu. Bolhov, O.V. Omelchuk. 2022. Сучасний стан та перспективи розвитку пріоритетних напрямків ендокринної хірургії в Україні. *Endokrynologia* 27:3, 195-202. [[Crossref](#)]
262. Jingjing Yang, Ya Zhang, Xingjia Li, Yueting Zhao, Xue Han, Guofang Chen, Xiaoqiu Chu, Ruiping Li, Jianhua Wang, Fei Huang, Chao Liu, Shuhang Xu. 2022. Efficacy and safety of ultrasound-guided microwave ablation versus surgical resection for Bethesda category IV thyroid nodules: A retrospective comparative study. *Frontiers in Endocrinology* 13. . [[Crossref](#)]
263. Lindsay A. Bischoff. 2022. Age Less Than 18 Is Not a Reliable Cutoff for the Pediatric Classification of Differentiated Thyroid Cancer. *Clinical Thyroidology* 34:9, 399-401. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
264. Jean-Nicolas Gallant, Sheau-Chiann Chen, Carlos A. Ortega, Sarah L. Rohde, Ryan H. Belcher, James L. Netterville, Naira Baregamian, Huiying Wang, Jiancong Liang, Fei Ye, Yuri E. Nikiforov, Marina N. Nikiforova, Vivian L. Weiss. 2022. Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children. *JAMA Oncology* 8:9, 1323. [[Crossref](#)]
265. Cristiano Pini, Fabrizia Gelardi, Martina Sollini. 2022. Present and future of target therapies and theranostics: refining traditions and exploring new frontiers—highlights from annals of Nuclear Medicine 2021. *European Journal of Nuclear Medicine and Molecular Imaging* 49:11, 3613-3621. [[Crossref](#)]
266. Sydney L. Olson, Martha-Conley E. Ingram, Peter M. Graffy, Peggy M. Murphy, Yao Tian, Jill H. Samis, Jami L. Josefson, Jeffery C. Rastatter, Mehul V. Raval. 2022. Effect of surgeon volume on pediatric thyroid surgery outcomes: A systematic review. *Journal of Pediatric Surgery* 57:9, 208-215. [[Crossref](#)]

267. Ana C Fernandes, Ana L Fitas, Joana Soares, Ana Nunes, Lurdes Lopes. 2022. Intrathyroidal ectopic thymus: A case series. *Journal of Paediatrics and Child Health* **58**:9, 1666-1668. [[Crossref](#)]
268. Asma Zbitou, Emmanuel Desandes, Sandra Guissou, Coralie Mallebranche, Brigitte Lacour. 2022. Thyroid cancers in children and adolescents in France: Incidence, survival and clinical management over the 2000–2018 period. *International Journal of Pediatric Otorhinolaryngology* **142**, 111325. [[Crossref](#)]
269. André Borsatto Zanella, Laura Marmitt, Tayane Muniz Fighera, Rafael Selbach Scheffel, Poli Mara Spritzer, José Miguel Dora, Ana Luiza Maia. 2022. Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma. *Metabolites* **12**:9, 842. [[Crossref](#)]
270. Sandeep Kumar Parvathareddy, Abdul K. Siraj, Padmanaban Annaiyappanaidu, Nabil Siraj, Wael Haqawi, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya. 2022. Tumor size is an independent negative prognostic factor for event free survival in children with differentiated thyroid cancer. *Frontiers in Endocrinology* **13**. . [[Crossref](#)]
271. Tetiana Bogdanova, Serhii Chernyshov, Liudmyla Zurnadzhy, Tatiana I. Rogounovitch, Norisato Mitsutake, Mykola Tronko, Masahiro Ito, Michael Bolgov, Sergii Masiuk, Shunichi Yamashita, Vladimir A. Saenko. 2022. The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients. *Frontiers in Endocrinology* **13**. . [[Crossref](#)]
272. Ali Sayan, Mehmet Üstün, Mehmet Mert, Cem Karaali, Gökhan Köylüoğlu. 2022. Endocrine Surgery and Pediatric Surgery Partnership Reduces Complication Rate of Pediatric Thyroidectomy. *Journal of Dr Behcet Uz Children s Hospital* **12**:2, 164-168. [[Crossref](#)]
273. Gary L. Francis. 2022. Trends in Lobectomy for Pediatric Thyroid Cancer. *Clinical Thyroidology* **34**:8, 347-350. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
274. Magdalena D. Ivanova, Biren P. Modi, Ari J. Wassner. 2022. Investigations Into Obesity and the Risk of Malignant Disease in Pediatric Thyroid Nodules—Reply. *JAMA Otolaryngology–Head & Neck Surgery* **148**:8, 793. [[Crossref](#)]
275. Teresa Rago, Massimo Tonacchera. 2022. Il ruolo dell'ecografia nella patologia nodulare tiroidea in età pediatrica. *L'Endocrinologo* **23**:S1, 92-94. [[Crossref](#)]
276. Kyorim Back, Ra-Yeong Song, Jun-Ho Choe, Jee Soo Kim, Yoo Shin Choi, Min Kyoon Kim, Jung-Han Kim. 2022. The clinical impact of extrathyroidal extensions on prognoses in pediatric differentiated thyroid cancers. *Journal of Pediatric Surgery* **57**:8, 1532-1537. [[Crossref](#)]
277. Richard M. Yeker, Amber D. Shaffer, Pushpa Viswanathan, Selma F. Witchel, Kevin Mollen, Linwah Yip, Sara E. Monaco, Umamaheswar Duvvuri, Jeffrey P. Simons. 2022. Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer. *The Laryngoscope* **132**:8, 1668-1674. [[Crossref](#)]
278. Mümtaz Köksal, Leonard Saur, Davide Scafa, Gustavo R Sarria, Christina Leitzen, Christopher Schmeel, Frederick Far, Sebastian Strieth, Frank A. Giordano. 2022. Late toxicity-related symptoms and fraction dose affect decision regret among patients receiving adjuvant radiotherapy for head and neck cancer. *Head & Neck* **44**:8, 1885-1895. [[Crossref](#)]
279. Eli Stein, Mehul V. Raval, Inbal Hazkani, Audra Reiter, Jami L. Josefson, Jill H. Samis, Jeffrey C. Rastatter. 2022. The 2015 American Thyroid Association guidelines and trends in hemithyroidectomy utilization for pediatric thyroid cancer. *Head & Neck* **44**:8, 1833-1841. [[Crossref](#)]
280. Alessandro Cattoni, Silvia Molinari, Alberto Gaiero, Paola De Lorenzo, Graziella Fichera, Benedetta Riva, Santo Di Marco, Chiara Tommesani, Eugenia Mariani, Francesco Medici, Fabio Pagni, Maria Laura Nicolosi, Donatella Fraschini, Sara Napolitano, Attilio Rovelli, Andrea Biondi, Maria Grazia Valsecchi, Adriana Balduzzi. 2022. Thyroid Disorders Following Hematopoietic Stem Cell Transplantation in Childhood: Impact of Conditioning Regimen on Thyroid Dysfunction, Volume Changes, and Occurrence of Nodules. *Transplantation and Cellular Therapy* **28**:8, 506.e1-506.e12. [[Crossref](#)]
281. Duy Quoc Ngo, Duong The Le, Quang Le. 2022. Prophylactic Central Neck Dissection to Improve Disease-Free Survival in Pediatric Papillary Thyroid Cancer. *Frontiers in Oncology* **12**. . [[Crossref](#)]
282. Cristina Martucci, Alessandro Crocoli, Maria Debora De Pasquale, Claudio Spinelli, Silvia Strambi, Paolo Brazzarola, Eleonora Morelli, Jessica Cassiani, Juliana Mancera, Juan Pablo Luengas, Pablo Lobos, Daniel Liberto, Estefania Astori, Sabine Sarnacki, Vincent Couloigner, François Simon, Cassandre Lambert, Simone de Campos Vieira Abib, Onivaldo Cervantes, Eliana Caran, Diana Delgado Lindman, Matthew O. Jones, Rajeev Shukla, Paul D. Losty, Alessandro Inserra. 2022. Thyroid cancer in children: A multicenter international study highlighting clinical features and surgical outcomes of primary and secondary tumors. *Frontiers in Pediatrics* **10**. . [[Crossref](#)]
283. Fanny Yeung, KP Wong, Brian HH Lang, Patrick HY Chung, Kenneth KY Wong. 2022. Paediatric thyroidectomy: When and why? A 25-year institutional experience. *Journal of Pediatric Surgery* **57**:7, 1196-1200. [[Crossref](#)]

284. Grace Sahyouni, Beth Osterbauer, Soyun Park, Connie Paik, Juliana Austin, Daniel Kwon, Gabriel Gomez. 2022. Incidence of thymic tissue in pediatric thyroidectomy. *International Journal of Pediatric Otorhinolaryngology* **158**, 111168. [[Crossref](#)]
285. Luisa Rodriguez, Catherine Dinauer, Gary Francis. 2022. Treatment of hypothyroidism in infants, children and adolescents. *Trends in Endocrinology & Metabolism* **33**:7, 522-532. [[Crossref](#)]
286. Gabby Atlas, Stephen Farrell, Margaret Zacharin. 2022. Secondary thyroid carcinoma in survivors of childhood cancer: A need to revise current screening recommendations. *Clinical Endocrinology* **97**:1, 137-139. [[Crossref](#)]
287. Yanjun Su, Shaohao Cheng, Chang Diao, Yunhai Ma, Jun Qian, Ruochuan Cheng. 2022. Surgical treatment of pediatric and adolescent papillary thyroid cancer: a retrospective study of 54 patients in a single center. *Jornal de Pediatria* **98**:4, 425-430. [[Crossref](#)]
288. Dongmei Huang, Jingtai Zhi, Jinming Zhang, Xuan Qin, Jingzhu Zhao, Xiangqian Zheng, Ming Gao. 2022. Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents. *Frontiers in Oncology* **12**. . [[Crossref](#)]
289. Yasemin Giles Şenyürek, Yalın İşcan, İsmail Cem Sormaz, Şükran Poyrazoğlu, Fatih Tunca. 2022. The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. *Journal of Clinical Research in Pediatric Endocrinology* **14**:2, 196-206. [[Crossref](#)]
290. Priya Mahajan, Rajkumar Venkatramani. 2022. Response to Selpercatinib in an Adolescent with RET Fusion-Positive Papillary Thyroid Carcinoma with Extensive Intracranial and Pulmonary Metastases. *VideoEndocrinology* **9**:2, 48-49. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
291. Ron S. Newfield, Wen Jiang, Daniel X. Sugganth, Feras M. Hantash, Euyhyun Lee, Robert O. Newbury. 2022. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common. *International Journal of Pediatric Otorhinolaryngology* **157**, 111121. [[Crossref](#)]
292. Emre Divarci, Hilmican Ulman, Geylani Ozok, Samim Ozen, Murat Ozdemir, Ozer Makay. 2022. Transoral endoscopic thyroidectomy vestibular approach (TOETVA): A novel surgical technique for scarless thyroidectomy in pediatric surgery. *Journal of Pediatric Surgery* **57**:6, 1149-1157. [[Crossref](#)]
293. Victoria Casado-Medrano, Alison O'Neill, Stephen Halada, Theodore W. Laetsch, Andrew J. Bauer, Aime T. Franco. 2022. NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives. *Cancer Genetics* **264-265**, 23-28. [[Crossref](#)]
294. B. J. Van Remortel, L. Chehab, A. J. Bauer, A. Isaza, Li Yimei, Heron D. Baumgarten, Aime T. Franco, Theodore W. Laetsch, Ken Kazahaya, N. Scott Adzick, Sogol Mostoufi-Moab. 2022. Surgical outcomes in survivors of childhood cancer undergoing thyroidectomy: A single-institution experience. *Pediatric Blood & Cancer* **69**:6. . [[Crossref](#)]
295. Connie Paik, Beth Osterbauer, Grace Sahyouni, Soyun Park, Gabriel Gomez, Daniel Kwon, Juliana Austin. 2022. Thyroid tumor ratio: Improving the assessment of the impact of size in pediatric thyroid cancer. *Head & Neck* **44**:6, 1342-1348. [[Crossref](#)]
296. Gillian R. Diercks, Jeff C. Rastatter, Ken Kazahaya, Dipti Kamani, Lourdes Quintanilla-Dieck, Maisie L. Shindo, Christopher Hartnick, Jennifer J. Shin, Michael C. Singer, Brendan C. Stack, Amy Y. Chen, Maie A. St. John, Joseph Scharpf, Nishant Agrawal, Asitha D. L. Jayawardena, Ayaka J. Iwata, Okenwa Okose, Bo Wang, Dioan McIlroy, Anthony Cheung, Che Wei Wu, Feng Yu Chiang, Gianlorenzo Dionigi, Marcin Barczynski, Katrin Brauckhoff, Kerstin Lorenz, Dana Hartl, Neil Tolley, Jennifer A. Brooks, Rick Schneider, Henning Dralle, Amr H. Abdelhamid Ahmed, Gregory W. Randolph. 2022. Pediatric intraoperative nerve monitoring during thyroid surgery: A review from the American Head and Neck Society Endocrine Surgery Section and the International Neural Monitoring Study Group. *Head & Neck* **44**:6, 1468-1480. [[Crossref](#)]
297. Irina Gavryutina, Lawrence Fordjour, Vivian L. Chin. 2022. Genetics of Thyroid Disorders. *Endocrines* **3**:2, 198-213. [[Crossref](#)]
298. Liwen Li, Xinguang Qiu. 2022. Safety and Efficacy of Ultrasound-Guided Radiofrequency Ablation for Benign Nonfunctional Thyroid Nodules in Children: A Retrospective Study of 62 Patients with Over Four Years of Follow-Up. *Thyroid* **32**:5, 525-535. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
299. Q. Wang, Q. Chang, R. Zhang, C. Sun, L. Li, S. Wang, Q. Wang, Z. Li, L. Niu. 2022. Diffuse sclerosing variant of papillary thyroid carcinoma: ultrasonographic and clinicopathological features in children/adolescents and adults. *Clinical Radiology* **77**:5, e356-e362. [[Crossref](#)]
300. Elisa Pasqual, Sara Schonfeld, Lindsay M. Morton, Daphnée Villoing, Choonsik Lee, Amy Berrington de Gonzalez, Cari M. Kitahara. 2022. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. *Journal of Clinical Oncology* **40**:13, 1439-1449. [[Crossref](#)]
301. Andrew M. McDonald, Brenessa Lindeman, Deepti Bahl. 2022. Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance. *Journal of Clinical Oncology* **40**:13, 1396-1399. [[Crossref](#)]

302. Charles Brady, Scott C. Manning, Erin Rudzinski, Vera Paulson, Xing Wang, Yajuan J. Liu, Sanjay R. Parikh, Julianna Bonilla-Velez, Douglas S. Hawkins, John Dahl. 2022. Clinical Outcomes of Diffuse Sclerosing Variant Papillary Thyroid Carcinoma in Pediatric Patients. *The Laryngoscope* **132**:5, 1132-1138. [[Crossref](#)]
303. Christine E. Cherella, Monica L. Hollowell, Jessica R. Smith, Benjamin Zendejas, Biren P. Modi, Edmund S. Cibas, Ari J. Wassner. 2022. Subtype of atypia on cytology and risk of malignancy in pediatric thyroid nodules. *Cancer Cytopathology* **130**:5, 330-335. [[Crossref](#)]
304. Jeffrey F. Krane. 2022. Improving risk assessment in indeterminate pediatric thyroid FNA biopsies. *Cancer Cytopathology* **130**:5, 326-327. [[Crossref](#)]
305. Alexander D. Chesover, Antoine Eskander, Rebecca Griffiths, Jesse D. Pasternak, Jason D. Pole, Nikolaus E. Wolter, Jonathan D. Wasserman. 2022. The Impact of Hospital Surgical Volume on Healthcare Utilization Outcomes After Pediatric Thyroidectomy. *World Journal of Surgery* **46**:5, 1082-1092. [[Crossref](#)]
306. V. A. Peterkova, O. B. Bezlepkina, T. U. Shiryaeva, T. A. Vadina, E. V. Nagaeva, O. A. Chikulaeva, E. V. Shreder, M. B. Konuhova, N. A. Makretskaya, E. A. Shestopalova, V. B. Mitkina. 2022. Clinical guideline of «congenital hypothyroidism». *Problems of Endocrinology* **68**:2, 90-103. [[Crossref](#)]
307. Ji Young You, Se-Woong An, Hoon Yub Kim, Da Won Park, Hyung Kwon Byeon, Serena Patroniti, Gianlorenzo Dionigi, Ralph P. Tufano. 2022. Considerations for Balance Between Fundamental Treatment and Improvement of Quality of Life of Pediatric Thyroid Cancer Patient: Comparative Analysis With Adult Using Propensity Score Matching. *Frontiers in Pediatrics* **10**. . [[Crossref](#)]
308. Soo Young Kim, Hyeok Jun Yun, Hojin Chang, Seok-Mo Kim, Soyoung Jeon, Sujee Lee, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. 2022. Aggressiveness of Differentiated Thyroid Carcinoma in Pediatric Patients Younger Than 16 years: A Propensity Score-Matched Analysis. *Frontiers in Oncology* **12**. . [[Crossref](#)]
309. Gary L. Francis. 2022. The Future of Molecular Profiling for the Treatment of Pediatric Thyroid Cancer. *Clinical Thyroidology* **34**:4, 157-160. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
310. Jennifer R. Hess, Dorothee K. Newbern, Kristen L. Beebe, Alexandra M. Walsh, Kristian T. Schafernak. 2022. High Prevalence of Gene Fusions and Copy Number Alterations in Pediatric Radiation Therapy-Induced Papillary and Follicular Thyroid Carcinomas. *Thyroid* **32**:4, 411-420. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
311. Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara. 2022. Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018). *Thyroid* **32**:4, 397-410. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
312. Magdalena D. Ivanova, Christine E. Cherella, Biren P. Modi, Jessica R. Smith, Ari J. Wassner. 2022. Association Between Body Mass Index and Thyroid Cancer in Children With Thyroid Nodules. *JAMA Otolaryngology–Head & Neck Surgery* **148**:4, 375. [[Crossref](#)]
313. Oded Cohen, Ralph P. Tufano, Angkoon Anuwong, Jonathon O. Russell, Niddal Assadi, Gianlorenzo Dionigi, Hoon Yub Kim, Antonio Bertelli, Avi Khafif. 2022. Trans-oral endoscopic thyroidectomy vestibular approach (TOETVA) for the pediatric population: a multicenter, large case series. *Surgical Endoscopy* **36**:4, 2507-2513. [[Crossref](#)]
314. David E. Wesson, Brittany L. Johnson, Charlene Barclay, Adam M. Vogel, Daniel C. Chelius, Amy L. Dimachkieh, Ioanna D. Athanassaki, Lefkothea P. Karaviti, Andrew C. Sher, Jose A. Hernandez, Nadia F. Mahmood, Priya Mahajan, Norma Quintanilla, Monica E. Lopez. 2022. Thyroid surgery outcomes at a children's hospital: The value of a multidisciplinary team approach. *Journal of Pediatric Surgery* **57**:4, 622-629. [[Crossref](#)]
315. Steven G. Waguespack, Sanjit O. Tewari, Naifa L. Busaidy, Mark E. Zafereo. 2022. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?. *JCO Precision Oncology* **31**:6. . [[Crossref](#)]
316. Julio C. Ricarte-Filho, Stephen Halada, Alison O'Neill, Victoria Casado-Medrano, Theodore W. Laetsch, Aime T. Franco, Andrew J. Bauer. 2022. The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. *Cancer Genetics* **262-263**, 57-63. [[Crossref](#)]
317. Hanna Borysewicz-Sańczyk, Beata Sawicka, Agata Karny, Filip Bossowski, Katarzyna Marcinkiewicz, Aleksandra Rusak, Janusz Dzięcioł, Artur Bossowski. 2022. Suspected Malignant Thyroid Nodules in Children and Adolescents According to Ultrasound Elastography and Ultrasound-Based Risk Stratification Systems—Experience from One Center. *Journal of Clinical Medicine* **11**:7, 1768. [[Crossref](#)]
318. Chuang Xi, Guo-Qiang Zhang, Hong-Jun Song, Chen-Tian Shen, Li-Ying Hou, Zhong-Ling Qiu, Quan-Yong Luo. 2022. Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients. *International Journal of Endocrinology* **2022**, 1-12. [[Crossref](#)]

319. Gary L. Francis. 2022. What's the Likelihood of Post-Lobectomy Hypothyroidism in Children?. *Clinical Thyroidology* 34:3, 100-102. [Citation] [Full Text] [PDF] [PDF Plus]
320. Kevin P. Mollen, Amber D. Shaffer, Linwah Yip, Sara E. Monaco, Phillip Huyett, Pushpa Viswanathan, Selma F. Witchel, Umamaheswar Duvvuri, Jeffrey P. Simons. 2022. Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer. *Thyroid* 32:3, 236-244. [Abstract] [Full Text] [PDF] [PDF Plus]
321. Angelina Cistaro, Natale Quartuccio, Maria Carmen Garganese, Maria Felicia Villani, Claudio Altini, Milena Pizzoferro, Arnaldo Piccardo, Manlio Cabria, Michela Massollo, Mohamad Maghnie, Alfredo Campenni, Massimiliano Siracusa, Sergio Baldari, Stefano Panareo, Luca Urso, Mirco Bartolomei, Diego De Palma, Armando Grossi, Angelica Mazzoletti, Francesco Dondi, Francesco Bertagna, Raffaele Giubbini, Domenico Albano. 2022. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. *European Journal of Nuclear Medicine and Molecular Imaging* 49:4, 1374-1385. [Crossref]
322. Takahiro Asakage. 2022. Epidemiology and treatment of head and neck malignancies in the AYA generation. *International Journal of Clinical Oncology* 27:3, 465-472. [Crossref]
323. Sajid S. Qureshi, Mufaddal Kazi, Jarin Noronha, Vasundhara Smriti, Sandeep Basu, Sneha Shah, Sanjay Talole. 2022. Factors Influencing Cervical Lymph Node Metastasis in Pediatric Differentiated Thyroid Cancers. *Indian Journal of Surgical Oncology* 13:1, 92-98. [Crossref]
324. Zaid Al-Qurayshi, Joseph D. Peterson, Mohamed A. Shama, Emad Kandil. 2022. Thyroidectomy practice in pediatric population: a national perspective. *American Journal of Otolaryngology* 43:2, 103298. [Crossref]
325. Laleh Ardeshirpour, Thomas O. Carpenter, Cemre Robinson. Hypercalcaemic and Hypocalcaemic Syndromes in Children 707-726. [Crossref]
326. Sergio Di Molfetta, Antonella Daniele, Chiara Gerardi, Eleonora Allocati, Carla Minoia, Giacomo Loseto, Francesco Giorgino, Attilio Guarini, Vitaliana De Sanctis. 2022. Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. *Cancers* 14:6, 1439. [Crossref]
327. Yan Gui, Dongmei Huang, Yun Hou, Xudong Wei, Jinming Zhang, Junyi Wang. 2022. Predictive Factors for Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents. *Frontiers in Oncology* 12. . [Crossref]
328. Kwangsoo Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung. 2022. Clinical Implications of Age in Differentiated Thyroid Cancer: Comparison of Clinical Outcomes between Children and Young Adults. *International Journal of Endocrinology* 2022, 1-10. [Crossref]
329. Kiminori Sugino, Mitsuji Nagahama, Wataru Kitagawa, Keiko Ohkuwa, Kenichi Matsuzu, Akifumi Suzuki, Chisato Tomoda, Kiyomi Yamada Hames, Junko Akaishi, Chie Masaki, Kana Yoshioka, Koichi Ito. 2022. Cutoff Age Between Pediatric and Adult Thyroid Differentiated Cancer: Is 18 Years Old Appropriate?. *Thyroid* 32:2, 145-152. [Abstract] [Full Text] [PDF] [PDF Plus]
330. Anca M. Avram, Katherine Zukotynski, Helen Ruth Nadel, Luca Giovanella. 2022. Management of Differentiated Thyroid Cancer: The Standard of Care. *Journal of Nuclear Medicine* 63:2, 189-195. [Crossref]
331. Ananya Tawde, Anita Jeyakumar. 2022. Surveillance, Epidemiology, and End Results Database update for pediatric thyroid carcinomas incidence and survival trends 2000–2016. *International Journal of Pediatric Otorhinolaryngology* 153, 111038. [Crossref]
332. M. Schlumberger. 2022. Cancer de la thyroïde : le surdiagnostic doit aussi être évité chez l'enfant et l'adolescent. *Bulletin de l'Académie Nationale de Médecine* 206:2, 246-249. [Crossref]
333. P. Fayoux, A. Maltezeanu. 2022. Masas cervicales en el niño. *EMC - Otorrinolaringología* 51:1, 1-19. [Crossref]
334. Xianlan Zhao, Mingjing Chen, Xiaojing Qi, Haizhen Zhu, Guangrong Yang, Yi Guo, Qiang Dong, Qiao Yang. 2022. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult. *Frontiers in Endocrinology* 12. . [Crossref]
335. Liu-Yang Zhang, Yong Chen, Ya-Zhou Ao. 2022. Value of thyroglobulin combined with ultrasound-guided fine-needle aspiration cytology for diagnosis of lymph node metastasis of thyroid carcinoma. *World Journal of Clinical Cases* 10:2, 492-501. [Crossref]
336. Agnes Stephanie Harahap, Desty Gusti Sari, Marini Stephanie, Alvita Dewi Siswoyo, Litta Septina Mahmelia Zaid, Diani Kartini, Maria Francisca Ham, Tri Juli Edi Tarigan. 2022. Clinicopathological Profile of Thyroid Carcinoma in Young Patients: An Indonesian Single-Center Study. *Journal of Thyroid Research* 2022, 1-8. [Crossref]
337. Alexandre Lugat, Joëlle Gaschet, Michel Chérel, Mathilde Allard, François Guérard, Françoise Kraeber-Bodéré, Catherine Ansquer. Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions . [Crossref]
338. Maura Massimino, Antje Redlich, Paola Collini, Peter Vorwerk. Thyroid Carcinomas 63-77. [Crossref]
339. Gülin Uçmak. Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer 97-134. [Crossref]

340. Ken Kazahya, David R. Lee. Thyroid and Parathyroid 343-356. [[Crossref](#)]
341. George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. Radioiodine Therapy in Differentiated Thyroid Cancer 171-184. [[Crossref](#)]
342. George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. PET-CT in Differentiated Thyroid Cancer 201-212. [[Crossref](#)]
343. Arnaldo Piccardo, Luca Foppiani, Gianluca Bottoni, Francesco Fiz. Pediatric issues in nuclear medicine therapy 368-379. [[Crossref](#)]
344. Takashi Matsuzuka, Satoru Suzuki, Satoshi Suzuki, Manabu Iwadate, Noriko Setou, Susumu Yokoya, Hiroki Shimura. Thyroid ultrasound examination program to address health concerns of Fukushima residents after the nuclear accidents 69-80. [[Crossref](#)]
345. Colin G. DeLong, Christopher J. McLaughlin, Afif N. Kulaylat, Robert E. Cilley. 2022. Development of a Standardized Program for the Collaboration of Adult and Children's Surgeons. *Journal of Surgical Research* **269**, 36-43. [[Crossref](#)]
346. Antje Redlich, Markus Luster, Kerstin Lorenz, Lienhard Lessel, Tilman R Rohrer, Kurt W Schmid, Michael C Frühwald, Peter Vorwerk, Michaela Kuhlen. 2022. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer. *The Journal of Clinical Endocrinology & Metabolism* **107**:1, e165-e177. [[Crossref](#)]
347. Evi Abada, Ahmed Alrajjal, Vinod B. Shidham. 2022. Fine needle aspiration of hematology lesions of the thyroid: Onsite adequacy and ancillary testing. *Cytojournal* **19**, 49. [[Crossref](#)]
348. Brandon Fornwalt, Manasa Melachuri, Matthew Kubina, Janice McDaniel, Anita Jeyakumar. 2022. Pediatric Thyroid Nodules: Ultrasound Characteristics as Indicators of Malignancy. *OTO Open* **6**:1. . [[Crossref](#)]
349. Robert M. Tuliszewski, Aileen P. Wertz. Thyroid Nodules 735-744. [[Crossref](#)]
350. Ryosei Iemura, Shizuka Kirino, Akito Sutani, Kenichi Kashimada, Kei Takasawa. 2022. Autonomously functioning thyroid nodule due to a somatic TSHR mutation. *Pediatrics International* **64**:1. . [[Crossref](#)]
351. Sule Canberk, Helena Barroca, Inês Girão, Ozlem Aydin, Aysun Uguz, Kivilcim Erdogan, Ebru Tastekin, Massimo Bongiovanni, Paula Soares, Valdemar Máximo, Fernando Schmitt. 2022. Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis. *Diagnostics* **12**:1, 179. [[Crossref](#)]
352. Kristina Cossen, Matthew T. Santore, Kara K. Prickett, Steven L. Goudy, Kurt F. Heiss, Kanika Shanker, Adina L. Alazraki, Briana C. Patterson. 2022. Unexpected Benefits in Single Institution Experience With Successful Implementation of a Standardized Perioperative Protocol in Pediatric Thyroidectomy. *Pediatric Quality & Safety* **7**:3, e568. [[Crossref](#)]
353. Shuo Li, Yihao Liu, Shaoxuan Liu, Gongbo Du, Zipeng Wang, Detao Yin. 2021. Predictive Values of Inflammation-Related Markers and Thyroid Function in Pediatric Thyroid Cancer Patients. *Frontiers in Pediatrics* **9**. . [[Crossref](#)]
354. Julia A. Baran, Andrew J. Bauer, Stephen Halada, Sogol Mostoufi-Moab, Amber Isaza, Stephanie Robbins, Aime T. Franco, N. Scott Adzick, Tasleema Patel, Ken Kazahaya. 2021. Clinical Course of Early Postoperative Hypothyroidism Following Thyroid Lobectomy in Pediatrics. *Thyroid* **31**:12, 1786-1793. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
355. Lourdes Quintanilla-Dieck, Hedieh K. Khalatbari, Catherine A. Dinauer, Jeffrey C. Rastatter, Daniel C. Chelius, William R. Katowitz, Maisie L. Shindo, Marguerite T. Parisi, Ken Kazahaya. 2021. Management of Pediatric Graves Disease. *JAMA Otolaryngology-Head & Neck Surgery* **147**:12, 1110. [[Crossref](#)]
356. Grace L. Banik, Maisie L. Shindo, Kristen L. Kraimer, Katherine L. Manzione, Abhita Reddy, Ken Kazahaya, Andrew J. Bauer, Jeffrey C. Rastatter, Mark E. Zafereo, Steven G. Waguespack, Daniel C. Chelius, Lourdes Quintanilla-Dieck. 2021. Prevalence and Risk Factors for Multifocality in Pediatric Thyroid Cancer. *JAMA Otolaryngology-Head & Neck Surgery* **147**:12, 1100. [[Crossref](#)]
357. Diego Yeste Fernández, Elizabeth Vega Amenabar, Ana Coma Muñoz, Larry Arciniegas Vallejo, María Clemente León, Marina Planes-Conangla, Carmela Iglesias Felip, Constantino Sábado Álvarez, Gabriela Guillén Burrieza, Ariadna Campos-Martorell. 2021. Ultrasound criteria (EU-TIRADS) to identify thyroid nodule malignancy risk in adolescents. Correlation with cyto-histological findings. *Endocrinología, Diabetes y Nutrición (English ed.)* **68**:10, 728-734. [[Crossref](#)]
358. Diego Yeste Fernández, Elizabeth Vega Amenabar, Ana Coma Muñoz, Larry Arciniegas Vallejo, María Clemente León, Marina Planes-Conangla, Carmela Iglesias Felip, Constantino Sábado Álvarez, Gabriela Guillén Burrieza, Ariadna Campos-Martorell. 2021. Criterios ecográficos (EU-TIRADS) para identificar el riesgo de malignidad de los nódulos tiroideos en adolescentes. Correlación con los hallazgos cito-histológicos. *Endocrinología, Diabetes y Nutrición* **68**:10, 728-734. [[Crossref](#)]
359. Jelena Rascon, Lukas Salasevicius, Giedre Rutkauskiene, Ewa Bien, Ieva Vincerzevskiene. 2021. The impact of incomplete registration on survival rate of children with very rare tumors. *Scientific Reports* **11**:1. . [[Crossref](#)]
360. Mohammed Hazem, Ossama M. Zakaria, Mohamed Yasser Ibrahim Daoud, Ibrahim Khalid Al Jabr, Abdulwahab A. AlYahya, Ahmed Gaber Hassanein, Abdulrahim A. Alabdulsalam, Mohammed Qasem AlAlwan, Nahla Mohamed Ali Hasan. 2021.

- Accuracy of shear wave elastography in characterization of thyroid nodules in children and adolescents. *Insights into Imaging* 12:1. . [[Crossref](#)]
361. Lorraine W. Lau, Sana Ghaznavi, Alexandra D. Frolkis, Alexandra Stephenson, Helen Lee Robertson, Doreen M. Rabi, Ralf Paschke. 2021. Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis. *Thyroid Research* 14:1. . [[Crossref](#)]
362. An-Ni Lin, Wei-Che Lin, Kai-Lun Cheng, Sheng-Dean Luo, Pi-Ling Chiang, Wei-Chih Chen, Yueh-Sheng Chen, Cheng-Kang Wang, Na-Ning Kan, Yan-Ye Su. 2021. Radiofrequency Ablation a Safe and Effective Treatment for Pediatric Benign Nodular Thyroid Goiter. *Frontiers in Pediatrics* 9. . [[Crossref](#)]
363. A. Yu. Shurinov, V. V. Krylov, E. V. Borodavina. 2021. Radioiodine Ablation for Thyroid Cancer. Historical and Modern Aspects. Literature Review. *Journal of oncology: diagnostic radiology and radiotherapy* 4:4, 9-19. [[Crossref](#)]
364. Lebohang Radebe, Daniëlle C M van der Kaay, Jonathan D Wasserman, Anna Goldenberg. 2021. Predicting Malignancy in Pediatric Thyroid Nodules: Early Experience With Machine Learning for Clinical Decision Support. *The Journal of Clinical Endocrinology & Metabolism* 106:12, e5236-e5246. [[Crossref](#)]
365. Ana Stosic, Fabio Fuligni, Nathaniel D. Anderson, Scott Davidson, Richard de Borja, Meryl Acker, Vito Forte, Paolo Campisi, Evan J. Propst, Nikolaus E. Wolter, Rose Chami, Ozgur Mete, David Malkin, Adam Shlien, Jonathan D. Wasserman. 2021. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma. *Cancer Research* 81:22, 5625-5637. [[Crossref](#)]
366. Gabriela Maia Nobre, Mariana Yoshii Tramontin, Natalia Treistman, Paulo Alonso Alves, Fernanda Accioly Andrade, Daniel Alves Bulzico, Rossana Corbo, Fernanda Vaisman. 2021. Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer. *Archives of Endocrinology and Metabolism* . [[Crossref](#)]
367. Gary L. Francis. 2021. How Does the Bethesda System for Cytopathology Perform in Children with Thyroid Nodules?. *Clinical Thyroidology* 33:11, 477-480. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
368. Kai Guo, Kai Qian, Yuan Shi, Tuanqi Sun, Licai Chen, Dongyu Mei, Kuiran Dong, Song Gu, Jiangbin Liu, Zhibao Lv, Zhuoying Wang. 2021. Clinical and Molecular Characterizations of Papillary Thyroid Cancer in Children and Young Adults: A Multicenter Retrospective Study. *Thyroid* 31:11, 1693-1706. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
369. Hiroki Shimura, Takashi Matsuzuka, Satoru Suzuki, Manabu Iwadate, Satoshi Suzuki, Susumu Yokoya, Tetsuya Ohira, Seiji Yasumura, Shinichi Suzuki, Hitoshi Ohto, Kenji Kamiya. 2021. Fine Needle Aspiration Cytology Implementation and Malignancy Rates in Children and Adolescents Based on Japanese Guidelines: The Fukushima Health Management Survey. *Thyroid* 31:11, 1683-1692. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
370. Bernadette L. Dekker, Anneke C. Muller Kobold, Adrienne H. Brouwers, Graham R. Williams, Marloes Nies, Mariëlle S. Klein Hesselink, Anouk N.A. van der Horst-Schrivers, Bas Havekes, Marry M. van den Heuvel-Eibrink, Heleen J.H. van der Pal, John Th. M. Plukker, Cecile M. Ronckers, Hanneke M. van Santen, Johannes G.M. Burgerhof, Eleonora P.M. Corssmit, Romana T. Netea-Maier, Robin P. Peeters, Eveline W.C.M. van Dam, Annemieke M. Boot, Wim J.E. Tissing, Gianni Bocca, Thera P. Links. 2021. Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: A Longitudinal Follow-Up Study. *Thyroid* 31:11, 1707-1714. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
371. Chad K. Sudoko, Carolyn M. Jenks, Andrew J. Bauer, Amber Isaza, Sogol Mostoufi-Moab, Lea F. Surrey, Tricia R. Bhatti, Aime Franco, N. Scott Adzick, Ken Kazahaya. 2021. Thyroid Lobectomy for T1 Papillary Thyroid Carcinoma in Pediatric Patients. *JAMA Otolaryngology-Head & Neck Surgery* 147:11, 943. [[Crossref](#)]
372. Gerdi Tuli, Jessica Munarin, Erica Agosto, Patrizia Matarazzo, Francesco Quaglino, Alberto Mormile, Luisa de Sanctis. 2021. Predictive factors of malignancy in pediatric patients with thyroid nodules and performance of the Italian classification (SIAPEC 2014) in the outcome of the cytological FNA categories. *Endocrine* 74:2, 365-374. [[Crossref](#)]
373. Viviana Albani, Luke D. Vale, Mark Pearce, Evgenia Ostroumova, Liudmila Liutsko. 2021. Aspects of economic costs and evaluation of health surveillance systems after a radiation accident with a focus on an ultrasound thyroid screening programme for children. *Environment International* 156, 106571. [[Crossref](#)]
374. J. Gómez-Herrera, M.A. Melo-Uribe, R. Parra-Medina. 2021. Echographic findings in ectopic intrathyroidal thymic tissue in children. A systematic review. *Radiología (English Edition)* 63:6, 512-518. [[Crossref](#)]
375. MS Goonoo, MF Arshad, F Tahir, SP Balasubramanian. 2021. Toxic adenoma: to biopsy or not to biopsy?. *The Annals of The Royal College of Surgeons of England* 103:10, e319-e323. [[Crossref](#)]
376. J. Gómez-Herrera, M.A. Melo-Uribe, R. Parra-Medina. 2021. Hallazgos ecográficos en el tejido tímico ectópico intratiroideo en niños y adolescentes. Una revisión sistemática. *Radiología* 63:6, 512-518. [[Crossref](#)]

377. Javier Ordóñez, Laura Pérez-Egido, María Antonia García-Casillas, Agustín del Cañizo, María Fanjul, Manuel de la Torre, Isabel Bada, María Dolores Blanco, Julio Cerdá, Esther Molina, David Peláez, Juan Carlos de Agustín. 2021. Management and results of thyroidectomies in pediatric patients with MEN 2 syndrome. *Journal of Pediatric Surgery* **56**:11, 2058-2061. [[Crossref](#)]
378. Tara Sepehrizadeh, Ian Jong, Michael DeVeer, Atul Malhotra. 2021. PET/MRI in paediatric disease. *European Journal of Radiology* **144**, 109987. [[Crossref](#)]
379. Lorenzo Scappaticcio, Maria Ida Maiorino, Sergio Iorio, Giovanni Docimo, Miriam Longo, Anna Grandone, Caterina Luongo, Immacolata Cozzolino, Arnaldo Piccardo, Pierpaolo Trimboli, Emanuele Miraglia Del Giudice, Katherine Esposito, Giuseppe Bellastella. 2021. Exploring the Performance of Ultrasound Risk Stratification Systems in Thyroid Nodules of Pediatric Patients. *Cancers* **13**:21, 5304. [[Crossref](#)]
380. Manish Ora, Aftab Hasan Nazar, Prabhakar Mishra, Sukanta Barai, Amitabh Arya, Prasanta Kumar Pradhan, Sanjay Gambhir. 2021. Factors predicting the risk of biochemical incomplete response in well-differentiated thyroid cancer after total thyroidectomy. *Nuclear Medicine Communications* **42**:11, 1187-1194. [[Crossref](#)]
381. Duy Q. Ngo, Duong T. Le, Giap N. Hoang, Quy X. Ngo, Quang V. Le. 2021. Case Report: Transoral Endoscopic Thyroidectomy via Vestibular Approach in Pediatric Thyroid Cancer. *Frontiers in Pediatrics* **9**. [[Crossref](#)]
382. Yubing Tao, Fei Wang, Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efsio Puxeddu, Laura Fugazzola, Carla Colombo, Barbara Jarzab, Agnieszka Czarniecka, Alfred K Lam, Caterina Mian, Federica Vianello, Linwah Yip, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Christine J O'Neill, Mark S Sywak, Roderick Clifton-Bligh, Bela Bendlova, Vlasta Sýkorová, Shihua Zhao, Yangang Wang, Mingzhao Xing. 2021. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. *The Journal of Clinical Endocrinology & Metabolism* **106**:11, 3228-3238. [[Crossref](#)]
383. Dustin A. Silverman, Ross Wanner, Patrick Walz, Matthew O. Old, Kris R. Jatana. Pediatric Head and Neck Malignancies . [[Crossref](#)]
384. Seul Bi Lee, Yeon Jin Cho, Seunghyun Lee, Young Hun Choi, Jung-Eun Cheon, Woo Sun Kim. 2021. Korean Society of Thyroid Radiology Guidelines for the Management of Pediatric Thyroid Nodules: Suitability and Risk Factors. *Thyroid* **31**:10, 1472-1480. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
385. Pyeong Hwa Kim, Hee Mang Yoon, Jisun Hwang, Jin Seong Lee, Ah Young Jung, Young Ah Cho, Jung Hwan Baek. 2021. Diagnostic performance of adult-based ATA and ACR-TIRADS ultrasound risk stratification systems in pediatric thyroid nodules: a systematic review and meta-analysis. *European Radiology* **31**:10, 7450-7463. [[Crossref](#)]
386. M. Capezzone, F. Maino, A. Sagnella, M. Campanile, C. Dalmiglio, T. Pilli, R. Forleo, M. G. Castagna. 2021. Clinical features of pediatric familial non-medullary thyroid cancer (FNMTC). *Journal of Endocrinological Investigation* **44**:10, 2319-2321. [[Crossref](#)]
387. Mohammed Hazem, Ibrahim Khalid Al Jabr, Abdulwahab A. AlYahya, Ahmed Gaber Hassanein, Hisham A. Elghany Algahlan. 2021. Reliability of shear wave elastography in the evaluation of diffuse thyroid diseases in children and adolescents. *European Journal of Radiology* **143**, 109942. [[Crossref](#)]
388. N. Gaspar, Q. Campbell-Hewson, S. Gallego Melcon, F. Locatelli, R. Venkatramani, S. Hecker-Nolting, M. Gambart, F. Bautista, E. Thebaud, I. Aerts, B. Morland, C. Rossig, A. Canete Nieto, A. Longhi, C. Lervat, N. Entz-Werle, S.J. Strauss, P. Marec-Berard, C.E. Okpara, C. He, L. Dutta, M. Casanova. 2021. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)#. *ESMO Open* **6**:5, 100250. [[Crossref](#)]
389. Serkan Guneyli, Murat Serhat Aygun, Orhun Cig Taskin, Ergin Sagtas, Bulent Colakoglu. 2021. Intrathyroidal Ectopic Thymus and Sonoelastographic Findings. *Current Medical Imaging Formerly Current Medical Imaging Reviews* **17**:10, 1209-1215. [[Crossref](#)]
390. Yu Min, Ke Xiang, Yang Feng, Hang Chen, Jialin Chen, Xiaoyuan Wei, Guobing Yin. 2021. Development and validation of a population-based model for predicting the regional lymph node metastasis in adolescent differentiated thyroid carcinoma. *Oral Oncology* **121**, 105507. [[Crossref](#)]
391. Grace Sahyouni, Beth Osterbauer, Soyun Park, Connie Paik, Juliana Austin, Gabriel Gomez, Daniel Kwon. 2021. Rate of Incidental Parathyroidectomy in a Pediatric Population. *OTO Open* **5**:4. [[Crossref](#)]
392. Yangmengyuan Xu, Yu Wang, Xinyue Zhang, Rui Huang, Rong Tian, Bin Liu. 2021. Prognostic value of lymph node ratio in children and adolescents with papillary thyroid cancer. *Clinical Endocrinology* **95**:4, 649-656. [[Crossref](#)]
393. Yun Jeong Lee, Yeon Jin Cho, You Joung Heo, Eun-Jae Chung, Young Hun Choi, Jong-Il Kim, Young Joo Park, Choong Ho Shin, Young Ah Lee. 2021. Thyroid nodules in childhood-onset Hashimoto's thyroiditis: Frequency, risk factors, follow-up course and genetic alterations of thyroid cancer. *Clinical Endocrinology* **95**:4, 638-648. [[Crossref](#)]
394. Ava Yap, Amy Shui, Jessica Gosnell, Chiung-Yu Huang, Julie Ann Sosa, Sanziana Roman. 2021. Accuracy of the Lymph Node Yield in Surgery for Papillary Thyroid Cancer in Children. *World Journal of Surgery* **45**:10, 3092-3098. [[Crossref](#)]

395. Loizos Loizou, Anna Demetriou, Friederike Erdmann, Arndt Borkhardt, Triantafyllia Brozou, Linda Sharp, Richard McNally. 2021. Increasing incidence and survival of paediatric and adolescent thyroid cancer in Cyprus 1998–2017: A population-based study from the Cyprus Pediatric Oncology Registry. *Cancer Epidemiology* **74**, 101979. [[Crossref](#)]
396. Iwona Ben-Skowronek, Joanna Sieniawska, Emilia Pach, Wiktoria Wrobel, Anna Skowronek, Zaklina Tomczyk, Anna Mlodawska, Magdalena Makuch, Magdalena Malka, Czeslaw Cielecki, Pawel Nachulewicz. 2021. Thyroid Cancer Risk Factors in Children with Thyroid Nodules: A One-Center Study. *Journal of Clinical Medicine* **10**:19, 4455. [[Crossref](#)]
397. Chantal Lebbink, Medard van den Broek, Annemiek Kwast, Joep Derikx, Miranda Dierselhuis, Schelto Kruijff, Thera Links, A. van Trotsenburg, Gerlof Valk, Menno Vriens, Annemarie Verrijn Stuart, Hanneke van Santen, Henrike Karim-Kos. 2021. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span. *Cancers* **13**:20, 5104. [[Crossref](#)]
398. Jesse J. van Rooijen, A. S. Paul van Trotsenburg, Daniël J. van de Berg, Nitash Zwaveling-Soonawala, Els J. M. Nieveen van Dijkum, Anton F. Engelsman, Joep P. M. Derikx, Christiaan F. Mooij. 2021. Complications After Thyroidectomy in Children: Lymph Node Dissection Is a Risk Factor for Permanent Hypocalcemia. *Frontiers in Endocrinology* **12**. . [[Crossref](#)]
399. Christine E Cherella, Danielle M Richman, Enju Liu, Mary C Frates, Biren P Modi, Benjamin Zendejas, Jessica R Smith, Justine A Barletta, Monica L Hollowell, Ari J Wassner. 2021. Predictors of Bilateral Disease in Pediatric Differentiated Thyroid Cancer. *The Journal of Clinical Endocrinology & Metabolism* **106**:10, e4242-e4250. [[Crossref](#)]
400. Aime T. Franco, Julio C. Ricarte-Filho, Theodore W. Laetsch, Andrew J. Bauer. 2021. Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer. *Journal of Clinical Investigation* **131**:18. . [[Crossref](#)]
401. Gary L. Francis. 2021. Sonographic Features of Cervical Lymph Node Metastases in Children with Thyroid Carcinoma. *Clinical Thyroidology* **33**:9, 397-399. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
402. Jasmine Bhinder, Kathleen Bethin, Moshim Kukar, Lucy D. Mastrandrea, David H. Rothstein. 2021. Association of same-day discharge with hospital readmission after pediatric thyroidectomy. *Pediatric Surgery International* **37**:9, 1259-1264. [[Crossref](#)]
403. Emine Ayça Cimbek, Recep Polat, Bircan Sönmez, Nazım Ercüment Beyhun, Hasan Dinç, Haluk Saruhan, Gülay Karagüzel. 2021. Clinical, sonographical, and pathological findings of pediatric thyroid nodules. *European Journal of Pediatrics* **180**:9, 2823-2829. [[Crossref](#)]
404. Ja-Seong Bae, Seung-Hyun Jung, Mitsuyoshi Hirokawa, Andrey Bychkov, Akira Miyauchi, Sohee Lee, Yeun-Jun Chung, Chan Kwon Jung. 2021. High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid. *Endocrine Pathology* **32**:3, 336-346. [[Crossref](#)]
405. Ari M. Abdullah, Hiwa O. Baba, Abdulwahid M. Salih, Aras J. Qaradakhly, Fahmi H. Kakamad, Berwn A. Abdulla, Shvan H. Mohammed. 2021. Co-occurrence of bilateral intrathyroidal parathyroid gland and papillary thyroid carcinoma; a case report. *International Journal of Surgery Case Reports* **86**, 106315. [[Crossref](#)]
406. Zhihui Huang, Yanying Chen, Liqin Pan, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Wei Ouyang. 2021. Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study. *Ultrasound in Medicine & Biology* **47**:9, 2514-2522. [[Crossref](#)]
407. Priyakumari Thankamony, Garima Nirmal, Rumesh Chandar, Anila K. R. Nair, Pradeep Veeramoni Iyer Mriduladevi. 2021. Differentiated thyroid carcinoma in children: A retrospective analysis of 125 pediatric cases from a single institution in India. *Pediatric Blood & Cancer* **68**:9. . [[Crossref](#)]
408. Rick Schneider, Andreas Machens, Carsten Sekulla, Kerstin Lorenz, Henning Dralle. 2021. Recurrent Laryngeal Nerve Preservation Strategies in Pediatric Thyroid Oncology: Continuous vs. Intermittent Nerve Monitoring. *Cancers* **13**:17, 4333. [[Crossref](#)]
409. Allison Keane, Darrin V. Bann, Meghan N. Wilson, David Goldenberg. 2021. Pediatric Thyroid Cancer: To Whom Do You Send the Referral?. *Cancers* **13**:17, 4416. [[Crossref](#)]
410. Arnaldo Piccardo, Francesco Fiz, Gianluca Bottoni, Camilla De Luca, Michela Massollo, Ugo Catrambone, Luca Foppiani, Monica Muraca, Alberto Garaventa, Pierpaolo Trimboli. 2021. Facing Thyroid Nodules in Paediatric Patients Previously Treated with Radiotherapy for Non-Thyroidal Cancers: Are Adult Ultrasound Risk Stratification Systems Reliable?. *Cancers* **13**:18, 4692. [[Crossref](#)]
411. Taylor B. Teplitzky, Nkechi Okonkwo, John C. Papadimitriou, Kevin D. Pereira. 2021. Adenochondroma of the Thyroid in a 3-Year-Old Female: A Case Report. *Ear, Nose & Throat Journal* **100**:5_suppl, 412S-414S. [[Crossref](#)]
412. İrem Ceren Erbaş, İbrahim Mert Erbaş, Olcay Evliyaoğlu. 2021. Clinical, biochemical, and radiological follow-up results of children and adolescents with Hashimoto's thyroiditis: a single-center experience. *Journal of Pediatric Endocrinology and Metabolism* **34**:8, 987-994. [[Crossref](#)]

413. Huy Gia Vuong, Duy Giang Bao Chung, Luan Minh Ngo, Thien Quoc Bui, Lewis Hassell, Chan Kwon Jung, Kennichi Kakudo, Andrey Bychkov. 2021. The Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysis. *Thyroid* 31:8, 1203-1211. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
414. Lisha Jiang, Yongzhao Xiang, Rui Huang, Rong Tian, Bin Liu. 2021. Clinical applications of single-photon emission computed tomography/computed tomography in post-ablation 131iodine scintigraphy in children and young adults with differentiated thyroid carcinoma. *Pediatric Radiology* 51:9, 1724-1731. [[Crossref](#)]
415. Max A. Schumm, Howard Q. Pyo, Jiyeon Kim, Chi-Hong Tseng, Michael W. Yeh, Angela M. Leung, Harvey K. Chiu. 2021. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults. *Clinical Endocrinology* 95:2, 344-353. [[Crossref](#)]
416. Sarah Jane Commander, Tamara N. Fitzgerald. 2021. Invited Commentary: "Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience.". *World Journal of Surgery* 45:8, 2480-2481. [[Crossref](#)]
417. Michelle D. Williams. 2021. Preoperative Molecular Testing of Thyroid Nodules. *Neuroimaging Clinics of North America* 31:3, 301-312. [[Crossref](#)]
418. Giulia Sapuppo, Dana Hartl, Brice Fresneau, Julien Hadoux, Ingrid Breuskin, Eric Baudin, Charlotte Rigaud, Joanne Guerlain, Abir Al Ghuzlan, Sophie Leboulleux, Martin Schlumberger, Livia Lamartina. 2021. Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease. *Cancers* 13:15, 3732. [[Crossref](#)]
419. Tzu-Yen Huang, Hoon-Yub Kim, Gianlorenzo Dionigi, I-Cheng Lu, Pi-Ying Chang, Feng-Yu Chiang, Yi-Chu Lin, Hsin-Yi Tseng, Cheng-Hsin Liu, Che-Wei Wu. 2021. Laryngeal Neural Monitoring during Pediatric Thyroid Cancer Surgery—Is Transcartilage Recording a Preferable Method?. *Cancers* 13:16, 4051. [[Crossref](#)]
420. F. M. Abdulkhabirova, O. B. Bezlepkina, D. N. Brovin, T. A. Vadina, G. A. Melnichenko, E. V. Nagaeva, L. V. Nikankina, V. A. Peterkova, N. M. Platonova, A. A. Rybakova, T. V. Soldatova, E. A. Troshina, T. Y. Shiryayeva. 2021. Clinical practice guidelines "Management of iodine deficiency disorders". *Problems of Endocrinology* 67:3, 10-25. [[Crossref](#)]
421. Erivelto Volpi, Leonardo Rangel. 2021. A Case Series of Practice Pattern Variation in Managing Pediatric Thyroid Nodules. *Clinical Thyroidology* 33:7, 309-311. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
422. Marla B. K. Sammer, Caroline L. Hollingsworth, A. Luana Stanesco, Ramesh S. Iyer. 2021. Employing caution when applying the American College of Radiology Thyroid Imaging Reporting and Data System for pediatric thyroid nodule management. *Pediatric Radiology* 51:8, 1290-1293. [[Crossref](#)]
423. Kelvin Memeh, Brian Ruhle, Salman Alsafran, Tanaz Vaghaiwalla, Edwin Kaplan, Peter Angelos, Xavier M. Keutgen. 2021. Total Thyroidectomy vs Thyroid Lobectomy for Localized Papillary Thyroid Cancer in Children: A Propensity-Matched Survival Analysis. *Journal of the American College of Surgeons* 233:1, 39-49. [[Crossref](#)]
424. Ian D. Hay, Suneetha Kaggal, Nicole M. Iniguez-Ariza, Megan S. Reinalda, Gregory A. Wiseman, Geoffrey B. Thompson. 2021. Inability of Radioiodine Remnant Ablation to Improve Postoperative Outcome in Adult Patients with Low-Risk Papillary Thyroid Carcinoma. *Mayo Clinic Proceedings* 96:7, 1727-1745. [[Crossref](#)]
425. David J. Crockett, Erynne A. Faucett, Sharon H. Gnagi. 2021. Thyroid Nodule/Differentiated Thyroid Carcinoma in the Pediatric Population. *Pediatric Annals* 50:7. . [[Crossref](#)]
426. Rahul K. Sharma, Bernice Huang, James A. Lee, Jennifer H. Kuo. 2021. Trends and Outcomes of Surgical Management of Primary Papillary Carcinoma in the Pediatric Population. *Journal of Surgical Research* 263, 207-214. [[Crossref](#)]
427. Maria Cecilia Schultze, Cintia Castro-Correia, Maria Bom-Sucesso, Marianne Becker. 2021. Papillary thyroid carcinoma in a 7-year-old boy presenting with a goitre without microcalcifications and enlarged cervical lymph nodes. *BMJ Case Reports* 14:7, e242278. [[Crossref](#)]
428. Elisabetta Macerola, Agnese Proietti, Anello Marcello Poma, Clara Ugolini, Liborio Torregrossa, Paola Vignali, Alessio Basolo, Gabriele Materazzi, Rossella Elisei, Ferruccio Santini, Fulvio Basolo. 2021. Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. *Cancers* 13:13, 3123. [[Crossref](#)]
429. In A Lee, Kwangsoon Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung. 2021. Comparison of Surgical Outcomes between Robotic Transaxillary and Conventional Open Thyroidectomy in Pediatric Thyroid Cancer. *Cancers* 13:13, 3293. [[Crossref](#)]
430. Gi Hyeon Seo, Kyoung Ae Kong, Bom Sahn Kim, Seo Young Kang, Byung Seok Moon, Hai-Jeon Yoon, Hye Ok Kim. 2021. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study. *The Journal of Clinical Endocrinology & Metabolism* 106:7, e2580-e2588. [[Crossref](#)]

431. Hira Ahmad, Ameer Al-Hadidi, Adam Bobbey, Summit Shah, Joseph Stanek, Kathleen Nicol, Robert P. Hoffman, Jennifer H. Aldrink. 2021. Pediatric adaptations are needed to improve the diagnostic accuracy of thyroid ultrasound using TI-RADS. *Journal of Pediatric Surgery* **56**:6, 1120-1125. [[Crossref](#)]
432. Pedro W Rosario, Theara de Castro Nicolau. 2021. Report of one case of malignancy among 17 autonomous thyroid nodules in children and adolescents. *Journal of Paediatrics and Child Health* **57**:6, 810-812. [[Crossref](#)]
433. Lin Yan, Ying Zhang, Bo Jiang, Yukun Luo. 2021. Radiofrequency Ablation for Cervical Metastatic Lymph Nodes in Children and Adolescents With Papillary Thyroid Carcinoma: A Preliminary Study. *Frontiers in Endocrinology* **12**. . [[Crossref](#)]
434. Kara D. Meister, Lisa A. Orloff. 2021. Understanding of Pulmonary Metastases in Pediatric Patients with Differentiated Thyroid Cancer Is Evolving. *Clinical Thyroidology* **33**:5, 217-220. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
435. Francisco J. Barrera, Karina Raygoza-Cortez, Mariana García-Leal, Juan P. Brito, Naykky M. Singh Ospina, René Rodríguez-Gutiérrez. 2021. Are American follow-up recommendations in endocrinology actionable? A systematic review of clinical practice guidelines. *Endocrine* **72**:2, 375-384. [[Crossref](#)]
436. M. Capezzone, E. Robenshtok, S. Cantara, M. G. Castagna. 2021. Familial non-medullary thyroid cancer: a critical review. *Journal of Endocrinological Investigation* **44**:5, 943-950. [[Crossref](#)]
437. C. Bolot, M. Mendjel-Herda, S. Saibi-Hajji, E. Grandeau, S. Blondeel-Gomes. 2021. Utilisation des médicaments radiopharmaceutiques en pédiatrie : spécificités et recommandations de la SoFRa (Société française de radiopharmacie). *Annales Pharmaceutiques Françaises* **79**:3, 230-243. [[Crossref](#)]
438. Andreea-Ioana Stefan, Andra Piciu, Maria Margareta Cosnarovici, Monica Dragomir, Romana Netea-Maier, Doina Piciu. 2021. Thyroid Microcarcinoma in Pediatric Population in Romania. *Children* **8**:5, 422. [[Crossref](#)]
439. Yu. Korsak, L. Nykytiuk. 2021. Діагностика, клінічне значення та лікування вузлів щитоподібної залози. *INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)* **17**:2, 155-159. [[Crossref](#)]
440. Pınar KOCAAY, Eda MENGEN, Seyit Ahmet UÇAKTÜRK. 2021. ÇOCUKLUK ÇAĞI TİROİD KANSERİ: RETROSPEKTİF BİR ÇALIŞMA. *Kırıkkale Üniversitesi Tıp Fakültesi Dergisi* **23**:1, 99-106. [[Crossref](#)]
441. Wen Jiang, Susan A. Phillips, Robert O. Newbury, John H. Naheedy, Ron S. Newfield. 2021. Diagnostic utility of fine needle aspiration cytology in pediatric thyroid nodules based on Bethesda Classification. *Journal of Pediatric Endocrinology and Metabolism* **34**:4, 449-455. [[Crossref](#)]
442. Huy Gia Vuong, Ayana Suzuki, Hee Young Na, Pham Van Tuyen, Doan Minh Khuy, Hiep Canh Nguyen, Tikamporn Jitpasutham, Agustina Abelardo, Takashi Amano, So Yeon Park, Chan Kwon Jung, Mitsuyoshi Hirokawa, Ryohei Katoh, Kennichi Kakudo, Andrey Bychkov. 2021. Application of the Bethesda System for Reporting Thyroid Cytopathology in the Pediatric Population. *American Journal of Clinical Pathology* **155**:5, 680-689. [[Crossref](#)]
443. Lokesh Khanna, Srinivasa R. Prasad, Sireesha Yedururi, Anand M. Parameswaran, Leonardo P. Marcal, Kumar Sandrasegaran, Sree Harsha Tirumani, Christine O. Menias, Venkata S. Katabathina. 2021. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings. *RadioGraphics* **74**, 200171. [[Crossref](#)]
444. Andrea Gillis, Fiemu Nwariaku. 2021. Intraoperative parathyroid hormone measurement facilitates outpatient thyroidectomy in children: Invited Commentary. *The American Journal of Surgery* **221**:4, 681-682. [[Crossref](#)]
445. Emily Christison-Lagay, Reto M. Baertschiger. 2021. Management of Differentiated Thyroid Carcinoma in Pediatric Patients. *Surgical Oncology Clinics of North America* **30**:2, 235-251. [[Crossref](#)]
446. David M. Bruss, Alexander J. Kovacs, Himala Kashmiri, Kevin C. Huoh. 2021. Initial outcomes at a nascent tertiary pediatric thyroid surgical center. *International Journal of Pediatric Otorhinolaryngology* **143**, 110639. [[Crossref](#)]
447. Brendan C. Stack, Christine Twining, Jeff Rastatter, Peter Angelos, Zubair Baloch, Gillian Diercks, William Faquin, Ken Kazahaya, Scott Rivkees, Tony Sheyn, Jennifer J. Shin, Jessica Smith, Geoffrey Thompson, Pushpa Viswanathan, Ari Wassner, Jennifer Brooks, Gregory W. Randolph. 2021. Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS-ES) on Pediatric Benign and Malignant Thyroid Surgery. *Head & Neck* **43**:4, 1027-1042. [[Crossref](#)]
448. Marloes Nies, Rena Vassilopoulou-Sellin, Roland L Bassett, Sireesha Yedururi, Mark E Zafereo, Maria E Cabanillas, Steven I Sherman, Thera P Links, Steven G Waguespack. 2021. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. *The Journal of Clinical Endocrinology & Metabolism* **106**:4, 1683-1697. [[Crossref](#)]
449. Ari J Wassner. 2021. Risk Stratification in Pediatric Thyroid Cancer: Growing Evidence for Individualized Therapy. *The Journal of Clinical Endocrinology & Metabolism* **106**:3, e1471-e1472. [[Crossref](#)]
450. John A. Ozolek. 2021. Selected Topics in the Pathology of the Thyroid and Parathyroid Glands in Children and Adolescents. *Head and Neck Pathology* **15**:1, 85-106. [[Crossref](#)]

451. Salvatore Vaccarella, Joannie Lortet-Tieulent, Murielle Colombet, Louise Davies, Charles A Stiller, Joachim Schüz, Kayo Togawa, Freddie Bray, Silvia Franceschi, Luigino Dal Maso, Eva Steliarova-Foucher. 2021. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. *The Lancet Diabetes & Endocrinology* 9:3, 144-152. [[Crossref](#)]
452. Brendan C. Stack, Christine Twining, Jeff Rastatter, Peter Angelos, Zubair Baloch, Gillian Diercks, William Faquin, Ken Kazahaya, Scott Rivkees, Tony Sheyn, Jennifer J. Shin, Jessica Smith, Geoffrey Thompson, Pushpa Viswanathan, Ari Wassner, Jennifer Brooks, Gregory W. Randolph. 2021. Consensus Statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS) on Pediatric Benign and Malignant Thyroid Surgery. *Endocrine Practice* 27:3, 174-184. [[Crossref](#)]
453. Mechteld C de Jong, Mark N Gaze, Elwira Szychot, Virginia Rozalén García, Caroline Brain, Mehul Dattani, Helen Spoudeas, Peter Hindmarsh, Tarek E Abdel-Aziz, Jamshed Bomanji, Ananth Shankar, Sara Stoneham, Simon Morley, Tim Beale, Susan Jawad, Sofia Otero, Ian Proctor, Sepideh Amin, Gary Butler, Richard J Hewitt, Tom R Kurzawinski. 2021. Treating papillary and follicular thyroid cancer in children and young people: Single UK-center experience between 2003 and 2018. *Journal of Pediatric Surgery* 56:3, 534-539. [[Crossref](#)]
454. Amit Ritter, Roy Hod, Yonatan Reuven, Thomas Shpitzer, Aviram Mizrachi, Eyal Raveh, Gideon Bachar. 2021. Role of intraoperative recurrent laryngeal nerve monitoring for pediatric thyroid surgery: Comparative analysis. *Head & Neck* 43:3, 849-857. [[Crossref](#)]
455. Evan Jon Propst, Jonathan Daniel Wasserman, Jonah Gorodensky, Bo-Yee Ngan, Nikolaus Ernst Wolter. 2021. Patterns and Predictors of Metastatic Spread to the Neck in Pediatric Thyroid Carcinoma. *The Laryngoscope* 131:3. . [[Crossref](#)]
456. Nádia Silva, Nuno Monteiro, Paula Tavares, Jose Coutinho. 2021. Paediatric papillary thyroid cancer: what to expect?. *BMJ Case Reports* 14:3, e240755. [[Crossref](#)]
457. Jose Miguel Dora, Rosa Paula Mello Biscolla, Gustavo Caldas, Janete Cerutti, Hans Graf, Ana O. Hoff, Glauca M. F. S. Mazeto, Patrícia Kunzle Ribeiro Magalhães, Cleo Otaviano Mesa, Rafael Selbach Scheffel, Patricia de Fatima dos Santos Teixeira, Fernanda Vaisman, Danilo Villagelin, Ana Luiza Maia. 2021. Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. *Archives of Endocrinology and Metabolism* . [[Crossref](#)]
458. Maria Navallas, Alan Daneman, Afsaneh Amirabadi, Bo-Yee Ngan, Jonathan Wasserman. 2021. Utility of sonography for identifying metastatic cervical adenopathy in children with differentiated thyroid carcinoma at presentation. *Pediatric Radiology* 51:2, 273-281. [[Crossref](#)]
459. Michele Klain, Emilia Zampella, Mariarosaria Manganeli, Valeria Gaudieri, Carmela Nappi, Adriana D'Antonio, Leandra Piscopo, Fabio Volpe, Leonardo Pace, Martin Schlumberger, Alberto Cuocolo. 2021. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. *Endocrine* 71:2, 378-384. [[Crossref](#)]
460. M.D. Aldridge, C. Peet, S. Wan, A. Shankar, J.E. Gains, J.B. Bomanji, M.N. Gaze. 2021. Paediatric Molecular Radiotherapy: Challenges and Opportunities. *Clinical Oncology* 33:2, 80-91. [[Crossref](#)]
461. Xiao-an Pang, Zhi-xiao Wei, Jun-hong Li, Xiao-qi Pang. 2021. Salivary gland function in women with Hashimoto's thyroiditis without xerostomia and the correlation with auto-thyroid antibodies. *Nuklearmedizin - NuclearMedicine* 60:01, 47-54. [[Crossref](#)]
462. John K. Thomas, Jujju Jacob Kurian, Anish Jacob Cherian, Julie Hephzibah, M. J. Paul, Deepak Thomas Abraham. 2021. Papillary Thyroid Carcinoma in Children: Clinicopathological Profile and Outcomes of Management. *World Journal of Surgery* 45:2, 496-506. [[Crossref](#)]
463. Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip. 2021. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. *Current Oncology* 28:1, 346-366. [[Crossref](#)]
464. Nthabiseng Ellen Mothata, Takalani Gidion Morulana, Nyaweleni Tshifularo, Phumudzo Bridgett Nemitaduni, Nozipho Elizabeth Nyakale, Moshawa Calvin Khaba. 2021. Metastatic Papillary Thyroid Carcinoma in a Paediatric Patient. *Case Reports in Endocrinology* 2021, 1-4. [[Crossref](#)]
465. Alexander D. Chesover, Reza Vali, Seyed Hamid Hemmati, Jonathan D. Wasserman. 2021. Lung Metastasis in Children with Differentiated Thyroid Cancer: Factors Associated with Diagnosis and Outcomes of Therapy. *Thyroid* 31:1, 50-60. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
466. Antje Redlich, Peter Bucsky, Peter Vorwerk. Late Effects After Treatment of Malignant Endocrine Tumors in Childhood and Adolescents 343-348. [[Crossref](#)]
467. Christine E. Cherella. Thyroid Imaging 223-225. [[Crossref](#)]
468. Jonathan D. Wasserman, Vito Forte. Clinical and Surgical Management of Pediatric Diseases of the Thyroid, Parathyroid, and Thymus 423-445. [[Crossref](#)]

469. Sarah J. Bottomley, Steven G. Waguespack. An Adolescent with Papillary Thyroid Carcinoma and Locally Metastatic Disease but No Distant Metastases 93-102. [[Crossref](#)]
470. Monica L. Arango, Steven G. Waguespack. A Child with Papillary Thyroid Cancer and Metastatic Pulmonary Disease: Role of Radioactive Iodine Therapy 209-219. [[Crossref](#)]
471. Xiang Da Dong, Rifat Latifi. Prophylactic Thyroidectomy 39-50. [[Crossref](#)]
472. Giuliana Geng-Ramos, Mingfei Wang, Pamela Mudd. Perioperative preparation, Intra-op monitoring during surgical removal of Thyroid Goiters in Children 279-293. [[Crossref](#)]
473. Julia Isabelle Staubitz, Thomas Johannes Musholt. Besondere Aspekte der Schilddrüsenchirurgie bei Kindern 1-6. [[Crossref](#)]
474. Scott Rivkees, Andrew J. Bauer. Thyroid Disorders in Children and Adolescents 395-424. [[Crossref](#)]
475. Gillian Diercks, Andrew J. Bauer, Jeff Rastatter, Ken Kazahaya, Sanjay Parikh. Pediatric Thyroid Cancer 255-263.e3. [[Crossref](#)]
476. Eric Monteiro, Carolyn Seib, Julie A. Sosa, Jonathan Irish. Quality Assessment in Thyroid and Parathyroid Surgery 426-432.e3. [[Crossref](#)]
477. Aaron L. Thatcher. Congenital and Inflammatory Neck Masses in Children 308-321. [[Crossref](#)]
478. Jennifer V. Brinkmeier, Aaron L. Thatcher. Pediatric Head and Neck Neoplasms 364-381. [[Crossref](#)]
479. Margaret R. Jia, Julia A. Baran, Andrew J. Bauer, Amber Isaza, Lea F. Surrey, Tricia Bhatti, Cindy McGrath, Jalal Jalaly, Sogol Mostoufi-Moab, N. Scott Adzick, Ken Kazahaya, Lindsay Sisko, Aime T. Franco, Fernando A. Escobar, Ganesh Krishnamurthy, Tasleema Patel, Zubair Baloch. 2021. Utility of Fine-Needle Aspirations to Diagnose Pediatric Thyroid Nodules. *Hormone Research in Paediatrics* **94**:7-8, 263-274. [[Crossref](#)]
480. Weili Liang, Lei Sheng, Liguang Zhou, Changyuan Ding, Zhongyang Yao, Chao Gao, Qingdong Zeng, Bo Chen. 2021. Risk Factors and Prediction Model for Lateral Lymph Node Metastasis of Papillary Thyroid Carcinoma in Children and Adolescents. *Cancer Management and Research* **Volume 13**, 1551-1558. [[Crossref](#)]
481. Eun Ju Ha, Sae Rom Chung, Dong Gyu Na, Hye Shin Ahn, Jin Chung, Ji Ye Lee, Jeong Seon Park, Roh-Eul Yoo, Jung Hwan Baek, Sun Mi Baek, Seong Whi Cho, Yoon Jung Choi, Soo Yeon Hahn, So Lyung Jung, Ji-hoon Kim, Seul Kee Kim, Soo Jin Kim, Chang Yoon Lee, Ho Kyu Lee, Jeong Hyun Lee, Young Hen Lee, Hyun Kyung Lim, Jung Hee Shin, Jung Suk Sim, Jin Young Sung, Jung Hyun Yoon, Miyoung Choi. 2021. 2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. *Korean Journal of Radiology* **22**:12, 2094. [[Crossref](#)]
482. Tomasz Bednarczuk. Levothyroxine and Cancer 109-120. [[Crossref](#)]
483. . Endocrinology 405-464. [[Crossref](#)]
484. Samara L. Potter, Jacquelyn Reuther, Raghu Chandramohan, Ilavarasi Gandhi, Faith Hollingsworth, Hadi Sayeed, Horatiu Voicu, Nipun Kakkar, Koel Sen Baksi, Stephen F. Sarabia, Monica E. Lopez, Daniel C. Chelius, Ioanna D. Athanassaki, Priya Mahajan, Rajkumar Venkatramani, Norma M. Quintanilla, Dolores H. Lopez-Terrada, Angshumoy Roy, D. Williams Parsons. 2021. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. *Pediatric Blood & Cancer* **68**:1. . [[Crossref](#)]
485. Zbigniew Adamczewski, Magdalena Stasiak, Bartłomiej Stasiak, Magdalena Adamczewska, Andrzej Lewiński. 2021. Interobserver Agreement and Plane-Dependent Intraobserver Variability of Shear Wave Sonoelastography in the Differential Diagnosis of Ectopic Thymus Tissue. *Journal of Clinical Medicine* **10**:2, 214. [[Crossref](#)]
486. Barbora Pekova, Vlasta Sykorova, Sarka Dvorakova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Jaromir Astl, Petr Vlcek, Daniela Kodetova, Josef Vcelak, Bela Bendlova. 2020. RET, NTRK, ALK, BRAF, and MET Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas. *Thyroid* **30**:12, 1771-1780. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
487. B. Riemann. 2020. Indikationen und Ergebnisse der Radiojodtherapie beim differenzierten Schilddrüsenkarzinom. *Der Chirurg* **91**:12, 1013-1016. [[Crossref](#)]
488. Olga Karapanou, Marinella Tzanela, Phoebe Rondogianni, Catherine Dacou-Voutetakis, Dimitrios Chiotis, Barbara Vlassopoulou, Dimitra Vassiliadi, Christina Kanaka-Gantenbein, Stylianos Tsagarakis. 2020. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence. *Endocrine* **70**:3, 566-574. [[Crossref](#)]
489. Andrew J. Bauer. 2020. Pediatric Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* **49**:4, 589-611. [[Crossref](#)]
490. Marco Maglione, Stefania Muzzica, Rosanna Mamone, Lucia Quaglietta. 2020. Tracheal collapse as acute presentation in metastatic thyroid cancer. *Pediatrics & Neonatology* **61**:6, 659-660. [[Crossref](#)]
491. Tian Tian, Lisha Jiang, Xinyue Zhang, Rui Huang, Bin Liu. 2020. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer. *Surgery* **168**:6, 1095-1100. [[Crossref](#)]

492. Joke Van Vlaenderen, Karl Logghe, Eva Schiettecatte, Hubert Vermeersch, Wouter Huvenne, Kathleen De Waele, Hanne Van Beveren, Jo Van Dorpe, David Creyten, Jean De Schepper. 2020. A synchronous papillary and follicular thyroid carcinoma presenting as a large toxic nodule in a female adolescent. *International Journal of Pediatric Endocrinology* 2020:1. . [[Crossref](#)]
493. Ozgur CAGLAR, Erdem KARADENİZ, Müfide AKCAY, Kamber KASALI. 2020. Surgical Management of Pediatric Patients with Thyroid Disorders and Assessment of Complication Rates Associated with 43 Cases: A Single-Center Experience. *Mustafa Kemal Üniversitesi Tıp Dergisi* 11:41, 113-117. [[Crossref](#)]
494. Sarah Azari, Jackson Randolph, Harry Shi, Travis Hoover, Daniel Weaver, Jillian Mattioni, Sri Kiran Chennupati. 2020. Outcomes of pediatric thyroidectomy: a cross-sectional evaluation. *World Journal of Pediatric Surgery* 3:4, e000185. [[Crossref](#)]
495. Magdalena Stasiak, Zbigniew Adamczewski, Renata Stawerska, Bartłomiej Stasiak, Andrzej Lewiński. 2020. Application of Shear Wave Sonoelastography in the Differential Diagnosis of Extra- and Intra-Thyroidal Ectopic Thymic Tissue. *Journal of Clinical Medicine* 9:12, 3816. [[Crossref](#)]
496. Ki Yoon Moon, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim. 2020. Clinical Characteristics of Pediatric & Adolescent Thyroid Cancer: A Single Institution Experience of 20 Years. *Korean Society for Head and Neck Oncology* 36:2, 1-7. [[Crossref](#)]
497. Byung Hyun Byun, Guk Haeng Lee, Dong Ho Kim, Jung Sub Lim, Ilhan Lim, Sang Moo Lim, Byeong Cheol Lee, Jun Ah Lee. 2020. Age and Tumor Size is a Prognostic Factor in Pediatric/Adolescent Differentiated Thyroid Carcinoma. *Korean Society for Head and Neck Oncology* 36:2, 9-15. [[Crossref](#)]
498. Paula Castro, Esteban Patiño, Fernando Fierro, Carolina Rojas, Giancarlo Buitrago, Natalia Olaya. 2020. Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma. *Journal of Pediatric Endocrinology and Metabolism* 33:11, 1457-1463. [[Crossref](#)]
499. Montserrat Negre Busó, Amparo García Burillo, Marc Simó Perdigó, Pere Galofré Mora, Maria Boronat de Ferrater, Gemma Cuberas Borrós, Constantino Sábado Álvarez, Joan Castell Conesa. 2020. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents. *Journal of Pediatric Endocrinology and Metabolism* 33:11, 1431-1441. [[Crossref](#)]
500. Dhritiman Chakraborty, Sunil Shakya, Sanjana Ballal, Shipra Agarwal, Chandrasekhar Bal. 2020. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. *Journal of Pediatric Endocrinology and Metabolism* 33:11, 1465-1474. [[Crossref](#)]
501. Catherine A. Dinauer. 2020. A Comparison of the Differences Between Dutch and American Thyroid Association Guidelines for the Management of Pediatric Thyroid Cancer. *Clinical Thyroidology* 32:11, 525-528. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
502. Jennifer Hess, Kristian Schafernak, Dorothee Newbern, Tamara Vern-Gross, Janet Foote, Dane Van Tassel, Ramin Jamshidi, Alexandra Walsh. 2020. Ultrasound is superior to palpation for thyroid cancer detection in high-risk childhood cancer and BMT survivors. *Supportive Care in Cancer* 28:11, 5117-5124. [[Crossref](#)]
503. Emily R. Christison-Lagay, Reto M. Baertschiger, Catherine Dinauer, Gary L. Francis, Marcus M. Malek, Timothy B Lutz, Jennifer H. Aldrink, Christa Grant, Daniel S. Rhee, Peter Ehrlich, Roshni Dasgupta, Shahab Abdessalam. 2020. Pediatric differentiated thyroid carcinoma: An update from the APSA Cancer Committee. *Journal of Pediatric Surgery* 55:11, 2273-2283. [[Crossref](#)]
504. Alan F. Utria, Paolo Goffredo, Mary Belding-Schmitt, Junlin Liao, Joel Shilyansky, Geeta Lal. 2020. Practice Patterns and Outcomes of Pediatric Thyroid Surgery: An NSQIP Analysis. *Journal of Surgical Research* 255, 181-187. [[Crossref](#)]
505. Kiminori Sugino, Mitsuji Nagahama, Wataru Kitagawa, Keiko Ohkuwa, Takashi Uruno, Kenichi Matsuzu, Akifumi Suzuki, Chisato Tomoda, Kiyomi Yamada Hames, Junko Akaishi, Chie Masaki, Koichi Ito. 2020. Distant Metastasis in Pediatric and Adolescent Differentiated Thyroid Cancer: Clinical Outcomes and Risk Factor Analyses. *The Journal of Clinical Endocrinology & Metabolism* 105:11, e3981-e3988. [[Crossref](#)]
506. Aline Rangel-Pozzo, Luiza Sisdelli, Maria Isabel V. Cordioli, Fernanda Vaisman, Paola Caria, Sabine Mai, Janete M. Cerutti. 2020. Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. *Cancers* 12:11, 3146. [[Crossref](#)]
507. Andreea-Ioana Ștefan, Andra Piciu, Simona Sorana Căinap, Katalin Gabora, Doina Piciu. 2020. Differentiated Thyroid Cancer in Children in the Last 20 Years: A Regional Study in Romania. *Journal of Clinical Medicine* 9:11, 3617. [[Crossref](#)]
508. Danielle Ellis, Tamara N. Fitzgerald. 2020. Invited Commentary: Clinical Assessment of Pediatric Patients with Differentiated Thyroid Carcinoma: A 30-Year Experience at the Single Institution. *World Journal of Surgery* 44:10, 3393-3394. [[Crossref](#)]
509. Kwangsoon Kim, Cho Rok Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung. 2020. Clinical Assessment of Pediatric Patients with Differentiated Thyroid Carcinoma: A 30-Year Experience at a Single Institution. *World Journal of Surgery* 44:10, 3383-3392. [[Crossref](#)]

510. Giuseppina Zirilli, Mariella Valenzise, Gianlorenzo Dionigi, Giovanni Tuccari, Carmelo Romeo, Alfredo Campenni, Andrea Corrias, Gerdi Tuli, Antonio Ieni, Giovanni Battista Pajno, Malgorzata Wasniewska. 2020. Hurthle cell carcinoma in childhood: A retrospective analysis of five cases and review of pediatric literature. *Pediatric Blood & Cancer* 67:9. . [[Crossref](#)]
511. Marloes Nies, Astrid E.P. Cantineau, Eus G.J.M. Arts, Marleen H. van den Berg, Flora E. van Leeuwen, Anneke C. Muller Kobold, Mariëlle S. Klein Hesselink, Johannes G.M. Burgerhof, Adrienne H. Brouwers, Eveline W.C.M. van Dam, Bas Havekes, Marry M. van den Heuvel-Eibrink, Eleonora P.M. Corssmit, Leontien C.M. Kremer, Romana T. Netea-Maier, Helena J.H. van der Pal, Robin P. Peeters, John T.M. Plukker, Cécile M. Ronckers, Hanneke M. van Santen, Anouk N.A. van der Horst-Schrivers, Wim J.E. Tissing, Gianni Bocca, Eline van Dulmen-den Broeder, Thera P. Links. 2020. Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma. *Thyroid* 30:8, 1169-1176. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
512. Ken Kazahaya, Kara K. Prickett, Vera A. Paulson, John P. Dahl, Scott C. Manning, Erin R. Rudzinski, Jeffrey C. Rastatter, Sanjay R. Parikh, Douglas S. Hawkins, Marcia S. Brose, Andrew J. Bauer. 2020. Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation. *JAMA Otolaryngology–Head & Neck Surgery* 146:8, 748. [[Crossref](#)]
513. Michael J. Zobel, Roger Long, Jessica Gosnell, Julie Ann Sosa, Benjamin E. Padilla. 2020. Postoperative Hypoparathyroidism After Total Thyroidectomy in Children. *Journal of Surgical Research* 252, 63-68. [[Crossref](#)]
514. Xinyue Zhang, Lina Liu, Yu Chen, Rui Huang, Bin Liu. 2020. Prognostic value of post-ablation 131 I scintigraphy in children with thyroid cancer. *Head & Neck* 42:8, 1738-1745. [[Crossref](#)]
515. Christoph Reiners, Rita Schneider, Tamara Platonova, Mikhail Fridman, Uwe Malzahn, Uwe Mäder, Alexis Vrachimis, Tatiana Bogdanova, Jolanta Krajewska, Rossella Elisei, Fernanda Vaisman, Jasna Mihailovic, Gracinda Costa, Valentina Drozd. 2020. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. *Frontiers in Endocrinology* 11. . [[Crossref](#)]
516. Catherine A. Dinauer. 2020. Total Thyroidectomy Remains Appropriate as Initial Treatment for Children with Papillary Thyroid Cancer That Frequently Harbors Occult Bilateral Disease. *Clinical Thyroidology* 32:7, 333-336. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
517. Neil K. Jain, Sogol Mostoufi-Moab, Colin P. Hawkes, Nya D. Nelson, Lea F. Surrey, Zachary S. Jones, N. Scott Adzick, Ken Kazahaya, Andrew J. Bauer. 2020. Extrathyroidal Extension is an Important Predictor of Regional Lymph Node Metastasis in Pediatric Differentiated Thyroid Cancer. *Thyroid* 30:7, 1037-1043. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
518. Lina Liu, Xinyue Zhang, Tian Tian, Rui Huang, Bin Liu. 2020. Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer. *Thyroid* 30:7, 1017-1024. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
519. N. Allen, N. Desai, C. Song, J. Yu, U. Prasad, G. Francis. 2020. Clinical features may help to identify children and adolescents with greatest risk for thyroid nodules. *Journal of Endocrinological Investigation* 43:7, 925-934. [[Crossref](#)]
520. R Elliott Overman, Lily B Hsieh, Ram Menon, Inas H. Thomas, Steven W Bruch. 2020. 4-Hour postoperative PTH level predicts hypocalcemia after thyroidectomy in children. *Journal of Pediatric Surgery* 55:7, 1265-1269. [[Crossref](#)]
521. Osama Ibrahim Almosallam, Ali Aseeri, Ahmed Alhumaid, Ali S. AlZahrani, Saif Alsobhi, Saud AlShanafey. 2020. Thyroid surgery in 103 children in a single institution from 2000-2014. *Annals of Saudi Medicine* 40:4, 316-320. [[Crossref](#)]
522. Rebecca D. Chernock, Barbara Rivera, Nicla Borrelli, D.Ashley Hill, Somayyeh Fahiminiya, Tasha Shah, Anne-Sophie Chong, Barina Aqil, Mitra Mehrad, Thomas J. Giordano, Rachel Sheridan, Meilan M. Rutter, Louis P. Dehner, William D. Foulkes, Yuri E. Nikiforov. 2020. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. *Modern Pathology* 33:7, 1264-1274. [[Crossref](#)]
523. Emily R Papadimos, Emily Perry, Bruce Goodwin, Louise S Conwell. 2020. Autonomous thyroid nodule: Not just a disease of adulthood. *Journal of Paediatrics and Child Health* 56:7, 1140-1143. [[Crossref](#)]
524. Julia I. Staubitz, Julia Bode, Alicia Poplawski, Felix Watzka, Joachim Pohlenz, Hauke Lang, Thomas J. Musholt. 2020. Thyroid surgery in children and young adults: potential overtreatment and complications. *Langenbeck's Archives of Surgery* 405:4, 451-460. [[Crossref](#)]
525. Byeong-Cheol Ahn. 2020. Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers. *Nuclear Medicine and Molecular Imaging* 54:3, 126-127. [[Crossref](#)]
526. Sophie Dream, Rongzhi Wang, Kelly Lovell, Pallavi Iyer, Herbert Chen, Brenessa Lindeman. 2020. Outpatient thyroidectomy in the pediatric population. *The American Journal of Surgery* 219:6, 890-893. [[Crossref](#)]

527. Duy Quoc Ngo, Quy Xuan Ngo, Quang Van Le. 2020. Pediatric thyroid cancer: Risk factors for central lymph node metastasis in patients with cN0 papillary carcinoma. *International Journal of Pediatric Otorhinolaryngology* **133**, 110000. [[Crossref](#)]
528. Heron Baumgarten, Carolyn M. Jenks, Amber Isaza, Tricia Bhatti, Sogol Mostoufi-Moab, Ken Kazahaya, N. Scott Adzick, Andrew J. Bauer. 2020. Bilateral papillary thyroid cancer in children: Risk factors and frequency of postoperative diagnosis. *Journal of Pediatric Surgery* **55**:6, 1117-1122. [[Crossref](#)]
529. Andrew J. Bauer. 2020. Papillary and Follicular Thyroid Cancer in children and adolescents: Current approach and future directions. *Seminars in Pediatric Surgery* **29**:3, 150920. [[Crossref](#)]
530. Michael J. Zobel, Benjamin E. Padilla. 2020. Surgical management of benign thyroid disease in children. *Seminars in Pediatric Surgery* **29**:3, 150922. [[Crossref](#)]
531. Ramin Jamshidi, J. Craig Egan. 2020. Pediatric parathyroid disease. *Seminars in Pediatric Surgery* **29**:3, 150923. [[Crossref](#)]
532. Darrin V. Bann, Vijay A. Patel, Robert Saadi, Neerav Goyal, John P. Gniady, Johnathan D. McGinn, David Goldenberg, Huseyin Isildak, Jason May, Meghan N. Wilson. 2020. Best Practice Recommendations for Pediatric Otolaryngology during the COVID-19 Pandemic. *Otolaryngology–Head and Neck Surgery* **162**:6, 783-794. [[Crossref](#)]
533. Pinki K. Prasad, Priya Mahajan, Douglas S. Hawkins, Sogol Mostoufi-Moab, Rajkumar Venkatramani. 2020. Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist. *Pediatric Blood & Cancer* **67**:6. . [[Crossref](#)]
534. Evan Jon Propst, Jonah Gorodensky, Jonathan Daniel Wasserman, Ethan Forde Glazman, Leona Ariel Tilis, Nikolaus Ernst Wolter. 2020. Recurrent laryngeal nerve monitoring with surface electrodes in pediatric thyroid surgery. *The Laryngoscope* **130**:6, 1583-1589. [[Crossref](#)]
535. Pierpaolo Trimboli, Arnaldo Piccardo, Alberto Signore, Stefano Valabrega, Agnese Barnabei, Giuliano Santolamazza, Arianna Di Paolo, Valeria Stati, Alfonsina Chiefari, Sebastiano Vottari, Maurizio Simmaco, Giulia Ferrarazzo, Luca Ceriani, Marialuisa Appetecchia, Luca Giovanella. 2020. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System. *Thyroid* **30**:5, 713-719. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
536. Emily Savoca, Sina J. Torabi, David Kasle, Elbert Mets, Michael Hajek, Erik H. Waldman. 2020. Pediatric thyroidectomies: A surgical subspecialty comparison. *International Journal of Pediatric Otorhinolaryngology* **132**, 109945. [[Crossref](#)]
537. Jill C. Rubinstein, Kayleigh Herrick-Reynolds, Catherine Dinauer, Raffaella Morotti, Daniel Solomon, Glenda G. Callender, Emily R. Christison-Lagay. 2020. Recurrence and Complications in Pediatric and Adolescent Papillary Thyroid Cancer in a High-Volume Practice. *Journal of Surgical Research* **249**, 58-66. [[Crossref](#)]
538. Cicero T. Silva, Oscar M. Navarro. 2020. Pearls and Pitfalls in Pediatric Thyroid Imaging. *Seminars in Ultrasound, CT and MRI* . [[Crossref](#)]
539. Rejane de Souza Reis, Gemma Gatta, Beatriz de Camargo. 2020. Thyroid carcinoma in children, adolescents, and young adults in Brazil: A report from 11 population-based cancer registries. *PLOS ONE* **15**:5, e0232416. [[Crossref](#)]
540. Qing Zhang, Jian Ma, Weijing Sun, Lanlan Zhang. 2020. Comparison of Diagnostic Performance between the American College of Radiology Thyroid Imaging Reporting and Data System and American Thyroid Association Guidelines: A Systematic Review. *Endocrine Practice* **26**:5, 552-563. [[Crossref](#)]
541. Jennifer L. Geurts, Erin A. Strong, Tracy S. Wang, Douglas B. Evans, Callisia N. Clarke. 2020. Screening guidelines and recommendations for patients at high risk of developing endocrine cancers. *Journal of Surgical Oncology* **121**:6, 975-983. [[Crossref](#)]
542. Tim I.M. Korevaar. 2020. Childhood Radioiodine Exposure Does Not Affect Ovarian Reserve in Adulthood. *Clinical Thyroidology* **32**:4, 184-186. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
543. Ioanna Tritou, Marina Vakaki, Rodanthi Sfakiotaki, Kalliroi Kalaitzaki, Maria Raissaki. 2020. Pediatric thyroid ultrasound: a radiologist's checklist. *Pediatric Radiology* **50**:4, 563-574. [[Crossref](#)]
544. Vijay A. Patel, Aliasgher Khaku, Michele M. Carr. 2020. Pediatric Thyroidectomy: NSQIP-P Analysis of Adverse Perioperative Outcomes. *Annals of Otolaryngology, Rhinology & Laryngology* **129**:4, 326-332. [[Crossref](#)]
545. Amer Heider, Stacy Arnold, Xin Jing. 2020. Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: Experience of a Tertiary Care Referral Center. *Archives of Pathology & Laboratory Medicine* **144**:4, 473-477. [[Crossref](#)]
546. Catherine A. Dinauer. 2020. Postoperative Preablation TSH-Stimulated Thyroglobulin May Predict Outcome of Differentiated Thyroid Cancer in Children. *Clinical Thyroidology* **32**:3, 131-134. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
547. Ulrich Paetow, Peter Bader, Wassim Chemaitilly. 2020. A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation. *Cancer and Metastasis Reviews* **39**:1, 69-78. [[Crossref](#)]
548. Qing Zhou, Li-Yong Zhang, Chao Xie, Mei-Lian Zhang, Yun-Jin Wang, Guang-Hua Liu. 2020. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents. *Pediatric Surgery International* **36**:2, 145-153. [[Crossref](#)]

549. Junghwan Suh, Han Saem Choi, Ahreum Kwon, Hyun Wook Chae, Ho-Seong Kim. 2020. Adolescents with thyroid nodules: retrospective analysis of factors predicting malignancy. *European Journal of Pediatrics* **179**:2, 317-325. [[Crossref](#)]
550. Danielle M. Richman, Carol B. Benson, Peter M. Doubilet, Ari J. Wassner, Elizabeth Asch, Christine E. Cherella, Jessica R. Smith, Mary C. Frates. 2020. Assessment of American College of Radiology Thyroid Imaging Reporting and Data System (TI-RADS) for Pediatric Thyroid Nodules. *Radiology* **294**:2, 415-420. [[Crossref](#)]
551. Si-Yuan Wu, Yi-Ju Chiang, Sarah B. Fisher, Erich M. Sturgis, Mark E. Zafereo, Sa Nguyen, Elizabeth G. Grubbs, Paul H. Graham, Jeffrey E. Lee, Steven G. Waguespack, Nancy D. Perrier. 2020. Risks of Hypoparathyroidism After Total Thyroidectomy in Children: A 21-Year Experience in a High-Volume Cancer Center. *World Journal of Surgery* **44**:2, 442-451. [[Crossref](#)]
552. Ioannis Iakovou, Evanthia Giannoula, Christos Sachpekidis. 2020. Imaging and Imaging-Based Management of Pediatric Thyroid Nodules. *Journal of Clinical Medicine* **9**:2, 384. [[Crossref](#)]
553. Andreea-Ioana Stefan, Andra Piciu, Alexandru Mester, Dragos Apostu, Marius Badan, Claudiu-Iulian Badulescu. 2020. Pediatric Thyroid Cancer in Europe: An Overdiagnosed Condition? A Literature Review. *Diagnostics* **10**:2, 112. [[Crossref](#)]
554. Anju Sukumaran, Valiparambil B Praveen Kumar. 2020. A case series and review on pediatric thyroid nodules. *Endocrinology&Metabolism International Journal* **8**:1. . [[Crossref](#)]
555. Jerome M. Hershman, Terry F. Davies, Charles H. Emerson, Peter A. Kopp. 2020. Retrospective View of Thyroid by Its Former Editors. *Thyroid* **30**:1, 2-7. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
556. Rachael Lawrence, Neil Bateman. Neck Swellings: Midline Neck Swellings 131-136. [[Crossref](#)]
557. Mahmoud F. Sakr. Solitary Thyroid Nodule 193-303. [[Crossref](#)]
558. Esra Karslioglu-French, Pushpa Viswanathan. Thyroid Disorders in Adolescence 431-447. [[Crossref](#)]
559. Heiko Krude, Annette Grüters-Kieslich. Schilddrüsenneoplasien bei Kindern und Jugendlichen 401-405. [[Crossref](#)]
560. Andrew J. Bauer. Thyroid Cancer in Children and Adolescents 49-62. [[Crossref](#)]
561. AlGhalya Al Maawali, Cyrus Matheson, Robert Baird, Geoffrey Blair. 2020. The thyroid nodules in kids study (ThyNK study): An evaluation of clinical practice variation. *Journal of Pediatric Surgery* **55**:5, 950. [[Crossref](#)]
562. L.A. Jonker, C.A. Lebbink, M.C.J. Jongmans, R.A.J. Nievelein, J.H.M. Merks, E.J.M. Nieveen van Dijkum, T.P. Links, N. Hoogerbrugge, A.S.P. van Trotsenburg, H.M. van Santen. 2020. Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome. *European Thyroid Journal* **9**:5, 234-242. [[Crossref](#)]
563. Shruthi Arora, Jane Khoury, Andrew T. Trout, Janet Chuang. 2020. Improving Malignancy Prediction in AUS/FLUS Pediatric Thyroid Nodules with the Aid of Ultrasound. *Hormone Research in Paediatrics* **93**:4, 239-244. [[Crossref](#)]
564. Julia A. Baran, Steven D. Tsai, Amber Isaza, Garrett M. Brodeur, Suzanne P. MacFarland, Kristin Zelle, Denise M. Adams, Aime T. Franco, Andrew J. Bauer. 2020. The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance. *Hormone Research in Paediatrics* **93**:11-12, 634-642. [[Crossref](#)]
565. Asmaa Gaber Abdou, Hayam Aiad, Nancy Asaad. 2020. Case Report: Multifocal non-invasive follicular thyroid neoplasm with papillary-like nuclear features presenting in a female child. *F1000Research* **9**, 645. [[Crossref](#)]
566. Yun-Woo Chang, Hee Min Kang, Eun Ji Lee. 2020. Long-Term Follow-Up Ultrasonographic Findings of Intrathyroidal Thymus in Children. *Korean Journal of Radiology* **21**:11, 1248. [[Crossref](#)]
567. Pavlo Korol, Mykola Tkachenko, Oleg Shcherbina. 2020. Twenty-year experience with SPECT/CT in nuclear medicine. *Radiation Diagnostics, Radiation Therapy* :1, 19-38. [[Crossref](#)]
568. Ping Dong, Li Wang, Rui Huang, Lin Li. 2020. Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy. *Medicine* **99**:31, e21398. [[Crossref](#)]
569. William Clarke, Lori J. Sokoll, Alex J. Rai. Immunoassays 201-214. [[Crossref](#)]
570. Cheong-Sil Rah, Won Woong Kim, Yu-mi Lee, Won Gu Kim, Dong Eun Song, Ki-Wook Chung, Seong Chul Kim, Suck Joon Hong, Tae-Yon Sung. 2019. Recent Trends in the Clinicopathological Features of Thyroid Nodules in Pediatric Patients: A Single Tertiary Center Experience over 25 Years. *International Journal of Endocrinology* **2019**, 1-8. [[Crossref](#)]
571. Jiangqiao Geng, Yuanhu Liu, Yongli Guo, Huanmin Wang, Jun Tai, Yaqiong Jin, Jie Zhang, Yongbo Yu, Shengcai Wang, Yingluan Song, Xin Ni. 2019. Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma. *Science China Life Sciences* **62**:12, 1563-1571. [[Crossref](#)]
572. Yves Réguerre, Lisa Golmard, Hervé J. Brisse, Isabelle Oliver Petit, Frédérique Savagner, Sabah Boudjemaa, Marion Gauthier-Villars, Julien Rod, Brice Fresneau, Daniel Orbach. 2019. Syndrome associé aux variants pathogènes constitutionnels de DICER1 : Où en sommes-nous en 2019 ?. *Bulletin du Cancer* **106**:12, 1177-1189. [[Crossref](#)]

573. Jozef Babala, Petra Zahradníková, Igor Béder, Lenka Fedorová, Martin Lindák, Ľudmila Košťálová, Zuzana Pribilincová, Juraj Staník, Róbert Králik. 2019. Risk factors of post-surgery complications in children with thyroid cancer. *International Journal of Pediatric Otorhinolaryngology* **127**, 109673. [[Crossref](#)]
574. Giuseppina Zirilli, Giuseppina Salzano, Domenico Corica, Giovanni Battista Pajno, Cristina Mignosa, Giorgia Pepe, Filippo De Luca, Giuseppe Crisafulli. 2019. Thyrotropin serum levels and coexistence with Hashimoto's thyroiditis as predictors of malignancy in children with thyroid nodules. *Italian Journal of Pediatrics* **45**:1. . [[Crossref](#)]
575. William L. Macken, Marc Tischkowitz, Katherine L. Lachlan. 2019. PTEN Hamartoma tumor syndrome in childhood: A review of the clinical literature. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* **181**:4, 591-610. [[Crossref](#)]
576. Hyung Kwon Byeon, Sang Bin Kim, Hyeon Seok Oh, Hong Kyu Kim, In Hak Choi, Hyunjung Kim, Jae-Gu Cho, Kyung Ho Oh, Seung-Kuk Baek, Jeong-Soo Woo, Soon-Young Kwon, Hoon Yub Kim, Kwang Yoon Jung. 2019. Clinical Analysis of Pediatric Thyroid Cancer: A Single Medical Institution Experience of 18 Years. *Annals of Otolaryngology & Rhinology* **128**:12, 1152-1157. [[Crossref](#)]
577. Marie-Odile Bernier, Cari M. Kitahara, Meredith S. Shiels. 2019. Reply to Natural history of thyroid cancer suggests beginning of the overdiagnosis of juvenile thyroid cancer in the United States and Harm of overdiagnosis or extremely early diagnosis behind trends in pediatric thyroid cancer. *Cancer* **125**:22, 4109-4110. [[Crossref](#)]
578. Suresh Kari, Vasyly V. Vasko, Shivam Priya, Lawrence S. Kirschner. 2019. PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer. *Frontiers in Endocrinology* **10**. . [[Crossref](#)]
579. Ilan I. Maizlin, Herbert Chen, Robert T. Russell. 2019. Factors Affecting Readmission After Pediatric Thyroid Resection: A National Surgical Quality Improvement Program-Pediatric Evaluation. *Journal of Surgical Research* **243**, 33-40. [[Crossref](#)]
580. Sarah Gammons, Brent K Presley, Perrin C White. 2019. Referrals for Elevated Thyroid Stimulating Hormone to Pediatric Endocrinologists. *Journal of the Endocrine Society* **3**:11, 2032-2040. [[Crossref](#)]
581. Constantine A. Stratakis, Emmanouil Saloustros. Endocrine Neoplasia 507-532. [[Crossref](#)]
582. Wassim Chemaitilly, Melissa M. Hudson. Endocrine Late Effects of Cancer Treatments 533-552. [[Crossref](#)]
583. Marguerite T. Parisi, Hedieh Khalatbari, Sanjay R. Parikh, Adina Alazraki. 2019. Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach. *Pediatric Radiology* **49**:11, 1391-1403. [[Crossref](#)]
584. Heron D. Baumgarten, Andrew J. Bauer, Amber Isaza, Sogol Mostoufi-Moab, Ken Kazahaya, N. Scott Adzick. 2019. Surgical management of pediatric thyroid disease: Complication rates after thyroidectomy at the Children's Hospital of Philadelphia high-volume Pediatric Thyroid Center. *Journal of Pediatric Surgery* **54**:10, 1969-1975. [[Crossref](#)]
585. Amy L. Dimachkieh, Ken Kazahaya, Daniel C. Chelius. 2019. Assessment and Management of Thyroid Disease in Children. *Otolaryngologic Clinics of North America* **52**:5, 957-967. [[Crossref](#)]
586. Tae Yoon Lee, Sohee Lee, Ja Seong Bae, Woo-Chan Park, Sung-Soo Park, Sung-Eun Lee, Jong Wook Lee, Seong Koo Kim, Bin Cho, Chan Kwon Jung. 2019. Distinct Clinical Manifestations of Thyroid Cancer After Hematopoietic Stem Cell Transplantation. *Annals of Surgical Oncology* **26**:11, 3586-3592. [[Crossref](#)]
587. Sara E. Monaco, Zubair W. Baloch, Esther Diana Rossi, Lisa A. Teot, Colleen Wright. 2019. The application of current classification systems in pediatric cytopathology: Perspectives from the pediatric cytopathology symposium at the 20th International Congress of Cytology 2019. *Cancer Cytopathology* **127**:10, 625-631. [[Crossref](#)]
588. Amer Heider, Stacy Arnold, Madelyn Lew, Judy Pang, Raja Rabah, Steven Bruch, Inas Thomas, Ram Menon, Richard Cantley, Robertson Davenport, Xin Jing. 2019. Malignant risk of indeterminate pediatric thyroid nodules—An institutional experience. *Diagnostic Cytopathology* **47**:10, 993-998. [[Crossref](#)]
589. Andrew J. Bauer. 2019. Thyroid nodules in children and adolescents. *Current Opinion in Endocrinology, Diabetes & Obesity* **26**:5, 266-274. [[Crossref](#)]
590. Allison S. Remiker, Janet Chuang, Sarah Corathers, Meilan M. Rutter, Michael J. Rutter, Charles M. Myer, Michael J. Gelfand, Andrew T. Trout, James I. Geller. 2019. Differentiated Thyroid Cancer in the Pediatric/Adolescent Population: Evolution of Treatment. *Journal of Pediatric Hematology/Oncology* **41**:7, 532-536. [[Crossref](#)]
591. Frances E. Carr. THYROID CANCER 415-444. [[Crossref](#)]
592. Ora Israel, O. Pellet, L. Biassoni, D. De Palma, E. Estrada-Lobato, G. Gnanasegaran, T. Kuwert, C. la Fougère, G. Mariani, S. Massalha, D. Paez, F. Giammarile. 2019. Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence. *European Journal of Nuclear Medicine and Molecular Imaging* **46**:10, 1990-2012. [[Crossref](#)]
593. R Michael Tuttle, Ali S Alzahrani. 2019. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. *The Journal of Clinical Endocrinology & Metabolism* **104**:9, 4087-4100. [[Crossref](#)]

594. Vera A. Paulson, Erin R. Rudzinski, Douglas S. Hawkins. 2019. Thyroid Cancer in the Pediatric Population. *Genes* **10**:9, 723. [[Crossref](#)]
595. Y. Yonekura, S. Mattsson, G. Flux, W.E. Bolch, L.T. Dauer, D.R. Fisher, M. Lassmann, S. Palm, M. Hosono, M. Doruff, C. Divgi, P. Zanzonico. 2019. ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. *Annals of the ICRP* **48**:1, 5-95. [[Crossref](#)]
596. Juanita K. Hodax, Kimberly Bowerman, Jose Bernardo Quintos. 2019. Benign thyroid nodules in pediatric patients: determining best practices for repeat ultrasound evaluations. *Journal of Pediatric Endocrinology and Metabolism* **32**:8, 895-901. [[Crossref](#)]
597. Xiao-Wen Liang, Yong-Yi Cai, Jin-Sui Yu, Jian-Yi Liao, Zhi-Yi Chen. 2019. Update on thyroid ultrasound. *Chinese Medical Journal* **132**:16, 1974-1982. [[Crossref](#)]
598. Francesca Galuppini, Federica Vianello, Simona Censi, Susi Barollo, Loris Bertazza, Sofia Carducci, Chiara Colato, Jacopo Manso, Massimo Rugge, Maurizio Iacobone, Sara Watutantrige Fernando, Gianmaria Pennelli, Caterina Mian. 2019. Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario. *Frontiers in Endocrinology* **10**. [[Crossref](#)]
599. Cherella Christine E., Angell Trevor E., Richman Danielle M., Frates Mary C., Benson Carol B., Moore Francis D., Barletta Justine A., Hollowell Monica, Smith Jessica R., Alexander Erik K., Cibas Edmund S., Wassner Ari J.. 2019. Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults. *Thyroid* **29**:8, 1097-1104. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
600. Jonathan C Howell, Susan R Rose. 2019. Pituitary disease in pediatric brain tumor survivors. *Expert Review of Endocrinology & Metabolism* **14**:4, 283-291. [[Crossref](#)]
601. Susan J. Hsiao, Ahmet Zehir, Anthony N. Sireci, Dara L. Aisner. 2019. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. *The Journal of Molecular Diagnostics* **21**:4, 553-571. [[Crossref](#)]
602. Jing Zeng, Xiao Ma, Jinjing Wang, Ran Liu, Yun Shao, Yanwei Hou, Zhiyuan Li, Yi Fang. 2019. Down-regulated HSDL2 expression suppresses cell proliferation and promotes apoptosis in papillary thyroid carcinoma. *Bioscience Reports* **39**:6. [[Crossref](#)]
603. Raad Alwithenani, Sarah DeBrabandere, Irina Rachinsky, S. Danielle MacNeil, Mahmoud Badreddine, Stan Van Uum. 2019. Performance of the American Thyroid Association Risk Classification in a Single Center Cohort of Pediatric Patients with Differentiated Thyroid Cancer: A Retrospective Study. *Journal of Thyroid Research* **2019**, 1-7. [[Crossref](#)]
604. Dinauer Catherine A.. 2019. Complication Rates for Pediatric Thyroid Surgery Are Lower at Higher-Volume U.S. Hospitals. *Clinical Thyroidology* **31**:6, 237-239. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
605. Gali Shapira-Zaltsberg, Elka Miller, Claudia Martinez-Rios, Juan Bass, Ellen B. Goldbloom, Ken Tang, Lamia Hayawi, Kerri Highmore. 2019. Comparison of the diagnostic performance of the 2017 ACR TI-RADS guideline to the Kwak guideline in children with thyroid nodules. *Pediatric Radiology* **49**:7, 862-868. [[Crossref](#)]
606. Jennifer E. Lim-Dunham. 2019. Ultrasound guidelines for pediatric thyroid nodules: proceeding with caution. *Pediatric Radiology* **49**:7, 851-853. [[Crossref](#)]
607. Clara Villalba Castaño, Atilano Carcavilla Urquí, Ángel Aragonés Gallego, Julia Sastre Marcos, Miguel Ángel Morlan López. 2019. Diagnosis of three cases of thyroid cancer in one year. *Anales de Pediatría (English Edition)* **90**:6, 397-399. [[Crossref](#)]
608. Clara Villalba Castaño, Atilano Carcavilla Urquí, Ángel Aragonés Gallego, Julia Sastre Marcos, Miguel Ángel Morlan López. 2019. Diagnóstico de 3 casos de cáncer de tiroides en un año. *Anales de Pediatría* **90**:6, 397-399. [[Crossref](#)]
609. K.A. Lee, M.T.A. Sharabiani, D. Tumino, J. Wadsley, V. Gill, G. Gerrard, R. Sindhu, M.N. Gaze, L. Moss, K. Newbold. 2019. Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature. *Clinical Oncology* **31**:6, 385-390. [[Crossref](#)]
610. Min Ji Hong, Jin Yong Sung, Jung Hwan Baek, Mi Su Je, Dong Whan Choi, Hyunju Yoo, Sae Jeong Yang, Sang Yu Nam, Eun Young Yoo. 2019. Safety and Efficacy of Radiofrequency Ablation for Nonfunctioning Benign Thyroid Nodules in Children and Adolescents in 14 Patients over a 10-Year Period. *Journal of Vascular and Interventional Radiology* **30**:6, 900-906. [[Crossref](#)]
611. Gustavo Bittar Cunha, Luciana Cristante Izar Marino, André Yamaya, Cristiane Kochi, Osmar Monte, Carlos Alberto Longui, Adriano Namo Cury, Eduardo de Faria Castro Fleury. 2019. Elastography for the evaluation of thyroid nodules in pediatric patients. *Radiologia Brasileira* **52**:3, 141-147. [[Crossref](#)]
612. Ihsan Esen, Deniz Okdemir. 2019. A case of follicular thyroid carcinoma associated with phosphatase and tensin homologue hamartoma tumour syndrome. *Journal of Paediatrics and Child Health* **55**:5, 601-603. [[Crossref](#)]
613. Magdalena Stasiak, Zbigniew Adamczewski, Renata Stawerska, Tomasz Krawczyk, Monika Tomaszewska, Andrzej Lewiński. 2019. Sonographic and Elastographic Features of Extra- and Intrathyroidal Ectopic Thymus Mimicking Malignancy: Differential Diagnosis in Children. *Frontiers in Endocrinology* **10**. [[Crossref](#)]

614. Dinauer Catherine A.. 2019. Malignancy Rates in Cytologically Indeterminate Thyroid Nodules among Children Are Lower Than Previously Reported but Remain Higher Than in Adults. *Clinical Thyroidology* 31:4, 158-161. [Citation] [Full Text] [PDF] [PDF Plus]
615. Ezekiel Maloney, Ramesh S. Iyer, Grace S. Phillips, Shina Menon, John J. Lee, Michael J. Callahan. 2019. Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions. *Pediatric Radiology* 49:4, 433-447. [Crossref]
616. Liane Eng, Lisa Underland, Leslie Lam. 2019. Intrathyroidal Thymic Tissue in an Adolescent with Graves' Disease: Case Report and Review of Current Literature. *Case Reports in Pediatrics* 2019, 1-4. [Crossref]
617. Huiying Wang, Mitra Mehrad, Kim A. Ely, Jiancong Liang, Carmen C. Solórzano, Wallace W. Neblett, Alice C. Coogan, Vivian L. Weiss. 2019. Incidence and malignancy rates of indeterminate pediatric thyroid nodules. *Cancer Cytopathology* 127:4, 231-239. [Crossref]
618. Danielle Pessôa-Pereira, Mateus Fernandes da Silva Medeiros, Virna Mendonça Sampaio Lima, Joaquim Custódio da Silva, Taíse Lima de Oliveira Cerqueira, Igor Campos da Silva, Luciano Espinheira Fonseca, Luiz José Lobão Sampaio, Cláudio Rogério Alves de Lima, Helton Estrela Ramos. 2019. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. *Archives of Endocrinology and Metabolism* . [Crossref]
619. . Thyroid Disorders 143-167. [Crossref]
620. D. Januś, M. Wójcik, A. Taczanowska, P. Sołtysiak, A. Wędrychowicz, D. Roztoczyńska, G. Drabik, Ł. Wyrobek, J. B. Starzyk. 2019. Follow-up of parenchymal changes in the thyroid gland with diffuse autoimmune thyroiditis in children prior to the development of papillary thyroid carcinoma. *Journal of Endocrinological Investigation* 42:3, 261-270. [Crossref]
621. Dorina Ylli, Douglas Van Nostrand, Leonard Wartofsky. 2019. Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* 48:1, 181-197. [Crossref]
622. Claudio Spinelli, Leonardo Rallo, Riccardo Morganti, Valentina Mazzotti, Alessandro Inserra, Giovanni Cecchetto, Maura Massimino, Paola Collini, Silvia Strambi. 2019. Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. *Journal of Pediatric Surgery* 54:3, 521-526. [Crossref]
623. Virginie Bussi eres, Shreyas Roy, Johnny Deladoey,  elisabeth Rousseau, Dickens St-Vil, Nelson Pich e. 2019. Pediatric thyroidectomy: Favorable outcomes can be achieved by a multidisciplinary team of pediatric providers. *Journal of Pediatric Surgery* 54:3, 527-530. [Crossref]
624. Leeyan S. Gilmour, Penny J. Hunt, Karen E. Mackenzie, Martin de Bock. 2019. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies—Letter. *Clinical Cancer Research* 25:5, 1688-1688. [Crossref]
625. Andrew J. Bauer, Douglas R. Stewart, Junne Kamihara, Anne K. Harris, Joyce Turner, Rachana Shah, Kami Wolfe Schneider, Katherine Schneider, Ann Garrity Carr, Laura A. Harney, A. Lindsay Frazier, Daniel Orbach, Dominik T. Schneider, David Malkin, Louis P. Dehner, Yoav H. Messinger, D. Ashley Hill, Kris Ann P. Schultz. 2019. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies—Response. *Clinical Cancer Research* 25:5, 1689-1690. [Crossref]
626. Giorgio Radetti, Sandro Loche, Valeria D'Antonio, Mariacarolina Salerno, Chiara Guzzetti, Tommaso Aversa, Alessandra Cassio, Marco Cappa, Roberto Gastaldi, Filippo Deluca, Maria Cristina Vigone, Giulia Maria Tronconi, Andrea Corrias. 2019. Influence of Hashimoto Thyroiditis on the Development of Thyroid Nodules and Cancer in Children and Adolescents. *Journal of the Endocrine Society* 3:3, 607-616. [Crossref]
627. A V Gostimskii, Y L Skorodok, A A Taraikovich, S S Peredereev. 2019. THE STRUCTURE OF THYROID NODULES IN CHILDREN SUBJECTED TO SURGICAL TREATMENT. *Bulletin of the Russian Military Medical Academy* 21:1, 63-66. [Crossref]
628. Karin van der Tuin, Leanne de Kock, Eveline J Kamping, Sabine E Hannema, Marie-Jose M Pouwels, Marek Niedziela, Tom van Wezel, Frederik J Hes, Marjolijn C Jongmans, William D Foulkes, Hans Morreau. 2019. Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome. *The Journal of Clinical Endocrinology & Metabolism* 104:2, 277-284. [Crossref]
629. Zeming Liu, Di Hu, Yihui Huang, Sichao Chen, Wen Zeng, Ling Zhou, Wei Zhou, Min Wang, Haifeng Feng, Wei Wei, Chao Zhang, Danyang Chen, Liang Guo. 2019. Factors associated with distant metastasis in pediatric thyroid cancer: evaluation of the SEER database. *Endocrine Connections* 8, 78-85. [Crossref]
630. Tharsana Selvakumar, Marloes Nies, Mari elle S. Klein Hesselink, Adrienne H. Brouwers, Anouk N.A. van der Horst-Schrivers, Esther N. Klein Hesselink, Wim J.E. Tissing, Arjan Vissink, Thera P. Links. 2019. Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma. *Journal of Nuclear Medicine* 60:2, 172-177. [Crossref]

631. Weijie Li, Daniel Dim, Lorien Paulson, Douglas Rivard. 2019. Diagnosis of intrathyroidal ectopic thymus in thyroid fine needle aspiration samples. *Journal of Clinical Pathology* 72:2, 145-151. [[Crossref](#)]
632. Luster Markus, Aktolun Cumali, Amendoeira Isabel, Barczyński Marcin, Bible Keith C., Duntas Leonidas H., Elisei Rossella, Handkiewicz-Junak Daria, Hoffmann Martha, Jarzab Barbara, Leenhardt Laurence, Musholt Thomas J., Newbold Kate, Nixon Iain J., Smit Johannes, Sobrinho-Simões Manuel, Sosa Julie Ann, Tuttle R. Michael, Verburg Frederik A., Wartofsky Leonard, Führer Dagmar. 2019. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. *Thyroid* 29:1, 7-26. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
633. Daniela Pinto, Sílvia Costa Dias. Value-Based Radiology in Pediatric Imaging 143-157. [[Crossref](#)]
634. Neha S. Kwatra, Marguerite T. Parisi, Barry L. Shulkin. Radioisotope Therapies: Iodine-131, I-131-MIBG, and Beyond 275-303. [[Crossref](#)]
635. Helen Nadel, Lorenzo Biassoni. SPECT/CT in Pediatric Oncology 75-89. [[Crossref](#)]
636. Young Ah Lee, Andrew J. Bauer. Thyroid Cancer in Children and Adolescents 563-582. [[Crossref](#)]
637. Jasna Mihailovic, Stanley J. Goldsmith. Radioiodine Therapy in Differentiated Thyroid Carcinoma 611-632. [[Crossref](#)]
638. Çiğdem Soydal, Elgin Özkan. A Child with Papillary Thyroid Carcinoma: Role of Radioactive Iodine Therapy in Pediatric Patients 415-418. [[Crossref](#)]
639. Zehra Özcan, Ülkem Yarabaş. Pediatric PTC with Diffuse Lung Metastases: Pulmonary Function Testing and Steroid Therapy Prior to RAI 419-422. [[Crossref](#)]
640. Pietro Zucchetta, Diego De Palma. Nuclear Medicine in Pediatrics 925-949. [[Crossref](#)]
641. Suma Uday, Christine Davies, Helena Gleeson. Disorders of the Thyroid in Childhood and Adolescence 609-628. [[Crossref](#)]
642. Ali Alkhars, Moumainn Abouzayd, Charles-Edouard Rouf, Hubert Lardy, David Bakhos, Soizick Pondaven-Letourmy, Sylvain Moriniere, Emmanuel Lescanne. 2019. Pediatric thyroid surgery: experience in 75 consecutive thyroidectomies. *European Archives of Oto-Rhino-Laryngology* 276:1, 217-222. [[Crossref](#)]
643. Wassim Chemaitilly, Laurie E. Cohen. Endocrine Late Effects in Childhood Cancer Survivors 221-239. [[Crossref](#)]
644. Ari J. Wassner. Thyroid Tumors in Children 327-334. [[Crossref](#)]
645. Pei-You Ren, Jia Liu, Shuai Xue, Guang Chen. 2019. Pediatric differentiated thyroid carcinoma: The clinicopathological features and the coexistence of Hashimoto's thyroiditis. *Asian Journal of Surgery* 42:1, 112-119. [[Crossref](#)]
646. Mikhail Fridman, Olga Krasko, Daniel Igor Branovan, Svatlana Dabryian, Arthur Pisarenko, Chung Yau Lo, Alfred King-yin Lam. 2019. Factors affecting the approaches and complications of surgery in childhood papillary thyroid carcinomas. *European Journal of Surgical Oncology* 45:11, 2078. [[Crossref](#)]
647. Ashok R. Shaha, R. Michael Tuttle. 2019. Pediatric Thyroid Cancer: A Surgical Challenge. *European Journal of Surgical Oncology* 45:11, 2001. [[Crossref](#)]
648. Jill C. Rubinstein, Catherine Dinauer, Kayleigh Herrick-Reynolds, Raffaella Morotti, Glenda G. Callender, Emily R. Christison-Lagay. 2019. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer. *Journal of Pediatric Surgery* 54:1, 129-132. [[Crossref](#)]
649. Steven G. Waguespack. 2019. Thyroid Sequelae of Pediatric Cancer Therapy. *Hormone Research in Paediatrics* 91:2, 104-117. [[Crossref](#)]
650. Ali S Alzahrani, Meshael Alswailem, Yosra Moria, Reem Almutairi, Metib Alotaibi, Avaniyapuram Kannan Murugan, Ebtesam Qasem, Balgees Alghamdi, Hindi Al-Hindi. 2019. Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome. *The Journal of Clinical Endocrinology & Metabolism* 104:1, 103-110. [[Crossref](#)]
651. Jennifer E. Lim-Dunham, Iclal Erdem Toslak, Michael P. Reiter, Brendan Martin. 2019. Assessment of the American College of Radiology Thyroid Imaging Reporting and Data System for Thyroid Nodule Malignancy Risk Stratification in a Pediatric Population. *American Journal of Roentgenology* 212:1, 188-194. [[Crossref](#)]
652. YaseminDurum Polat, VeliSüha Öztürk, Nimet Ersoz, Ahmet Anık, CanZafer Karaman. 2019. Is thyroid imaging reporting and data system useful as an adult ultrasonographic malignancy risk stratification method in pediatric thyroid nodules?. *Journal of Medical Ultrasound* 27:3, 141. [[Crossref](#)]
653. Robert J. Amdur, Roi Dagan. 2019. The University of Florida Department of Radiation Oncology Guidelines for Treatment of Differentiated Thyroid Cancer With I-131 or External-beam Radiotherapy. *American Journal of Clinical Oncology* 42:1, 92-98. [[Crossref](#)]

654. Ana Creo, Fares Alahdab, Alaa Al Nofal, Kristen Thomas, Amy Kolbe, Siobhan Pittock. 2019. Diagnostic accuracy of the McGill thyroid nodule score in paediatric patients. *Clinical Endocrinology* **90**:1, 200-207. [[Crossref](#)]
655. Nadia Merchant, Johanna M. Viau-Colindres, Kelly A. Hicks, Andrea E. Balazs, David E. Wesson, Monica E. Lopez, Lefkothea Karaviti. 2019. McCune-Albright Syndrome With Unremitting Hyperthyroidism at Early Age: Management Perspective for Early Thyroidectomy. *Global Pediatric Health* **6**. . [[Crossref](#)]
656. Fred A. Mettler, Milton J. Guiberteau. Thyroid, Parathyroid, and Salivary Glands 85-115. [[Crossref](#)]
657. Lourdes Ibáñez, Konstantina Barouti, Georgios K. Markantes, Anastasia K. Armeni, Neoklis A. Georgopoulos. 2018. Pediatric endocrinology: an overview of the last decade. *Hormones* **17**:4, 439-449. [[Crossref](#)]
658. Hadiza S. Kazaure, Julie Ann Sosa. 2018. Surgical Hypoparathyroidism. *Endocrinology and Metabolism Clinics of North America* **47**:4, 783-796. [[Crossref](#)]
659. Yuqing Zong, Kai Li, Kuiran Dong, Wei Yao, Gongbao Liu, Xianmin Xiao. 2018. The surgical choice for unilateral thyroid carcinoma in pediatrics: Lobectomy or total thyroidectomy?. *Journal of Pediatric Surgery* **53**:12, 2449-2453. [[Crossref](#)]
660. Maria F. Villani, Armando Grossi, Bartolomeo Cassano, Milena Pizzoferro, Graziamaria Ubertini, Mariaconcetta Longo, Maria C. Garganese. 2018. Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence. *Nuclear Medicine Communications* **39**:12, 1121-1128. [[Crossref](#)]
661. Feng Chen, Yaqiong Jin, Lin Feng, Jie Zhang, Jun Tai, Jin Shi, Yongbo Yu, Jie Lu, Shengcai Wang, Xin Li, Ping Chu, Shujing Han, Shujun Cheng, Yongli Guo, Xin Ni. 2018. RRS1 gene expression involved in the progression of papillary thyroid carcinoma. *Cancer Cell International* **18**:1. . [[Crossref](#)]
662. Giuseppina Zirilli, Laura Cannavò, Francesco Vermiglio, Maria Antonia Violi, Filippo De Luca, Malgorzata Wasniewska. 2018. Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. *Italian Journal of Pediatrics* **44**:1. . [[Crossref](#)]
663. Mahajan Priya, Dawrant Jonathan, Kheradpour Albert, Quintanilla Norma M., Lopez Monica E., Orth Robert C., Athanassaki Ioanna, Venkatramani Rajkumar. 2018. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma. *Thyroid* **28**:11, 1450-1454. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
664. 2018. AIUM-ACR-SPR-SRU Practice Parameter for the Performance and Interpretation of a Diagnostic Ultrasound Examination of the Extracranial Head and Neck. *Journal of Ultrasound in Medicine* **37**:11. . [[Crossref](#)]
665. Meiling Huang, Changjiao Yan, Hongliang Wei, Yonggang Lv, Rui Ling. 2018. Clinicopathological characteristics and prognosis of thyroid cancer in northwest China: A population-based retrospective study of 2490 patients. *Thoracic Cancer* **9**:11, 1453-1460. [[Crossref](#)]
666. Partha S Choudhury, Manoj Gupta. 2018. Differentiated thyroid cancer theranostics: radioiodine and beyond. *The British Journal of Radiology* **91**:1091. . [[Crossref](#)]
667. Nisha Bhavani, Kingini Bhadrán, Vasantha Nair, Usha V. Menon, Praveen V. Pavithran, Arun S. Menon, Nithya Abraham, Aswin Pankaj, Harish Kumar. 2018. Treatment outcomes in pediatric differentiated thyroid carcinoma. *Journal of Pediatric Endocrinology and Metabolism* **31**:10, 1117-1122. [[Crossref](#)]
668. James Blackburn, Dinesh Giri, Barbara Ciolka, Nicole Gossan, Mohammad Didi, George Kokai, Alison Waghorn, Matthew Jones, Senthil Senniappan. 2018. A Rare Case of Heterozygous Gain of Function Thyrotropin Receptor Mutation Associated with Development of Thyroid Follicular Carcinoma. *Case Reports in Genetics* **2018**, 1-5. [[Crossref](#)]
669. N. S. Grachev, I. N. Vorozhtsov, N. V. Babaskina, E. Iu. Iaremenko. 2018. ESTIMATING THE EFFECTIVENESS OF SURGICAL TREATMENT OF CHILDREN WITH THYROID NEOPLASMS. *Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care* **8**:2, 33-47. [[Crossref](#)]
670. Zanella André Borsatto, Scheffel Rafael Selbach, Nava Carla Fernanda, Golbert Lenara, Laurini de Souza Meyer Erika, Punaes Márcia, Gonçalves Iracema, Dora José Miguel, Maia Ana Luiza. 2018. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer. *Thyroid* **28**:10, 1285-1292. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
671. Alfredo Campenni, Salvatore Antonio Pignata, Sergio Baldari. 2018. Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low-intermediate risk differentiated thyroid cancer. *Clinical and Translational Imaging* **6**:5, 347-355. [[Crossref](#)]
672. Sarah Ogle, Alexa Merz, Ralitzia Parina, Mahmoud Alsayed, Mira Milas. 2018. Ultrasound and the Evaluation of Pediatric Thyroid Malignancy: Current Recommendations for Diagnosis and Follow-up. *Journal of Ultrasound in Medicine* **37**:10, 2311-2324. [[Crossref](#)]
673. Peter Angelos. 2018. The Problem of the Indeterminate Thyroid Nodule. *JAMA Surgery* **153**:9, 824. [[Crossref](#)]
674. T. J. Musholt, A. Bockisch, T. Clerici, C. Dotzenrath, H. Dralle, P. E. Goretzki, M. Hermann, K. Holzer, W. Karges, H. Krude, J. Kussmann, K. Lorenz, M. Luster, B. Niederle, C. Nies, P. Riss, J. Schabram, P. Schabram, K. W. Schmid, D. Simon, Ch.

- Spitzweg, Th. Steinmüller, A. Trupka, C. Vorländer, T. Weber, D. K. Bartsch. 2018. Aktualisierung der S2k-Leitlinie. *Der Chirurg* **89**:9, 699-709. [[Crossref](#)]
675. Pedro Wesley Rosario, Gabriela Franco Mourão. 2018. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in children and adolescents. *Endocrine* **61**:3, 542-544. [[Crossref](#)]
676. Christine E Cherella, Henry A Feldman, Monica Hollowell, Danielle M Richman, Edmund S Cibas, Jessica R Smith, Trevor E Angell, Zhihong Wang, Erik K Alexander, Ari J Wassner. 2018. Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children. *The Journal of Clinical Endocrinology & Metabolism* **103**:9, 3557-3565. [[Crossref](#)]
677. Wendy Allen-Rhoades, Sarah B. Whittle, Nino Rainusso. 2018. Pediatric Solid Tumors in Children and Adolescents: An Overview. *Pediatrics In Review* **39**:9, 444-453. [[Crossref](#)]
678. Marco Russo, Pasqualino Malandrino, Mariacarla Moleti, Francesco Vermiglio, Antonio D'Angelo, Giuliana La Rosa, Giulia Sapuppo, Francesca Calaciura, Concetto Regalbuto, Antonino Belfiore, Riccardo Vigneri, Gabriella Pellegriti. 2018. Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. *Pediatric Blood & Cancer* **65**:9. . [[Crossref](#)]
679. Darlene Metter, William T. Phillips, Ronald C. Walker, Ralph Blumhardt. 2018. To Use or Not to Use 131I in Thyroid Cancer. *Clinical Nuclear Medicine* **43**:9, 670-671. [[Crossref](#)]
680. Marwan H. Adly, Mohamed Sobhy, Mohamed A. Rezk, Medhat Ishak, Mahmoud A. Afifi, Ayman El Shafie, Mahmoud Ahmed Ali, Wael Zekri, Ahmad Samir Alfaar, Wafaa M. Rashed. 2018. Risk of second malignancies among survivors of pediatric thyroid cancer. *International Journal of Clinical Oncology* **23**:4, 625-633. [[Crossref](#)]
681. Danielle M. Richman, Carol B. Benson, Peter M. Doubilet, Hope E. Peters, Stephen A. Huang, Elizabeth Asch, Ari J. Wassner, Jessica R. Smith, Christine E. Cherella, Mary C. Frates. 2018. Thyroid Nodules in Pediatric Patients: Sonographic Characteristics and Likelihood of Cancer. *Radiology* **288**:2, 591-599. [[Crossref](#)]
682. Suzanne P MacFarland, Andrew J Bauer, N Scott Adzick, Lea F Surrey, Jessica Noyes, Ken Kazahaya, Sogol Mostoufi-Moab. 2018. Disease Burden and Outcome in Children and Young Adults With Concurrent Graves Disease and Differentiated Thyroid Carcinoma. *The Journal of Clinical Endocrinology & Metabolism* **103**:8, 2918-2925. [[Crossref](#)]
683. Sarah Hampson, Derek Stephens, Jonathan D. Wasserman. 2018. Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma. *Clinical Endocrinology* **89**:2, 212-218. [[Crossref](#)]
684. Maura Massimino, Douglas B. Evans, Marta Podda, Claudio Spinelli, Paola Collini, Natalia Pizzi, Archie Bleyer. 2018. Thyroid cancer in adolescents and young adults. *Pediatric Blood & Cancer* **65**:8. . [[Crossref](#)]
685. C. Spinelli, F. Tognetti, S. Strambi, R. Morganti, M. Massimino, P. Collini. 2018. Cervical Lymph Node Metastases of Papillary Thyroid Carcinoma, in the Central and Lateral Compartments, in Children and Adolescents: Predictive Factors. *World Journal of Surgery* **42**:8, 2444-2453. [[Crossref](#)]
686. Priya Pathak, Pooja Sharma, Aditi Daga, Sonal Sharma. 2018. Cyto-morphologic spectrum of thyroid lesions in children. *Diagnostic Cytopathology* **46**:7, 572-577. [[Crossref](#)]
687. Joon Ho Jang, So Hyun Park, Kyung soon Cho, Won Kyung Cho, Young Jin Suh, Byung Kyu Suh, Dae Kyun Koh. 2018. Cancer in thyroid nodules with fine-needle aspiration in Korean pediatric populations. *Annals of Pediatric Endocrinology & Metabolism* **23**:2, 94-98. [[Crossref](#)]
688. Sawka Anna M., Carty Sally E., Haugen Bryan R., Hennessey James V., Kopp Peter A., Pearce Elizabeth N., Sosa Julie A., Tufano Ralph P., Jonklaas Jacqueline. 2018. American Thyroid Association Guidelines and Statements: Past, Present, and Future. *Thyroid* **28**:6, 692-706. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
689. Anil K. D'Cruz, Richa Vaish, Abhishek Vaidya, Iain J. Nixon, Michelle D. Williams, Vincent Vander Poorten, Fernando López, Peter Angelos, Ashok R. Shaha, Avi Khafif, Alena Skalova, Alessandra Rinaldo, Jennifer L. Hunt, Alfio Ferlito. 2018. Molecular markers in well-differentiated thyroid cancer. *European Archives of Oto-Rhino-Laryngology* **275**:6, 1375-1384. [[Crossref](#)]
690. Mikhail Fridman, Olga Krasko, Alfred King-yin Lam. 2018. Optimizing treatment for children and adolescents with papillary thyroid carcinoma in post-Chernobyl exposed region: The roles of lymph node dissections in the central and lateral neck compartments. *European Journal of Surgical Oncology* **44**:6, 733-743. [[Crossref](#)]
691. Rachel A. Mariani, Rachel Kadakia, Nicoleta C. Arva. 2018. Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: Should it also be reclassified in children?. *Pediatric Blood & Cancer* **65**:6. . [[Crossref](#)]
692. Katrina Korhonen, Hongming Zhuang. 2018. Pediatric Patient With Cerebral Metastasis From Papillary Thyroid Cancer. *Clinical Nuclear Medicine* **43**:6, 471-473. [[Crossref](#)]
693. Consolato Sergi, Aneesh Dhiman, Jo-Ann Gray. 2018. Fine Needle Aspiration Cytology for Neck Masses in Childhood. An Illustrative Approach. *Diagnostics* **8**:2, 28. [[Crossref](#)]

694. M. Benzon, Nora Katabi, Laura Boucai, Ashok Shaha. 2018. Follicular Carcinoma Masquerading as a Hot Nodule in a Pediatric Patient. *The American Surgeon*TM **84**:6, 1117-1119. [[Crossref](#)]
695. Kris Ann P. Schultz, Gretchen M. Williams, Junne Kamihara, Douglas R. Stewart, Anne K. Harris, Andrew J. Bauer, Joyce Turner, Rachana Shah, Katherine Schneider, Kami Wolfe Schneider, Ann Garrity Carr, Laura A. Harney, Shari Baldinger, A. Lindsay Frazier, Daniel Orbach, Dominik T. Schneider, David Malkin, Louis P. Dehner, Yoav H. Messinger, D. Ashley Hill. 2018. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. *Clinical Cancer Research* **24**:10, 2251-2261. [[Crossref](#)]
696. Anthony W Gannon, Jill E Langer, Richard Bellah, Sarah Ratcliffe, Jennifer Pizza, Sogol Mostoufi-Moab, Anne R Cappola, Andrew J Bauer. 2018. Diagnostic Accuracy of Ultrasound With Color Flow Doppler in Children With Thyroid Nodules. *The Journal of Clinical Endocrinology & Metabolism* **103**:5, 1958-1965. [[Crossref](#)]
697. Jonathan D Wasserman, Nelly Sabbaghian, Somayyeh Fahiminiya, Rose Chami, Ozgur Mete, Meryl Acker, Mona K Wu, Adam Shlien, Leanne de Kock, William D Foulkes. 2018. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. *The Journal of Clinical Endocrinology & Metabolism* **103**:5, 2009-2015. [[Crossref](#)]
698. Nikolai S. Grachev, Elena V. Feoktistova, Igor N. Vorozhtsov, Natalia V. Babaskina, Ekaterina Yu. Iaremenko, Dmitrii I. Shubin. 2018. The Accuracy of ACR TI-RADS Classification of Neck Ultrasound as a First-Line Diagnostic Approach for Thyroid Neoplasms in Pediatric Patients: A Retrospective Study. *Oncopediatrics* **5**:1, 13-23. [[Crossref](#)]
699. Zeyad T. Sahli, Philip W. Smith, Christopher B. Umbricht, Martha A. Zeiger. 2018. Preoperative Molecular Markers in Thyroid Nodules. *Frontiers in Endocrinology* **9**. . [[Crossref](#)]
700. Ji Hye Won, Ji Ye Lee, Hyun Sook Hong, Sun Hye Jeong. 2018. Thyroid nodules and cancer in children and adolescents affected by hashimoto's thyroiditis. *The British Journal of Radiology* **104**, 20180014. [[Crossref](#)]
701. Stephanie L Samuels, Lea F Surrey, Colin P Hawkes, Madeline Amberge, Sogol Mostoufi-Moab, Jill E Langer, N Scott Adzick, Ken Kazahaya, Tricia Bhatti, Zubair Baloch, Virginia A LiVolsi, Andrew J Bauer. 2018. Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort. *The Journal of Clinical Endocrinology & Metabolism* **103**:4, 1639-1648. [[Crossref](#)]
702. Yohana Azhar, Dimiyati Achmad, Kiki Lukman, Dani Hilmanto. 2018. Pediatric Differentiated Thyroid Carcinoma Risk Factor For Analysis For Disease Free Survival. *Indian Journal of Medical and Paediatric Oncology* **39**:02, 153-158. [[Crossref](#)]
703. Fausto Fama, Alessandro Sindoni, Marco Cicciu, Francesca Polito, Arnaud Piquard, Olivier Saint-Marc, Maria Gioffre'-Florio, Salvatore Benvenga. 2018. Preoperatively undiagnosed papillary thyroid carcinoma in patients thyroidectomized for benign multinodular goiter. *Archives of Endocrinology and Metabolism* . [[Crossref](#)]
704. Roberto Solis, Allison Ordemann, Eric E. Berg. 2018. Surgical Management of Thyroid Disease in Children. *Current Otorhinolaryngology Reports* **6**:1, 56-63. [[Crossref](#)]
705. D. Januś, M. Wójcik, G. Drabik, Ł. Wyrobek, J. B. Starzyk. 2018. Ultrasound variants of autoimmune thyroiditis in children and adolescents and their clinical implication in relation to papillary thyroid carcinoma development. *Journal of Endocrinological Investigation* **41**:3, 371-380. [[Crossref](#)]
706. Marloes Nies, Bernadette L Dekker, Esther Sulkers, Gea A Huizinga, Mariëlle S Klein Hesselink, Heleen Maurice-Stam, Martha A Grootenhuis, Adrienne H Brouwers, Johannes G M Burgerhof, Eveline W C M van Dam, Bas Havekes, Marry M van den Heuvel-Eibrink, Eleonora P M Corssmit, Leontien C M Kremer, Romana T Netea-Maier, Heleen J H van der Pal, Robin P Peeters, John T M Plukker, Cécile M Ronckers, Hanneke M van Santen, Anouk N A van der Horst-Schrivers, Wim J E Tissing, Gianni Bocca, Thera P Links. 2018. Psychosocial development in survivors of childhood differentiated thyroid carcinoma: a cross-sectional study. *European Journal of Endocrinology* **40**, 215-223. [[Crossref](#)]
707. Mary C. Frates, Carol B. Benson, David M. Dorfman, Edmund S. Cibas, Stephen A. Huang. 2018. Ectopic Intrathyroidal Thymic Tissue Mimicking Thyroid Nodules in Children. *Journal of Ultrasound in Medicine* **37**:3, 783-791. [[Crossref](#)]
708. Jeon Min Ji, Kim Young Nam, Sung Tae-Yong, Hong Suck Joon, Cho Yoon Young, Kim Tae Yong, Shong Young Kee, Kim Won Bae, Kim Sun Wook, Chung Jae Hoon, Kim Tae Hyuk, Kim Won Gu. 2018. Practical Initial Risk Stratification Based on Lymph Node Metastases in Pediatric and Adolescent Differentiated Thyroid Cancer. *Thyroid* **28**:2, 193-200. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
709. S.C. Clement, L.C.M. Kremer, F.A. Verburg, J.H. Simmons, M. Goldfarb, R.P. Peeters, E.K. Alexander, E. Bardi, E. Brignardello, L.S. Constine, C.A. Dinauer, V.M. Drozd, F. Felicetti, E. Frey, A. Heinzl, M.M. van den Heuvel-Eibrink, S.A. Huang, T.P. Links, K. Lorenz, R.L. Mulder, S.J. Neggers, E.J.M. Nieveen van Dijkum, K.C. Oeffinger, R.R. van Rijn, S.A. Rivkees, C.M. Ronckers, A.B. Schneider, R. Skinner, J.D. Wasserman, T. Wynn, M.M. Hudson, P.C. Nathan, H.M. van Santen. 2018. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer:

- Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *Cancer Treatment Reviews* **63**, 28-39. [[Crossref](#)]
710. Shabana Kalladi Puthanpurayil, Gary L. Francis, Adele O. Kraft, Uma Prasad, Rajanya S. Petersson. 2018. Papillary thyroid carcinoma presenting as acute suppurative thyroiditis: A case report and review of the literature. *International Journal of Pediatric Otorhinolaryngology* **105**, 12-15. [[Crossref](#)]
711. Neha A. Patel, Randall A. Bly, Seth Adams, Kristen Carlin, Sanjay R. Parikh, John P. Dahl, Scott Manning. 2018. A clinical pathway for the postoperative management of hypocalcemia after pediatric thyroidectomy reduces blood draws. *International Journal of Pediatric Otorhinolaryngology* **105**, 132-137. [[Crossref](#)]
712. Linda M. Youngwirth, Mohamed A. Adam, Samantha M. Thomas, Sanziana A. Roman, Julie A. Sosa, Randall P. Scheri. 2018. Pediatric thyroid cancer patients referred to high-volume facilities have improved short-term outcomes. *Surgery* **163**:2, 361-366. [[Crossref](#)]
713. Ian D. Hay, Tammi R. Johnson, Suneetha Kaggal, Megan S. Reinalda, Nicole M. Iniguez-Ariza, Clive S. Grant, Siobhan T. Pittock, Geoffrey B. Thompson. 2018. Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015). *World Journal of Surgery* **42**:2, 329-342. [[Crossref](#)]
714. Mostoufi-Moab Sogol, Labourier Emmanuel, Sullivan Lisa, LiVolsi Virginia, Li Yimei, Xiao Rui, Beaudenon-Huibregtse Sylvie, Kazahaya Ken, Adzick N. Scott, Baloch Zubair, Bauer Andrew J.. 2018. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions. *Thyroid* **28**:1, 60-67. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
715. Yamashita Shunichi, Suzuki Shinichi, Suzuki Satoru, Shimura Hiroki, Saenko Vladimir. 2018. Lessons from Fukushima: Latest Findings of Thyroid Cancer After the Fukushima Nuclear Power Plant Accident. *Thyroid* **28**:1, 11-22. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
716. Siobhan Pittock. Thyroid Nodules in Children 207-231. [[Crossref](#)]
717. Jolanta M. Durski, Trond Velde Bogsrud. Nuclear Medicine in Evaluation and Therapy of Nodular Thyroid 35-62. [[Crossref](#)]
718. Andrew J. Bauer, Steven G. Waguespack, Amelia Grover, Gary L. Francis. Thyroid Neoplasia 439-476. [[Crossref](#)]
719. M. John Hicks. Salivary Gland, Thyroid, and Parathyroid Neoplasms: Molecular Features 203-238. [[Crossref](#)]
720. Steven G. Waguespack, Jonathan D. Wasserman. Pediatric Differentiated Thyroid Carcinoma 273-294. [[Crossref](#)]
721. Heiko Krude, Annette Grüters-Kieslich. Schilddrüsenneoplasien bei Kindern und Jugendlichen 1-5. [[Crossref](#)]
722. Geoffrey K. Blair, Daniel J. Ledbetter. Thyroid Nodules in Children 31-37. [[Crossref](#)]
723. Daniel J. Ledbetter. Thyroid Cancer in Children 39-50. [[Crossref](#)]
724. Claudia Martinez-Rios, Alan Daneman, Lydia Bajno, Danielle C. M. van der Kaay, Rahim Moineddin, Jonathan D. Wasserman. 2018. Utility of adult-based ultrasound malignancy risk stratifications in pediatric thyroid nodules. *Pediatric Radiology* **48**:1, 74-84. [[Crossref](#)]
725. Barbara Jarzab, Jolanta Krajewska. Radioactive Iodine 688-692. [[Crossref](#)]
726. Barbara Jarzab, Daria Handkiewicz-Junak, Jolanta Krajewska. Thyroid and Irradiation 539-544. [[Crossref](#)]
727. Lourdes Quintanilla-Dieck, Maisie Shindo. Evidence-Based Practice 175-184. [[Crossref](#)]
728. . Follicular Adenoma 460-465. [[Crossref](#)]
729. . Follicular Thyroid Carcinoma 478-485. [[Crossref](#)]
730. Gustavo Triana, Sergio Valencia, Anibal J. Morillo. 2018. Pediatric American Thyroid Association Guidelines Are Not Completely Applicable to Pediatric Nodule Evaluation. *Radiology* **289**:3, 881. [[Crossref](#)]
731. Bernadette L. Dekker, Kate L. Newbold, Dagmar Führer, Steven G. Waguespack, Daria Handkiewicz-Junak, Thera P. Links. 2018. Survey on Paediatric Differentiated Thyroid Cancer Care in Europe. *Hormone Research in Paediatrics* **89**:1, 58-62. [[Crossref](#)]
732. I. Erdem Toslak, B. Martin, G.A. Barkan, A.I. Kılıç, J.E. Lim-Dunham. 2018. Patterns of Sonographically Detectable Echogenic Foci in Pediatric Thyroid Carcinoma with Corresponding Histopathology: An Observational Study. *American Journal of Neuroradiology* **39**:1, 156-161. [[Crossref](#)]
733. Ravishankar Palaniappan, Arvind Krishnamurthy, SSwaminathan Rajaraman, RKrishna Kumar. 2018. Management outcomes of pediatric and adolescent papillary thyroid cancers with a brief review of literature. *Indian Journal of Cancer* **55**:1, 105. [[Crossref](#)]
734. Kwangsoon Kim, Won Woong Kim, Jung Bum Choi, Min Jhi Kim, Cho Rok Lee, Jandee Lee, Sang-Wook Kang, Kee-Hyun Nam, Woong Youn Chung, Jong Ju Jeong. 2018. Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma. *Annals of Surgical Treatment and Research* **95**:4, 222. [[Crossref](#)]

735. Esther Diana Rossi, Swati Mehrotra, Ayse Irem Kilic, Iclal Erdem Toslak, Jennifer Lim-Dunham, Maurizio Martini, Guido Fadda, Celestino Pio Lombardi, Luigi Maria Larocca, Güliz A. Barkan. 2018. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group. *Cancer Cytopathology* **126**:1, 27-35. [[Crossref](#)]
736. Ana Creo, Fares Alahdab, Alaa Al Nofal, Kristen Thomas, Amy Kolbe, Siobhan T. Pittock. 2018. Ultrasonography and the American Thyroid Association Ultrasound-Based Risk Stratification Tool: Utility in Pediatric and Adolescent Thyroid Nodules. *Hormone Research in Paediatrics* **90**:2, 93-101. [[Crossref](#)]
737. Klein Hesselink Mariëlle S., Bocca Gianni, Hummel Yoran M., Brouwers Adrienne H., Burgerhof Johannes G.M., van Dam Eveline W.C.M., Gietema Jourik A., Havekes Bas, van den Heuvel-Eibrink Marry M., Corssmit Eleonora P.M., Kremer Leontien C.M., Netea-Maier Romana T., van der Pal Helena J.H., Peeters Robin P., Plukker John T.M., Ronckers Cécile M., van Santen Hanneke M., van der Meer Peter, Links Thera P., Tissing Wim J.E.. 2017. Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. *Thyroid* **27**:12, 1481-1489. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
738. K. Busiah, É. Giabicani. 2017. Hipotiroidismo e hipertiroidismo infantil. *EMC - Tratado de Medicina* **21**:4, 1-9. [[Crossref](#)]
739. Hideto Takahashi, Kunihiko Takahashi, Hiroki Shimura, Seiji Yasumura, Satoru Suzuki, Akira Ohtsuru, Sanae Midorikawa, Tetsuya Ohira, Hitoshi Ohto, Shunichi Yamashita, Kenji Kamiya. 2017. Simulation of expected childhood and adolescent thyroid cancer cases in Japan using a cancer-progression model based on the National Cancer Registry. *Medicine* **96**:48, e8631. [[Crossref](#)]
740. Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada. 2017. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report. *BMC Cancer* **17**:1. . [[Crossref](#)]
741. Animesh Sharma. 2017. Marine-Lenhart syndrome in two adolescents, including one with thyroid cancer: a case series and review of the literature. *Journal of Pediatric Endocrinology and Metabolism* **30**:12. . [[Crossref](#)]
742. Dorothée Bouron-Dal Soglio, Leanne de Kock, Richard Gauci, Nelly Sabbaghian, Elizabeth Thomas, Helen C. Atkinson, Nicholas Pachter, Simon Ryan, John P. Walsh, M. Priyanthi Kumarasinghe, Karen Carpenter, Ayça Aydoğan, Colin J.R. Stewart, William D. Foulkes, Catherine S. Choong. 2017. A Case Report of Syndromic Multinodular Goitre in Adolescence: Exploring the Phenotype Overlap between Cowden and DICER1 Syndromes. *European Thyroid Journal* . [[Crossref](#)]
743. S. Zerdoud, S. Leboulleux, J. Clerc, L. Leenhardt, C. Bournaud, A. Al Ghuzlan, I. Keller, S. Bardet, A.-L. Giraudet, L. Groussin, F. Sebag, R. Garrel, P.-J. Lamy, M.-E. Toubert, É. Mirallié, E. Hindié, D. Taïeb. 2017. Traitement par iode 131 des cancers thyroïdiens différenciés : recommandations 2017 des sociétés françaises SFMN/SFE/SFP/SFBC/AFCE/SFORL. *Médecine Nucléaire* **41**, S1-S22. [[Crossref](#)]
744. Domenico Albano, Francesco Bertagna, Maria Beatrice Panarotto, Raffaele Giubbini. 2017. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. *Pediatric Blood & Cancer* **64**:11. . [[Crossref](#)]
745. Jiadong Chi, Xiangqian Zheng, Ming Gao, Jingzhu Zhao, Dapeng Li, Jiansen Li, Li Dong, Xianhui Ruan. 2017. Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors. *Oncology Letters* . [[Crossref](#)]
746. Seo Young Sohn, Young Nam Kim, Hye In Kim, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung. 2017. Validation of dynamic risk stratification in pediatric differentiated thyroid cancer. *Endocrine* **58**:1, 167-175. [[Crossref](#)]
747. Nii Koney, Soran Mahmood, Anthony Gannon, Mark S. Finkelstein, Tejal Mody. 2017. Pediatric Thyroid Cancer: Imaging and Therapy Update. *Current Radiology Reports* **5**:10. . [[Crossref](#)]
748. Sandip Basu, Ashwini Kalshetty. 2017. Volumetric high-resolution computed tomography in evaluating pulmonary metastases from differentiated thyroid carcinoma. *Nuclear Medicine Communications* **38**:10, 881-882. [[Crossref](#)]
749. Alex C. Essenmacher, Peter H. Joyce, Simon C. Kao, Monica Epelman, Liuska M. Pesce, Michael P. D'Alessandro, Yutaka Sato, Craig M. Johnson, Daniel J. Podberesky. 2017. Sonographic Evaluation of Pediatric Thyroid Nodules. *RadioGraphics* **37**:6, 1731-1752. [[Crossref](#)]
750. Hyun Sook Hong, Ji Ye Lee, Sun Hye Jeong. 2017. Thyroid disease in children and adolescents. *Ultrasonography* **36**:4, 287-291. [[Crossref](#)]
751. Michael Canfarotta, Douglas Moote, Christine Finck, Rebecca Riba-Wolman, Shefali Thaker, Trudy J. Lerer, Richard J. Payne, Valerie Cote. 2017. McGill Thyroid Nodule Score in Differentiating Benign and Malignant Pediatric Thyroid Nodules: A Pilot Study. *Otolaryngology-Head and Neck Surgery* **157**:4, 589-595. [[Crossref](#)]
752. Marlene Rodrigues, Helena Ferreira, Ana Antunes, Olinda Marques. 2017. Toxic multinodular goitre: a surprising finding. *BMJ Case Reports* **22**, bcr-2017-221913. [[Crossref](#)]
753. Agathoklis Konstantinidis, Elizabeth Tracy, Julie Ann Sosa, Sanziana A. Roman. 2017. Risk prediction in children and adults less than 45 years old with papillary thyroid cancer. *Expert Review of Endocrinology & Metabolism* **12**:5, 355-365. [[Crossref](#)]

754. Katherine J. Baxter, Heather L. Short, Mitali A. Thakore, Jeremy G. Fisher, David H. Rothstein, Kurt F. Heiss, Mehul V. Raval. 2017. Cost comparison of initial lobectomy versus fine-needle aspiration for diagnostic workup of thyroid nodules in children. *Journal of Pediatric Surgery* **52**:9, 1471-1474. [[Crossref](#)]
755. Ari J Wassner, Margaret Della Vecchia, Petr Jarolim, Henry A Feldman, Stephen A Huang. 2017. Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer. *The Journal of Clinical Endocrinology & Metabolism* **102**:9, 3146-3153. [[Crossref](#)]
756. Yuan Qu, Rui Huang, Lin Li. 2017. Clinical analysis of the factors that influence disease progression of differentiated thyroid carcinoma in children. *Journal of Paediatrics and Child Health* **53**:9, 903-907. [[Crossref](#)]
757. Hakan Taşkınlar, Gökhan Berktuğ Bahadır, İsa Killı, Doğan Yigit, Rabia Bozdoğan Arpacı, Yusuf Vayisoğlu, Elvan Çağlar Çıtak, Ali Naycı. 2017. Çocukluk çağı tiroid nodüllerine yaklaşım. *Mersin Üniversitesi Sağlık Bilimleri Dergisi* 125-131. [[Crossref](#)]
758. Pole Jason D., Zuk Aleksandra M., Wasserman Jonathan D.. 2017. Diagnostic and Treatment Patterns Among Children, Adolescents, and Young Adults with Thyroid Cancer in Ontario: 1992–2010. *Thyroid* **27**:8, 1025-1033. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
759. Christine M. Chan, Jonathan Young, Jeremy Prager, Sharon Travers. 2017. Pediatric Thyroid Cancer. *Advances in Pediatrics* **64**:1, 171-190. [[Crossref](#)]
760. Esther Diana Rossi, Maurizio Martini, Tonia Cenci, Sara Capodimonti, Luigi Maria Larocca. 2017. The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature. *Cancer Cytopathology* **125**:8, 594-603. [[Crossref](#)]
761. Bin Ye, Jun Shi, Chenling Shen, Longhao Wang, Haixia Hu, Yan Ma, Quan Wang, Jingrong Lu, Guangjun Yu, Mingliang Xiang. 2017. Comparison of differentiated thyroid carcinoma recurrence and its clinical features in children of different ages. *Oncotarget* **8**:29. . [[Crossref](#)]
762. Derya Cayir, Mine Araz. Radioiodine Therapy of Malignant Thyroid Diseases . [[Crossref](#)]
763. Jiangqiao Geng, Huanmin Wang, Yuanhu Liu, Jun Tai, Yaqiong Jin, Jie Zhang, Lejian He, Libing Fu, Hong Qin, Yingluan Song, Jinzhu Su, Aiyang Zhang, Xin Wen, Yongli Guo, Xin Ni. 2017. Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. *Science China Life Sciences* **60**:7, 729-738. [[Crossref](#)]
764. Slimane Zerdoud, Anne-Laure Giraudet, Sophie Leboulleux, Laurence Leenhardt, Stéphane Bardet, Jérôme Clerc, Marie-Elisabeth Toubert, Abir Al Ghuzlan, Pierre-Jean Lamy, Claire Bournaud, Isabelle Keller, Frédéric Sebag, Renaud Garrel, Eric Mirallié, Lionel Groussin, Elif Hindié, David Täieb. 2017. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. *Annales d'Endocrinologie* **78**:3, 162-175. [[Crossref](#)]
765. Paul D. Judge, Joseph Menousek, Jordan C. Schramm, Robert Cusick, William Lydiatt. 2017. Does Surgical Volume Influence the Need for Second Surgery? A Pilot Study. *OTO Open* **1**:3. . [[Crossref](#)]
766. Kris Ann P. Schultz, Surya P. Rednam, Junne Kamihara, Leslie Doros, Maria Isabel Achatz, Jonathan D. Wasserman, Lisa R. Diller, Laurence Brugières, Harriet Druker, Katherine A. Schneider, Rose B. McGee, William D. Foulkes. 2017. PTEN, DICER1, FH , and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clinical Cancer Research* **23**:12, e76-e82. [[Crossref](#)]
767. Sevinç Odabaşı Güneş, Ayça Törel Ergür. 2017. Çocukluk çağı tiroid nodüllerine yaklaşım. *TURKISH JOURNAL of CLINICS and LABORATORY* 70-70. [[Crossref](#)]
768. Zanella André, Scheffel Rafael Selbach, Pasa Marina Weber, Dora José Miguel, Maia Ana Luiza. 2017. Role of Postoperative Stimulated Thyroglobulin as Prognostic Factor for Differentiated Thyroid Cancer in Children and Adolescents. *Thyroid* **27**:6, 787-792. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
769. Emily S. Tonorezos, Dana Barnea, Chaya S. Moskowitz, Joanne F. Chou, Charles A. Sklar, Elena B. Elkin, Richard J. Wong, Duan Li, R. Michael Tuttle, Deborah Korenstein, Suzanne L. Wolden, Kevin C. Oeffinger. 2017. Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. *Journal of Cancer Survivorship* **11**:3, 302-308. [[Crossref](#)]
770. Frederik A. Verburg, Heribert Hänscheid, Markus Luster. 2017. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. *Best Practice & Research Clinical Endocrinology & Metabolism* **31**:3, 279-290. [[Crossref](#)]
771. Andrew J. Bauer. 2017. Molecular Genetics of Thyroid Cancer in Children and Adolescents. *Endocrinology and Metabolism Clinics of North America* **46**:2, 389-403. [[Crossref](#)]
772. Sameer Alvi, Omar Karadaghy, Michelle Manalang, Robert Weatherly. 2017. Clinical manifestations of neuroblastoma with head and neck involvement in children. *International Journal of Pediatric Otorhinolaryngology* **97**, 157-162. [[Crossref](#)]

773. William J. Hammond, Todd E. Heaton, Benjamin A. Farber, Usman A. Mahmood, Jill S. Gluskin, Suzanne L. Wolden, Michael P. La Quaglia, Charles A. Sklar, Anita P. Price. 2017. Thyroid neoplasms: incidental findings on extent of disease evaluation CT for other pediatric malignancies. *Journal of Pediatric Surgery* **52**:6, 938-943. [[Crossref](#)]
774. Daniela Victoria Pirela Araque, Archie Bleyer, Juan P Brito. 2017. Thyroid cancer in adolescents and young adults. *Future Oncology* **13**:14, 1253-1261. [[Crossref](#)]
775. Benedikt Schmidbauer, Karin Menhart, Dirk Hellwig, Jirka Grosse. 2017. Differentiated Thyroid Cancer—Treatment: State of the Art. *International Journal of Molecular Sciences* **18**:6, 1292. [[Crossref](#)]
776. Steven Hardee, Manju L Prasad, Pei Hui, Catherine A Dinauer, Raffaella A Morotti. 2017. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAF V600E Mutation in Pediatric Papillary Thyroid Carcinoma. *Pediatric and Developmental Pathology* **20**:3, 206-212. [[Crossref](#)]
777. Nicholas E. Khan, Andrew J. Bauer, Kris Ann P. Schultz, Leslie Doros, Rosamma M. Decastro, Alexander Ling, Maya B. Lodish, Laura A. Harney, Ron G. Kase, Ann G. Carr, Christopher T. Rossi, Amanda Field, Anne K. Harris, Gretchen M. Williams, Louis P. Dehner, Yoav H. Messinger, D. Ashley Hill, Douglas R. Stewart. 2017. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study. *The Journal of Clinical Endocrinology & Metabolism* **102**:5, 1614-1622. [[Crossref](#)]
778. Xiao-chun Mao, Wen-qiao Yu, Jin-biao Shang, Ke-jing Wang. 2017. Clinical characteristics and treatment of thyroid cancer in children and adolescents: a retrospective analysis of 83 patients. *Journal of Zhejiang University-SCIENCE B* **18**:5, 430-436. [[Crossref](#)]
779. Wassim Chemaitilly, Laurie E Cohen. 2017. DIAGNOSIS OF ENDOCRINE DISEASE: Endocrine late-effects of childhood cancer and its treatments. *European Journal of Endocrinology* **176**:4, R183-R203. [[Crossref](#)]
780. Wouter P. Kluijfhout, Jesse D. Pasternak, Danielle van der Kaay, Menno R. Vriens, Evan J. Propst, Jonathan D. Wasserman. 2017. Is it time to reconsider lobectomy in low-risk paediatric thyroid cancer?. *Clinical Endocrinology* **86**:4, 591-596. [[Crossref](#)]
781. Prasanthi Pasala, Gary L. Francis. 2017. Autoimmune thyroid diseases in children. *Expert Review of Endocrinology & Metabolism* **12**:2, 129-142. [[Crossref](#)]
782. Markus Luster, Andreas Pfestroff, Heribert Hänscheid, Frederik A. Verburg. 2017. Radioiodine Therapy. *Seminars in Nuclear Medicine* **47**:2, 126-134. [[Crossref](#)]
783. Pierre Vanden Borre, Alexa B. Schrock, Peter M. Anderson, John C. Morris, Andreas M. Heilmann, Oliver Holmes, Kai Wang, Adrienne Johnson, Steven G. Waguespack, Sai-Hong Ignatius Ou, Saad Khan, Kar-Ming Fung, Philip J. Stephens, Rachel L. Erlich, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali. 2017. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. *The Oncologist* **22**:3, 255-263. [[Crossref](#)]
784. Alzahrani Ali S., Murugan Avaniyapuram Kannan, Qasem Ebtesam, Alswailem Meshael, Al-Hindi Hindi, Shi Yufei. 2017. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. *Thyroid* **27**:2, 189-196. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
785. Cordioli Maria Isabel C. Vieira, Moraes Lais, Bastos André U., Besson Paloma, Alves Maria Teresa de Seixas, Delcelo Rosana, Monte Osmar, Longui Carlos, Cury Adriano Namo, Cerutti Janete M.. 2017. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children. *Thyroid* **27**:2, 182-188. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
786. Mohamed Abdelgadir Adam, Samantha Thomas, Linda Youngwirth, Terry Hyslop, Shelby D. Reed, Randall P. Scheri, Sanziana A. Roman, Julie A. Sosa. 2017. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?. *Annals of Surgery* **265**:2, 402-407. [[Crossref](#)]
787. Curtis Hanba, Peter F. Svider, Bianca Siegel, Anthony Sheyn, Mahdi Shkoukani, Ho-Sheng Lin, S. Naweed Raza. 2017. Pediatric Thyroidectomy: Hospital Course and Perioperative Complications. *Otolaryngology-Head and Neck Surgery* **156**:2, 360-367. [[Crossref](#)]
788. E. D. Rossi, T. Bizzarro, M. Martini, S. Capodimonti, T. Cenci, G. Fadda, F. Schmitt, L. M. Larocca. 2017. Morphological features that can predict BRAF V600E -mutated carcinoma in paediatric thyroid cytology. *Cytopathology* **28**:1, 55-64. [[Crossref](#)]
789. Emilio García-García, Mercedes López-González, Rosa Cabello-Laureano, Elena Navarro-González. 2017. Multinodular goiter in children: treatment controversies. *Journal of Pediatric Endocrinology and Metabolism* **30**:8. . [[Crossref](#)]
790. Jennifer E. Lim-Dunham, Iclal Erdem Toslak, Khalid Alsabban, Amany Aziz, Brendan Martin, Gokcan Okur, Katherine C. Longo. 2017. Ultrasound risk stratification for malignancy using the 2015 American Thyroid Association Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. *Pediatric Radiology* **86**. . [[Crossref](#)]
791. Courtney Olmsted, Rajalakshmi Arunachalam, Xiang Gao, Liuska Pesce, Geeta Lal. 2017. Pediatric differentiated thyroid carcinoma: trends in practice and outcomes over 40 years at a single tertiary care institution. *Journal of Pediatric Endocrinology and Metabolism* **30**:10. . [[Crossref](#)]

792. Janeil M. Belle, Nektarios Vasilottos, Todd D. Nebesio, Benjamin C. James. 2017. Pediatric toxic polycystic thyroid. *Journal of Pediatric Endocrinology and Metabolism* **30**:7. . [\[Crossref\]](#)
793. Snehal G. Patel, Linwah Yip. Surgical Intervention for Indeterminate Thyroid Nodules 147-162. [\[Crossref\]](#)
794. Scott A. Rivkees, Catherine A. Dinauer. The Pediatric Thyroid Nodule and Papillary Thyroid Cancer Management 199-216. [\[Crossref\]](#)
795. Melanie Goldfarb, Trevan Fischer. Pediatric Thyroid Cancer 125-133. [\[Crossref\]](#)
796. Doina Piciu, Patriciu Achimaş-Cadariu, Alexandru Irimie, Andra Piciu. The Thyroid Gland 61-177. [\[Crossref\]](#)
797. Christoph Reiners, Johannes Biko, Yuri E. Demidchik, Valentina M. Drozd. Results of Treatment in Children and Adolescents With Differentiated Thyroid Carcinoma Not Exposed and Exposed to Radiation From the Chernobyl Accident 109-119. [\[Crossref\]](#)
798. Gerry Thomas. Somatic Genomics of Childhood Thyroid Cancer 121-132. [\[Crossref\]](#)
799. Richard Nicollas, Éric Moreddu. Masses cervicales 271-280. [\[Crossref\]](#)
800. Jina Kim, Zhifei Sun, Mohamed A. Adam, Obinna O. Adibe, Henry E. Rice, Sanziana A. Roman, Elisabeth T. Tracy. 2017. Predictors of nodal metastasis in pediatric differentiated thyroid cancer. *Journal of Pediatric Surgery* **52**:1, 120-123. [\[Crossref\]](#)
801. Alexander L. Shifrin, Michele Fischer, Trevor Paul, Brian Erler, Katherine Gheysens, Prachi Baodhankar, Joanna W. Song-Yang, Samantha Taylor, Venkata Arun Timmaraju, Arthur Topilow, Alidad Mireskandari, Gyanendra Kumar. 2017. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients. *Surgery* **161**:1, 176-187. [\[Crossref\]](#)
802. Elna Kochummen, Schuyler Tong, Vatcharapan Umpaichitra, Vivian L. Chin. 2017. A Unique Case of Bilateral Hürthle Cell Adenoma in an Adolescent. *Hormone Research in Paediatrics* **87**:2, 136-142. [\[Crossref\]](#)
803. Hyo-Jun Kim, Ji-Won Han, Joong Kee Youn, Hee-Beom Yang, Chaeyoun Oh, Hyun-Young Kim, Sung-Eun Jung, Kwi-Won Park. 2017. Thyroid Cancer in Pediatric Age: A Single Institution Experience. *Journal of the Korean Association of Pediatric Surgeons* **23**:2, 42. [\[Crossref\]](#)
804. Markus Luster, Andreas Pfestroff, Frederik A. Verburg. 2017. Recent advances in nuclear medicine in endocrine oncology. *Current Opinion in Oncology* **29**:1, 1-6. [\[Crossref\]](#)
805. Avaniyapuram Kannan Murugan, Ebtesam Qasem, Hindi Al-Hindi, Yufei Shi, Ali S. Alzahrani. 2016. Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. *Journal of Translational Medicine* **14**:1. . [\[Crossref\]](#)
806. Wen Jiang, Robert O. Newbury, Ron S. Newfield. 2016. Pediatric thyroid surgery and management of thyroid nodules – an institutional experience over a 10-year period. *International Journal of Pediatric Endocrinology* **2016**:1. . [\[Crossref\]](#)
807. María José Orellana, Angelo Fulle, Diego Carrillo, Lucía Escobar, Alicia Ebersperger, Raúl Martínez, Hana Rumié Carmi. 2016. Carcinoma papilar de tiroides en un niño con hipotiroidismo congénito dishormonogénico. Reporte de un caso. *Revista Chilena de Pediatría* **87**:6, 504-509. [\[Crossref\]](#)
808. Masha J. Livhits, Jesse D. Pasternak, Maggie Xiong, Ning Li, Jessica E. Gosnell, Michael W. Yeh, Harvey K. Chiu. 2016. Pre-Ablation Thyroglobulin and Thyroglobulin to Thyroid-Stimulating Hormone Ratio may be Associated with Pulmonary Metastases in Children with Differentiated Thyroid Cancer. *Endocrine Practice* **22**:11, 1259-1266. [\[Crossref\]](#)
809. Elmira Amirazodi, Evan J. Propst, Catherine T. Chung, Dimitri A. Parra, Jonathan D. Wasserman. 2016. Pediatric thyroid FNA biopsy: Outcomes and impact on management over 24 years at a tertiary care center. *Cancer Cytopathology* **124**:11, 801-810. [\[Crossref\]](#)
810. Sherif Said. Disorders of the Thyroid Gland and Parathyroid Glands 471-504. [\[Crossref\]](#)
811. Pires Barbara Pereira, Alves Paulo Alonso Garcia Jr., Bordallo Maria Alice, Bulzico Daniel Alves, Lopes Flavia Paiva Proença Lobo, Farias Terence, Dias Fernando, Lima Roberto Araújo, Santos Gisler Izabella Costa, Coeli Claudia Medina, Carvalhaes de Oliveira Raquel Vasconcellos, Corbo Rossana, Vaisman Mario, Vaisman Fernanda. 2016. Prognostic Factors for Early and Long-Term Remission in Pediatric Differentiated Thyroid Carcinoma: The Role of Sex, Age, Clinical Presentation, and the Newly Proposed American Thyroid Association Risk Stratification System. *Thyroid* **26**:10, 1480-1487. [\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#) [\[PDF Plus\]](#)
812. Mohamed Mostafa, Reza Vali, Jeffrey Chan, Yusuf Omar Khalil, Amer Shammam. 2016. Variants and pitfalls on radioiodine scans in pediatric patients with differentiated thyroid carcinoma. *Pediatric Radiology* **46**:11, 1579-1589. [\[Crossref\]](#)
813. Takahiro Fukuhara, Masayuki Miyoshi, Taihei Fujii, Naritomo Miyake, Kenkichi Taira, Satoshi Koyama, Daizo Taguchi, Kazunori Fujiwara, Hideyuki Kataoka, Hiroya Kitano, Hiromi Takeuchi. 2016. Post-laryngectomy voice rehabilitation with a voice prosthesis in a young girl with advanced thyroid cancer. *Auris Nasus Larynx* **43**:5, 579-583. [\[Crossref\]](#)
814. Sarah Dermody, Andrew Walls, Earl H. Harley. 2016. Pediatric thyroid cancer: An update from the SEER database 2007-2012. *International Journal of Pediatric Otorhinolaryngology* **89**, 121-126. [\[Crossref\]](#)

815. Kristina J. Nicholson, Kelly L. McCoy, Selma F. Witchel, Michael T. Stang, Sally E. Carty, Linwah Yip. 2016. Comparative characteristics of primary hyperparathyroidism in pediatric and young adult patients. *Surgery* **160**:4, 1008-1016. [[Crossref](#)]
816. Pedro W. Rosario, Gabriela F. Mourão, Maria R. Calsolari. 2016. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin. *Nuclear Medicine Communications* **37**:10, 1024-1029. [[Crossref](#)]
817. Samantha Ly, Mary C. Frates, Carol B. Benson, Hope E. Peters, Frederick D. Grant, Laura A. Drubach, Stephan D. Voss, Henry A. Feldman, Jessica R. Smith, Justine Barletta, Monica Hollowell, Edmund S. Cibas, Francis D. Moore, Biren Modi, Robert C. Shamberger, Stephen A. Huang. 2016. Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. *The Journal of Clinical Endocrinology & Metabolism* **101**:10, 3856-3862. [[Crossref](#)]
818. Pedro Wesley Rosario, Gabriela Franco Mourão, Maria Regina Calsolari. 2016. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?. *Clinical Endocrinology* **85**:4, 596-601. [[Crossref](#)]
819. Malandrino Pasqualino, Russo Marco, Regalbuto Concetto, Pellegriti Gabriella, Moleti Mariacarla, Caff Andrea, Squatrito Sebastiano, Vigneri Riccardo. 2016. Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. *Thyroid* **26**:9, 1285-1292. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
820. Kyung Hee Kim, Seung Hoon Woo. 2016. An Occupational Study in Nurses: Prevalence of Thyroid Nodules and Cancer in Comparison to Health Check-up Female. *Clinical and Experimental Otorhinolaryngology* **9**:3, 252-256. [[Crossref](#)]
821. Michael Canfarotta, Rebecca Riba-Wolman, Andrea D. Orsey, Fabiola Balarezo, Christine Finck. 2016. DICER1 syndrome and thyroid disease. *Journal of Pediatric Surgery Case Reports* **11**, 31-34. [[Crossref](#)]
822. Jason Trahan, Abhita Reddy, Ellen Chang, Ricardo Gomez, Pinki Prasad, Anita Jeyakumar. 2016. Pediatric thyroid nodules: A single center experience. *International Journal of Pediatric Otorhinolaryngology* **87**, 94-97. [[Crossref](#)]
823. Andreas Machens, Malik Elwerr, Phuong Nguyen Thanh, Kerstin Lorenz, Rick Schneider, Henning Dralle. 2016. Impact of central node dissection on postoperative morbidity in pediatric patients with suspected or proven thyroid cancer. *Surgery* **160**:2, 484-492. [[Crossref](#)]
824. Andrew J. Bauer, Gary L. Francis. 2016. Evaluation and management of thyroid nodules in children. *Current Opinion in Pediatrics* **28**:4, 536-544. [[Crossref](#)]
825. Kathryn E Coan, Tracy S Wang. 2016. Initial Surgical Management of Medullary Thyroid Cancer. *International Journal of Endocrine Oncology* **3**:3, 259-266. [[Crossref](#)]
826. Kristen L. Partyka, Eric C. Huang, Harvey M. Cramer, Shaoxiong Chen, Howard H. Wu. 2016. Histologic and clinical follow-up of thyroid fine-needle aspirates in pediatric patients. *Cancer Cytopathology* **124**:7, 467-471. [[Crossref](#)]
827. Maria Isabel C. V. Cordioli, Lais Moraes, Gianna Carvalheira, Luiza Sisdelli, Maria Teresa S. Alves, Rosana Delcelo, Osmar Monte, Carlos A. Longui, Adriano N. Cury, Janete M. Cerutti. 2016. AGK - BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma. *Cancer Medicine* **5**:7, 1535-1541. [[Crossref](#)]
828. Semen Onder, Sule Ozturk Sari, Gulcin Yegen, Ismail Cem Sormaz, Ismail Yilmaz, Sukran Poyrazoglu, Yasemin Sanli, Yasemin Giles Senyurek, Yersu Kapran, Ozgur Mete. 2016. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF V600E Harboring Pediatric Papillary Thyroid Carcinomas. *Endocrine Pathology* **27**:2, 153-161. [[Crossref](#)]
829. Josef Machac. 2016. Thyroid Cancer in Pediatrics. *Endocrinology and Metabolism Clinics of North America* **45**:2, 359-404. [[Crossref](#)]
830. Susan R. Rose, Vincent E. Horne, Jonathan Howell, Sarah A. Lawson, Meilan M. Rutter, Gylynthia E. Trotman, Sarah D. Corathers. 2016. Late endocrine effects of childhood cancer. *Nature Reviews Endocrinology* **12**:6, 319-336. [[Crossref](#)]
831. Alanna M Windsor, Eleanor P Kiell, Eric E Berg, Ken Kazahaya. 2016. Surgery of the Thyroid in Children: Current Trends in Practice. *International Journal of Head and Neck Surgery* **7**:2, 57-63. [[Crossref](#)]
832. A L Mitchell, A Gandhi, D Scott-Coombes, P Perros. 2016. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. *The Journal of Laryngology & Otolaryngology* **130**:S2, S150-S160. [[Crossref](#)]
833. Phillip Huyett, Sara E. Monaco, Sukgi S. Choi, Jeffrey P. Simons. 2016. Utility of Fine-Needle Aspiration Biopsy in the Evaluation of Pediatric Head and Neck Masses. *Otolaryngology-Head and Neck Surgery* **154**:5, 928-935. [[Crossref](#)]
834. Anita K Ying, Thomas W Feeley, Michael E Porter. 2016. Value-Based Healthcare: Implications for Thyroid Cancer. *International Journal of Endocrine Oncology* **3**:2, 115-129. [[Crossref](#)]
835. Juan José Díez, Juan Carlos Galofré, Amelia Oleaga, Enrique Grande, Mercedes Mitjavila, Pablo Moreno. 2016. Declaración de consenso para la acreditación de unidades multidisciplinares en cáncer de tiroides. *Endocrinología y Nutrición* **63**:3, e1-e15. [[Crossref](#)]

836. Marguerite T. Parisi, Hedieh Eslamy, David Mankoff. 2016. Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines. *Seminars in Nuclear Medicine* 46:2, 147-164. [[Crossref](#)]
837. Sun Hye Jeong, Hyun Sook Hong, Eun Hye Lee, Jeong Ja Kwak. 2016. The Diffuse Sclerosing Variant of Papillary Thyroid Cancer Presenting as Innumerable Diffuse Microcalcifications in Underlying Adolescent Hashimoto's Thyroiditis. *Medicine* 95:12, e3141. [[Crossref](#)]
838. Juanita K. Hodax, Steven E. Reinert, Jose Bernardo Quintos. 2016. Autonomously Functioning Thyroid Nodules In Patients <21 Years Of Age: The Rhode Island Hospital Experience From 2003Â€“2013. *Endocrine Practice* 22:3, 328-337. [[Crossref](#)]
839. Jennifer L. Picarsic, Melissa A. Buryk, John Ozolek, Sarangarajan Ranganathan, Sara E. Monaco, Jeffrey P. Simons, Selma F. Witchel, Nursen Gurtunca, Judith Joyce, Shan Zhong, Marina N. Nikiforova, Yuri E. Nikiforov. 2016. Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. *Pediatric and Developmental Pathology* 19:2, 115-122. [[Crossref](#)]
840. Nikita Maria Eleni, Jiang Wen, Cheng Shih-Min, Hantash Feras M., McPhaul Michael J., Newbury Robert O., Phillips Susan A., Reitz Richard E., Waldman Frederic M., Newfield Ron S.. 2016. Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. *Thyroid* 26:2, 227-234. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
841. Alzahrani Ali S., Qasem Ebtesam, Murugan Avaniyapuram Kannan, Al-Hindi Hindi N., AlKhafaji Dania, Almohanna Mai, Xing Mingzhao, Alhomaidah Doha, AlSwailem Meshael. 2016. Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer. *Thyroid* 26:2, 235-241. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
842. Karolis Ulinckas, Edita Mišeikytė-Kaubrienė, Giedrė Smailytė. 2016. SKYDLIAUKĖS VĖŽYS LIETUVOJE: IŠGYVENAMUMO POKYČIAI IR JIEMS ĮTAKOS TURINTYS VEIKSNIAI. *Medicinos teorija ir praktika* 22:1, 39-45. [[Crossref](#)]
843. Haugen Bryan R., Alexander Erik K., Bible Keith C., Doherty Gerard M., Mandel Susan J., Nikiforov Yuri E., Pacini Furio, Randolph Gregory W., Sawka Anna M., Schlumberger Martin, Schuff Kathryn G., Sherman Steven I., Sosa Julie Ann, Steward David L., Tuttle R. Michael, Wartofsky Leonard. 2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 26:1, 1-133. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
844. Andrew J. Bauer. Thyroid Nodules in Children and Cancer Risk 335-346. [[Crossref](#)]
845. Andrew J. Bauer, Sogol Mostoufi-Moab. Papillary Cancer: Special Aspects in Children 551-563. [[Crossref](#)]
846. Jacqueline Jonklaas. Importance of Thyroid Hormone Replacement Therapy in Patients with Medullary Thyroid Cancer 137-149. [[Crossref](#)]
847. Elisabeth T. Tracy, Sanziana A. Roman. 2016. Current management of pediatric thyroid disease and differentiated thyroid cancer. *Current Opinion in Oncology* 28:1, 37-42. [[Crossref](#)]
848. Caitlin Agrawal, Lory Guthrie, Mollie S. Sturm, Joseph Stanek, Laura Martin, Maria Henwood-Finley, Jennifer H. Aldrink, Randal Olshefski, Sarah H. O'Brien. 2016. Comparison of Thyroid Nodule Prevalence by Ultrasound in Childhood Cancer Survivors With and Without Thyroid Radiation Exposure. *Journal of Pediatric Hematology/Oncology* 38:1, 43-48. [[Crossref](#)]
849. Maria Isabel Cunha Vieira Cordioli, Lais Moraes, Maria Teresa de Seixas Alves, Rosana Delcelo, Osmar Monte, Carlos Alberto Longui, Adriano Namó Cury, Janete Maria Cerutti. 2016. Thyroid-Specific Genes Expression Uncovered Age-Related Differences in Pediatric Thyroid Carcinomas. *International Journal of Endocrinology* 2016, 1-9. [[Crossref](#)]
850. Sun Hye Jeong, Hyun Sook Hong, Eun Hye Lee, Jeong Ja Kwak. 2016. Papillary Thyroid Carcinoma Arising in Children and Adolescent Hashimoto's Thyroiditis: Ultrasonographic and Pathologic Findings. *International Journal of Endocrinology* 2016, 1-6. [[Crossref](#)]
851. Melanie Metallo, Lelia Groza, Laurent Brunaud, Marc Klein, Georges Weryha, Eva Feigerlova. 2016. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I 131 during Adolescence and Young Adulthood. *International Journal of Endocrinology* 2016, 1-7. [[Crossref](#)]
852. Hanna Borysewicz-Sanczyk, Janusz Dzieciol, Beata Sawicka, Artur Bossowski. 2016. Practical Application of Elastography in the Diagnosis of Thyroid Nodules in Children and Adolescents. *Hormone Research in Paediatrics* 86:1, 39-44. [[Crossref](#)]
853. Elpis-Athina Vlachopapadopoulou, Marina Vakaki, Fotini-Eleni Karachaliou, Irene Kaloumenou, Kleantchi Kalogerakou, Christina Gali, Stefanos Michalacos. 2016. Ectopic Intrathyroidal Thymus in Childhood: A Sonographic Finding Leading to Misdiagnosis. *Hormone Research in Paediatrics* 86:5, 325-329. [[Crossref](#)]
854. David P. Sparling, Kendra Fabian, Lara Harik, Vaidehi Jobanputra, Kwame Anyane-Yeboah, Sharon E. Oberfield, Ilene Fennoy. 2016. Congenital hypothyroidism and thyroid dysmorphogenesis: a case report of siblings with a newly identified mutation in thyroperoxidase. *Journal of Pediatric Endocrinology and Metabolism* 29:5. . [[Crossref](#)]

855. Bo Da Nam, Yun-Woo Chang, Seong Sook Hong, Ji-Young Hwang, Hyun Kyung Lim, Jeong Ho Lee, Dong Hwan Lee. 2016. Characteristic Sonographic and Follow Up Features of Thyroid Nodules According to Childhood Age Groups. *Journal of the Korean Society of Radiology* 75:2, 126. [[Crossref](#)]
856. Tracy S. Wang, Julie Ann Sosa. Who Should Do Thyroid Surgery? 57-66. [[Crossref](#)]
857. Sarah J. Bottomley, Steven G. Waguespack. A Child with Papillary Thyroid Cancer and Locally Advanced Disease but No Distant Metastasis 111-118. [[Crossref](#)]
858. Dennis M. Styne. Disorders of the Thyroid Gland 91-121. [[Crossref](#)]
859. Monica L. Arango, Steven G. Waguespack. A Young Child with Papillary Thyroid Cancer and Metastatic Pulmonary Disease: Role of Radioactive Iodine Therapy in Children 229-236. [[Crossref](#)]
860. Robert Howman-Giles, Christopher Cowell. Thyroid Cancer in Childhood and Adolescence 317-336. [[Crossref](#)]
861. Salvatore Benvenga, Alessandro Antonelli, Roberto Vita. 2015. Thyroid nodules and thyroid autoimmunity in the context of environmental pollution. *Reviews in Endocrine and Metabolic Disorders* 16:4, 319-340. [[Crossref](#)]
862. Daria Handkiewicz-Junak, Tomasz Gawlik, Jozef Rozkosz, Zbigniew Puch, Barbara Michalik, Elżbieta Gubala, Jolanta Krajewska, Aneta Kluczevska, Barbara Jarzab. 2015. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. *European Journal of Endocrinology* 173:6, 873-881. [[Crossref](#)]
863. Maria Isabel C Vieira Cordioli, Lais Moraes, Adriano Namó Cury, Janete M Cerutti. 2015. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?. *Endocrine-Related Cancer* 22:6, R311-R324. [[Crossref](#)]
864. Xi Jin, Liam Masterson, Anant Patel, Liz Hook, James Nicholson, Sarah Jefferies, Mark Gaze, Ramez Nassif, Robert Eller, Tony Hulse, Piyush Jani. 2015. Conservative or radical surgery for pediatric papillary thyroid carcinoma: A systematic review of the literature. *International Journal of Pediatric Otorhinolaryngology* 79:10, 1620-1624. [[Crossref](#)]
865. Scott A. Rivkees. 2015. Evaluating the Rare and Predicting the Worst: Lessons for Thyroid Nodules. *The Journal of Pediatrics* 167:4, 790-791. [[Crossref](#)]
866. LaFranchi Stephen H.. 2015. Inaugural Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer: Children Are Not Small Adults. *Thyroid* 25:7, 713-715. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
867. Pedro Wesley Rosario, Gabriela Franco Mourão, Maria Regina Calsolari. 2015. Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?. *International Journal of Endocrinology* 2015, 1-5. [[Crossref](#)]